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Abstract
Since Kraepelin first dichotomised the functional psychoses into dementia praecox 
and manic-depressive insanity at the end of the 19th century, the validity of the 
distinction has been challenged. Phenomenological, neurobiological, family, and 
molecular-genetic studies suggest that there is no neat biological distinction between 
these entities which are now known as schizophrenia and bipolar disorder.
The aim of this thesis was to explore the familial correlation of clinical measures 
within a large harmonised clinical dataset comprising samples of (a) families enriched 
for bipolar disorder, and (b) families enriched for schizophrenia. Analyses were 
performed across traditional diagnostic boundaries.
I carried out systematic clinical ratings on 835 individuals previously collected as part 
of ongoing molecular genetic studies. After an intensive training period, which 
included reliability exercises, I rated each case on approximately 200 variables, 
including a new set of rating scales developed as part of the PhD project.
I performed mixed-effects regression analysis on the data to estimate the intra-class 
correlation coefficient (ICC) and significance for each variable. After controlling for 
sample-of-origin and gender, thirty-one variables were significantly correlated within 
families. Amongst the most significant were age at onset (ICC=0.287, p=0.0006), 
longest admission (ICC=0.287, p=0.0006) and cannabis abuse/dependence 
(ICC=0.639, p=0.0007). Such variables may be influenced by genetic factors and may 
therefore be used to identify subgroups of patients more likely to share common 
underlying genetic susceptibilities.
In an analysis of a subset of sibling-pairs that were enriched for schizoaffective 
disorder I found that genetic similarity at chromosome lq42 was significantly 
associated with phenotypic similarity for the most severe depressive episode.
I also undertook clinical ratings on a sample of previously-collected patients with 
Velo-Cardio-Facial Syndrome (VCFS) and found high-rates of both mood- 
disturbance and psychosis.
My findings show that clinical ratings can be a useful adjunct to categorical diagnoses 
and identify specific phenotypes to consider in genetic studies.
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1 Introduction
1.1 Thesis Overview
The main aim of this thesis was to undertake a large number of systematic 
clinical ratings in a dataset comprising families enriched for psychotic and affective 
disorders. Analyses could then be performed across traditional diagnostic boundaries 
to identify clinical items which were significantly clustered within families and which 
were therefore more likely to be influenced by genetic factors. These clinical 
variables may be useful in refining the phenotype in future molecular genetic studies 
of these debilitating illnesses.
1.2 Literature Search
A systematic literature search was performed on topics relevant to this thesis 
(discussed below) using the online databases Embase (1980-2008), Ovid MEDLINE 
(1950-2008) and Ovid OLDMEDLINE (1948-1965). Searches were restricted to 
English-language journals. Literature searches were performed on a regular basis 
from October 2004 until September 2008. A list of search-terms included can be 
found in Appendix T. In addition I included any papers brought to my attention by 
my supervisor and by other members of the research team.
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1.3 The functional psychoses: Major mood and psychotic disorders of 
adulthood.
The group of severe mood and psychotic disorders of adulthood are divided 
into two categories, the organic psychoses and the functional psychoses. In the 
former the psychiatric symptoms are judged to be due to a general medical condition. 
In the latter, the term “functional” is somewhat misleading as it implies that their 
pathogenesis is primarily influenced by psychological factors. It is now recognised 
that the aetiological processes underlying these disorders are complex and multi­
factorial, involving biological, psychological and social factors.
Since Emil Kraepelin’s original suggestion (Kraepelin 1919; see below), and 
continuing in current diagnostic practice, the functional psychoses are divided into 
two broad categories: the affective psychoses, which include bipolar disorder; and the 
schizophrenic psychoses. This distinction is formalised within diagnostic 
classification systems such as the Diagnostic and Statistical Manual of Mental 
Disorders (DSMIV; APA 2000a), the ICD-10 Classification of Mental and 
Behavioural Disorders (WHO 1993) and the Research Diagnostic Criteria (RDC; 
Spitzer et al. 1978). Although the work of this thesis is motivated by the substantial 
data that suggest that the functional psychoses do not divide neatly into two disease 
entities, much work has been conducted on this basis. It is, therefore, useful to 
consider briefly what types of illness are included within the diagnostic categories.
1.3.1 A brief introduction to schizophrenia
Schizophrenia is a debilitating illness typically characterised by positive 
symptoms such as delusions and hallucinations, negative features such as restricted 
affect and psychomotor retardation, and severe functional impairment (Murray et al,
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2008b). Schizophrenia is traditionally associated with a chronic and deteriorating 
course; however recent studies suggest that although schizophrenia is a chronic 
illness, the majority of patients show some improvement over time (Rabinowitz et al. 
2007).
Although estimates vary, a recent review (Tandon et al. 2008) estimates that 
the annual incidence of schizophrenia is approximately 15 cases per 100,000 
individuals, the point prevalence is approximately 4.5 per population of 1,000, and the 
lifetime morbid risk of developing the disorder is approximately 0.7%.
Schizophrenia typically presents in late adolescence or early adulthood, 
although it can manifest at any time from early childhood to late adult life (Murray et 
al. 2008a). Early epidemiological studies demonstrated approximately equal rates of 
schizophrenia in men and women; however this may be because the broad concept of 
the illness used in the past resulted in the inclusion of a disproportionate number of 
women with mood disorders. A recent systematic review confirmed that the 
incidence of schizophrenia is higher amongst males than females, with a mean rate 
ratio of 1.4 (McGrath et al. 2004). Onset is typically earlier in males than in females; 
the mean age at first admission in the UK is approximately 22 for men and 27 for 
women (Castle and Murray 1991);(Kirkbride et al. 2006).
The first line of treatment in both acute and chronic schizophrenia is anti­
psychotic medications which are often successful in treating both acute and chronic 
illness. Their introduction in the 1950s led to individuals with schizophrenia being 
treated as outpatients for the first time (Murray et al. 2008a). Today, anti-psychotic 
drugs (often second generation so-called “atypical antipsychotics”) are frequently 
used alongside psychosocial interventions and psychological therapies to maximise 
the therapeutic response (Murray et al. 2008b).
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It is well documented that the aetiology of schizophrenia is influenced by both 
genetic and environmental factors. A wealth of family, twin and adoption studies 
support the role of genes in schizophrenia pathogenesis (Gottesman 1991). Studies 
report that the children and siblings of individuals with a diagnosis of schizophrenia 
are approximately 10 times more likely than the general population to develop the 
illness themselves (Craddock et al. 2005). In a review of twin-studies of 
schizophrenia, Cardno & Gottesman (2000) report concordance rates of 
approximately 41-65% in monozygotic twins and 0-28% in dizygotic twins. These 
studies suggest that heritability is high and genes are responsible for approximately 
80% of liability for the illness (Cardno et al. 1999). Studies are consistent with the 
existence of multiple susceptibility genes of small to moderate effect (McGuffin et al. 
1995).
Environmental factors which have been reported to influence risk include 
antenatal factors (e.g. pre-natal malnutrition and maternal infection), obstetric and 
peri-natal complications, childhood trauma and adolescent cannabis-abuse, as well as 
factors such as immigration and urbanicity (Tandon et al. 2008). However the exact 
effects of these factors remain unclear and evidence suggests that no single 
environmental effect is sufficient or necessary to result in the manifestation of 
schizophrenia.
1.3.2 A brief introduction to bipolar disorder
Bipolar disorder (also known as manic-depression) is characterised by severe 
mood disturbance. To receive a diagnosis of bipolar I disorder (BPI), an individual 
must have had at least one episode of highly elated or irritable mood known as mania. 
Depressive episodes may also have occurred but are not necessary for a BPI
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diagnosis. Bipolar II disorder (BPII) is characterised by episodes of less severe high 
mood, known as hypomania, which do not meet the criteria for a full manic episode, 
and which are accompanied by episodes of depression.
As reviewed in Goodwin & Jamison (2007), findings of recent studies suggest 
an overall lifetime prevalence of approximately 1% for BPI, although this rises to 
approximately 3.0%-8.3% if a broader bipolar spectrum is considered, which includes 
diagnoses such as BPII. Illness-onset tends to occur in early adulthood; Goodwin & 
Jamison (2007) pooled data from 15 studies examining age at onset, and derived a 
weighted-average onset of 22.2 years, with no significant difference between males 
and females. They also report roughly equal rates of bipolar disorder in males and 
females.
Bipolar disorder is associated with an episodic, remitting course. The majority 
of patients will experience multiple episodes of illness over their lifetime; for 
example, Tohen et al (1990) reported that in their sample of 75 patients with a 
diagnosis of bipolar disorder, only 28% remained in remission over the four year 
period in which they were followed up. Further studies suggest that the length of 
remission between episodes decreases as the number of episodes experienced 
increases (for example, Roy-Byme et al. 1985), although results have not been 
consistent -  for example, Angst & Sellaro (2000) found this to be true for the first few 
episodes, but not in later episodes. Long-term studies suggest that up to one-third of 
patients achieve full-remission and a similar proportion achieve complete functional 
recovery; approximately 20% of patients continue to experience chronic symptoms 
(Goodwin and Jamison 2007).
The treatment of bipolar disorder was revolutionised by the discovery of the 
mood-stabilising properties of lithium carbonate (first published by Cade, 1949)
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which has been shown to be effective during all phases of bipolar illness and may be 
particularly effective in suicide-prevention (reviewed in Fountoulakis et al. 2007). 
Both first and second generation anti-psychotic medications are also widely 
prescribed for the treatment of acute mania. Anti-depressants are sometimes 
prescribed alongside mood-stabilisers for episodes of depression, although caution is 
advised due to their association with switching polarity and cycle-acceleration (Salvi 
et al. 2008). Psychological therapies are also recommended as an adjunct to 
medication and have been shown to be effective in helping to prevent relapse in 
patients with bipolar disorder (Scott et al. 2007).
Like schizophrenia, bipolar disorder aggregates within families, suggesting 
that genetic factors influence susceptibility to illness. This is supported by family, 
twin and adoption studies (for example, reviewed in Jones 2004), although most 
studies have considered fairly small samples. The two largest twin-studies published 
to date suggest a heritability of approximately 80% for bipolar disorder and studies 
suggest that inherited susceptibility to the disorder is most likely explained by 
multiple genes of small effect (for example, Berrettini 1998).
Environmental factors have not been studied as extensively in bipolar disorder 
as they have in schizophrenia; however there is some evidence to suggest that 
individuals who were abused during childhood or who suffered from early maternal 
loss are more likely to develop the disorder. Studies also suggest that stressful life- 
events may be responsible for triggering episodes of illness in some people, as well as 
sleep disturbance, alcohol, anti-depressant use, stressful life events and hormonal 
alterations which occur as a result of childbirth or the menopause (Leboyer and Henry 
2005);(Goodwin and Jamison 2007).
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As mentioned above, the dichotomisation of the functional psychoses into 
schizophrenia and bipolar disorder is based on the pioneering work of Emil Kraepelin 
in the late 19th and early 20th centuries. This is discussed below.
1.4 Classification and nosology of the functional psychoses: Kraepelin’s 
dichotomy
1.4.1 Introduction to Kraepelin’s Dichotomy
Emil Kraepelin (1856-1926) was a prominent German psychiatrist whose 
pioneering work on the classification of psychiatric disorders led to him being 
described as “the founder of modem scientific psychiatry, psychopharmacology and 
psychiatric genetics.” (Eysenck et al. 1972). Pre-Kraepelin, the wide spectrum of 
illness manifestations described collectively as the “functional psychoses” were 
conceptualised in numerous complicated systems, for example; Guislain, 1833; 
Kahlbaum, 1882 (reviewed in Angst and Selloro 2000) none of which were widely 
accepted in the psychiatric community.
Kraepelin sought to create a classification system based on systematic 
observations of his patients. Whereas the majority of previous nosologists (with the 
notable exception of Kahlbaum, 1882) categorised patients according to the presence 
of specific symptoms, Kraepelin also took into account the family-history and illness- 
course of his patients. In this way he aimed to create a system that would facilitate 
accurate prognosis, successful treatment and ultimately illness-prevention (Angst 
2002).
It was Kraepelin’s work that led to the dichotomisation of the functional 
psychoses into two distinct entities: dementia praecox, characterised by a chronic and
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deteriorating course; and manic-depressive insanity, characterised by remitting 
episodes of illness and a more favourable prognosis.
1.4.2 Operational Diagnostic Systems
The classification of psychiatric illness is an extremely important issue. 
Clinically the definition of boundaries between distinct disease entities or diagnoses 
allows judgements to be made regarding the best course of treatment and the likely 
prognosis of a patient, as well as enabling effective communication between health 
professionals.
In research, these diagnostic categories can be used to define groups which 
form the basis on which hypotheses can be made and tested. The introduction of 
operational diagnostic systems in the latter half of the twentieth century benefited the 
field of psychiatry by enhancing the reliability of diagnostic categories. In the US/UK 
diagnostic project, (Cooper et al. 1972) demonstrated that diagnoses made by trained 
interviewers, using structured interviews and diagnostic criteria were more reliable 
than those made by untrained clinicians making a diagnosis on the basis of a clinical 
interview.
Kraepelin’s distinction between dementia praecox and manic-depressive 
insanity is enshrined today within operational diagnostic classification systems such 
as DSMIV (APA 2000b), the ICD10 (WHO 1993) and the RDC (Spitzer et al. 1978) 
under the diagnostic categories schizophrenia and bipolar disorder which are 
described above. These systems aimed to standardize psychiatric language and 
increase reliability, thus enhancing communication within the field.
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The tables below summarise the diagnostic criteria for schizophrenia and 
bipolar disorder, under each of these three operational diagnostic systems.
In research studies of patient populations, data are usually gathered from a number of 
different sources including a structured lifetime psychiatric interview with the patient, 
information from informants, and written material such as hospital casenotes or 
referral letters. The standard diagnostic procedure used by researchers is known as 
the “best estimate approach” (Leckman et al. 1982). This involves multiple 
researchers reviewing all the available information for each patient and subsequently 
coming to a consensus diagnosis that they agree upon.
The introduction of operational diagnostic systems led to an improvement in 
diagnostic reliability, which is further facilitated in research by the use of the best 
estimate approach to diagnosing patients. However, with no definitive diagnostic test 
to confirm the presence or absence of specific disorders, the validity of these 
diagnostic categories remains unknown.
As described above, evidence from family, twin and adoption studies suggests 
that aetiologically schizophrenia and bipolar disorder are influenced by both genetic 
and environmental factors (Smoller and Finn 2003). The recent advances in 
molecular genetic techniques have provided researchers with a powerful tool with 
which to investigate the biological contributions to disease and potentially provide 
biological validation to disease categories. However, research in this area has not 
progressed as quickly as was originally anticipated and results have, to date, been 
inconclusive, with even the most promising findings failing to be consistently 
replicated.
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DSMIV ICD10 RDC
Symptom
Criteria
Two (or more) of the following have been present 
for a  significant proportion of time over a  one- 
month period: delusions, hallucinations, 
disorganised speech, grossly disorganised or 
catatonic behaviour, negative sym ptom s
NB: Only one symptom is necessary  if delusions 
are bizarre or if auditory hallucinations a re  present 
which talk in the third person or give a  running 
commentary.
Im pairm ent: For a significant proportion of time 
since illness-onset, one or more major a re as  of 
functioning such a s  work, interpersonal relations or 
self-care are  markedly below the level achieved 
prior to the onset (or failure to achieve expected 
level of achievem ent if illness-onset is in childhood 
or adolescence).
At least one from list (1) or two from list (2) are 
experienced during an episode of psychotic illness 
lasting for a t least one month:
(1) Thought echo, insertion, withdrawal, or 
broadcasting; delusions of control, influence or 
passivity clearly referred to body or limb 
m ovem ents or sensations; delusional perception; 
running com m entary voices; third person auditory 
hallucinations or other types of hallucinatory voices 
coming from som e part of the body; persistent 
delusions of other kinds that are culturally 
inappropriate or completely impossible.
(2) P ersistent hallucinations which occur every day 
for a t least one month, when accom panied by 
delusions without clear affective content, or when 
accom panied by consistent over-valued ideas; 
neologisms, breaks or interpolations in train of 
thought resulting in incoherence or irrelevant 
speech; catatonic behaviour; negative symptoms.
At least two of the following have been  presen t 
during the  active p h ase  of illness:
Thought broadcasting, insertion or withdrawal; 
delusions of being controlled (or influenced), other 
bizarre delusions or multiple delusions; somatic, 
grandiose, religious, or other delusions without 
persecutory or jealous content lasting a t least one 
week; running com m entary voices or two or more 
voices conversing with each  other; non-affective 
verbal auditory hallucinations spoken to the 
subject; hallucinations of any type which last 
throughout the day for several days or intermittently 
for a t least one month; definite instances of marked 
formal thought disorder accom panied by either 
blunted or inappropriate affect, delusions or 
hallucinations of any type, or grossly disorganised 
behaviour.
Duration
Criteria
Continuous signs of the disturbance persist for at 
least 6 months. This period m ust include at least 1 
month of sym ptom s (less if successfully treated) 
that m eet the Symptom Criteria listed above, and 
may include prodromal or residual sym ptom s which 
may be characterised by only negative sym ptom s 
or two or more sym ptom s presen t in an attenuated  
form.
At least one month.
Signs of illness have lasted a t least 2 w eeks from 
onse t of a  noticeable change in the subject’s  usual 
condition.
Exclusion
Criteria
Schizoaffective disorder and mood disorder with 
psychotic features have been ruled out.
Disturbance is not due to a  general medical 
condition.
If there is a history of autistic disorder or pervasive 
developm ental disorder, the additional diagnosis of 
SZP is only m ade if prominent delusions or 
hallucinations a re  presen t for at least one month.
If patient also m eets the criteria for a  m anic or 
depressive episode, the symptom criteria listed 
above m ust have been met before the disturbance 
in mood developed.
Disorder is not attributable to organic brain d isease , 
or to alcohol or drug-related intoxication, 
dependence or withdrawal.
At no time during the active period of illness being 
considered did the individual m eet criteria for either 
probable or definite manic or depressive syndrom e 
to such a  degree that it w as a  prominent part of the 
illness.
Sym ptom s only occur during periods of alcohol or 
drug-use or withdrawal from them.
Table 1-1: Comparison of diagnostic criteria for schizophrenia using DSM-IV (APA 1994); ICD-10 (WHO 1992); RDC (Spitzer et al. 1975)
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DSMIV ICD10 RDC
Symptom
Criteria
Two (or more) of the following have been  present 
for a  significant proportion of time over a  one- 
month period: delusions, hallucinations, 
disorganised speech, grossly disorganised or 
catatonic behaviour, negative sym ptom s
NB: Only one symptom is necessary  if delusions 
are bizarre or if auditory hallucinations are  p resen t 
which talk in the third person or give a  running 
commentary.
Im pairm ent: For a  significant proportion of time 
since illness-onset, one or more major a re a s  of 
functioning such a s  work, interpersonal relations or 
self-care are  markedly below the level achieved 
prior to the onse t (or failure to achieve expected 
level of achievem ent if illness-onset is in childhood 
or adolescence).
At least one from list (1) or two from list (2) are 
experienced during an episode of psychotic illness 
lasting for a t least one month:
(1) Thought echo, insertion, withdrawal, or 
broadcasting; delusions of control, influence or 
passivity clearly referred to body or limb 
m ovem ents or sensations; delusional perception; 
running com m entary voices; third person auditory 
hallucinations or other types of hallucinatory voices 
coming from som e part of the body; persistent 
delusions of other kinds that are culturally 
inappropriate or completely impossible.
(2) Persistent hallucinations which occur every day 
for a t least one month, when accom panied by 
delusions without clear affective content, or when 
accom panied by consistent over-valued ideas; 
neologisms, breaks or interpolations in train of 
thought resulting in incoherence or irrelevant 
speech; catatonic behaviour; negative symptoms.
At least two of the following have been presen t 
during the active p hase  of illness:
Thought broadcasting, insertion or withdrawal; 
delusions of being controlled (or influenced), other 
bizarre delusions or multiple delusions; somatic, 
grandiose, religious, or other delusions without 
persecutory or jealous content lasting a t least one 
week; running com m entary voices or two or more 
voices conversing with each  other; non-affective 
verbal auditory hallucinations spoken to the 
subject; hallucinations of any type which last 
throughout the day for several days or intermittently 
for a t least one month; definite instances of marked 
formal thought disorder accom panied by either 
blunted or inappropriate affect, delusions or 
hallucinations of any type, or grossly disorganised 
behaviour.
Duration
Criteria
Continuous signs of the disturbance persist for at 
least 6 months. This period m ust include a t least 1 
month of sym ptom s (less if successfully treated) 
that m eet the Symptom Criteria listed above, and 
may include prodromal or residual sym ptom s which 
may be characterised by only negative sym ptom s 
or two or more sym ptom s present in an attenuated 
form.
At least one month.
Signs of illness have lasted a t least 2 w eeks from 
onse t of a  noticeable change in the subject’s  usual 
condition.
Exclusion
Criteria
Schizoaffective disorder and mood disorder with 
psychotic features have been ruled out.
Disturbance is not due to a  general medical 
condition.
If there is a  history of autistic disorder or pervasive 
developm ental disorder, the additional diagnosis of 
SZP is only m ade if prominent delusions or 
hallucinations are p resen t for a t least one month.
If patient also m eets the criteria for a  manic or 
depressive episode, the symptom criteria listed 
above must have been met before the disturbance 
in mood developed.
Disorder is not attributable to organic brain d isease , 
or to alcohol or drug-related intoxication, 
dependence or withdrawal.
At no time during the active period of illness being 
considered did the individual m eet criteria for either 
probable or definite manic or depressive syndrom e 
to such a  degree that it w as a  prominent part of the 
illness.
Sym ptom s only occur during periods of alcohol or 
drug-use or withdrawal from them.
Table 1-1: Comparison of diagnostic criteria for schizophrenia using DSM-IV (APA 1994); ICD-10 (WHO 1992); RDC (Spitzer et al. 1975)
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1.4.3 Challenging the dichotomy
The validity of Kraepelin’s dichotomisation of the functional psychoses into 
the syndromes we know today as schizophrenia and bipolar disorder has received 
some support from a number of family studies. Several studies have shown increased 
risk of schizophrenia but not bipolar disorder in families of probands with typical 
schizophrenia, and increased risk of bipolar disorder but not schizophrenia in 
probands with typical bipolar disorder (Frangos et al. 1985; Gershon et al. 1982). 
This evidence, along with the conceptual simplicity of Kraepelin’s dichotomy - which 
is in stark contrast to its numerous complicated and chaotic predecessors - is perhaps 
the main reason that the dichotomy has withstood the test of time.
However, despite its widespread acceptance in the field of psychiatry, the 
validity of Kraepelin’s dichotomy was questioned almost from its point of conception, 
most notably by Kraepelin himself who, towards the end of his life, stated, “It is 
becoming increasingly clear that we cannot distinguish satisfactorily between these 
two illnesses and this brings home the suspicion that our formulation of the problem 
may be incorrect.” (Kraepelin 1920). Kraepelin’s doubts about the validity of his 
dichotomy have been supported by a growing body of research suggesting overlap 
between schizophrenia and bipolar disorder. In this introduction I have chosen to 
focus on the three areas most relevant to the themes of this PhD: overlapping clinical 
presentations, evidence from family studies and evidence from molecular genetic 
studies. These are discussed below.
i. Overlapping clinical presentations
Many clinical features overlap the traditional Kraepelinian divide, occurring 
commonly in both illnesses labelled as schizophrenic and those labelled as affective in 
nature, and it is widely recognised that there are no pathognomic indicators of either
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diagnostic category. Schizophrenic patients often present with prominent symptoms 
of affective disturbance, whereas patients with affective disorder frequently present 
with psychotic features. For example, in their review of phenomenological studies 
focussing on the specificity of “schizophrenic” symptoms, Pope & Lipinski (1978) 
found that psychotic features were present in 20%-50% of patients with an acute 
manic episode. More recently, Coryell et al (2001) found that 90 out of the 139 
(64.7%) manic patients in their study had psychotic features.
Schneider (1959) described a set of “first rank symptoms” of schizophrenia 
which included thought interference, thought echo, auditory hallucinations in the 3rd 
person, running commentary voices, delusions of passivity and primary delusional 
perception. Schneider proposed that, providing there was no evidence of coarse brain 
disease, any one of these symptoms was diagnostic of schizophrenia. These 
symptoms show high inter-rater reliability and have had considerable influence in the 
field of psychiatry; they are also incorporated within diagnostic systems such as those 
mentioned above. However, studies have shown that these are not uncommon in 
affective-disorder, for example, Tanenberg-Karant (1995) found that 29% of 
psychotic bipolar patients had first-rank symptoms at their first admission.
Symptoms of affective disturbance are also frequently reported in patients 
with schizophrenia. For example, in their study examining retrospective depressive 
symptoms in patients diagnosed with schizophrenia at their first admission, Hafner et 
al (2005) reported the lifetime prevalence of depressed mood (lasting at least 2 weeks) 
to be 83%. Additionally they found that 71% of patients presented with clinically 
significant depressive symptoms during their first psychotic episode (with 23% 
fulfilling ICD-10 criteria for a depressive episode).
The identification of mood symptoms in schizophrenic illness is made more
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difficult by diagnostic-specific labels given to certain clinical features, i.e. symptoms 
which are similar in clinical presentation are sometimes labeled differently depending 
on whether they occur in schizophrenic or affective illness. For example, in a 
schizophrenic illness, symptoms such as poor motivation, poor energy, psychomotor 
retardation, anhedonia and restricted affect would be described as negative symptoms, 
which are thought to reflect a loss of normal functioning (as opposed to positive 
symptoms such as delusions and hallucinations which reflect an excess or distortion 
of functioning). However, the same clinical features experienced in a patient who 
does not have a typically schizophrenic illness are likely to be described as depressive 
symptoms. Similarly, symptoms such as incoherence and pressured speech are likely 
to be thought of as being indicative of positive formal thought disorder in 
schizophrenia and as symptoms characteristic of mania in affective illness. This is 
due to assumed-differences in the mechanisms underlying these clinical features, 
although there is little evidence to confirm that these differences are present in reality 
and this may well result in the under-reporting of affective-disturbance in 
schizophrenic illness.
In an attempt to demonstrate a dichotomy between schizophrenia and bipolar 
disorder patients, Brockington et al (1979) performed discriminant function analysis 
using 24 clinical variables covering phenotypic characteristics (e.g. family history, 
manic syndrome, schizophrenic psychotic symptoms, etc). They failed to find 
convincing evidence that the functional psychoses fall neatly into these two diagnostic 
categories.
This overlap in clinical presentation is best demonstrated by patients 
demonstrating prominent schizophrenic symptoms and prominent affective 
disturbance simultaneously, leading to diagnostic dilemmas. In fact, some of the first
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criticisms of the dichotomy were based on the observation that many individuals did 
not fit easily into either diagnostic category.
In a study looking at 468 of Kraepelin’s patients originally diagnosed with 
dementia praecox, Zendig (1909) found that 30% had a good prognosis, inconsistent 
with their original diagnoses (reviewed in Angst 2007). At the time, Zendig attributed 
this to mis-diagnosis, although later Kraepelin saw it as evidence of a weakness in his 
dichotomy, stating that, “The cases which are not classifiable are unfortunately very 
frequent.”
The fact that Kraepelin’s dichotomy failed to describe all cases of illness 
constituting the functional psychoses led to the development of a third diagnostic 
category, schizoaffective disorder (SAD). Some diagnostic traditions have also 
continued to recognise other specific diagnostic categories which have a particular 
mix of mood and psychotic features, including cycloid psychosis in Germany 
(Leonhard 1961) boufee delirante in France (Pichot 1986) and atypical psychosis in 
Japan (Mitsuda 1965).
The term schizoaffective was first proposed by Kasanin (1994) who 
described “acute schizoaffective psychosis”, it could be used to categorise these 
“difficult-to-diagnose” patients who had prominent symptoms of both schizophrenia 
and affective disturbance. Since this time, researchers have debated whether 
schizoaffective disorder is a subtype of schizophrenia, a subtype of affective disorder, 
or an entity in its own right. Others have suggested that schizoaffective disorder does 
not exist at all and is merely a form of psychotic mood disorder (Lake and Hurwitz 
2007a).
In clinical practise schizoaffective disorder has been a useful tool with which 
to diagnose difficult-to-classify patients, facilitating communication between medical
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practitioners. However, no unequivocal definition of schizoaffective disorder exists, 
as demonstrated by the variations in diagnostic criteria between DSMIV, ICD10 and 
RDC (see chapter 3). Studies have also shown inter-rater reliability to be extremely 
low in diagnosing schizoaffective disorder; for example Maj et al (2000) reported a 
Cohen’s kappa of 0.22 for the diagnosis of schizoaffective disorder, compared to 0.71 
for a manic episode and 0.82 for a major depressive episode.
Studies have shown schizoaffective disorder to occupy an intermediate 
position between schizophrenia and affective disorder in terms of illness course, 
family morbidity, symptomatology and other clinical variables such as age at onset, 
comorbidity with substance abuse and response to drug treatment (reviewed in 
Cheniaux et al. 2008a). However, schizoaffective disorder is not clearly distinct from 
either schizophrenia or bipolar disorder and the boundaries between all three 
diagnostic entities are ambiguous.
In diagnostic systems, the difficulties caused by these overlaps are overcome 
due to the implementation of the diagnostic hierarchy (Spitzer and Williams 1990). 
This states that diagnoses “higher up” in the hierarchy take precedence over co­
occurring diagnoses which are further down (illustrated in figure 1.1 below).
Organic disorders
I
Schizophrenia
I
Schizoaffective Disorder
*
Affective Disorders
i
Neuroses
F igure 1-1: R ep resen tation  o f  the d iagn ostic  h ierarchy  in w hich  h igh er-level d iagnoses “ tru m p ” 
d iagn oses fu rth er dow n the h ierarchy  (F ou ld s 1965).
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This is enshrined within diagnostic criteria, for example an exclusion criteria 
for bipolar disorder states that the illness must not be better accounted for by “schizo­
affective disorder, schizophrenia or other psychotic disorder”. Therefore, if an 
individual had chronic schizophrenia but had also had a manic episode at some point 
during their illness, unless the mood symptoms were prominent enough to warrant a 
diagnosis of schizoaffective disorder, they would not be considered in the diagnosis.
The diagnostic hierarchy and the introduction of schizoaffective disorder have 
helped solve diagnostic-dilemmas and facilitated communication in the field of 
psychiatry. However the evidence for the clinical overlap which occurs between 
schizophrenia, schizoaffective disorder and bipolar disorder, along with the fact that 
no points of rarity have been identified between them, does not support the hypothesis 
that these separate diagnostic categories represent biologically distinct entities.
ii. Family studies
Family studies investigate how phenotypically similar genetically related 
individuals are for a specific trait or disease. If a disease is shown to aggregate within 
families, this suggests that shared genetic and/or environmental factors play an 
aetiological role. As stated above, both bipolar disorder and schizophrenia have been 
shown to “breed true” within families. However, these findings have not been 
consistent and other family-studies suggest that there is a non-trivial degree of 
familial co-aggregation between schizophrenia, schizoaffective disorder, and bipolar 
disorder.
One line of evidence supporting genetic overlap between diagnostic entities is 
the description of families in which multiple diagnoses are represented. For example, 
Pope & Yurgelun-Todd (1990) described two pedigrees in which schizophrenic 
individuals had first-degree relatives with bipolar disorder. Further, St Clair et al
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(1990) described a large Scottish pedigree in which a chromosomal translocation co­
segregated with a wide-spectrum of psychotic and affective illness, including 
schizophrenia, bipolar disorder and major recurrent depression.
McGuffin et al (1982) described a set of monozygotic triplets, two of whom 
met the Research Diagnostic Criteria (RDC) for schizophrenia, whilst the third met 
RDC criteria for bipolar disorder. This provides evidence in support of a genetic 
contribution to the functional psychoses in general, but against the hypothesis that 
schizophrenia and bipolar disorder are biologically distinct entities.
Recent research carried out on larger samples of patients has also found 
significant familial co-aggregation of these disorders. For example, Valles et al 
(2000) examined the prevalence of psychiatric disorders in an inpatient-sample of 103 
patients with bipolar disorder and found that the morbid risk of both bipolar disorder 
(4.9%) and'schizophrenia (2.8%) were higher in relatives of these patients compared 
with relatives of a control group of psychiatrically-well inpatients of a general 
hospital.
Similarly, Tsuang et al (1980) found elevated risk of both bipolar disorder and 
schizophrenia in relatives of probands with schizophrenia and relatives of probands 
with mania. Further, Kendler et al (1995) found increased risk of schizoaffective 
illness in relatives of probands with schizophrenic illness and probands with bipolar 
illness.
A limitation of the majority of previous research into the functional psychoses 
is that the majority of studies have been carried out under the assumptions of the 
diagnostic hierarchy, described above. If symptoms of affective disorder have 
occurred in schizophrenia, unless they are particularly prominent over the course of 
the illness they will be considered non-specific and not considered in analysis. Under
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the alternative hypothesis that manic episodes which occur within the context of a 
schizophrenia diagnosis may be due to the existence of common risk factors, Cardno 
et al (2002) performed analysis unconstrained by the hierarchy, allowing a single 
individual to meet the criteria for more than one syndrome in their sample of 
monozygotic and same-sex dizygotic twin-pairs. They found evidence of both 
common and syndrome-specific genetic contributions to the schizophrenic and manic- 
syndrome.
Evidence from family studies suggests that there is a more complex 
relationship between the functional psychoses than is suggested by Kraepelin’s 
dichotomy.
Hi. Challenges from molecular genetic studies
Recent advances in molecular genetic techniques have provided researchers 
with a powerful tool with which to investigate genetic contributions to psychiatric 
illness. Family samples can be used to identify chromosomal regions likely to 
harbour susceptibility genes by investigating associations between variation in DNA 
markers covering the entire genome and the presence or absence of a specific 
trait/disease. This is known as linkage analysis. Genetic linkage is said to be present 
when the alleles of a marker and trait locus are observed to co-segregate within 
families. Because the location of the marker is known, the approximate location of 
the disease-gene can also be deduced.
Linkage analyses have been undertaken in samples of both schizophrenia and 
bipolar disorder families and numerous linkage regions have been identified for each 
disorder (for example, Ivleva et al. 2008; Lewis et al. 2003; Segurado et al. 2003). 
However, with the increasing number of linkage studies being undertaken, it soon
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became apparent that several regions were being implicated in both disorders, 
suggesting that common genes within these regions may be involved in the 
susceptibility of both schizophrenia and bipolar disorder.
Overlapping regions identified include 13q, 22q, 18 and 6q (reviewed in Owen 
et al. 2007). However, results have not been consistent. For example, in the two 
meta-analyses performed on linkage analyses, Badner & Gershon (2002) found the 
most robustly replicated evidence for schizophrenia on 22q, 13q and 8p; and for 22q 
and 13q for bipolar disorder, suggesting that 22q and 13q are likely locations of 
common susceptibility genes. However, a second meta-analysis (Lewis et al. 2003) 
using a different technique found no significant linkage for bipolar disorder (although 
the strongest evidence was identified for 9p, lOq and 14q -  (Segurado et al. 2003)), 
and evidence for genome-wide significant linkage in 12 regions in schizophrenia. 
Kelsoe (2007) suggests that the reason for the inconsistent findings in these two 
studies is most likely to be due to the large number of genes involved in the disorders 
and due to sampling effects.
Linkage regions have also been identified for intermediate phenotypes 
incorporating both features typically associated with affective illness and those 
typically associated with schizophrenia. For example Hamshere et al (2005) 
demonstrated genome-wide significant linkage at lq42 and suggestive linkage at 
22ql 1, in a sample of pedigrees enriched for schizoaffective disorder. These families 
were taken from two separate samples of patients, one enriched for bipolar disorder 
and the other enriched for schizophrenia. Analysis suggested that evidence for 
linkage was contributed from both samples equally.
The evidence from linkage analyses are consistent with the existence of 
common genes which are involved in susceptibility to both schizophrenia and bipolar
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disorder. However, an alternative explanation for these overlapping regions is that 
they may contain both genes influencing susceptibility to schizophrenia and genes 
influencing susceptibility to bipolar disorder. A third possibility is that there is a gene 
within this region that influences susceptibility to a range of disorders or symptoms 
Evidence that the first explanation is the more probable in certain cases is provided by 
association studies, in which genetic variation in a sample of cases is compared with 
that in a sample of controls. These have succeeded in identifying genes which appear 
to influence susceptibility across the traditional Kraepelinian divide, including those 
summarised in Table 1-1 below. However, it must be noted that findings have been 
inconsistent and that negative, as well as positive, results have been reported for each 
of these genes.
Gene Chromosome Evidence in SZP Evidence in BPD
COMT 22q Li et al (1996) Papolos et al (1998) -  rapid cycling subtype
DISCI iq Blackwood et al (2001) Hodgkinson et al (2004)
Dysbindin 6p Straub et al (2002)
Kohn et al (2004-psychotic 
bipolar disorder)
DAOA 13q Chumakov et al (2002) Hattori et al (2003)
Neuregulin 1 8p Stefansson et al (2002) Thomson et al (2007)
Table 1-3: A summary of some of the overlapping susceptibility genes identified for
schizophrenia and bipolar disorder
Evidence from molecular genetic studies suggests at least a partial overlap
between genes involved in schizophrenia and those involved in bipolar disorder. 
Kelsoe (2007) proposes four possible models of genetic overlap to explain how 
common genes could result in different disorders: 1. Different mutations within the 
same gene might predispose to different disorders; 2. Common genes operate in both 
disorders and different environmental factors result in different disorders; 3. The same 
genes are involved in both, but different combinations of genes result in different
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disorders; 4. Common genes are involved in both disorders and their effects add 
together along a single risk continuum -  above a certain threshold results in bipolar 
disorder, above a higher threshold results in schizophrenia (this is known as the 
quantitative multiple threshold model).
Molecular genetic studies have provided researchers with an extremely 
powerful tool with which to investigate the genetic relationship between affective and 
psychotic disorders. This research, along with evidence produced from family, twin 
and adoption studies, supports the existence of overlapping genes. However, no 
overwhelmingly conclusive results have yet been produced.
1.4.4 Refining the phenotype
The majority of previous studies have been undertaken using samples of cases 
selected according to their lifetime diagnoses. However, as described above, studies 
have demonstrated that these diagnostic categories are highly heterogeneous and have 
many overlapping features. The identification of more phenotypically homogeneous 
subgroups, that may reflect underlying biological/genetic homogeneity, may facilitate 
molecular genetic studies in the future (e.g. by increasing power to detect linkage).
Such sub-groups can be identified by refining the phenotype, a process which 
aims to reduce clinical variability whilst maintaining or increasing heritability (or, in a 
more general sense, biological validity). Clinical variables that aggregate within 
families may be influenced genetically (although common environmental influences 
must also be considered) therefore familiality can be used with caution as a proxy for 
heritability. The identification of such variables is an important first step in the 
refinement of the phenotype, and has been the focus of numerous studies.
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For example, O’Mahoney et al (2002) looked at a set of clinical variables in a 
sample of sibling-pairs with bipolar disorder. They found significant intra-pair 
correlations for age at onset, a dimensional score of psychosis and proportion of 
manic to depressive episodes, all of which remained significant after corrections were 
made for multiple testing. They also found significant intra-pair correlations for 
mania, a dimensional measure of incongruence, and frequency of manic and 
depressive episodes, although these did not remain significant after correcting for 
multiple comparisons.
In a family-based sample of individuals with bipolar disorder, Schulze et al 
(2006a) investigated the familiality of 40 diverse phenotypic variables. They found 
that substance abuse, alcoholism, psychosis, history of attempted suicide and level of 
social functioning were all highly familial. They also found suggestive evidence for 
familiality of age at onset and co-morbid panic disorder.
Numerous other studies have been undertaken to help identify other such 
variables which aggregate within families with bipolar disorder; these findings are 
summarised in table 1-2 below and represent phenotypic features which are likely to 
help reduce heterogeneity in future molecular genetic studies.
Similar studies have been undertaken in samples of schizophrenia families. 
For example Kendler et al (1997) examined the familiality of clinical variables within 
a sample of 457 sibling pairs with schizophrenia. They found significant intra-pair 
correlations for global course, outcome, depressive symptoms, manic symptoms, 
positive and negative thought disorder, affective deterioration, catatonic symptoms 
and delusions.
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Further variables which have been shown to aggregate within families affected 
by schizophrenia are summarised in Table 1-3 below.
Clinical variables showing familiality in bipolar disorder samples
Age of onseta,c,t
Lifetime ever occurrence of mood-incongruent psychotic symptoms c,g_____
Lifetime ever occurrence of psychotic symptoms c’J____________________
Severity of mania0_______________________________________________
Rapid cyclingJ__________________________________________________
Rapid mood switchingJ__________ _________________________________
Lifetime presence of panic disorder ’ J_______________________________
Lifetime occurrence of puerperal psychosis 1__________________________
Alcohol abuse J _____________________________________________
Episode frequencyc’______________________________________________
Polarity at onset of illnesse________________________________________
Substance abuse_________________________________________________
Suicide attempt__________________________________________________
Suicidal thoughtsJ_______ ________________________________________
Level of social functioning________________________________________
Marital status *
Table 1-4: Clinical variables showing intra-familial aggregation in bipolar disorder.
a. Leboyer et al (1998); b. Potash et al (2000); c. O ’Mahony et al (2002); d. Fisfalen et al (2005); e. 
Kassem et al (2006); f  Schulze et al (2006b); g. Goes et al (2007); h. MacKinnon et al (2002); i. Jones 
& Craddock (2001); j. Saunders et al (2008).
Clinical variable showing familiality in schizophrenia samples
Age of onseta,d
Negative symptom dimension *»__________________________________
Disorganisation dimension 8,6,1___________________________________
Depressive symptoms CJ________________________________________
Manic symptoms c_____________________________________________
Lifetime course of illness c>______________________________________
Outcome c’k
Anhedonia___________________________________________________
Positive formal thought disorderc________________________________
Negative formal thought disorderc________________________________
Catatonic symptoms c’
 rr-------------------------------------------------------------------------------------------------------------- — ------------------
Auditory hallucinations_________________________________________
Visual hallucinationsJ__________________________________________
Hallucinations c_______________________________________________
Delusions c___________________________________________________
First rank symptomsc__________________________________________
Reality distortion factor a_______________________________________
Delusional proneness___________________________________________
Table 1-5: Clinical variables showing intra-familial aggregation in schizophrenia.
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a. Burke et al (1996); b. Choi et al (2007); c. Kendler et al (1997) ; d. Tsuang et al (1967); e. Loftus et 
al (1998); f  Schurhoff et al (2003a); g. Ristner et al (2005); h. Peralta & Cuesta (2007b); i. Cardno et 
al (1999); j. DeLisi et al (1987); k. Blueler (1978).
As described above, the ultimate aim of studies attempting to identify clinical 
variables which cluster within families is to inform sample-selection in molecular 
genetic studies. This is based on the theory that such variables are more likely to have 
a distinct genetic basis. The implementation of clinical variables showing familiality 
in molecular genetic studies has already demonstrated promising results.
For example, as presented in Table 1-2, a number of studies have identified 
psychotic symptoms to aggregate within families in samples of bipolar patients. 
Based on the hypothesis that patients with psychotic bipolar disorder may represent a 
genetically distinct subgroup, Potash et al (2003) performed linkage analysis in a 
sample of bipolar disorder patients who were labelled as “affected” only if they had a 
psychotic mood disorder. They detected two linkage regions, 13q and 22q, both of 
which had been previously implicated in schizophrenia and bipolar disorder.
Park et al (2004) also classed the bipolar cases in their sample according to the 
presence or absence of psychotic symptoms. They found evidence for significant 
linkage at 9p31 and 8p21, regions that had not previously been implicated in bipolar 
disorder but which had been implicated in schizophrenia (for example, reviewed in 
Baron 2001). They also found suggestive evidence for linkage on 9 further regions 
including 13q32.
In an attempt to detect loci which influence women’s susceptibility to episodes 
of illness after childbirth, Jones et al (2007) performed a genome-wide linkage scan in 
a sub-sample of 35 bipolar disorder pedigrees enriched for puerperal psychosis. They 
found genome-wide significant linkage on 16pl3 and suggestive linkage at 8p24;
31
neither region had been implicated in their original sample of pedigrees with bipolar 
disorder.
As stated above, one clinical feature that has been shown to aggregate within 
families affected by schizophrenia is the occurrence of depressive features (DeLisi et 
al. 1987; Kendler et al. 1997). This prompted Hamshere et al (2006) to include the 
presence or absence of depression as a covariate within their genome-wide linkage 
scan in a sample of schizophrenia pedigrees. They detected a genome-wide 
significant linkage signal on chromosome 4q28 (LOD=4.59 representing a 
significantly higher linkage peak than that found in their univariate analysis). They 
also report suggestive evidence for linkage on 20ql 1.21.
As stated above, these results may be interpreted as support for genetically 
distinct subgroups of patients with specific phenotypic presentations. Alternatively, 
there may be genes within these regions that increase risk across a broad range of 
symptoms that cut across traditional diagnostic boundaries.
Association studies also provide evidence that “refined” phenotypes can 
facilitate the detection of genes increasing susceptibility across the Kraepelinian 
divide. For example, D-amino-acid-oxidase activator (DAOA, formerly known as 
G72) is involved in modulating glutamate signalling by activating D-amino-acid 
oxidase. It is often referred to as DAOA/G30 due to the fact that it overlaps with the 
gene G30; the two are transcribed on opposite DNA strands. DAOA/G30 was 
originally implicated in schizophrenia susceptibility (Chumakov et al. 2002) and has 
since been reported as showing association in studies of bipolar disorder (Craddock et 
al. 2005; DePaulo 2004). Williams et al (2006) undertook a large systematic study of 
polymorphisms across the DAOA/G30 locus in a large well-characterised sample of 
schizophrenia and bipolar disorder cases. They found evidence for association in the
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bipolar disorder sample but failed to detect such evidence in the schizophrenia 
sample. However, including only the schizophrenia patients who had experienced at 
least one episode of mood disturbance in the analysis, they found that their results 
were similar to those produced for the bipolar disorder sample.
Neuregulin 1 (NRG1) has previously been implicated in both schizophrenia 
(for example, Stefansson et al. 2002) and bipolar disorder (for example, Thomson et 
al. 2007). Green et al (2005a) performed case-control analysis on a sample of patients 
with bipolar disorder and a sample with schizophrenia and found similar effect sizes 
in both. However, they found a greater effect size in bipolar patients who had 
experienced mood-incongruent psychotic symptoms and in schizophrenic patients 
who had experienced manic features, suggesting that NRG1 may exert a specific 
influence on cases characterised by a mixture of psychotic and affective features. 
This is consistent with the linkage study by Hamshere et al (2005, described earlier) 
that suggests a relatively specific genetic contribution to schizoaffective illness.
The studies summarised above provide evidence for the existence of genes 
which influence susceptibility to psychiatric illness across the traditional boundaries 
imposed by diagnostic classification systems. The identification of such genes should 
help to increase our understanding of the relationship between mood disturbance and 
psychosis and about the biological and environmental processes involved in the 
pathogenesis of these debilitating conditions.
1.5 Measurement of psychopathology
As stated above, molecular genetic studies are likely to be facilitated by the 
identification of areas of the phenotype which aggregate within families. These may
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be identified using statistical techniques; however, the use of such methods first 
requires the areas of the phenotype to be measured, i.e. they must be defined and 
described precisely in a way that allows them to be utilised in the necessary statistical 
analyses.
The introduction of operational definitions of psychiatric disorders led to the 
development of numerous structured and semi-structured standardised interviews, in 
which questions relating to each criterion can be asked. The aim of standardised 
interviews is to ensure that each individual is presented with exactly the same 
questions in a standard way, thus providing a, “comprehensive, accurate and 
technically specifiable means of describing and classifying phenomena in order to 
make comparisons” (WHO 1992). Such interviews include a standard, detailed 
definition for each symptom and guide questions can be added or modified in order to 
determine whether or not each symptom is present.
One such interview is the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN), which is designed as “a set of schedules for the assessment, 
measurement and classification of psychopathology and behaviour associated with 
adult psychiatric disorders” (Wing et al. 1990). SCAN is a semi-structured interview 
based on the Present State Examination (Wing et al. 1974). It was designed for use 
within clinical populations and covers domains such as mania, depression, anxiety 
and alcohol and substance abuse.
A major advantage of SCAN is its glossary which contains detailed definitions of the 
symptoms and signs which are rated as part of the interview. Questions relating to 
each symptom are asked in order to determine both their presence and also their 
degree of severity. In this way a detailed and reliable picture of the clinical illness
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can be established. This can be used alongside other sources of information to make 
clinical ratings which further describe the data.
The literature contains numerous descriptions of different rating scales and 
categorical approaches which can be used to measure various aspects of the clinical 
phenotype in patients with severe psychiatric illness. For example, the Operational 
Criteria (OPCRIT) (McGuffin et al. 1991), a symptom checklist designed to be used 
along with a computer program to generate diagnoses; the Bipolar Affective Disorder 
Dimension Scales (BADDS) (Craddock et al. 2004a) and the Global Assessment 
Scale (GAS) (Endicott et al. 1976) -  these are all described in detail in Chapter 2. 
The value of such measures can be defined in terms of their reliability and validity 
(reviewed in Farmer et al. 2002).
Reliability analyses can be used to test the consistency of the measure. A 
measure which has good reliability will result in the same outcome/rating when used 
under the same circumstances. There are several ways to test reliability. Inter-rater 
reliability can be tested when two or more individuals examine the same information 
and make ratings on the measure independently. The degree of agreement between 
the two can be assessed. Other types of reliability include test-retest reliability, in 
which the same measure is used on the same information at two different time points; 
and intra-rater reliability in which the same measure is used on the same information 
by the same individual at two different time points -  the consistency of the ratings can 
subsequently be assessed.
It is essential that measures selected for use in research show high levels of 
reliability. Unreliable measures will introduce varying degrees of random variation 
which are likely to make it substantially more difficult to detect significant effects.
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In general, a reliable measure will be well-constructed, the instructions for 
their application must be explicit, and there needs to be clear guidance regarding the 
differences between ratings (Wittenbom, 1972, cited in Farmer et al. 2002). Although 
there is no absolute cut-off point above which reliability is considered acceptable, it is 
generally accepted that to be considered reliable a measure should produce a 
reliability coefficient of about 0.8.
There are a number of statistical tests which can be used to assess reliability; 
the nature of the data determines the test used. For example, Cohen’s Kappa is often 
used to report inter-rater reliability statistics for dichotomous variables. The test is 
thought to be more useful than simply reporting percentage-agreement, because it also 
takes into account agreement that is likely to occur by chance (Cohen 1960).
For continuous data, intra-class correlations can be used to measure the level 
of agreement for a particular variable between two members within a group (e.g. two 
siblings within a larger family-based sample). In this method, the mean and standard 
deviation of the measure are calculated from the pooled data, across all members of 
the group. The intra-class correlation gives the proportion of variance that is 
attributable to between-group differences (Hinton 2004).
Validity refers to whether or not the measure succeeds in assessing the 
psychopathological construct it intends to. A number of terms are used to describe 
the different aspects of validity, such as face validity (does the measure appear to 
assess the construct of interest?), content validity (does the measure provide good 
coverage of the relevant domain(s)?), predictive validity (does the measure agree with 
a “gold standard” of accuracy?) and construct validity (does the measure correlate 
with external validators?).
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For a test to be valid it must be reliable. However, it is possible for a test to be 
reliable but not valid, for example even though a measure gives consistent ratings, 
these ratings may not be measuring the target variable. In psychiatric research, some 
evidence for construct validity of a measure is suggested by the aggregation of scores 
on the measure within families, as this suggests that the measure may relate to 
underlying biological variability.
Robins & Guze (1970) proposed five criteria which, if fulfilled, indicate 
validity: clear and consistent clinical features; uniform aetiology or pathogenesis; 
uniform clinical course; increased prevalence in close relatives; an investigatory 
marker of the disorder, such as a laboratory test. Their emphasis on the role of family 
history in validating diagnostic groups is particularly relevant to the focus of this 
thesis, which aims to use clinical measures to identify variables which aggregate 
within families.
1.6 Summary
Emil Kraepelin’s dichotomisation of the functional psychoses into the clinical 
entities today known as schizophrenia and bipolar disorder has had substantial 
influence over the field of psychiatry for over a century, due to the clinical utility and 
reliability of these diagnoses, and their tendency to “breed true” within families.
However, the evidence summarised above suggests that there is no neat 
biological distinction between the two, and that using diagnostic categories alone in 
the selection of cases for use in molecular genetics studies is likely to obscure 
biologically meaningful findings.
Research studies focussing on the discovery of phenotypic variables which 
aggregate within families, and which are therefore more likely to be genetically
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influenced, will facilitate the definition of subgroups of patients more likely to reflect 
underlying genetic homogeneity.
When used in molecular genetic studies, such groups should help facilitate the 
identification of genetic pathways involved in the pathogenesis of these debilitating 
illnesses, and provide clues about the underlying biology which will help researchers 
develop new treatments to act specifically on the known biological pathways involved 
in illness.
This highlights the need for large family-based samples in which the 
phenotype is well characterised. Such samples would enable analyses to be 
performed on a wide-spectrum of phenotypic characteristics, with the aim of 
identifying areas of the phenotype that are familial and therefore more likely to be 
influenced by genetic factors.
1.7 Thesis Aims
The aim of this thesis was to contribute to this area of research by identifying 
clinical items that show familial aggregation in families affected by mood-psychosis 
illness and which may, therefore, be useful as covariates in genetic studies. This was 
achieved by:
1. Developing a set of tools which could be used across the Kraepelinian dichotomy 
in patients with psychotic features and/or affective disturbance. Existing phenotypic 
measures were utilised along with a novel set of measures which were developed 
specifically for this purpose.
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2. Using these measures to make new ratings and investigate the phenotype within a 
sample of patients with Velo-Cardio-Facial Syndrome (VCFS) and within a family- 
sample enriched for schizoaffective disorder.
3. Using these measures to make new ratings within a sample of families enriched for 
bipolar disorder and within an independent sample of families enriched for 
schizophrenia.
4. Combining the samples to form a single large, well-characterised dataset 
comprising cases representing a spectrum of affective and psychotic illness.
5. Performing mixed-effects regression analysis within this dataset to investigate 
which clinical items showed familial aggregation.
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2 General Methods: Detailed Characterisation of the 
Phenotype
As discussed in chapter one, studies have consistently demonstrated clinical 
overlap between schizophrenia and bipolar disorder, the diagnostic categories based 
on Kraepelin’s dichotomisation of the functional psychoses. Despite this, the 
majority of studies into the causes of these debilitating illnesses have been carried out 
under the assumptions of the dichotomy. Previous research has demonstrated that 
using clinical measures alongside diagnostic categories can be useful in refining 
molecular genetic studies. To identify the clinical variables most likely to be useful in 
such studies, analyses can be performed to identify which of these aggregate within 
families, and are therefore more likely to be influenced by genetic factors. The 
identification of such variables was the primary focus of this thesis, and this could not 
be undertaken without first carrying out systematic ratings within the samples of 
interest. This enabled the formation of a large, richly described sample in which 
analyses could be undertaken. The methods involved in this process are discussed 
below.
2.1 Samples
This thesis focussed on three samples of interest: a sample of patients with 
Velo-Cardio-Facial Syndrome (VCFS) and a major psychiatric diagnosis; a sample of 
sibling-pairs enriched for schizoaffective disorder-bipolar type, recently used within a 
genome-wide linkage study by Hamshere et al (2005); a large dataset formed by 
combining the large schizophrenia and bipolar disorder family-based samples,
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recruited within the Department of Psychological Medicine, Cardiff University, as a 
result of ongoing molecular genetic studies. The two former samples are discussed in 
detail in chapters 2 and 5 of this thesis. The schizophrenia and bipolar disorder 
samples used to form the dataset which was used in the primary analyses of this thesis 
(described in chapter 5) are described below.
2.1.1 Description o f  the schizophrenia family sample
The Schizophrenia family sample comprised 196 sibling-pairs from 154 
nuclear-families. It was originally described by Williams et al (1999) as part of a 
two-stage genome scan for schizophrenia susceptibility genes, in a study led by 
Professor Mike Owen and Professor Peter McGuffin. Families were ascertained 
through mental health services and mental health support groups in Wales, England, 
Scotland and Southern Ireland. The sample consisted of 216 males and 111 females, 
all of whom were Caucasian and had been bom in the UK or in the Republic of 
Ireland. Each family was composed of a proband who met DSM-IV (APA 1994) 
criteria for schizophrenia, along with at least one sibling with a DSMIV-diagnosis of 
either schizophrenia or schizoaffective disorder. Where possible information was also 
collected on further affected family members.
Each individual was interviewed using the Schedule for Clinical Assessment 
in Neuropsychiatry (SCAN) (Wing et al. 1990) a semi-structured interview aimed at 
assessing, measuring and classifying psychopathology and behaviour associated with 
psychiatric illness. Each interview was conducted by a member of the Schizophrenia 
Research Team, including trained psychologists (Dr Lisa Jones and Dr Rob Sanders) 
and trained psychiatrists (Dr Alistair Cardno, Dr Marion Gray, Dr Geraldine 
McCarthy and Professor Kieran Murphy). Case notes were reviewed and a vignette 
was compiled from the clinical data available.
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Clinical ratings were also made by the interviewer using several rating scales 
including the Operational Criteria (OPCRIT) (McGuffin et al. 1991), the Scales for 
Assessment of Positive and Negative Symptoms (SAPS/SANS) (Andreasen 1984a, 
1984b) and the Global Assessment Scale (GAS) (Endicott et al. 1976).
During the recruitment process, regular reliability meetings were held in 
which cases were discussed and each case was diagnosed according to best estimate 
procedures (as described in chapter 1).
2.1.2 Description o f  the Bipolar-Disorder Family Sample
The Bipolar-Disorder family sample consisted of 395 sibling-pairs from 286 
nuclear-families, ascertained as part of the Wellcome Trust UK-Irish bipolar affective 
disorder sibling-pair genome screen, in a study led by Professor Nick Craddock and 
Professor Michael Gill (Bennett et al. 2002b; Lambert et al. 2005b). Patients were 
recruited through mental health services, patient support groups and articles in the 
national media. The sample consisted of 402 males and 587 females and all but three 
families were of European Caucasian origin. Again, where possible, information was 
collected on further affected family members.
Each family consisted of a proband who met DSMIV criteria for bipolar I 
disorder (BPI) and at least one sibling with either BPI, schizoaffective disorder -  
bipolar type (SABP), bipolar II disorder (BPII) or bipolar disorder -  not otherwise 
specified (BP-NOS).
Data for each case was collected using similar methods to those used in the 
schizophrenia sample. Each individual was interviewed by a fully trained member of 
the Bipolar Disorder Research Team, again using the SCAN (Wing et al. 1990). Case
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notes were reviewed and a vignette was compiled from the clinical data available. 
Again, regular reliability meetings were held during the recruitment process, and 
diagnoses for each case were agreed upon using the best estimate method (see chapter 
1).
Both the schizophrenia and the bipolar disorder samples were collected prior 
to the commencement of this PhD and have been used extensively within the 
department as part of numerous published molecular genetic studies (Green et al. 
2005a; Green et al. 2006; Williams et al. 2006) and clinical studies (Forty et al. 2008; 
Jones et al. 2005).
Typical data for each case included:
• An interview vignette summarising the information collected as a result of 
interviewing each patient using the SCAN.
• Copies of hospital case-notes or a case-note vignette summarising this 
information.
• Copies of referral letters.
In the majority of cases an Operational Criteria (OPCRIT) symptom checklist 
had been completed (described below), and in the schizophrenia sample ratings had 
been made on the Scale for the Assessment of Positive Symptoms (SAPS) and the 
Scale for the Assessment of Negative Symptoms (SANS).
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2.2 The Creation of a Single Harmonised Dataset
The research described in this thesis aimed to perform analyses across 
traditional diagnostic boundaries, and this could be achieved by combining the 
schizophrenia and bipolar disorder family-based samples, described above. The 
strengths and limitations of this method are discussed in Chapter 5.
However, although similar information was collected for both samples, using 
similar methodologies, it was not possible to simply combine them. Despite the use 
of detailed rating guidelines and the demonstration of acceptable levels of reliability, 
clinical rating scales involve an element of subjectivity. When used by different 
research teams, who may adopt slightly different approaches to the ratings, it is 
possible that systematic differences may occur, superimposed over noise introduced 
as a result of the subjective nature of these ratings.
To ensure that the schizophrenia and bipolar disorder samples were 
compatible, it was important to develop a common set of phenotype measures 
covering a wide range of clinical characteristics which showed variability across 
diagnostic boundaries. These could then be used to rate each case within the samples, 
using identical techniques and well-defined methods. The schizophrenia and bipolar 
disorder samples could then be combined to form a single large harmonised dataset.
2.3 Developing a Common Set of Phenotype Measures
In selecting a set of phenotype measures that could be used across the samples 
there were several factors to be taken into consideration. It was important to cover a 
wide range of clinical variables thus providing a rich description of each case. My
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study built upon the measures that had been used extensively by the Mood Disorders 
Research Team over a period of more than 10 years. A set of detailed rating 
guidelines had been developed, ensuring ease of use and excellent reliability. These 
established tools of measurement used to record clinical details on each case are 
described in Part I below.
2.4 Measuring the Phenotype Part I -  Established Tools of Measurement
For all measures previously used within the team, a set of detailed rating 
guidelines had been developed. These ensured ease of use and excellent reliability.
Prior to rating any cases that would be used in analysis, I undertook a rigorous 
training period. This was particularly important given that I had received no clinical 
training prior to the commencement of this PhD. This issue is discussed further in 
Chapter 5.
Initially my training period involved observing interviews carried out by 
trained members of the research team in order to gain a better understanding of how 
information was collected from participants. During this early stage I also read a 
large number of case notes and interview vignettes from the schizophrenia and bipolar 
disorder samples, in order to increase my knowledge of these illnesses particularly in 
terms of the type and range of symptoms experienced. This also gave me the 
opportunity to learn about symptom definitions and classifications.
The second stage of my training period involved rating a large number of 
cases (approximately 150) on these established measures and discussing these in 
detail with experienced members of the research team. I also attended regular
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meetings in which a case that had been rated independently by members of the 
research team was discussed in detail, and consensus ratings were agreed upon for 
each measure. Attending these meetings during the year prior to the rating of these 
large datasets enabled me to develop a level of expertise.
Ratings were made on more than 200 clinical variables for each case 
contributing to the large harmonised dataset. Previously described rating-scales used 
as part of this thesis are described below. A full list of these along with the additional 
variables recorded for each case can be found in Appendix A.
2.5 Rating Scales Used
2.5.1 The Global Assessment Scale
The Global Assessment Scale (Endicott et al. 1976) was developed to measure 
the overall severity of psychiatric disturbance over a specific time period (usually the 
week prior to evaluation). The GAS was based on the Health-Sickness Rating Scale, 
originally developed by Luborksy in 1971, and sought to improve it by adding further 
anchor points which described more behaviourally-orientated systems, and by 
abolishing the diagnostic constraints described in the original scale.
The GAS is a 1-100 scale ranging from severe impairment to superior 
functioning. A score of 1 would be given to the hypothetically sickest individual 
whilst a score of 100 would be used to describe the hypothetically healthiest (see 
Appendix B).
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The scale consists of ten clearly defined anchor points (1-10, 11-20, 
etc). A rating is made by selecting the lowest interval at which an individual’s 
functioning can be described during the time-period specified. The rater must then 
decide where this individual lies within this range, by considering the descriptions of 
the intervals below and above that selected, and deciding whether one description 
describes their level of impairment more closely than the other.
The authors report good levels of inter-rater reliability, with intra-class 
correlation coefficients ranging from 0.69 to 0.91 and standard error measurements of 
between 5 and 6.
Since it was derived the GAS has been used extensively in research. Pillmann 
& Mameros (2005) carried out a study comparing the long-term course of individuals 
with acute and transient psychotic disorders and a control group of individuals with 
positive schizophrenia, using the GAS to measure level of functioning at three time- 
points, covering a period of seven years following the index episode. They found a 
significant difference between the GAS scores of the two groups at the third follow 
up; scores in the positive schizophrenia sample significantly decreased, whereas 
scores in the acute and transient psychotic group remained unchanged.
The GAS is also frequently used to assess treatment efficacy. For example, 
using GAS scores to measure level of functioning, Temple & Ho (2005) used the 
GAS to compare the level of functioning in schizophrenic patients who had received 
cognitive therapy for persistent psychosis, with a “treatment-as-usual” group, who had 
received no such therapy. They found significantly greater improvement in patients 
receiving the cognitive therapy as an adjunct to their regular treatment.
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In the current research, the GAS was used to record the lowest level of 
functioning during the following periods: i) during the most severe episode of mania, 
ii) during the most severe episode of depression, iii) during the most severe psychotic 
episode, iv) during the most severe post-natal episode, v) during the most severe non- 
post-natal episode, vi) during the most severe episode overall, vii) during the week 
prior to interview. A score of 1-100 was assigned to each period, where applicable. 
In the vast majority of cases, only a subset of the above periods were rated, the 
remainder being recorded as either “Unknown” (where there was insufficient 
information to make a confident rating) or “Not Applicable” (where an individual had 
not experienced the state being rated).
2.5.2 Operational Criteria
The Operational Criteria (OPCRIT) were originally designed by McGuffin et 
al. (1991) as a diagnostic system consisting of a checklist of items of psychopathology 
and background information (defined by a brief glossary, see Appendix C) along with 
a suite of computer programs able to use this data to generate diagnoses according to 
multiple diagnostic systems (e.g. ICD-10, RDC).
The original paper reported good reliability in general with the majority of 
kappa scores ranging from 0.4-1.0 for items of psychopathology rated, and ranging 
from 0.57-0.87 for diagnoses generated. Craddock et al (1996) utilised the OPCRIT 
on a sample of 100 cases -  50 individuals from families enriched for bipolar disorder 
and 50 from families enriched for schizophrenia. They compared the diagnoses 
generated via the OPCRIT system with those made according to lifetime best-estimate 
consensus procedures (described in chapter 1). Good to excellent agreement between
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the two different methods was generated, with Cohen’s kappa statistics ranging from
0.67-0.97, providing support for the validity of the scale on samples of patients with 
bipolar and schizophrenic illness.
As well as using symptomatic data to produce multiple diagnoses, many 
studies have used OPCRIT simply to record the presence or absence of specific items 
of psychopathology during periods of illness. For example, Schulze et al (2005) 
carried out genotype-phenotype analysis looking at association between the 
DAOA/G30 locus (previously implicated in both schizophrenia and bipolar disorder) 
and psychotic features in a sample of bipolar affective disorder patients. They 
collected information on 21 psychotic symptoms using the OPCRIT checklist and 
performed logistic regression analysis, entering these symptoms into the model as 
explanatory variables. This analysis identified “lifetime history of persecutory 
delusions” as the only significant explanatory variable for the DAOA/G30 risk 
genotype, suggesting that bipolar disorder with persecutory delusions may be a 
distinct subgroup of bipolar disorder which overlaps with schizophrenia.
One limitation of the OPCRIT symptom definitions is that they are not 
independent of diagnostic concepts -  the traditional assumptions regarding the 
dichotomisation of the affective disorders and schizophrenia are enshrined within the 
rating guidelines (as discussed by Craddock et al. 2007). For example, symptoms 
typically associated with affective disorder (such as anhedonia, irritability, impaired 
concentration, psychomotor retardation/agitation) are only rated if they are 
experienced within the context of an episode of disturbed mood. This meant that if, 
during a psychotic episode, an individual experienced several symptoms indicative of 
mood disturbance, but not enough to constitute an episode, these symptoms would not
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have been recorded. Similarly, certain features rated in the Psychosis section of 
OPCRIT, would only have been rated positively if they occurred outside of a mood 
episode, due to assumptions made about the underlying causes. For example, “speech 
difficult to understand” and “inappropriate affect” would not have been rated 
positively if they occurred within the context of a manic episode as it was assumed 
that the underlying mechanisms involved in the manifestation of these symptoms 
during mania were different than those involved when mood was considered 
euthymic.
The aim of the current research was to examine the phenotype without being 
constrained by such assumptions. Therefore, as well as recording symptoms which 
occurred during affective episodes, I also completed “context-independent” ratings,
i.e. if a symptom described met the OPCRIT glossary-defined definition, it was 
recorded independently of whether or not it was experienced during an episode of 
mania, depression, or euthymia. So, for example, if an individual was dysphoric 
during a psychotic episode but did not meet the criteria for a depressive episode, 
whereas in the past this symptom would have been ignored, using this method it was 
recorded as present, therefore providing a richer description of the phenotype.
2.5.3 Bipolar Affective Disorder Dimension Scales
Inspired by the limitations of diagnostic categories in defining illness, the 
Bipolar Affective Disorder Dimension Scales (BADDS) (Craddock et al. 2004b) use a 
dimensional approach to provide a rich description of psychopathology in the 
functional psychoses.
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These scales were developed by the research teams in the Department of 
Psychological Medicine in Cardiff University and the Department of Psychiatry in the 
University of Birmingham, as part of the ongoing collaboration between these two 
centres. Although published in 2004, these scales had been extensively used within 
the research teams for over 5 years prior to their publication.
The BADDS comprise four 0-100 scales which pick up on the lifetime-ever 
occurrence of mood disturbance, psychosis, and the relationship between psychotic 
symptoms and mood (see Appendix D). The dimensions are defined as follows:
BADDS Mania (BADDSM) -  Rated according to the presence, severity and 
frequency of manic symptoms or episodes ranging from no evidence of mania to 
many incapacitating episodes.
BADDS Depression (BADDSD) -  Rated according to the presence, severity 
and frequency of depressive symptoms or episodes, ranging from no evidence of 
depression to many incapacitating episodes.
BADDS Psychosis (BADDSP) -  Rated according to the presence and 
predominance of psychotic disturbance throughout the illness, ranging from no 
psychotic or near-psychotic features, through to prominent psychotic symptoms 
present throughout the illness.
BADDS Incongruence (BADDSI) -  Defines the relationship between psychotic 
and affective disturbance and is only rated in individuals who have experienced 
psychosis at some point during the illness. The bottom of the scale reflects an illness 
in which psychotic symptoms have been experienced only in the context of an 
affective-episode and are completely congruent with mood state (for example,
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delusions of grandiosity in the context of mania); scores at the top of the scale reflect 
an illness characterised by prominent psychotic symptoms which occur chronically 
outside, or in the absence of, mood disturbance.
Each scale is rated according to a set of clearly defined anchor-points which 
enable excellent inter-rater reliability. Craddock et al (2004b) report mean 
agreements of between 0.86 (for the Psychosis dimension) and 0.96 (for the mania 
dimension). Further, on a sample of “diagnostically challenging” cases, they report 
intra-class correlations of 0.91 for the mania dimension, 0.80 for the depression 
dimension, 0.96 for the psychosis dimension and 0.78 for the incongruence 
dimension.
The BADDS have been used widely both within the department and externally 
and have been important in a number of studies which provide further support for the 
advantages of using a richer description of lifetime psychopathology in both 
molecular genetic studies and studies of familiality. For example, in their study 
investigating the role of Neuregulin 1 (NRG1), traditionally considered to be a 
schizophrenia susceptibility gene, in bipolar disorder Green et al (2005b) found a 
greater effect in the bipolar cases with predominantly mood-incongruent psychotic 
features and in the schizophrenia cases with mania (both measured using BADDS), 
than in either the full schizophrenia family sample or the full bipolar disorder sample. 
This suggested that NRG1 may exert a specific effect on a subset of functional 
psychosis which includes features of mania and mood-incongruent psychosis.
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2.6 Measuring the Phenotype Part II -  Developing new ways in which to 
measure the phenotype in the functional psychoses.
A primary aim of this thesis was to make optimal use of the vast amount of 
information available in the family-samples described above, with the intention of 
identifying features of illness that cluster within families. Established tools of 
measurement, such as those described above, provide a useful way of describing the 
phenotype, reflecting the high degree of heterogeneity which occurs within diagnostic 
categories. The value of including this extra information in analysis is supported by a 
growing body of research, as discussed in chapter 1.
During my training period I rated a large number of cases using the 
established measures described above (approximately N=200). During this time it 
became apparent that there were several features of illness which occurred commonly 
within the samples but were not picked up on by the rating scales and measures 
already in use. I therefore became involved in designing a new set of measures, 
known as the Extended Rating Scales, developed to pick up on this extra detail.
2.7 Designing the Extended Rating Scales
These scales were developed as a result of an interactive and iterative process 
involving myself and Professor Nick Craddock. Scale definitions were agreed upon 
after detailed discussion. We focussed on clinical features of illness that varied across 
samples involving mood disturbance and/or psychotic features, appeared to be 
potentially important in distinguishing between cases, and were not picked up on 
adequately by established measures.
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After scale definitions had been agreed upon, I developed an initial draft of the 
new scales. Scales were each discussed during regular meetings between myself and 
Professor Craddock. Drafts were refined according to issues arising from these 
discussions. When a detailed first complete-draft of the scales was complete, it was 
distributed amongst members of the Mood Disorders Research Team for comment, 
along with several practise vignettes which were rated and subsequently discussed in 
several Joint Field Team Meetings. Modifications were subsequently made to 
improve reliability and ease of utility. This work resulted in 9 new clinical rating 
scales, summarised below. Full rating guidelines for each scale can be found in 
Appendix E.
2.7.1 Extended Rating Scale 1: Predominance o f manic episodes
Score on ERS1 =
Total no. manic episodes
Total no. episodes affective 
disturbance
50% Depression 
50% Mania
100% Depression OR 100% Mixed 0% Depression
0% Mania 100% Mania
Figure 2-1: Summary of rating guidelines for ERS1: predominance of mixed affective episodes
The aim of Extended Rating Scale 1 (ERS1) was to measure the proportion of 
high mood relative to the total mood disturbance over the lifetime course of the 
illness. ERS1 is a 0-100 scale, with a score of “100” indicating a clinical picture in 
which affective disturbance was characterised entirely by mania, without the 
occurrence of mixed or depressive episodes. Conversely, a score of “0” indicates that
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no manic episodes have occurred and that the occurrence of affective disturbance is 
entirely mixed or depressive in nature. If an individual has experienced no affective 
episodes, they should not be scored on ERS1.
As demonstrated in Figure 2-1, an individual’s score on ERS1 is calculated by 
dividing the total number of manic episodes experienced over the entire duration of 
illness, by the total number of affective episodes (manic and depressive in nature) 
experienced over the lifetime duration, and multiplying this value by 100. Mixed 
episodes were treated differently according to whether they were predominantly 
manic in nature, e.g. dysphoric mania (in which case 0.75 was added to the total 
number of manic episodes and 0.25 to the total number of depressive episodes), 
predominantly depressive in nature (0.25 was added to the total number of manic 
episodes and 0.75 to the total number of depressive episodes), or comprised a roughly 
balanced mixture of depressive and manic symptoms (0.5 was added to each total). 
The scale therefore gave a measure of to what extent the affective element of the 
illness was characterised by high mood.
One limitation of this measure is the fact that it relies on the detailed
documentation of each episode of illness. Because individuals are less likely to seek
treatment during milder episodes of illness, these are less likely to be recorded in 
case-notes. Mild episodes of depression in particular are at risk of being excluded 
from the calculation. However, in general participants were asked in detail about the 
number and nature of episodes of mood disturbance they had experienced over the
lifetime course of their illness at interview (see Chapter 6).
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This scale was developed under the hypothesis that variation in the 
predominance of high mood relative to depressed mood corresponds with underlying 
genetic variation.
2.7.2 Extended Rating Scale 2: Relationshiv between psychotic and affective
features
Score Rating Criteria
-20 Episodes of clinically significant mood disturbance. No psychotic or near psychotic features occur
-19 Illness is predominantly affective but includes near psychotic features - occasional at low end of range, frequent at high end of range
0 Psychotic symptoms occur only during affective episodes and are entirely mood-congruent
20 Psychotic symptoms occur only during affective episodes. There is an approx. balance between congruent and incongruent symptoms
40 Psychotic symptoms occur only during affective episodes and are entirely mood-incongruent
43/47 Psychotic symptoms occur only during affective episodes and include one or more first rank symptoms
50 Psychotic symptoms are probably present outside of an episode of mood-disturbance
60 Psychotic symptoms are definitely present in the absence of an affective episode on at least one occasion
SO Psychotic symptoms are definitely present in the absence of an affective episode on many occasions
100 Psychotic symptoms dominate illness and occur chronically outside affective episodes. Affective episodes occur but are not a major feature of illness.
110 Psychotic symptoms dominate illness. Affective symptoms occur which do not meet criteria for an episode of mood-disturbance.
120 Illness is characterised by psychotic features in the absence of any disturbance in mood.
Table 2-1: Summary of rating guidelines for ERS2, which measures the relationship between 
affective and psychotic symptoms over the lifetime course of the illness.
As an extended version of the BADDS Incongruence dimension (BADDSI, 
see above), Extended Rating Scale 2 (ERS2) measures the relationship between 
affective and psychotic symptoms over the lifetime course of the illness. The 
BADDS Incongruence Dimension is a 0-100 scale, which can be used on any 
individual who has experienced psychotic symptoms, with or without symptoms or 
episodes of affective disturbance. A score of “0” on the BADDSI dimension indicates 
that, psychotic symptoms have occurred only during affective episodes, did not
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include “first rank” symptoms (Schneider 1959)(see chapter 1) and were entirely 
congruent with the affective state in which they were experienced (such as grandiose 
delusions in the context of mania). A score of 100 indicates that psychotic features 
have dominated the clinical features and have occurred chronically outside of, or in 
the absence of, any episodes of affective disturbance. Ratings on the BADDSI 
dimension can therefore be used only on individuals who have experienced clear-cut 
psychotic symptoms, and it does not differentiate between those who have a 
predominantly psychotic illness but have also experienced minor symptoms of mood 
disturbance and those who have not experienced any symptoms indicative of mood 
disturbance.
ERS2 therefore extends the bottom end of the scale from “0” to “-20” - which 
can be used to describe an illness characterised entirely by episodes of mood 
disturbance, with no psychotic or near psychotic features. Scores between -19 and -2 
can be used to indicate the increasing frequency of near-psychotic features (as defined 
by DSMIV, which includes features such as odd beliefs, magical thinking that 
influences behaviour and is inconsistent with sub-cultural norms, unusual perceptual 
experiences, suspiciousness or paranoid ideation, etc). At the opposite extreme, the 
top end of the scale has been extended from “100” to “120”, with scores between 101 
and 120 indicating increasing confidence that no symptoms indicative of mood 
disturbance have been experienced during the lifetime course of the illness.
Scores within the range 0-100 remain identical to those in the BADDS 
Incongruence dimension, with intermediate scores increasing firstly with the 
increasing incongruence of psychotic features, and then with the simultaneous
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decreasing prominence of affective features and increasing prominence of psychotic 
features.
ERS2 was developed under the hypothesis that variability in the predominance 
of psychotic and affective features, and the relationship between these two symptom 
domains reflects underlying genetic variability.
2.7.3 Extended Rating Scale 3: Fluctuations in mood.
Score Rating Criteria
100 Fluctuations in mood occur over 1 day
90 Fluctuations in mood occur over 4 days
80 Fluctuations in mood occur over 1 week
70 Fluctuations in mood occur over 10 days
60 Fluctuations in mood occur over 2 weeks
50 Fluctuations in mood occur over 4 weeks
40 Fluctuations in mood occur over 8 weeks
30 Fluctuations in mood occur over 12 weeks
20 Fluctuations in mood occur over 26 weeks
10 Fluctuations in mood occur over 52 weeks
0 No fluctuations in mood occur
Table 2-2: Summary of rating guidelines for ERS3 which measures the rapidity of mood
The aim of Extended Rating Scale 3 (ERS3) was to indicate the presence and 
rapidity of mood fluctuations within periods of affective disturbance. Scores on 
ERS3 were calculated by measuring the shortest time-period over which a fluctuation 
had occurred. In the case of ERS3, “fluctuation” refers to an acute phase of illness in 
which at least two switches in mood polarity (e.g. from depression to mania to 
depression, or vice versa) have occurred, with fewer than 8 weeks separating 
episodes. Ratings are then assigned according to the guidelines summarised in Table 
2 .2 .
For example, Figure 2.2 below illustrates an illness in which an individual has 
experienced a manic episode, followed by an episode of major depression, which has
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then switched to hypomania, before more minor depressed mood is experienced. In 
this example, the shortest period of time over which mood has fluctuated from one 
state, to another, and then back again is 2 weeks; this would be assigned a score of 
“60” on ERS3.
Mania
Hypomania
Euthymia
Minor depression
Major depression
♦■Time (w eek s)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Indicates shortest time period 
between switches in polarity
Figure 2-2: Example to demonstrate how fluctuations in mood are measured using ERS3.
To be considered when calculating an individual’s score on this scale, the 
episode of mood disturbance must meet the DSMIV criteria for a manic, mixed or 
depressive episode.
ERS3 was developed under the hypothesis that variability in the occurrence 
and rapidity of fluctuating mood represents underlying genetic variability.
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2.7.4 Extended Rating Scale 4: Instability o f  clinical state
Score Rating Criteria(refers to most variable month o f illness)
100 Clinical state varies significantly during a period o f 10 mins
80 Clinical state varies significantly during a period o f 1 day
60 Clinical state varies significantly during a period o f 1 week
40 Clinical state varies significantly during a period o f 2 weeks
20 Clinical state varies significantly during a period o f  4 weeks
0 No variability in clinical state
Table 2-3: Summary of guidelines used to rate ERS4 which measures clinical instability within 
the functional psychoses.
Extended Rating Scale 4 (ERS4) was developed as a result of issues arising 
from the pilot-work undertaken using ERS3. It was common for fluctuations in 
clinical state to be mentioned in the case notes with no further detail. This meant it 
was impossible to say with any certainty whether fluctuations occurred between 
clinically significant episodes of mood (required to rate ERS3), or between milder 
affective states, different clinical presentations within an episode (e.g. periods of high 
energy and activity to periods of slowed activity and lethargy), or even between 
euthymia and periods of illness.
ERS4 therefore looks at “clinical instability” which refers to substantial 
changes in the psychopathological state and includes the domains of mood (both 
episodes of mood and more subtle fluctuations), perception, cognition and behaviour. 
Each individual is scored from 0-100 and scores are based on the most variable month 
of illness recorded. As presented in Table 2-3, a score of 0 would indicate that no 
clinical instability has occurred; a score of 100 suggests that clinical state varies 
significantly over a period of ten minutes or less.
Anchor points were also specified for ERS4, to deal with cases in which 
instability was referred to without specific reference either to the time period over
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which variations occurred, or to the nature of the fluctuations in clinical state. For 
example, references to “lability” were commonly found in the notes, without further 
detail. These were given a score of 90*. References to for example, “fluctuating 
mood” or “mood up and down” were given a score of 80*. In both cases, a “*” was 
used to indicate that an anchor point had been used thus differentiating these scores 
from those made using more detailed clinical information.
ERS4 was developed under the hypothesis that the occurrence of, and 
variation in clinical instability reflects underlying genetic variation.
2.7.5 Extended Ratins Scale 5: Periodicity o f acute phases o f  illness
Score Rating Criteria
100 5 acute phases of illness in 1 year
90 2 acute phases of illness in 1 year
70 2 acute phases of illness in 2 years
50 2 acute phases of illness in 5 years
30 2 acute phases of illness in 8 years
20 2 acute phases of illness in 10 years
10 2 acute phases of illness in 50 years
1 2 acute phases of illness in 50 years
0 Only 1 acute phase of illness
Table 2-4: Summary of rating guidelines for ERS5, which measures periodicity of acute phases of 
illness.
Extended Rating Scale 5 (ERS5) measures the tendency to recurrence of acute 
phases of illness during the lifetime course. “Acute phase of illness” was used as 
opposed to “episode of illness” due to the potential confusion caused by differences in 
the way the term “episode” may be interpreted. For example, if an individual had an 
episode of depression, immediately followed by an episode of mania, some would 
consider this to be a single episode of illness, as there was no recovery before the 
switch in mood polarity, whereas others would consider it to be two episodes of
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illness, as both a manic and a depressive episode occurred within this time. “Acute 
phase of illness” therefore refers to a continuous period of time during which an 
individual has functional impairment (which is in contrast to their usual level of 
functioning). A period of at least 8 weeks of normal functioning was required to 
distinguish between these acute phases.
ERS5 is, again, a 0-100 scale, with 0 indicating “only one acute phase of 
illness” and a maximum of 100 indicating “5 acute phases of illness in one year”. 
Scores between these extremes increase with increasing frequency of episodes within 
a shorter period of time, as demonstrated in Table 2.4.
ERS5 was developed under the hypothesis that variability in the frequency 
with which acute phases of illness occur, reflects underlying genetic variability.
2.7.6 Extended Rating Scale 6: Predominance o f a mixed affective state.
S c o r e  o n  E R S 6
T ota l no . m ixed  e p i s o d e s
T o ta l no . e p i s o d e s  a ffec tiv e  
d is tu rb a n c e
50%  m ixed
0% m ixed 50% m a n ic /d e p re s s iv e 100%  m ixed
100%  m a n ic /d e p re s s iv e 0% m a n ic /d e p re s s iv e
Figure 2-3: Summary of rating guidelines for ERS6, which measure the predominance of a mixed 
affective state.
In the same way that ERS1 measures the proportion of manic episodes to 
depressive episodes during the illness course, Extended Rating Scale 6 (ERS6) was 
developed to measure the proportion of mixed episodes over the lifetime course of
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illness. As demonstrated in Figure 2.3, an individual’s score on this scale is 
calculated by dividing the total number of mixed episodes (as defined by DSMIV) by 
the total number of episodes of mood disturbance overall, and then multiplying this 
value by 100. As the proportion of mixed episodes increases, so too does the score on 
ERS6 with a maximum score of 100 indicating that the individual has only 
experienced mixed affective episodes, with no episodes of mania or depression.
This scale was developed under the hypothesis that variation in the 
predominance of a mixed affective state over the lifetime course of illness reflects 
underlying genetic variability.
2.7.7 Extended Rating Scale 7: A measure o f  dvsvhoric mania
Score Rating Criteria
100 Mania with 6 depressive items according to DSMIV
90 Mania with 5 depressive items according to DSMIV
80 Mania with 4 depressive items according to DSMIV
70 Mania with 3 depressive items according to DSMIV
60 Mania with 2 depressive items according to DSMIV
50 Mania with 1 depressive items according to DSMIV
40 Mania characterised by irritable mood and no elated mood
30 Mania with predominantly irritable mood and some elated mood
20 Mania with a rough balance o f irritable and elated mood
10 Mania with predominantly elated mood and some irritable mood
0 Mania with elevated mood and no irritability or dysphoric features
Table 2-5: Summary of rating guidelines for ERS7, which gives a measure of the most dysphoric 
episode of mania experienced over the lifetime course of illness
Extended Rating Scale 7 (ERS7) was developed to give an indication of the 
extent of irritable or depressive symptoms in the most dysphoric manic episode 
experienced by the participant. Scores on this scale would only be made for 
individuals who have had at least one manic (or mixed) episode. As demonstrated in 
Table 2.5, a score of 0 indicates that any manic episodes experienced were 
characterised entirely by elevated mood, with no signs of irritability or depressive
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symptomatology. An assumption made by the design of this scale, is that irritability 
within a manic episode is related to dysphoric mania, therefore scores increase firstly 
with the balance of elated to irritable mood and then with the increasing number of 
depressive symptoms experienced during this episode. A score of 100 indicates an 
episode of mania with at least 6 depressive items according to DSMIV.
ERS7 was developed under the hypothesis that variation in the extent to which 
manic episodes are dysphoric in nature is reflective of underlying genetic variability.
2.7.8 Extended Rating Scale 8: Extent to which illness reflects “prototypical 
schizophrenia ” vs. “prototypical affective disorder ”.
B alance of
p ro to typ ical
s c h izo p h ren ic  and
0 affective fea tu re s 1 0 0
Pro to typ ical 5 0 P ro to typ ical
affective d iso rd e r sch izo p h ren ia
Figure 2-4: Summary of rating guidelines for ERS8, which measures the extent to which the 
lifetime illness reflects prototypical schizophrenia vs. prototypical affective disorder.
Unlike the other novel scales described here, Extended Rating Scale 8 (ERS8) 
specifies no anchor points and is based entirely on the rater’s judgement. The rater 
must use all the information available for each case to assess how “schizophrenic” or 
“affective” they judge the illness to be. As demonstrated in Figure 2.4, a score of 0 
would indicate that the rater considers this illness to be totally characteristic of pure 
affective illness (bipolar disorder or depressive disorder) with no symptoms indicative 
or suggestive of their perception of prototypical schizophrenic illness. A score of 100 
would indicate that the rater considers the illness to be characteristic of prototypical
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schizophrenia. Scores between these two extremes increase as the illness goes from 
being considered prototypical ly affective in nature, to being increasingly 
“schizophrenic”.
Prototypical affective disorder in this scale is considered to be an episodic 
illness characterised by one or more manic or depressive episodes with a remitting 
course and no evidence of psychotic or near psychotic symptoms. Prototypical 
schizophrenia is defined as a chronic illness characterised by an insidious onset, 
positive and negative symptoms, and no evidence of mood disturbance. Other than 
the definitions of these two extremes, raters are given no guidelines as to how to rate 
intermediate forms of illness, but must make a judgement as to what point on the scale 
they feel an individual would be best represented.
This scale was developed under the hypothesis that variability in the extent to 
which an illness is considered to be characteristic of the prototypical forms of the 
diagnostic categories, which are based on Kraepelin’s original dichotomisation of the 
functional psychoses, is associated with underlying genetic variability.
2.7.9 Extended Rating Scale 9: Predominance o f a chronic defect state.
0
B alance o f reversib le  
a c u te  sy m p to m s and  
nega tive  sy m p to m s
1 0 0
Illness c h a ra c te r ise d  
by a c u te  rev e rsib le  
sy m p to m s
5 0 Illness c h a ra c te r ise d  
by ch ro n ic  d e fe c t 
s ta te
Figure 2-5: Summary of rating guidelines for ERS9, which measures the predominance of a 
chronic defect state over the lifetime course of illness.
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The aim of Extended Rating Scale 9 (ERS9) was to give an indication of 
whether positive or negative features predominate the clinical picture. In this scale, a 
“chronic defect state” refers to negative, non-reversible symptoms such as affective 
flattening, alogia, anhedonia, etc. As demonstrated in Figure 2.5, a score of 0 would 
be used to indicate an individual with an illness characterised by acute, reversible 
symptoms, including positive symptoms such as affective symptoms, psychotic 
symptoms, bizarre behaviour and formal thought disorder.
At the extreme end of this scale, a score of 100 would reflect a case in which a 
chronic defect state persisted throughout the lifetime course of the illness, with no 
occurrence of positive features such as mood disturbance or psychotic symptoms. It 
was as a result of such a case that this scale was developed. During my training 
period I encountered a case characterised purely by chronic negative symptoms. 
Despite the debilitating nature of the illness, because no positive symptoms had been 
encountered, few positive ratings could be made on existing measures, and there was 
no way to indicate the nature of the illness. This scale both allows the nature of the 
illness to be recorded, and picks up on the predominance of negative symptoms over 
the lifetime course of the illness.
It should be noted that a well-known method for measuring negative 
symptoms has already been described; the Scales for the Assessment of Negative 
Symptoms (SANS) (Andreasen 1984a). These allow the rater to record the 
occurrence and severity of negative symptoms, on a scale of 0 (not present) to 5 
(severe), under five major headings: i. Affective flattening or blunting; ii. Alogia; iii. 
Avolition-apathy; iv. Anhedonia-asociality; v. Attention. The SANS were designed 
to measure negative symptomatology at a specific time-point, usually when
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examining the patient, and is therefore difficult to rate in the samples used in this 
thesis. ERS9 on the other hand is designed to be used on previously-collected cases, 
providing that they are richly described, and gives an overall measure of negative 
symptoms experienced over the life-time course of the illness.
In this way ERS 9 can also be used to identify individuals with the deficit 
syndrome of schizophrenia (e.g. Carpenter et al, 1988). This describes a group of 
patients who have clinically significant negative symptoms that have persisted for at 
least 12 months during periods of clinical stability and which are not secondary to 
factors (e.g. drug-effects, anxiety, mental-retardation) other than the disease process. 
Individuals with the deficit syndrome would score at the top end of this scale and in 
this way could be differentiated from individuals without the syndrome.
ERS9 was developed under the hypothesis that variation in the extent to which 
an illness is characterised by positive vs. negative symptoms reflects underlying 
genetic variability.
Extended Rating Scales 10 and 11
Unlike the Extended Rating Scales 1 to 9, Extended Rating Scales 10 and 11 
were developed prior to the commencement of this PhD by Dr George Kirov in the 
Department of Psychological Medicine, Cardiff University. These scales were 
included within the Extended Rating Scales as they measured symptom dimensions 
which varied both within and across samples and it was hypothesised that they may be 
useful in distinguishing between cases. These scales are described below.
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2.7.10 Extended Ratine Scale 10: Catatonic Svmvtoms
Symptom
Waxy flexibility
Stupor (clear description of catatonic stupor = 2 points)
One point is awarded for the 
presence of any of the followingPhysiological pillow
Excessive purposeless over-activity symptoms (unless otherwise 
stated) up to a maximum of 4 
pointsMannerisms
Grimacing
Echolalia, echopraxia, automatic obedience
Negativism (clear description needed)
Figure 2-6: Summary of rating guidelines for ERS10, which gives a measure of catatonic 
symptoms, experienced over the lifetime course of illness.
Extended Rating Scale 10 (ERS 10) measures the occurrence of catatonic 
symptoms experienced over the life-time course of the illness, on a 5-point scale from 
0-4, as demonstrated in Figure 2-6 above. It was measured in two ways, firstly 
excluding symptoms that were “explicable by affective change”, and secondly on a 
context-independent basis, which included symptoms experienced within affective 
disturbance, provided they were adequately described by the symptom definitions of 
ERS 10. For example, within the context of a manic episode, “excessive activity” 
would not be scored on this scale unless it was excessive, purposeless, and 
sufficiently extreme for the rater to differentiate it from the conventional descriptions 
of over-activity described in mania. This is discussed further in chapter 5.
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2.7.11 Extended Ratine Scale 11: Disorganised Behaviour
Symptom
Patient talks him/herself
Laughing for no reason One point is awarded for the
Hoarding rubbish presence of any of the following symptoms up to a 
maximum of 2 pointsOdd, inappropriate behaviour
Acts of senseless violence
Extremely poor personal hygiene
Figure 2-7: Summary of rating guidelines for ERS11, which gives a measure of disorganised 
behaviour, experienced over the lifetime course of illness.
Extended Rating Scale 11 (ERS 11) gave a measure of the occurrence of 
catatonic symptoms experienced over the life-time course of the illness, on a 3-point 
scale from 0-2, as summarised in Figure 2.7 above. Like ERS 10, scores on ERS 11 
were measured in two ways, firstly excluding symptoms that were “explicable by 
affective change”, and secondly on a context-independent basis, in which symptoms 
experienced within episodes of affective disturbance were rated, provided they were 
adequately severe and could be differentiated from typical symptoms of affective 
disturbance on account of the severity or nature of the symptom described. Again, 
this is discussed further in chapter 5.
2.8 Reliability
To test reliability of these scales, a sample of 20 cases was rated by at least 
two members of the research team (including myself and Professor Nick Craddock, 
Dr Danny Smith, Dr James Walters, Ms Liz Forty and Ms Christine Fraser). These 
included cases representing a range of diagnoses, including schizophrenia, 
schizoaffective disorder, bipolar disorder and major depressive disorder. Meetings
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were held in which ratings for each new scale were discussed for each case and 
consensus ratings were reached.
Reliability calculations were performed by comparing my own ratings with the 
consensus agreed on after discussing the case. All 11 scales were shown to have good 
to excellent reliability, with intra-class correlation coefficients ranging from 0.786- 
1.000 as presented in the table below:
Rating Scale
Predominance Mania (ERS1) 
Affective vs. Psychotic Illness (ERS2) 
Fluctuations in Mood (ERS3) 
Instability o f Clinical State (ERS4) 
Periodicity o f Acute Illness Phases (ERS5) 
Predominance Mixed Episodes (ERS6) 
Most Dysphoric Manic Episode (ERS7) 
Prototypical Affective Illness vs. SZP (ERS8) 
Predominance Chronic Defect State (ERS9)
Rating Scale
Catatonic Symptoms (ERS 10) 
Disorganised Behaviour (ERS11)
ICC
0.987
0.979
1.000
0.998
0.941
0.999
0.872
0.853
0.806
[ Cohen’s Kappa
0.955
0.786
Table 2-6: Results of inter-rater reliability analyses performed on the Extended Rating Scales 
(ICC -  Intra-class correlation).
2.8.1 Further novel measures included within the OPCRIT symptom checklist
As well as developing new rating scales, two other items of psychopathology 
were developed as part of my PhD work.
At an early stage of the rating process it became evident that there were certain 
features of illness that occurred relatively frequently in the samples and appeared 
potentially important for distinguishing between cases, but were not captured 
adequately by the current OPCRIT checklist. The two which occurred most
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frequently were increased or inappropriate sexual behaviour and aggressive 
behaviour.
Previously, increased sexual activity was likely to be rated within the 
definition of “Excessive Activity” item in the section of OPCRIT describing manic 
symptoms. Inappropriate sexual behaviour would generally be rated under “Increased 
Sociability”. Although there is an argument for continuing to categorise it in this 
way, related to assumptions made about the origins of the symptom, this method 
meant that an individual who, for example, was over familiar with strangers would 
not be differentiated from someone who engaged in aggressive, non-consensual 
sexual behaviour when ill. I therefore added an additional item to the OPCRIT 
symptom checklist, “28a: Increased sexual activity.” This comprised a 0-2 scale 
which allows the occurrence of the symptom to be recorded and gives an indication of 
severity.
Aggressive behaviour, in its milder form, would generally have been rated 
under irritability in the past. Again, this does not distinguish between people who are 
short-tempered when ill and those who become extremely aggressive and physically 
violent. I therefore added a further measure to the OPCRIT symptom checklist: “54a. 
Aggressive behaviour”. Ratings were made on a four-point scale ranging from 
behaviour perceived as threatening and out of proportion with the circumstances, to 
multiple acts of severe aggression resulting in physical injury to others or police 
involvement.
The main objective in the development of these additional ratings was to 
enable behaviours to be recorded, without making assumptions about their underlying
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causes, or the context in which they were experienced. Rating guidelines can be 
found in Appendix C.
2.9 Summary
This chapter describes a set of clinical measures that were selected and 
developed to measure clinical variability across the traditional diagnostic boundaries 
dictated by Kraepelin’s dichotomisation of the functional psychoses. These measures 
were subsequently implemented on three samples of interest:
1. A large, harmonised dataset comprising families enriched for schizophrenia 
and families enriched for bipolar disorder; the creation and characteristics of this 
sample are described in detail in chapter 5.
2. A sample of patients with Velo-Cardio-Facial Syndrome (VCFS) and a 
major psychiatric disorder, as described in chapter 3.
3. A sub-set of individuals from the large-harmonised dataset comprising 
sibling-pairs enriched for schizoaffective disorder, as described in chapter 4.
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3 Phenotype assessment in a sample of patients with Velo- 
Cardio-Facial Syndrome and a psychiatric disorder
3.1 Introduction
Velo-cardio-facial syndrome (VCFS) is a genetic disorder associated with 
hemizygous interstitial micro-deletions on chromosome 22. It is one of the most 
common genetic disorders with a minimum prevalence of approximately 1 in 5000 
live births (Botto et al. 2003). VCFS is characterised by a range of phenotypic 
characteristics, the most common of which include cleft palate, cardiac defects and 
characteristic facial features, e.g. long face, retruded lower jaw, broad nasal root and 
tip, malar flatness and narrow palpebral fissures (Goldberg et al. 1993). It is also 
associated with speech and language impairments, developmental delays and learning 
disabilities.
The term VCFS was first coined in 1978 by Robert Shprintzen, a speech 
pathologist, who described a familial syndrome associated with cleft palate, 
velopharyngeal incompetence (resulting in hypemasal speech), heart defects, learning 
disabilities and characteristic facial features. The VCFS phenotype was later 
expanded to include over 180 characteristic features (with each patient displaying a 
selection of these).
As the VCFS phenotype expanded, it was noted that there was a symptomatic 
overlap between VCFS and the previously described DiGeorge syndrome (Pinsky and 
Digeorge 1965), known to be associated with deletions at chromosome 22ql 1. It was 
this overlap that prompted Driscoll et al (1992) to carry out molecular genetic tests on 
their sample of VCFS patients, under the hypothesis that VCFS and DiGeorge 
syndrome may share a common pathogenesis. Fourteen out of their sample of fifteen
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patients with VCFS had deletions at chromosome 22qll, supporting the association. 
This finding has since been replicated in numerous studies (Amati et al. 1999).
Strikingly VCFS is also strongly associated with high levels of psychiatric 
disturbance. In 1992 Shprintzen reported that of the approximately 90 VCFS cases 
seen by both himself and his colleagues at the Centre for Craniofacial Disorders, over 
10% had developed psychiatric disorders. When they looked only at those individuals 
aged 16 or above, this rose to nearly 38%. Shprintzen reported that these psychiatric 
disorders most commonly resembled “chronic schizophrenia with paranoid 
delusions”.
Since this time, the psychiatric phenotype associated with VCFS has been the 
focus of much research, although reported findings have varied. The most common 
psychiatric disorder associated with VCFS in the literature is schizophrenia (e.g. 
Bassett et al. 1998; Driscoll et al. 1992; Gothelf et al. 1999; Shprintzen et al. 1992, 
Murphy et al. 1999). However, other studies report high rates of mood disorders. For 
example, a study carried out by Papolos et al (1996) aimed to examine the 
behavioural phenotype of 25 children and adolescents with VCFS, in order to further 
investigate the suggested association between VCFS and schizophrenia. The analysis 
was later expanded to include adults, as findings were not consistent with this 
expected association. Instead, they reported high rates of bipolar-spectrum conditions 
(64% of their sample) including BPI (12%), BPII (40%), Cyclothymia (4%) and 
Schizoaffective Disorder-Manic type (8%). Of these, four (25%) had experienced 
psychotic symptoms (both schizoaffective patients and two BPI patients).
Arnold et al (2001) found that twelve out of their sample of twenty VCFS 
patients (60%) met the Diagnostic and Statistical Manual of Mental Disorders IV 
(DSMIV) criteria for a psychiatric disorder. Of these, eight (67%) had mood
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disorders (dysthymia and major depressive disorder). Although no true psychotic 
symptoms were reported, three also had schizotypal traits.
One potential explanation for these disparate results is the age differences in 
ascertainment groups used in the various studies. It is of note that the two studies 
mentioned above, which report high rates of mood disturbance and not schizophrenia, 
have studied samples largely consisting of children and adolescents. The age-range of 
the sample collected by Papolos et al was 5 to 34 with a mean age of 15.6 years. In 
the sample collected by Arnold and colleagues, age at ascertainment ranged from 6 to 
20, with a mean age of 11 years.
In contrast, studies reporting high rates of schizophrenia generally used 
samples drawn from adult populations (Murphy et al. 1999 - mean age 34 years); 
(Gothelf et al. 1999 - mean age 26.5 years); (Bassett et al. 2003 - mean age 31.5 
years), suggesting the possibility of a clinical course in which affective disturbance 
occurs in the early stages of the illness, whereas features more typically associated 
with schizophrenia manifest at a later stage.
Under the diagnostic hierarchy (see chapter 1), unless they are a prominent 
feature of the illness and have overlapped at some point with schizophrenic features, 
episodes of mood disturbance will not generally have been considered in studies 
focussing solely on diagnostic categories. If mood symptoms have occurred at a 
relatively early stage of the psychiatric disturbance, they are less likely to be picked 
up in studies of adult populations.
A further explanation for the differences in the psychiatric phenotypes 
associated with VCFS reported by various studies may be diagnostic disagreement -  
different clinicians or researchers applying diagnostic criteria in slightly different 
ways, or interpreting symptoms observed or reported differently. An example of this
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is given by Papolos et al (1996), who reassessed a patient who had originally 
participated in a study by Pulver et al (1994). Whereas, in Pulver’s study, this 
individual was diagnosed with schizophrenia, Papolos and colleagues diagnosed them 
as BPI (rapid cycling) and described an illness course “far more consistent with 
mood-congruent psychotic depression followed by irritable manic episodes”.
Despite the fact that the exact psychiatric phenotype associated with VCFS 
remains somewhat ambiguous, the relevance of the syndrome in the search for genes 
increasing susceptibility to psychiatric illness cannot be denied. The association of 
VCFS with known deletions at 22ql 1 have made this chromosomal region the target 
of numerous molecular genetic studies.
Suggestive evidence for linkage at chromosome 22ql 1 has been reported in 
family-samples of both bipolar disorder (Edenberg et al. 1997; Kelsoe 2003; Lachman 
et al. 1997), and schizophrenia (Coon et al. 1994; Shaw et al. 1998; Williams et al. 
2003). In a meta-analysis of published whole-genome linkage scans of both bipolar 
disorder and schizophrenia, Badner and Gershon (2002) found that the strongest 
evidence for regions harbouring susceptibility loci for both bipolar disorder and 
schizophrenia was produced for regions 13q and 22q.
Recent studies, focussing on phenotypes which incorporate features of mood- 
disturbance and psychosis, have yielded further interesting results. Potash et al (2003) 
performed linkage analysis on a sample of 65 bipolar disorder pedigrees in order to 
test the hypothesis that those families enriched for psychotic symptoms would show 
increased evidence for linkage to regions previously implicated in both schizophrenia 
and bipolar disorder samples. Their findings were consistent with this; the ten bipolar 
families enriched for psychotic regions showed linkage to 13q31 and 22ql2 (with
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respective LOD scores of 2.52 and 3.06), whereas little or no evidence at these 
regions was produced in analysis performed on the full sample of 65 families.
Suggestive evidence for linkage at 22qll was produced in a genome-wide 
linkage scan performed by Hamshere et al (2005) in a sample enriched for 
schizoaffective disorder (LOD score = 1.96). Again, this supports the hypothesis that 
this region may harbour genes that influence susceptibility to psychiatric illness 
incorporating features characteristic of both mood disturbance and schizophrenia. 
This sample is described further in chapter 4).
The region of chromosome 22 which is deleted in VCFS contains 
approximately 48 genes. Of these, several have been identified as promising 
candidate genes for psychiatric illness (Murphy 2005; Shprintzen et al. 2005; 
Williams et al. 2008) and work is ongoing to identify specific genetic variations 
which influence susceptibility.
Findings from both molecular genetic studies, implicating 22qll in 
schizophrenia, bipolar disorder, and intermediate-phenotypes, along with the 
reportedly high rates of psychiatric disturbance incorporating both psychosis and 
mood disturbance in patients deleted at this region, support the hypothesis that this 
region of chromosome 22 may harbour a gene or genes which increases susceptibility 
to psychiatric illness across the traditional Kraepelinian divide.
It could be argued that the main limitation of many previous studies which 
have focussed on the characterisation of the psychiatric phenotype in VCFS, or the 
search for chromosomal regions and genes implicated in psychiatric illness, is their 
tendency to focus solely on diagnostic categories. As discussed in chapters 1 and 2, 
using these categories alone can lead to heterogeneous samples. This is likely to be 
particularly problematic in clinical samples associated with multiple diagnoses, as is
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the case in VCFS, as these are likely to reflect a more variable clinical picture which 
is more difficult to classify.
It is of note that one of the most promising linkage findings on chromosome 
22 was reported in a study using a more homogeneous sample -  bipolar patients who 
had also experienced psychotic symptoms (Potash et al. 2003). This supports the 
hypothesis that this region is associated with a psychiatric phenotype involving both 
disturbances in mood and psychosis, and highlights the benefits of looking more 
closely at the clinical picture in patients with VCFS. It is on this reasoning that my 
work is based.
Clinical information was available in the department for 21 individuals with 
VCFS from a sample previously collected by Professor Kieran Murphy and 
colleagues in the late 1990s. In the largest study of adult patients to date, Murphy et 
al (1999) evaluated 50 patients with VCFS in order to characterise the psychiatric- 
phenotype. They found that 21 individuals (42%) met criteria for a major psychiatric 
disorder, although the authors note that this may be partially due to ascertainment bias 
as 6 individuals from the sample were recruited through psychiatric services (see 
discussion). Of these, 12 (57%) met DSMIV-criteria for schizophrenia. The 
remainder were given diagnoses of major depression (N=6), bipolar disorder (N=l), 
schizoaffective disorder - bipolar type (N=l) and psychosis -  not otherwise specified 
(N=l).
The study also compared schizophrenic patients in the VCFS sample 
(“SZ/VCFS group”) with a matched control group of patients with schizophrenia who 
did not have a chromosome 22ql 1 deletion (“SZ group”). Murphy et al reported that 
the SZ/V CFS group had significantly fewer negative symptoms and a significantly 
later age of onset than the SZ group.
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My research aimed to extend the work of Murphy et al by rating the sample of 
21 individuals who met criteria for a major psychiatric disorder, on the large number 
of phenotypic characteristics described in chapter 2, paying particular attention to the 
prevalence of and relationship between mood symptoms and psychotic symptoms, 
under the hypothesis that affective-disturbance may be more prevalent in the sample 
than the DSMIV-diagnoses suggest.
3.2 Methods
3.2.1 Subjects
The sample comprised twenty-one individuals with a diagnosis of VCFS and 
major psychiatric disorder. This was a subset of fifty individuals originally collected 
by Professor Kieran Murphy and colleagues, with the intention of characterising the 
psychiatric phenotype in a comparatively large sample (as described above). The 
sample consisted of five males and sixteen females, with age at ascertainment ranging 
from seventeen to fifty-two years (mean 35.9 years, standard deviation 11.8 years).
The majority of these individuals (N=34) were recruited through departments 
of medical genetics throughout England and Wales. Others were recruited from 
psychiatric services (N=6), the UK VCFS support group (N=5), the local cardiology 
department (N=4), and one individual self-referred.
Each participant had been interviewed by Murphy and colleagues, using either 
the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) (Wing et al. 1990) 
or the Psychiatric Assessment Schedule for Adults with Developmental Disability. 
Using this information an interview vignette had been constructed for each case. 
Where applicable, summaries from other sources of information such as casenotes
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were also provided. As mentioned, DSMIV-diagnoses were made using all available 
information and 21 cases were found to meet criteria for a major psychiatric disorder 
(schizophrenia - 12; major depressive disorder -  6; schizoaffective disorder, bipolar 
type - 1; bipolar I disorder, rapid cycling -  1; psychosis-not otherwise specified -1).
The most up-to-date genetic data available confirmed deletions at 22ql 1 in all 
21 cases with VCFS and major psychiatric disorder.
3.2.2 Assessment o f  the Phenotype
In order to explore the phenotype of this sample further, each case needed to 
be rated on the large number of variables, detailed in the previous chapter. The rating 
of these cases took place in the relatively early stages of my research, and because of 
this, the items rated differed slightly from those used when rating the combined 
schizophrenia and bipolar disorder datasets (see Chapter 5); this was due to the 
identification of areas of the phenotype that could be better captured by altering 
existing rating guidelines, or by adding further items, during the rating of this large 
combined sample (this process is described in detail in chapters 2 and 5) A copy of 
the rating sheet used to rate the VCFS cases can be found in Appendix F. Ratings 
were made blind to Professor Murphy’s original diagnoses of these cases.
Each case was rated on approximately 150 items of psychopathology, 
including the occurrence of specific symptoms (using the Operational Criteria 
symptom checklist (Modified OPCRIT -  version 6 -  01.12.05), ages of onset, number 
of episodes, and scores on the Bipolar Affective Disorder Dimension Scales 
(BADDS)(Craddock et al. 2004b) and the Global Assessment Scale (GAS)(Endicott 
et al. 1976) (see chapter 2). Diagnoses were also made according to DSMIV, the
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ICD-10 Classification of Mental and Behavioural Disorders (WHO 1993) and the 
Research Diagnostic Criteria (RDC) (Spitzer et al. 1975).
Each case was examined in detail and ratings were made by three individuals 
independently -  two psychiatrists (Professor Nick Craddock and Dr James Walters) 
and one psychologist (myself). All individuals had been fully trained in the use of 
these methods. As part of my training, a series of meetings were held in which each 
case was discussed in detail, and a consensus rating was reached for each item.
3.2.3 Examination o f  the data
Comparison o f  Diagnoses
DSMIV-diagnoses made by KM and colleagues were compared on a case-by- 
case basis with RDC-diagnoses made as part of the current research. RDC uses less 
restrictive criteria in the diagnosis of schizoaffective disorder and is more sensitive in 
picking up on cases with a mixture of affective and psychotic symptomatology. For 
the same reason I also allowed a single individual to receive more than one diagnosis. 
Prevalence o f  Mood Disturbance
The prevalence of mood disturbance was defined in two ways: firstly as the 
occurrence of one or more episodes of mood disturbance over the course of the 
illness; secondly as the definite presence of affective symptoms which did not 
necessarily meet the criteria for an episode of mood disturbance.
To identify cases in which episodes of mood disturbance had occurred, scores 
on the Bipolar Affective Disorder Dimension Scales (BADDS; previously discussed 
in chapter 2) were used. A score of 40 or above on the BADDS Mania dimension 
indicates that an individual has had at least one episode of hypomania. Scores above
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60 indicate at least one manic episode. On the BADDS Depression scale, scores over
40 indicate at least one major depressive episode.
Cases in which mood-symptoms had definitely occurred were identified using 
BADDS scores of greater than 18. In the BADDS rating guidelines, a range of 1-19 is 
used to identify cases in which “mild sub-hypomanic” or “sub-minor depression” has 
occurred. A rating of 19 was used to indicate that there was evidence for mood 
disturbance, but not enough information was available (e.g. regarding duration or 
number of symptoms) to make a higher rating with the certainty required by the 
guidelines. For example, references to “lability of mood”, or “depressive 
symptomatology” were not rated higher than 19, even though they are statements 
suggestive of more prominent mood disturbance.
3.3 Results
3.3.1 Comparison o f  Diagnoses
When DSMIV diagnoses made by Professor Kieran Murphy and colleagues 
were compared with RDC diagnoses made as part of the current research, diagnoses
“differed” in 11 (52.3%) cases (see table 3-1 below for summary).
Of the original twelve cases diagnosed as Schizophrenic using DSMIV 
criteria, diagnoses made using RDC remained the same in four cases. In a further 
single case, KM’s diagnosis of schizophrenia remained unchanged but the individual 
also met RDC criteria for Major Recurrent Depressive Disorder. This second 
diagnosis would not have been recognised under the diagnostic hierarchy, which 
states that a diagnosis of schizophrenia “trumps” that of affective disorders.
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ID DSMIV (KM) RDC (ER)
V01/04 Schizophrenia Schizophrenia
V03/03 Schizophrenia Schizoaffective Disorder -  Depressed Type
V06/02 Schizophrenia Schizoaffective Disorder -  Depressed Type
V08/02 Major Depressive Disorder Major Depressive Disorder (Recurrent)
V09/03 Bipolar Disorder Schizoaffective Disorder -  Bipolar Type
V11/04 Major Depressive Disorder Major Depressive Disorder (Recurrent)
V12/04 Schizophrenia Schizophrenia and Major Depressive Disorder (Recurrent)
V14/02 Major Depressive Disorder Minor Depressive Disorder
V15/01 Schizophrenia Schizophrenia
V18/05 Schizophrenia Schizoaffective Disorder -  Depressed Type
V19/03 Schizophrenia Schizoaffective Disorder -  Bipolar Type
V22/02 Major Depressive Disorder Major Depressive Disorder (Recurrent)
V23/02 Major Depressive Disorder Major Depressive Disorder (Single Episode)
V24/02 Schizophrenia Schizoaffective Disorder -  Depressed Type
V25/04 Major Depressive Disorder Major Depressive Disorder (Single Episode)
V31/03 Schizophrenia Schizoaffective Disorder -  Depressed Type
V33/06 Other Psychotic Disorder Schizoaffective Disorder -  Depressed Type
V34/02 Schizophrenia Schizophrenia
V35/01 Schizophrenia Schizoaffective Disorder -  Depressed Type
V43/10 Schizoaffective Disorder -  Bipolar Type
Schizoaffective Disorder -  Bipolar 
Type
V44/03 Schizophrenia Schizophrenia
Table 3-1: Comparison of diagnoses made by KM and colleagues using DSMIV, with diagnoses 
made by ER and colleagues using RDC.
Of the remaining seven cases, six met RDC-criteria for Schizoaffective Disorder -  
Depressed Type and the remaining case met RDC-criteria for Schizoaffective 
Disorder -  Bipolar Type.
These, along with the three other cases in which diagnoses “differed” when using 
different criteria, are summarised in Table 3-2 below, which compares the DSMIV 
diagnoses made by KM et al, with the RDC diagnoses made by ER et al.
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Diagnosis BPI SABP MDD SADep SZP
BPI 0 1 0 0 0
SABP 0 1 0 0 0
MDD 0 0 6 0 0
SADep 0 0 0 0 0
SZP 0 1 0 6 5
OPD 0 0 0 1 0
Table 3-2: Summary of diagnoses when different diagnostic criteria were implemented within the 
sample.
BPI -  bipolar I disorder; SABP -  schizoaffective disorder, bipolar type; MDD -  major depressive 
disorder; SADep -  schizoaffective disorder, depressed type; SZP -  schizophrenia; OPD -  other
psychotic disorder.
3.3.2 Prevalence o f mood symptoms
Out of the sample of 21 patients with VCFS and a psychiatric disorder, 17 
(81%) had experienced at least one depressive, manic or hypomanic episode. The 
majority of these (11/17) also experienced psychotic symptoms. Only four 
individuals had experienced psychotic symptoms without definite episodes of mood 
disturbance.
Mood Episode Only Mood Episode and 
Psychosis
Psychosis without 
Mood Episode
□ Psychosis Only
□ Mania and Depression
■ Depression Only
■  Mania only
Figure 3-1: Prevalence of and relationship between affective episodes and psychotic symptoms 
within a sample of VCFS patients with a major psychiatric diagnosis.
When looking at the prevalence of mood symptoms in the sample (i.e. 
BADDS Scores > 19), rather than the more narrowly defined-mood episodes, the 
number of individuals experiencing mood disturbance increases to twenty out of
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twenty-one (95%). Only a single individual had a pure psychotic illness with no 
evidence of symptoms indicative of affective disturbance.
n iLJ I___ 1
6
Mood Disturbance 
Only
14
Mood disturbance 
And psychosis
1
Psychosis without 
Mood Disturbance
□  Psychosis Only
□  Mania and Depression
■  Depression Only
■  Mania only
Figure 3-2: Prevalence and relationship between affective disturbance and psychotic symptoms 
within a sample of VCFS patients with a major psychiatric diagnosis.
3.4 Discussion
Detailed phenotype examination of a sample of patients with VCFS and a major 
psychiatric disorder revealed high rates of mood disturbance. Of the 21 patients in the 
sample, 81% (N=17) had experienced at least one episode of hypomania, mania or 
major depression. This increases to 95% (N=20) when including mood disturbance 
that did not necessarily meet diagnostic criteria for an episode.
This sample was originally collected by Professor Kieran Murphy and 
colleagues, with the aim of further investigating rates and types of psychiatric 
disturbance associated with VCFS. They reported high rates of psychosis in the 
sample (15/21), most commonly fitting diagnostic criteria for DSMIV defined 
schizophrenia (12/21). However, when RDC, rather than DSMIV, criteria were used 
to diagnose these patients, diagnoses differed in 52.3% of cases. The table below 
shows the frequency in which each diagnostic category was assigned to cases in this 
sample under DSMIV criteria (KM) and RDC criteria (ER).
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Diagnostic Category DSMIV (KM) RDC (ER)
Schizophrenia 12 4(1)
Schizoaffective
Disorder 1 10
Depressive Disorder 6 6(1)
Bipolar Disorder 1 0
Other Psychotic 
Disorder 1 0
Table 3-3: Comparison of the frequencies with which diagnoses are made using different 
diagnostic criteria in a sample of VCFS patients with a major psychiatric disorder
[(1) patient met criteria for Schizophrenia and Depressive Disorder]
The most striking difference when RDC, as opposed to DSMIV, criteria were 
applied was the rise in the number of patients meeting criteria for schizoaffective 
disorder, and the concurrent fall in those diagnosed with schizophrenia. RDC uses 
less restrictive criteria for the diagnosis of schizoaffective disorder (see chapter 4), for 
example, in terms of the required prominence of the affective disturbance. A 
diagnosis of schizoaffective disorder according to RDC requires the occurrence of 
only a single episode of mood disturbance, which has at some point overlapped with 
symptoms suggestive of schizophrenia for a schizoaffective diagnosis. In DSMIV a 
diagnosis of schizoaffective disorder requires that symptoms which meet the criteria 
for an episode of mood-disturbance are present for a substantial proportion of the total 
duration of illness.
In the current study, RDC diagnoses better reflect the high incidence of mood 
disturbance within the VCFS sample, suggesting that this sample is associated with a 
clinical picture involving both psychotic features and mood disturbance. The 
narrower definition of schizoaffective disorder under DSMIV means that this level of 
detail is lost, with features of mood disorder being disregarded under the diagnostic 
hierarchy, unless they are present for a substantial proportion of the total illness.
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However, although the RDC definition of schizoaffective disorder better recognises 
the occurrence of manic and depressive symptoms, it does not distinguish between 
patients who have had a single episode of mood disturbance and those who 
experience many episodes of affective illness concurrent with a schizophrenic 
syndrome.
As outlined in the introduction above, results of previous studies which have 
attempted to characterise the psychiatric phenotype associated with this syndrome, 
have been mixed, with some reporting high rates of schizophrenia (e.g. Shprintzen et 
al. 1992) and others high rates of mood disorder (e.g. Arnold et al. 2001). The results 
summarised in the tables above demonstrate how, even when investigating the same 
sample of patients, different ways of measuring the phenotype can lead researchers to 
different conclusions.
Another possible explanation for the discrepant findings between previous 
studies could be related to the age range of the samples studied. Investigations 
studying the psychiatric phenotype associated with VCFS which report high rates of 
mood disturbance have involved samples consisting largely of children and 
adolescents (Papolos et al. 1996), whereas those reporting higher rates of 
schizophrenia tend to be based on adult samples. This may suggest a characteristic 
clinical course of illness involving early disturbance of mood, with features typically 
associated with schizophrenia only occurring at a later stage of the illness. Mood 
symptoms which occur at a relatively early stage of the illness are less likely to be 
picked up in studies of adult populations.
In the current sample, a comparison of ages at onset of mood and psychosis 
revealed that the average age at first psychotic symptom was lower than the average 
age at first mood disturbance (average age at first psychosis = 23.29, average age at
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first mood disturbance = 26.38), which does not support the hypothesis of a 
characteristic course involving early mood disturbance and later psychotic features. 
However, as stated in the introduction to this chapter this may be because if mood 
symptoms have occurred at a relatively early stage of the psychiatric disturbance they 
are less likely to be picked up in studies of adult populations such as this. Due to the 
sample size no formal statistical tests were performed on this sample.
The possibility of a characteristic course of illness involving early mood 
disturbance and the later development of symptoms characteristic of schizophrenia 
could be investigated further using a longitudinal study design which included 
detailed characterisation of the psychiatric phenotype in individuals with VCFS at 
regular intervals, ideally starting in early childhood.
A further explanation for the differences in previous findings could be that the 
initial reports suggesting that VCFS was associated with schizophrenia may, to some 
extent, have resulted in systematic differences in studies seeking to further investigate 
this association. It is possible that the symptoms indicative of mood-disturbance were 
explored less rigorously than those suggestive of schizophrenic illness. This may have 
led to subjects being given a diagnosis of schizophrenia when, if the clinical picture 
was examined more closely, a diagnosis of schizoaffective disorder, or even major 
depression with psychotic features or bipolar disorder (as described above in the case 
originally collected by Pulver and re-examined by Papolos et al, 1996), may have 
been appropriate.
Similarly, despite efforts made to prevent it, systematic differences may have 
been introduced in the current study which was carried out under the hypothesis that 
symptoms of affective disturbance were more prevalent in the sample than Professor 
Murphy’s original DSMIV diagnoses suggested. This can be examined further by
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comparing the original DSMIV diagnoses made by Murphy et al (1999) with DSMIV 
diagnoses my Russell et al, described in this chapter.
ID DSMIV (KM) DSMIV (ER) RDC (ER)
V01/04 Schizophrenia Schizophrenia Schizophrenia
V03/03 Schizophrenia Schizoaffective Disorder -  Depressed Type
Schizoaffective Disorder -  
Depressed Type
V06/02 Schizophrenia Schizoaffective Disorder -  Depressed Type
Schizoaffective Disorder-  
Depressed Type
V08/02 Major Depressive Disorder Major Depressive Disorder (Recurrent)
Major Depressive Disorder 
(Recurrent)
V09/03 Bipolar Disorder Bipolar Disorder Schizoaffective Disorder-  Bipolar Type
V11/04 Major Depressive Disorder Major Depressive Disorder (Recurrent)
Major Depressive Disorder 
(Recurrent)
V12/04 Schizophrenia Schizophrenia and Major Depressive Disorder (Recurrent)
Schizophrenia and Major 
Depressive Disorder (Recurrent)
V14/02 Major Depressive Disorder Depressive Disorder -  Not Otherwise Specified Minor Depressive Disorder
V15/01 Schizophrenia Schizophrenia Schizophrenia
V18/05 Schizophrenia Schizoaffective Disorder -  Depressed Type
Schizoaffective Disorder-  
Depressed Type
V19/03 Schizophrenia Schizoaffective Disorder -  Bipolar Type
Schizoaffective Disorder-  
Bipolar Type
V22/02 Major Depressive Disorder Major Depressive Disorder Major Depressive Disorder (Recurrent)
V23/02 Major Depressive Disorder Depressive Disorder -  Not Otherwise Specified
Major Depressive Disorder 
(Single Episode)
V24/02 Schizophrenia Schizoaffective Disorder -  Depressed Type
Schizoaffective Disorder-  
Depressed Type
V25/04 Major Depressive Disorder Major Depressive Disorder (Single Episode)
Major Depressive Disorder 
(Single Episode)
V31/03 Schizophrenia Schizoaffective Disorder -  Depressed Type
Schizoaffective Disorder-  
Depressed Type
V33/06 Other Psychotic Disorder Other Psychotic Disorder Schizoaffective Disorder-  Depressed Type
V34/02 Schizophrenia Schizophrenia Schizophrenia
V35/01 Schizophrenia Schizophrenia Schizoaffective Disorder-  Depressed Type
V43/10 Schizoaffective Disorder -  Bipolar Type
Schizoaffective Disorder -  
Bipolar Type
Schizoaffective Disorder -  
Bipolar Type
V44/03 Schizophrenia Schizophrenia Schizophrenia
Table 3-2: Comparison of diagnoses made by KM and colleagues using DSMIV, with diagnoses
made by ER and colleagues using DSMIV.
As shown in the table above, even when using the same diagnostic criteria,
diagnostic differences still occurred between the two research-groups. Six of the 
eight individuals diagnosed with schizophrenia by Murphy et al (1999) were 
diagnosed with schizoaffective disorder when the same diagnostic criteria were
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applied by Russell et al, suggesting some element of bias by one or both groups. To 
meet the criteria for schizoaffective disorder as defined by DSMIV an individual must 
experience symptoms that meet the criteria for a mood episode for a “substantial 
portion of the total duration of the active and residual periods of the illness”. What 
constitutes a “substantial portion” of the total duration of illness is open to a degree of 
interpretation and therefore may result in diagnostic differences in cases which 
comprise a mixture of psychotic and affective symptoms.
The fact that these diagnostic differences occurred when using the same 
diagnostic criteria further demonstrates the limitations of diagnostic classification 
systems and the importance of using clinical variables as an adjunct to diagnosis to 
give a fuller description of the clinical picture.
VCFS is of particular interest to molecular genetic researchers because it 
involves the association of a known chromosomal abnormality with high rates of 
psychiatric disturbance. This suggests that there may be a gene or genes in this area 
which influence susceptibility to this disturbance in the general population. Murphy 
et al (2005) suggested that if a disease is truly associated with a gene: i) there should 
be increased incidence of the disease in a population of individuals with a specific 
chromosomal abnormality; ii) there should be an increased incidence of the 
chromosomal abnormality in a population of individuals with the disease and; iii) 
molecular genetic studies should suggest that a susceptibility locus for the disease 
may be located at the region associated with the chromosomal abnormality.
In the case of VCFS, points i) and iii) have already been discussed; there is an 
increased incidence of psychiatric illness in populations with deletions at chromosome 
22ql 1 and this region has been implicated in molecular genetic studies. Studies have 
also been carried out to investigate point ii) and have provided support for the
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hypothesis that deletions in the VCFS region are more common in populations with 
schizophrenia than in the general population.
The effects of the deletion will vary according to the mechanism by which a 
risk allele influences illness. For example, the effects of a loss of function allele will 
be made more obvious by the presence of a deletion, whereas gain of function alleles 
will be relatively unaffected by the deletion.
The reported prevalence rates of 22ql 1 deletions in samples of patients with 
schizophrenia vary from 2% (Wiehahn et al. 2004) to 53% (Bassett et al. 1998). The 
highest prevalence reported was in a sample of patients selected on the basis that they 
had a DSMIV diagnosis of schizophrenia (N=7) or schizoaffective disorder (N=l) 
along with at least two physical features associated with VCFS (e.g. palatal 
abnormalities, cardiac abnormalities, dysmorphic facies or other physical congenital 
abnormalities).
In a random sample of schizophrenic patients (N=100) Karayiorgou and 
colleagues (1995) found that 2% were deleted at chromosome 22qll. Usiskin et al 
(1999) reported deletions at chromosome 22qll in 6% of their sample of childhood- 
onset schizophrenia cases (N=43, onset of psychosis below the age of 12). Both are 
well above the estimated prevalence of 22ql 1 deletions in the general population 
(approx. 0.02%, Botto et al. 2003).
It is of note that higher rates of deletions at the VCFS region are reported in 
samples in which the phenotype has been refined (e.g. only including patients with 
early onset schizophrenia). Further characterisation of the psychiatric phenotype 
associated with the syndrome will enable the selection of samples which are more 
representative of psychiatric disturbance in VCFS -  for example, it may be that a 
sample of patients with a DSMIV diagnosis of schizophrenia who have also had at
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least one episode of mood disturbance would show increased numbers of deletions at 
chromosome 22ql 1.
In the case of molecular genetic studies, the identification of a more precise 
psychiatric phenotype associated with VCFS would be beneficial because, as it is 
associated with a specific chromosomal abnormality, it is likely to describe a 
genetically meaningful subgroup of patients. The use of samples that are more 
reflective of this better-defined phenotype is more likely to yield more interesting and 
significant results in both linkage and association studies.
There are several limitations to this study. Firstly it was retrospective, i.e. the 
VCFS sample had been recruited prior to the start of my PhD. This meant that 
participants could not be asked directly about specific items of psychopathology that 
were rated during this study. The advantages and disadvantages of retrospective 
studies are discussed further in chapter 6.
A major limitation of the work described in this chapter is sample size. The 
small number of individuals (N=21) with VCFS and a psychiatric disorder meant that 
formal statistical tests were unfeasible as there would be insufficient power to detect 
true effects. Such a small sample is also less likely to be representative of the larger 
population of individuals with VCFS and a psychiatric disorder. Large, well- 
characterised samples of patients with VCFS and psychiatric disorder would facilitate 
future work in this area.
There may also be an ascertainment bias within the sample. As discussed by 
Murphy et al (1999), the majority of individuals in the sample were ascertained 
because they had a child with VCFS. It is therefore possible that the patients 
collected in this way may represent a higher functioning group (as individuals with 
more debilitating illnesses are less likely to have children).
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Further ascertainment bias may have been introduced by the fact that 6 
individuals within the sample were recruited through psychiatric services. As well as 
inflating the levels of psychiatric illness reported in this sample of VCFS patients (as 
acknowledged by Professor Murphy and colleagues) it would also have had an impact 
on the types of illness represented within the sample. Individuals who have had 
contact with psychiatric services are more likely to have experienced a more severe 
clinical picture which has had a greater impact on their everyday levels of 
functioning.
A more representative sample could be ascertained through systematic 
recruitment. As discussed above, longitudinal studies which include detailed 
examination of the psychiatric phenotype at various stages throughout the lives of 
individuals with VCFS would allow more robust conclusions to be drawn regarding 
the psychiatric phenotype of individuals with this syndrome.
The result from this study suggests that depression is particularly prevalent in 
the VCFS sample. However, high rates of depression are also reported in 
schizophrenia samples that are not specifically associated with deletions on 
chromosome 22ql 1 (for example, reviewed in Hausmann and Fleischhacker 2000). 
More detailed examination of the phenotype in studies focussing on general 
schizophrenia samples would facilitate the identification of genetically-meaningful 
subtypes.
3.5 Conclusions
Detailed phenotype examination revealed high rates of mood-disturbance 
(depression in particular) in a sample of VCFS patients with a major psychiatric 
disorder. These results must be interpreted with caution due to the limitations 
discussed above. However, they are consistent with the hypothesis that a gene or
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genes located in the deleted region of chromosome 22ql 1 may be associated with a 
psychiatric phenotype characterised by a mixture of psychotic symptoms and affective 
disturbance.
94
4 Phenotype Analysis in a Sample of Pedigrees 
Enriched for Schizoaffective Disorder
4.1 Introduction
The disadvantages of conducting molecular genetic studies into the functional 
psychoses based on the assumptions of the Kraepelinian dichotomy have already been 
covered extensively in this thesis. The concept of schizophrenia and bipolar disorder 
as separate disease entities suggests separate underlying aetiologies. In fact there is a 
degree of overlap in both the clinical features of these illnesses, and in the genes and 
chromosomal regions implicated in genetic analyses (as reviewed in Chapter 1).
The concept of schizoaffective disorder was developed to facilitate the 
classification of these “difficult-to-diagnose” cases, characterised by substantial 
overlap between features indicative of schizophrenia, and those typical of mood 
disorder. Kasanin (1994) first conceptualised schizoaffective disorder as ‘'acute 
schizoaffective psychosis” in 1933. Since this time it has been operationalised and 
included in diagnostic systems such as the Diagnostic and Statistical Manual of 
Mental Disorders (DSMIV) (APA 1994), the ICD-10 Classification of Mental and 
Behavioural Disorders (WHO 1992) and the Research Diagnostic Criteria (RDC) 
(Spitzer et al. 1975).
Although useful in resolving diagnostic-dilemmas, schizoaffective disorder 
remains a poorly-defined category. Differences in the criteria for schizoaffective 
disorder specified by the individual diagnostic systems exist, and are summarised in 
table 4-1.
DSMIV-defined schizoaffective disorder is further complicated by the 
duration criterion for mood disturbance. What constitutes a “substantial proportion”
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Table 4-1: Summary of diagnostic criteria for schizoaffective disorder for DSM-IV (APA 1994); ICD-10 (WHO 1992); RDC (Spitzer et al. 1975)
of the overall illness is subjective and therefore susceptible to diagnostic-bias. It also 
creates diagnostic instability, in that the proportion of affective disturbance over the 
total duration of illness is subject to change over time. An individual with prominent 
mood features in the first few years of illness, which then diminish may have an initial 
diagnosis of schizoaffective disorder which is later changed to schizophrenia.
Studies investigating the diagnostic stability of schizoaffective disorder have 
emphasised this issue. A study by Nardi et al (2005) reassessed a sample of 61 
patients five-years after they had received a diagnosis of schizoaffective disorder. 
They found that less than half of these patients sustained their original diagnoses, with 
the majority (61%) subsequently meeting diagnostic-criteria for bipolar disorder. 
Another study found high rates of schizophrenia diagnoses in those originally 
diagnosed with schizoaffective disorder (Schwartz et al. 2000).
The nature of schizoaffective disorder has been an issue of debate since it was 
first described in the literature. One possibility is that schizoaffective disorder reflects 
the coincidental co-occurrence of schizophrenia and a mood disorder, both of which 
are relatively common illnesses. As discussed by Abrams and colleagues (2008) if 
this is the case then schizoaffective disorder would not merit unique identification in 
psychiatric nosology. Alternatively it may be a relatively specific disorder in its own 
right.
Several further nosological concepts have been suggested. These include: 1. 
That schizoaffective disorder is a variant of affective disorder (Pope et al. 1980); 2. 
That it is a variant of schizophrenia (Evans et al. 1999); 3. That it is an intermediate 
entity between schizophrenia and affective disorders (Tsuang and Dempsey 1979); 4. 
That is the mid-point of a continuum of the functional psychoses, with schizophrenia 
at one end and bipolar disorder at the other (Angst et al. 1983).
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In their systematic review of the literature, Cheniaux et al (Cheniaux et al. 
2008b) conclude that schizoaffective disorder is best conceptualised as a mid-point 
along a continuum of psychotic-affective illness, or as a heterogeneous group 
comprising patients with a mixture of affective disorders and schizophrenia. In 
another recent review (Lake and Hurwitz 2007b) the authors suggest that patients 
diagnosed as schizoaffective are more likely to have a psychotic mood disorder. They 
go as far as to suggest that schizoaffective disorder should be eliminated from the 
nomenclature, suggesting that patients with a schizoaffective diagnosis are more 
likely to receive sub-standard treatment.
Despite concerns regarding the validity of the schizoaffective diagnosis, it has 
proved useful both clinically (e.g. in allowing predictions to be made about illness 
course and treatment response) and in research. In terms of molecular genetic studies, 
cases involving intermediate forms of illness which involve features typical of both 
mood disorders and schizophrenia have been shown to be familial (Schulze et al. 
2006b; Schurhoff et al. 2003b). Picking out cases involving mixed symptomatology 
would also help to “purify” samples by reducing heterogeneity. This would result in 
more homogeneous groups, more reflective of “prototypical” forms of schizophrenia 
and affective disorder, which may be more useful in molecular genetic studies.
To date, few molecular genetic studies have focussed on schizoaffective 
disorder as a diagnostic category, although as reviewed in chapter 1 there are 
numerous chromosomal regions that have been implicated in both schizophrenia, 
bipolar disorder, and in intermediate forms of the disorders (e.g. bipolar disorder with 
mood incongruent psychotic features) (O'Mahony et al. 2002). As with studies of 
schizophrenia and bipolar disorder, the heterogeneity of the schizoaffective diagnosis 
is likely to hinder genetic analyses.
98
Hamshere et al (2005) performed the first systematic genome-wide linkage 
scan to search for loci influencing susceptibility to schizoaffective disorder. They 
found a genome-wide significant signal on chromosome lq42 (LOD = 3.54) -  a 
region previously implicated in both schizophrenia and bipolar disorder. Suggestive 
evidence for linkage was also produced at regions 22qll (LOD = 1.96) (see Chapter 
3) and 19pl3 (LOD = 1.85). This study provides evidence to support the hypothesis 
that there is genetic susceptibility which is specific to schizoaffective illness. 
Alternatively there may be a gene or genes within this region that have relatively 
broad effects, increasing risk for a range of disorders or symptoms.
The significant finding at chromosome lq42 is particularly interesting as it is 
close to the gene Disrupted in Schizophrenia 1 (DISCI). DISCI was originally 
discovered in a large Scottish pedigree, in which a balanced translocation between 
chromosomes lq42 and llq l4  was found to segregate with a broad range of 
psychiatric illness manifestations, including schizophrenia, bipolar disorder, major 
recurrent depressive disorder, adolescent conduct disorder and emotional disorders 
(St-Clair et al. 1990). A maximum LOD score of 7.1 was produced using a broad 
diagnostic model including schizophrenia, bipolar disorder and major recurrent 
depression (Blackwood et al. 2001).
As mentioned previously, the chromosomal region lq42 has been implicated 
in both schizophrenia and bipolar disorder (Porteous et al. 2006). Analyses focussing 
on the DISCI gene have also shown significant association between numerous 
diagnoses including bipolar disorder, schizophrenia and schizoaffective disorder 
(Hodgkinson et al. 2004).
The implication of the chromosomal region containing a gene associated with 
such a range of psychiatric diagnoses, comprising both psychotic illness and affective
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disturbance, makes it an attractive candidate for phenotype refinement, particularly in 
light of the study described above, which provides evidence for linkage in a sample 
enriched for schizoaffective disorder. This research, conducted by Dr Hamshere and 
colleagues, was conducted in the Department of Psychological Medicine in Cardiff 
University and it was possible to access hard copies of the data contributing to this 
study. This included detailed clinical information on each case in the sample.
In keeping with the theme of this thesis, my research aimed to further 
investigate the phenotype associated with the increased allele sharing identified at the 
linkage peaks in the sample described by Hamshere et al. Conducting research on this 
sample also allowed me to pilot methods to be used in the primary analyses of this 
PhD, described in Chapter 5.
4.1.1
4.2 Method
4.2.1 Sample
The sample used in this study comprised a subset of cases taken from the 
family-based samples originally collected as part of two independent linkage studies, 
one investigating bipolar disorder and the other schizophrenia (Bennett et al. 2002a; 
Lambert et al. 2005b; Williams et al. 1999). These samples formed the basis of my 
primary analyses, and detailed descriptions can be found in chapters 2 and 5.
From these samples, Hamshere and colleagues (Hamshere et al. 2005) selected 
pedigrees in which at least one family-member had a DSMIV-defmed diagnosis of 
schizoaffective disorder, bipolar type and an additional member had a diagnosis of 
schizoaffective disorder bipolar type, schizophrenia or bipolar disorder (also 
according to DSMIV criteria).
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The total sample consisted of 53 individuals from 24 pedigrees (11 from the 
schizophrenia family sample and 13 from the bipolar disorder family sample), which 
comprised 35 affected sibling-pairs. There were a total number of 24 females and 29 
males, forming 9 male-male pairs, 10 female-female pairs and 16 mixed-sex pairs.
Each participant was interviewed by a trained psychologist or psychiatrist, 
using the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) (Wing et al. 
1990), a semi-structured interview aimed at assessing, measuring and classifying 
psychopathology and behaviour associated with psychiatric illness. Where possible, 
copies of the patients’ case-notes had been reviewed, and a vignette was compiled 
summarising this information in detail.
4.2.2 Data available fo r  a typical case
A typical case in this sample would consist of the following information:
• An interview vignette detailing information on episodes of illness ascertained 
using the SCAN semi-structured interview.
• Case-notes, usually in the form of a case-note vignette describing the illness 
on an episode-by-episode basis.
• Referral letters.
• Completed rating scales including an Operational Criteria symptom checklist 
(version 3.31; OPCRIT) (McGuffin et al. 1991), the Scales for Assessment of 
Positive and Negative Symptoms (Andreasen 1984a, 1984b) and the Global 
Assessment Scale (GAS) (Endicott et al. 1976).
4.2.3 Genetic Data A vailable
Estimations of the maximum-likelihood identical-by-descent (IBD) allele-sharing 
probabilities were available for each sibling-pair in the sample at the chromosomal
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locations in which significant and suggestive linkage had been shown by Hamshere et 
al (2005), i.e. Iq42.2, 22q ll.l and 19pl3.2.
4.2.4 Phenotype Assessment
All relevant data were examined in detail for each case, and ratings were made on 
23 continuous variables, including the Bipolar Affective Disorder Dimension Scales 
(BADDS) the Global Assessment Scale (GAS): A full list of variables rated can be 
found in Appendix G.
Because this was a pilot for the methods used in creating the large harmonised 
dataset described (LHD) in Chapter 5, ratings made for this sample were identical to 
those made for the LHD with two exceptions: at this point, the additional OPCRIT 
items (28a -  increased sexual behaviour and 54a -  aggressive behaviour) had not yet 
been included. These ratings were added as a result of observations made during the 
rating of the pilot phase (which included work described in this chapter and the initial 
stages of the work undertaken in chapter 5).
Reliability
Each case in this sample was rated on the set of variables shown in Appendix 
G by both myself and Professor Nick Craddock. Ratings were made independently 
and meetings were held in which each case was discussed in detail and a consensus 
rating was agreed upon for each measure. Where no agreement could be reached, a 
third fully-trained individual was consulted (Dr Ian Jones) and a consensus was 
reached in this way. Excellent reliability was demonstrated for the majority of 
variables, as shown in Appendix H.
Analysis
Analysis was performed on a set of continuous variables (N=23). These were 
a subset of the ratings made for this sample, and were selected because it had been
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possible to rate them on a substantial number of cases, there was sufficient variability 
within the data, and it was thought that they may reflect measures that are biologically 
relevant. For each sibling-pair, the between-sibling difference in the scores for each 
variable was squared to give a value used as the dependent variable in this analysis 
(i.e. (sibl score (variableX) -  sib2 score (variableX)) 2). Using SPSS (Statistical 
Package for the Social Sciences), Spearman’s Rho correlations were then performed 
on these data, correlating the dependent variables with the IBD scores for the linkage 
peaks at lq42, 22qll and 19p 13. This is consistent with a method originally 
described by Haseman and Elston (1972), in which linkage was investigated by 
regressing the squared difference in trait values with the estimated proportion of IBD 
alleles shared. Corrections were then made for multiple testing (by multiplying the 
original p-value by the number of statistical tests performed -  N=23).
The Spearman’s Rho analyses were used to measure the strength and direction 
of associations between genetic similarity and phenotypic similarity (as measured by 
individual clinical variables) in a sample comprising related pairs. One-tailed tests 
were used as only significant negative correlations could be interpreted as being 
biologically meaningful (negative correlations indicate that increased allele sharing is 
associated with increased sibling-similarity on the variable being tested, whereas the 
reverse is true for positive correlations). For this reason all positive correlations were 
considered to be non-significant (see tables below).
A disadvantage of using the Spearman’s Rho analysis is that it assumes that 
the pairs included in the sample are independent. If a single family contributes more 
than one pair to the sample, these pairs cannot be considered independent, therefore 
this assumption was violated in the SABP sample. However, only using a single pair
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from each family reduces the sample size and therefore the power to detect significant 
effects.
To address this issue, data were first analysed using the full sample, which 
included all pairs. Where significant results were found, the analysis for that variable 
was then performed in a sub-sample of case which comprised a single pair from each 
family.
In the creation of the sub-sample of patients, a single pair was randomly 
selected from each family using an online computer program, in which data entered in 
list-form is randomised (www.random.org/lists). The identification numbers for each 
pedigree were entered into the program as a list and then randomised. The two 
individuals which were at the top of the list for each pedigree after randomisation 
were selected for inclusion within the smaller sample of independent pairs.
Because the region of lq42 had been shown to be associated with 
schizoaffective disorder, one possible prediction was that IBD at this region would be 
associated with clinical variables which take into account both mood and psychotic 
symptoms. For example, the BADDS Incongruence dimension, which measures the 
relationship between mood and psychosis, or Extended Rating Scale 8 which rates 
each individual according to how “prototypically” affective vs. schizophrenic their 
overall clinical picture is considered (see chapter 5).
However, because this region had previously been implicated with 
schizophrenia, bipolar disorder and major recurrent depressive disorder (as reviewed 
in Porteous et al, 2006), and therefore may be considered a more general genetic risk 
factor for a broad range of psychiatric illnesses, it was difficult to make firm 
predictions.
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4.3 Results
Results for chromosome lq42
The results from the Spearman’s-rho analyses for the IBD-data at lq42 are 
presented in the table below.
Variable
Chromosome
lq42
Rs P
BADDS Mania -.136 .222
BADDS Depression .079 NS
BADDS Psychosis .111 NS
BADDS Incongruence -.076 .345
GAS Depression -.737 .00021
GAS Mania -.013 .949
GAS Psychosis -.275 .083
GAS Worst Ever -.173 .169
GAS Past Week -.276 .082
No. Manic Episodes -.179 .078
No. Dep. Episodes -.166 .143
AOO Impairment -.322 .044
Age of first mania .030 NS
Age of first depression -.304 .055
Age of first psychosis -.137 .141
ERS1 .236 NS
ERS2 .090 NS
ERS4 -.100 .310
ERS5 -.048 .397
ERS7 .207 NS
ERS8 -.028 .438
ERS9 -.116 .268
Course of Disorder -.113 .132
Table 4-2: Results of Spearman’s-rho analyses correlating genetic similarity at lq42 with 
phenotypic similarity in a sample of sibling pairs. NS = Non-significant.
As shown in table 4-2, the genetic similarity of sibling-pairs at lq42 is 
significantly correlated with the phenotypic-similarity in impairment, as measured 
using the GAS, during the worst episode of depression; a significant negative 
correlation was also found between the IBD-scores at lq42 and sibling-similarity of 
onset-age. The two variables for which significant results were produced were then
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analysed in the smaller dataset, comprising a single pair from each family. Results 
are presented in the table below, which compares results produced in the full sample, 
with the results produced in the sample of independent pairs. A significant result was 
maintained for GAS-depression but not for Age of onset.
Variable Sample N pairs Rs P
GAS-
Depression
Full Sample 20 -0.737 0.00021
Independent 
pairs only 18 -0.696 0.0029
Age of Onset
Full Sample 28 -0.322 0.044
Independent 
pairs only 19 -0.273 p > 0.05
Table 4-3: Results of Spearman’s-rho analyses correlating genetic similarity at lq42 with 
phenotypic similarity, in the full sample and a reduced sample of independent pairs
The table below presents the results after corrections have been made for 
multiple testing (using the Bonferroni method). As shown, only the GAS-Depression 
scores in the full dataset remain significant, although a trend towards significance was 
found in the smaller dataset comprising independent pairs.
Variable Sample N pairs Rs P
GAS-
Depression
Full Sample 20 -0.737 0.00483
Independent 
pairs only 18 -0.696 0.0667
Age of Onset
Full Sample 28 -0.322 p > 0.05
Independent 
pairs only 19 -0.273 p > 0.05
Table 4-4: Results of Spearman’s-rho analyses correlating genetic similarity at lq42 with 
phenotypic similarity, in the full sample and a reduced sample of independent pairs after 
corrections were made for multiple testing.
Results for 19pl3 and 22ql3
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These analyses were also undertaken using IBD scores at the regions which 
showed suggestive linkage in the sample enriched for schizoaffective disorder, 19pl3 
and 22ql 1. These results are presented in the table below.
Variable
19pl3 
(1-tailed)
22ql 1 
(1-tailed)
rs P rs P
BADDS Mania .211 NS -.193 .138
BADDS Depression .026 NS -.058 .373
BADDS Psychosis .084 NS .305 NS
BADDS Incongruence .298 NS .141 NS
GAS Depression -.178 .227 -.205 .193
GAS Mania .355 NS .097 NS
GAS Psychosis .003 NS -.269 .088
GAS Worst Ever .051 NS -.418 .008
GAS Past Week .068 NS .289 NS
No. Manic Episodes -.074 .339 -.200 .129
No. Dep. Episodes .065 NS -.061 .372
AOO Impairment -.162 .201 .080 NS
Age of first mania .041 NS -.083 .357
Age of first depression -.296 .117 .355 NS
Age of first psychosis .018 NS .199 NS
ERS1 -.055 .354 .003 NS
ERS2 -.157 .189 -.216 .110
ERS4 .106 NS -.173 .195
ERS5 .086 NS .392 NS
ERS7 .040 NS .004 NS
ERS8 -.045 .400 -.011 .476
ERS9 .012 NS .186 NS
Course of Disorder -.050 .389 -.225 .101
Table 4-5: Results of Spearman’s-rho analyses correlating genetic similarity at 19pl3 and 22qll 
with phenotypic similarity in a sample of sibling pairs. NS = Non-significant.
As shown in table 4-5, a significant negative correlation was found between 
the genetic similarity of the siblings at 22qll and the phenotypic-similarity for GAS 
scores during their worst ever episodes of illness. The analysis was then performed in 
the smaller sample, comprising a single pair from each family. As shown in table 4-6, 
a significant negative correlation was also found in the smaller sample of independent 
pairs. However, neither result withstood corrections for multiple testing.
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Variable Sample N pairs Rs P
GAS-Worst 
Ever Episode
Full Sample 33 -0.418 .008
Independent 
pairs only 21 -0.432 0.025
Table 4-6: Results of Spearman’s-rho analyses correlating genetic similarity at 22qll with 
phenotypic similarity in the full sample and a reduced sample of independent pairs
4.3.1 Review o f Pilot Work
As well as the statistical analyses performed in the sample, this study also served 
as a means of piloting methods to be used in the bipolar disorder and schizophrenia 
family-based samples. There were three key issues that it was important to assess: 
utility of methods planned, length of time taken to complete a typical case, and 
reliability of ratings made.
Methods involved in rating each case were found to be straightforward, facilitated 
by an extensive training period undertaken prior to the rating of these cases (see 
Chapter 2) and by detailed, project-specific rating guidelines (see Chapter 5). This is 
supported by the generally excellent inter-rater reliability demonstrated, as discussed 
earlier.
The time-taken to complete each case was an important issue, as this would 
influence time-planning when completing the ratings for the large harmonised dataset. 
It was found that the time needed to complete each case, i.e. complete initial ratings, 
agree on consensus ratings and enter the data, was approximately two hours.
In terms of the Extended Rating Scales, Scales 3 (fluctuations in mood) and 6 
(predominance of mixed affective illness) were not included in analyses due to the 
small number of participants who could be scored on these scales. This was most 
frequently due to the lack of scale-specific information in the cases (e.g. not enough 
information on specific symptoms to be able to state with confidence that an episode
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of affective illness was mixed). A second reason was that neither scale could be used 
in individuals who had not experienced mood disturbance. However, due to the small 
sample size and the success of using these scales in previous samples (e.g. the VCFS 
sample) this did not cause particular concern. See Chapter 6 for further discussion 
regarding the utility of these scales.
4.4 Discussion
A set of clinical ratings were applied to a sample enriched for schizoaffective 
disorder-bipolar type, in which a genome-wide linkage scan had previously reported 
genome-wide significant linkage on chromosome lq42, and suggestive evidence for 
linkage on chromosomes 19pl3 and 22qll. Spearman’s-rho analyses were used to 
test for associations between the IBD allele-sharing probabilities and the squared 
difference in sibling pair scores (DISPS; which gave an indication of how similar the 
pair was with respect to each variable). The only result that withstood corrections for 
multiple testing was that produced when IBD data at lq42 were correlated with 
DISPS for level of impairment (as measured using the GAS) during the worst episode 
of depression (N=20, rs=-0.737, p=0.00483). A significant result was also found 
when this variable was analysed in the smaller sample comprising independent pairs, 
(N=18, rs=-0.696, p=0.0029), although this did not withstand corrections for multiple 
testing. The scatter plots below demonstrate the relationship between genetic- 
similarity (IBD scores) and phenotypic similarity for impairment during depression 
(squared difference of sibs’ scores on the GAS scale rated for worst episode of 
depression). Graph 4-1 presents the data from the full sample and Graph 4-2 presents 
the data from the sample comprising a single pair from each family.
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Figure 4-1: Scatter-plot to demonstrate the relationship between allele-sharing at lq42 and 
sibling-similarity during their worst episode of depression (as measured using the GAS). All 
pairs included.
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Figure 4-2: Scatter-plot to demonstrate the relationship between allele-sharing at lq42 and 
sibling-similarity during their worst episode of depression (as measured using the GAS). Sample 
comprising independent sibling-pairs.
Significant negative correlations were also found when IBD sharing was 
correlated with age at onset (N=22, rs=-0.322, p=0.044). However, this significant 
result was not maintained after corrections were made for multiple testing, and was
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not significant in the sample of independent sibling pairs. The fact that no significant 
result was found in the sample comprising independent pairs may be due to the 
decreased sample size (from N=29 to N=18), resulting in loss of power. An 
alternative explanation may be that the sibling-pairs excluded from this second 
analysis contributed to the initial significant result.
The analyses were also performed using the genetic data for the regions which 
showed suggestive evidence of linkage in the study by Hamshere et al (2005). No 
significant correlations were found for the data on 19p 13. However, a significant 
negative correlation was produced when the estimated maximum IBD allele sharing 
probabilities were correlated with the similarity of siblings’ scores on the Global 
Assessment Scale, measured during their worst ever episodes of illness (N=33, rs=- 
0.418, p=0.008). A significant result was also found when the data were analysed in 
the smaller sample of independent sibling pairs (N=21, rs=-0.432, p=0.025. However 
neither of these results withstood corrections made for multiple testing.
The fact that the two most significant results for these analyses related to 
scores on the Global Assessment Scale is of interest particularly because the 
significant results were found using the genetic data on different chromosomal 
regions. The results provide tentative support for the hypothesis that impairment 
caused by illness is influenced by genetic factors.
As well as significant negative correlations, significant positive correlations 
were also found using the Spearman’s-rho correlations (i.e. for the BADDS Psychosis 
dimension and scores on Extended Rating Scale 5 measures the periodicity of illness 
episodes). As stated above, if IBD scores increase as the difference between sibs’ 
scores on a particular variable decrease, this indicates that genetic similarity is 
associated with similarity for the variable being tested (e.g. the GAS-Depression
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scores on lq42). In contrast, a positive correlation suggests that the less genetically 
similar a related pair are, the more similar they are with respect to the variable being 
tested. Because this research aimed to identify variables which may be genetically 
influenced (which would be inferred by significant negative correlations), one-tailed 
tests were performed on the data and the positive correlations found were attributed to 
chance.
One strength of this study was the level of detail which had been collected 
when the patients were originally recruited. This facilitated the rating process and 
enabled ratings to be made on the majority of cases. As mentioned above, excellent 
reliability was also demonstrated for the majority of variables tested.
One of the main limitations of this study was the number of tests performed, 
leading to an increased risk of false positives. These multiple-testing issues came 
about due to the exploratory nature of this analysis, i.e. the aim was to identify 
hypotheses worth testing in future studies. Further work attempting to replicate these 
findings is important.
The Bonferonni method was used to correct for multiple testing. However, 
this approach assumes that all tests performed are independent; this was not the case 
for all of the measures tested in this study. For example, the Global Assessment Scale 
(GAS) was scored for 5 different states (GAS-Depression, GAS-Mania, GAS- 
Psychosis, GAS-Worst Ever, and GAS-Past Week) and scores for these would not 
always have been independent. If an individual’s worst ever level of functioning 
occurred during an episode of psychotic depression, their scores on the GAS- 
Depression, GAS-Psychosis and GAS-Worst Ever measures would be the same. For 
this reason, it is likely that the corrections made for multiple testing were somewhat 
over-conservative.
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A second limitation of the study was the relatively small sample-size. This 
was exacerbated in variables which were more difficult to rate or which could only be 
rated on a proportion of the sample (e.g. ERS7 could only be rated for individuals 
who had experienced an episode of mania). A larger sample would have increased 
power to detect smaller effects. However, this study was exploratory in nature and 
the significant results identified can be used to formulate and test hypotheses in future 
studies.
Despite the limitations discussed above, a significant negative correlation was 
produced which suggested that increased allele sharing was significantly correlated 
with greater similarity between siblings’ scores on a measure of impairment in 
functioning experienced during their worst depressive episode.
4.5 Summary and Conclusions
In the first known study of its kind, Hamshere et al (2005) undertook genome- 
wide linkage analysis in a sample enriched for schizoaffective disorder, and provided 
evidence to support the existence of loci which influence susceptibility to 
schizoaffective illness. Further investigation of clinical characteristics associated with 
increased allele-sharing at these loci revealed a significant negative correlation 
between IBD score and the similarity of between-sibling scores on the GAS- 
Depression which measures impairment in functioning during the worst episode of 
depressive illness. This suggests that the impairment caused by the illness, 
particularly in relation to depressive episodes, may reflect underlying genetic 
variability in patients with schizoaffective illness, and therefore may be useful in 
future molecular genetic studies.
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Future work involving large well-defined samples of patients with schizoaffective 
illness will help to further investigate the relationship between genetic factors and 
clinical measures in these illnesses.
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5 Assessment of the Familiality of Phenotypic Variables in 
a Large Harmonised Dataset Comprising Families 
Enriched for Bipolar Disorder and Schizophrenia
5.1 Introduction
The work described in this chapter was undertaken with the aim of creating a 
large, richly-described dataset consisting of families enriched for schizophrenia and 
families enriched for bipolar disorder. This was made possible by implementing the 
methods described in chapter 2 on two large family samples which had been 
previously collected as part of ongoing molecular genetic studies within the 
Department of Psychological Medicine, Cardiff University. These samples were then 
combined to form a single Large Harmonised Dataset. Using the methods described 
below, it was subsequently possible to perform analysis to identify clinical variables 
which correlate within families.
5.2 Method
5.2.1 Participants
As stated above, the participants involved in this research were taken from the 
schizophrenia and bipolar disorder family-based samples, which are both described in 
detail in chapter 2. The samples were originally recruited as part of two separate 
linkage studies; one attempting to locate chromosomal regions implicated in 
schizophrenia and the other in bipolar disorder (Bennett et al. 2002b; Lambert et al. 
2005a; Williams et al. 1999). Both samples were recruited in the 1990s, prior to the
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commencement of the current research. Participants were recruited via mental health 
services, mental health support groups and articles in the national media. After 
applying the methods described below, the total sample comprised 835 individuals 
from 373 families. Further details of these samples are presented in the table below, 
as well as in the results section of this chapter
Individuals from 
SZP family sample
Individuals from 
BPD family sample Full Sample
Individuals (N) 399 436 835
Families (N) 198 175 373
Family Size (mean 
(sd)) 2.02 (0.858) 2.49(1.04) 2.24 (.978)
Males (N) 261 173 434
Females (N) 138 263 401
Age at recruitment 
(mean (sd)) 41.67(12.91) 46.31 (14.67) 44.10(14.04)
Table 5-1: Summary of sample characteristics in the large harmonised dataset (LHD), and in the 
schizophrenia and bipolar disorder sub-samples from which the LHD was comprised.
5.2.2 The Rating Process
As described in detail in chapter 2, a common set of clinical measures were 
developed to be used in an identical way across each of the cases in the bipolar 
disorder and schizophrenia family-based samples. Ratings were made on 
approximately 200 variables for each case. These included:
• Ages of onset (years)
• Items from the Operational Criteria (OPCRIT) symptom checklist (McGuffin 
et al. 1991).
• Variables relating to illness course and onset.
• Dimensional ratings using the Bipolar Affective Disorder Dimension Scales 
(Craddock et al. 2004a).
• Global Assessment Scale (GAS) scores (Endicott et al. 1976) which give a 
measure of impairment caused by the illness.
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• Measures of the number and length of illness episodes.
• Ratings made on the novel measures developed during this PhD (see chapter 
2), the Extended Rating Scales (ERS).
A full list of items rated can be found in an example rating-sheet, found in 
Appendix I. A sheet such as this was completed for each case in the sample. Data 
were then entered into a Microsoft Excel spreadsheet.
5.2.3 Checks performed on the data
Data checks were carried out on this sample prior to conducting any analyses 
in the following ways:
The minimum and maximum data-values for each variable were checked to 
ensure that they were consistent with those in the rating guidelines.
- Approximately 1 in 20 cases were subject to a detailed checking procedure in 
which the hard data (i.e. the data on the original rating-sheet) were checked 
against the data contained within the electronic data-file.
- Both gender and age of onset were rated twice, firstly in the “general 
information” section rated at the beginning of the case, and secondly in the “extra 
OPCRIT items”, rated at the end of the case. Ratings made could be compared to 
check for consistency.
The Identification numbers for each case within the sample were checked against 
the “sample-of-origin” (SOO) rating. Cases originating from the schizophrenia 
family sample were rated “1” on the SOO rating; cases originating from the bipolar 
disorder sub-sample were rated as “2”. Checks were made to ensure that the IDs 
allocated to schizophrenia-families and those allocated to bipolar disorder-families
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were correctly identified prior to analyses. It was extremely important that this 
information was accurate because SOO was included as a covariate in the primary 
analyses, as discussed below. The SOO variable was also used to dichotomise the 
LHD into the two sub-samples so analyses could be performed on the schizophrenia 
and bipolar disorder data individually.
5.2.4 OPCRIT Item 84: A measure o f data quality
The information contained in cases varied both in quantity and quality. In the 
majority of instances the data were detailed and informative, and it was therefore 
possible to be confident that ratings made were as accurate as possible.
However, the sample also contained cases for which the quantity or quality of 
information was such that the ratings made were likely to be less valid and reliable. 
For example, sometimes it had not been possible to acquire case-note information, 
despite the fact that numerous inpatient admissions had been mentioned in other 
sources of data (usually in the patient’s interview vignette). Because it is common for 
people not to remember episodes of illness clearly, particularly those that happened 
many years prior to their participation in the research, the impression given of an 
individual’s clinical picture based on the interview alone is almost inevitably going to 
be less accurate and detailed than if multiple sources of information were available for 
this case. This point is supported by Brockington et al (1992) who carried out a study 
examining the relative strength of data collected via patient interviews, informant 
interviews and casenotes. They found that, in general, the weakest source of 
information was that collected via patient-interview, whereas the strongest was the 
information collected from casenotes.
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Sometimes multiple sources of information were available for only a relatively 
brief proportion of the illness. For example, an individual may have had a total 
illness-duration of 20 years, but detailed information was only available for 5 of these. 
Because many ratings are made over the lifetime course of the illness, this missing 
information is likely to have an effect on results. It was therefore important to be able 
to pick out such cases and exclude them from the primary analyses.
This issue was addressed by adapting a rating from the OPCRIT -  OPCRIT 
84: Information not credible. Originally this was a 0/1 rating used to indicate where 
the participant had given “misleading answers to questions” and/or had provided a 
“jumbled, incoherent or inconsistent account”. I expanded this definition to include 
cases in which the quality or quantity of data could be called into question. A three- 
point scale was used: 0 = no major concerns with quality or quantity of data; 1 = some 
concerns with quality or quantity of data; 2 = significant concerns with quantity or 
quality of data. Anonymised examples of cases which would meet criteria 0, 1 and 2 
are included in Appendix L.
Three major points were considered when scoring an individual on this 
variable: Firstly the level of detail contained within the case; secondly the number of 
sources of information considered in total; thirdly the proportion of the overall illness 
described within the case. Analyses could then be performed on either the whole 
sample, or on a sample comprising solely of cases in which the quality and quantity of 
data caused little or no concern. Test-retest reliability analyses were performed for 
OPCRIT Item 84 on a sub-set of 25 cases from the LHD. Excellent reliability was 
demonstrated (Kappa=0.903; p<0.001).
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5.2.5 Selecting Samples for A nalysis
In selecting the cases to be used in the primary analyses I aimed to maximise 
the validity of the data whilst maintaining as large a sample-size as possible. 
OPCRIT item 84 was used to indicate cases in which the quality or quantity of the 
data was considered insufficient to make ratings with confidence. Cases which scored 
a “1” or “2” on this item were excluded from the sample when certain variables were 
analysed. These variables included ratings made using the OPCRIT symptom 
checklist.
The OPCRIT symptom checklist allows the rater to indicate whether or not a 
symptom has been present during the illness. In the analyses described in this thesis, 
“context independent lifetime ever” ratings were used. A positive rating was used to 
indicate that the symptom had definitely been present at some point over the illness 
course, independently of the context in which it was experienced. A rating of “1”, 
indicating that a symptom had definitely occurred, could be made with confidence 
because, to achieve this rating, a clear description of the symptom must have been 
present within the information available for the case. A rating of “0” was used where 
there was no evidence to indicate that the symptom had occurred. However, a score 
of “0” does not necessarily mean that this symptom had not occurred at some point 
during the lifetime course of the illness (or, of course, that it would not occur at a later 
stage of the illness). This introduced a rating-bias more likely to occur where data 
was considered “not credible” according to OPCRIT 84 (i.e. cases containing less 
information were less likely to include the descriptive detail necessary to rate these 
specific symptoms). To address this issue, when data from the OPCRIT symptom 
checklist were analysed, only cases which had been scored “0” on OPCRIT item 84 -
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indicating that there were no major concerns regarding the quality or quantity of the 
information available for the case - were included within the sample.
Other variables for which uncertainty about the rating made could be 
indicated, were the Bipolar Affective Disorder Dimension Scales (BADDS). For 
these scales, uncertainty was indicated either by using a score of “-99” 
(unknown/uncertain) or by marking the rating made with a The latter method 
was used where, given the evidence available, at least two trained researchers agreed 
that this rating was the most appropriate, although the evidence was not sufficient to 
assign this rating to the case with total certainty. For example, an instance in which 
this rating may be used would be where not enough symptoms had been described to 
constitute an episode of mood disturbance, although the overall evidence included 
within the case suggested that an episode had occurred. Because of the element of 
uncertainty indicated by a BADDS rating, these data were excluded from the 
analyses.
For other rating scales, uncertainty was indicated by a score of “-99”, which 
was given where the information available was not sufficient to make a confident 
rating; these were automatically excluded from any analyses.
5.2.6 Reliability o f  Ratings Made
As discussed in chapter 2, good to excellent reliability has been demonstrated 
for each of the measures selected for use within this research, both in the papers in 
which they were originally described (for example, Craddock et al. 2004b) and within 
the Mood Disorders Research Team (See Appendix K). However, it was crucial that 
my own ratings were consistent as it was these ratings that formed the dataset on 
which the primary analyses were undertaken. The extensive training period
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undertaken during the early stages of my PhD provided me with the expertise required 
to carry out these procedures with confidence. Excellent inter-rater reliability has 
already been demonstrated in Chapter 4, for the pilot study on sibling-pairs enriched 
for schizoaffective disorder, in which ratings were made on a subset of cases from this 
sample. During the extensive period over which the ratings were made, I also 
participated in regular reliability meetings with the Mood Disorders Research team, 
thus minimising rater-drift.
Good reliability in the current large sample was maintained and assessed in the 
following ways:
Inter-rater reliability
Consensus meetings
This procedure is identical to that described in chapter 3. Over the duration of 
the period in which ratings were made, 20 cases were selected and rated by two fully- 
trained raters independently (myself and Professor Nick Craddock). Meetings were 
then held in which each case was discussed in detail, any discrepant ratings were 
examined and a consensus rating was agreed upon for each variable.
Reliability of cases rated in this way was assessed and good to excellent 
reliability was demonstrated for the majority of variables (ICCs range from 0.517- 
LOO; kappa scores from 0.455-1.00, see Appendix M), with only two variables 
scoring less then 0.6 (considered to represent good inter-rater agreement). These 
variables were “longest duration of mania” (k=0.517) and the OPCRIT item 
“delusions of passivity” (k=0.455).
One factor that differentiated this method from those described below was the 
fact that cases were not selected at random. In fact, several cases were selected 
because they were considered to be more difficult to rate. The detailed discussion
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between several members of the team was therefore beneficial in highlighting these 
issues and coming to an agreement regarding the most appropriate rating.
It is possible that it was issues relating to the two variables for which only 
moderate agreement was demonstrated that resulted in these cases being selected for 
consensus rating in this way. This would account for the lower kappa scores. 
However, given that the cases selected for consensus-rating in this way were enriched 
for more “tricky” cases, it is reassuring that moderate to excellent agreement was 
demonstrated for all variables.
Consensus review of ratings
This was a shorter procedure which was utilised on the majority of cases in the 
sample. I undertook ratings on the full set of cases. These were often annotated with 
notes about how I had reached a particular score. Cases were then reviewed by 
Professor Nick Craddock, who examined each case, along with the ratings I had made 
and indicated any ratings with which he disagreed. Following this, I reviewed any 
changes suggested by Professor Craddock. Any significant disagreements could then 
be discussed, although in reality this occurred rarely, as where changes were made 
they tended to be slight. In this way a consensus rating was reached for each item.
To assess inter-rater reliability using method ii a sample of 20 cases were 
selected at random (10 from the schizophrenia dataset and 10 from the bipolar 
disorder dataset). This was achieved by entering a complete list of case ID-numbers 
for each sample into an online program, which randomises list-order 
(www.random.orgl. For each sample the top-ten cases in the list generated by the 
program were initially selected. Cases that had been consensus rated using method i) 
above were excluded and an additional case was added to the bottom of the list where 
this occurred. If more than one individual from the same family had been included on
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the list, the family member who appeared lower down would have been excluded and 
a case would have been added to the bottom of the list (in reality this did not occur).
Inter-rater reliability was then assessed using ratings made by myself vs. 
ratings made by Professor Craddock. Excellent reliability was shown (ICCs range 
from 0.975-1.00; kappa scores from 0.902-1.00, as shown in Appendix N).
Test - Re-test Reliability
Because a single individual was largely responsible for rating this large 
sample over a period of almost two years, it was important to check for rater-drift. 
Rater drift occurs when an individual’s rating techniques change gradually over time. 
Rater-drift can be assessed by re-rating a series of cases that were rated at an earlier 
stage of the research.
Twenty cases were selected at random using the list-randomisation method 
described above (again, 10 were selected from the schizophrenia sample and 10 from 
the bipolar disorder sample) each of which I rated for a second time (without referring 
to the ratings made previously). Reliability analyses were then performed to compare 
the ratings made for each measure at the two different time-points.
Good or excellent reliability was demonstrated for all variables tested (ICCs 
range from 0.734-1.00; kappa scores from 0.64-1.00, see Appendix O) thus providing 
reassurance that no significant rater-drift had occurred over the time-period in which 
ratings had been made.
5.2.7 The Creation o f  a Large Harmonised Dataset
As described in chapter 2 and in the introduction above, the main aim of this 
research was the formation of a large harmonised dataset comprising families 
enriched for illnesses representing a spectrum of the functional psychoses. To do this,
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cases from the bipolar disorder and schizophrenia family-based samples were rated 
using identical methods on the same set of clinical measures. On completion of the 
methods described above, the individual samples could be combined to form a large 
sample of 835 individuals representing 373 families, on which analyses could be 
performed.
5.2.8 Statistical Methods
Prior to undertaking any statistical analyses, advice was sought from experts in 
the area who are based in the Department of Psychological Medicine: Professor Peter 
Holmans, Professor of Biostatistics and Genetic Epidemiology; and Dr Marian 
Hamshere, Research Fellow in Statistical Genetics. There were several issues to take 
into consideration when selecting a method of analysing familiality in this dataset. 
Firstly, data did not follow the normal distribution for any variable tested, despite 
attempts to transform the data; therefore the assumptions of many parametric 
statistical tests were violated.
A second issue involved the use of methods which utilised paired-data (i.e. 
sibl vs. sib2). Because many families consisted of more than 2 individuals, using 
these methods a single family would often contribute multiple, non-independent pairs 
to the sample. To create a sample consisting solely of independent pairs, one pair 
from each family could be used. However, this would result in a large loss of data 
and therefore loss of power.
Thirdly, the option of including covariates within the statistical model was 
desirable (for reasons discussed later on in this chapter).
125
The statistical methods considered were: i) Spearman’s Rho correlations 
(Statistical Package for the Social Sciences, Version 12.0.2, 2004); ii. Tetrachoric and 
polychoric correlations (performed using Mx) (Neale et al. 2003); iii) Mixed-effects 
regression analysis (performed using The FORTRAN programs MIXOR for ordinal 
data, and MIXREG for continuous data; (Hedeker and Gibbons 1996a).
After considering all three main options, mixed-effects regression was selected 
for the primary analyses. This is described below, along with the advantages and 
disadvantages of all three methods considered.
Mixed Effects Regression Analysis
The mixed-effects regression methods used in the primary analysis of this 
thesis employed a logistic regression approach to test data-likelihood under different 
models (Hosmer & Lemeshow, 1989).
Logistic regression aims to obtain the best-fitting model to describe the 
relationship between a dependent variable and a set of predictor variables by seeking 
to maximise the likelihood of observing sample values. Binary logistic regression 
seeks to predict membership of two categories, using logit transformations. The 
methods described here further extend this process to consider multiple ordinal 
categories.
Mixed-effects regression can be used to analyse clustered data - in this study 
clusters represented families. Analyses could be performed using the FORTRAN 
programs MIXOR (for binary and ordinal outcome variables) and MIXREG (for 
continuous outcome variables) (Hedeker & Gibbons, 1996a). However, MIXREG 
analyses data on the assumption that they are normally distributed. As stated above
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this was not the case for any variable considered here, therefore the assumption of 
normality would be consistently violated. This posed a major problem in the analysis 
of continuous data which was overcome by creating ordinal categories from 
continuous variables and analysing these data using MIXOR
The analysis was carried out under two different models: 1. All data were 
assumed to be independent; 2. Data within clusters (families) were assumed to be 
dependent. The degree of dependency was estimated by the program and an intra­
class correlation was produced for each outcome variable.
These methods have a number of advantages. Unlike the other methods 
considered, both programs allow for the consideration of differing numbers of 
individuals per cluster/family. This meant that the entire dataset could be included in 
analysis, thus making optimal use of the data. Further, because data weren’t paired, 
order effects were avoided as was the issue of non-independent pairs (this is discussed 
below).
MIXOR and MIXREG also allow for the inclusion of covariates within the 
model, allowing for variables which may influence the phenotype, such as gender, to 
be controlled for. This is discussed more fully later in this chapter.
Both MIXOR and MIXREG have been used successfully in previous studies, 
including that by Schulze et al. (2006a) which used both programs to look at the 
familiality of phenotypic variables in a sample of bipolar disorder-pedigrees.
Other Statistical Methods Considered 
Spearman’s Rho -  non-parametric correlations performed using SPSS.
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Spearman’s Rho correlations can be performed on non-parametric data, to 
assess the magnitude and direction of an association between two variables (in this 
case it is the association of scores between two related individuals for each variable 
considered). One of the main advantages of Spearman’s Rho correlations is that, 
once the data are in the correct format, analyses are easy and quick to perform, with 
the SPSS output producing a correlation coefficient and a p-value. A second 
advantage is that the same method can be used on both continuous and ordinal data, 
meaning that the raw data for each variable can be used.
In terms of disadvantages, results produced using this method are influenced 
by the order of the siblings in the pairs, i.e. sibling 1 vs. sibling 2; switching the order 
of these may give different results. Secondly, because this analysis utilises paired- 
data, there are problems caused by non-independent pairs from the same family. In 
using this method, a decision would have had to be made as to whether to include all 
pairs within the analyses, accepting that many of them are non-independent, or 
whether to use a single pair from each family which would result in decreased power 
and wasted data.
Tetrachoric and polychoric correlations
Tetrachoric and polychoric correlations can be used where dichotomous and 
ordinal variables are assumed to represent underlying continuous bivariate normal 
distributions. These have been commonly used in twin and sibling-pair studies (e.g. 
Cannon et al, 1998; Sullivan et al, 2003). They could be performed on this sample 
using Mx (Neale et al. 2003) (www.vcu.edu/mxf in conjunction with scripts written 
by Dr Stuart McGregor in the Department of Psychological Medicine at Cardiff 
University.
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Because this method of analysis utilises paired-data, the issues regarding non- 
independent pairs, discussed above, are also relevant here. Mx also requires the use 
of scripts which require increased knowledge of computer-programming when 
compared with the other methods considered in this chapter. This method was 
therefore disregarded for the primary analyses in favour of MIXOR, which uses a 
mixed-effects regression model to analyse data.
5.2.9 The Primary A nalyses
Because it was the only method described which was consistent with using the 
entire dataset, did not require normally distributed data and allowed for variation in 
family-size, MIXOR (Hedeker and Gibbons 1996a) was used in the primary analyses. 
This required the transformation of continuous data into ordinal categories, as 
described at a later point in this chapter.
MIXOR can be used to perform mixed-effects ordinal regression. In this 
study, participants were clustered within families. The mixed-effects model assumes 
that data within clusters (i.e. families) are dependent and variance between families is 
used to estimate the degree of dependency.
Before the analyses could be performed, the data-file containing the 
information to be analysed had to be set up in a very precise way. Data-files were 
prepared in spreadsheet-form using Microsoft Excel. To ensure that MIXOR would 
run properly the data had to be in standard-text format, each field had to be separated 
by at least one blank and only numerical data could be included in the file. This was 
achieved by preparing the files in Microsoft Excel and saving them in “Text (tab- 
delimited)” format. Letters (e.g. “m” indicated that only mixed episodes had occurred 
in the BADDS Mania dimension), and symbols (e.g. “+”s and “*”s -  see Chapter 2) 
were replaced with numerical indicators (e.g. “.1” replaced each “+”). Blanks within
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the data prevented the program from running so a value of “-99” was used to indicate 
missing data. Careful records were kept specifying which column of data contained 
each variable (column headings could not be included in the files).
Data-checks could then be made by comparing data within the input file used 
in the analysis with the data in the original raw-data file, using Excel formulae. 
Examples of input-data and the output produced by MIXOR can be found in 
Appendices P-Q.
5.2.10 The inclusion o f  “sample-of-origin ” and gender as covariates
A major advantage of using MIXOR as opposed to the other methods of 
analysis considered is that it allows for the inclusion of covariates within the model. 
Doing so controls for any familiality which may be caused by these effects. Because 
previous studies have identified gender-effects in both schizophrenia and bipolar 
disorder samples (for example, Benedetti et al. 2007; Tang et al. 2007), gender was 
included as a covariate within the model.
A second variable which was included as a covariate was sample-of-origin. 
This relates to whether a family was originally collected as part of the bipolar disorder 
sample or as part of the schizophrenia sample. Although there are many clinical 
overlaps between bipolar disorder and schizophrenia, there are also features that are 
more distinctive of one syndrome than the other. Further, certain rating scales (for 
example the BADDS Incongruence dimension) were designed with these more 
diagnosis-specific characteristics in mind (for example, one anchor point is dictated 
by the presence of the “S set” of symptoms, traditionally associated with a more 
schizophrenic clinical-picture, as discussed in chapter 1). If sample-of-origin was not 
controlled for, in a number of cases significant correlations produced could be 
attributed to differences between the two separate samples which make up the large
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harmonised dataset -  schizophrenia families vs. bipolar disorder families. The aim of 
this thesis was to look for correlations over and above this simple dichotomy.
MIXOR: Set-up prior to analysis
To set the MIXOR program up prior to performing analysis in this sample the 
following had to be specified for each file of data: the electronic location of the 
definition, input and output files; the field containing Level-2 Units (family ID 
numbers); value used to indicate missing data (in this case, “-99”); and fields 
containing covariates.
Before running the analysis, the field containing the outcome-variable of 
interest had to be specified along with the number of ordinal outcome variable 
categories, and the number associated with each category (e.g. 3 categories defined 
using number 0, 1 or 2).
For each variable, the analysis was run twice, using two different models -  the 
first included clustering (including family membership as a random effect), the second 
ignored clustering. An estimated intra-class correlation was produced, representing 
the proportion of the variance that is accounted for by family membership. To obtain 
a p-value, a likelihood-ratio test was performed for each variable, comparing the log- 
likelihood values for each model.
The Formation of Ordinal Categories from Continuous Variables
The continuous variables considered in this study were as follows: Scores on 
the BADDS; GAS scores; number and duration of episodes of illness; ages of onset; 
number of hospital admissions and length of the longest admission; proportion of time 
admitted over the duration of illness; proportion of time individual had been well 
since illness onset; and the Extended Rating Scales. Continuous measures were taken
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one at a time, considered carefully, and ordinal categories were created for each. The 
following points were taken into consideration during this process:
Technical Issues
The distribution o f  the data. Histograms were produced for each measure and 
natural breaks in the data were noted. It was considered to be more appropriate to 
divide data into separate categories at points of rarity.
The number o f  individuals included in each ordinal category. MIXOR is most 
likely to produce stable parameter estimates when the number of individuals per 
category is fairly balanced. This was not possible for all variables (see discussion). 
Where categories contain relatively few individuals, the program will not produce an 
output. In general, as long as categories contained at least ten individuals the program 
would run correctly.
Issues Relating to Phenotype
Anchor points included in scale definitions. These could be used to differentiate 
adjacent scores which were more similar from adjacent scores which were less 
similar. For example, on the BADDS Mania dimension, scores 78 and 79 are more 
similar than scores 79 and 80. The former both indicate that at least one manic 
episode has occurred; the difference in scores is due to the number and severity of 
additional episodes. In the latter example, the higher score reflects that the individual 
has had a single incapacitating episode of illness (for example, the episode may have 
included psychotic features, or may have resulted in the individual being sectioned 
under the Mental Health Act). Therefore, although quantitatively identical, the 
difference between scores 79 and 80 is qualitatively greater than the difference
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between 78 and 79. It was considered more appropriate to divide data into separate 
categories at adjacent scores that were less similar.
The number o f ordinal categories for each measure. MIXOR allowed a 
maximum of 16 ordinal categories to be specified for each measure. To better reflect 
the continuous nature of the data, as many ordinal categories as was appropriate were 
defined for each continuous variable.
A summary of the ordinal-categories along with details of the data-points in the 
raw-data they correspond to can be found in Appendix R.
As discussed below, the analysis was performed firstly on the large harmonised 
dataset (LHD). Where significant intra-familial correlations were found in the LHD, 
the sample was dichotomised and the analyses were performed on the bipolar disorder 
and schizophrenia sub-samples separately. On a number of occasions it was not 
possible to use identical ordinal categories specified for the LHD. Splitting the large 
dataset into the two sub-samples meant that the distribution of data differed from the 
LHD. It was common for certain categories not to be represented at all in a single 
sub-sample. An example of this is shown below.
Sample
100 _ .
S ch izoph ren ia  
m  family sam p le  
_  B ipolar d iso rde r 
m  family sam p le
Figure 5-1: The distribution of ordinal categories for Extended Rating Scale 2 showing the 
relative contributions from the SZP and BPD sub-samples for each ordinal category.
S c o r e  o n  E x te n d e d  R a tin g  S c a le  2
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In the case of Extended Rating Scale 2, ordinal category “14” did not contain 
any individuals at all in the bipolar disorder sample, therefore MIXOR did not run and 
no output was produced. To deal with this problem, for each sub-sample the 
distribution of scores within ordinal categories was examined. Where possible, the 
ordinal categories were kept the same. Where there were fewer than 10 individuals 
within a specific category, the categories either side were examined (e.g. if looking at 
ERS2 “14”, ERS2 “13” and ERS2 “15” would be examined). Taking into 
consideration the number of individuals in the adjacent categories, along with points 
discussed above, categories with few numbers would either be combined with 
adjacent categories, split between adjacent categories or removed altogether (in cases 
where a specific category was “empty, e.g. ERS2 “14” above).
The opposite problem also occurred, in that a large proportion of the subgroup 
would fit into a single ordinal category. For example, ERS2 “1” above contains a 
large proportion of the Bipolar Disorder Sample. In this case, again examining the 
data and taking into consideration the points discussed above, data may be split to 
better reflect the distribution within the sub-sample.
This method ensured that ordinal categories remained as similar as possible to 
those originally specified in the Large Harmonised Dataset, whilst still representing 
the variation within each sub-sample and maintaining the necessary criteria required 
for the MIXOR program to run successfully.
Where significant results were generated, sensitivity checks were performed. 
This involved altering the way in which the continuous variables were reduced to 
ordinal categories, and re-running the analyses. Significant results were maintained 
for all of the variables tested.
134
Program-Performance Checks (MIXOR)
It was possible to check that the MIXOR program had run correctly for each 
variable. Maximum and minimum values were produced for each variable considered 
in the analysis, which could then be checked against the minimum and maximum 
values in the raw data file. For each variable, MIXOR produces means and standard 
deviations. When the program has run correctly, these are identical to those produced 
using SPSS in the raw data file. These checks provided reassurance that the program 
was running properly and producing meaningful results.
5.2.11 Performing the Primary Analyses
The mixed-effects logistic regression analysis performed using MIXOR was 
undertaken firstly on the data contained in the Large Harmonised Dataset. P-values 
were then calculated for the intra-class correlation produced for each variable (using 
likelihood-ratio tests). Where a significant intra-familial effect was demonstrated, 
after controlling for sample-of-origin and gender, the data from the LHD was 
dichotomised into the individual subsets, i.e. the schizophrenia and bipolar disorder 
sub-samples. After carrying out the procedure described in the “creation of ordinal 
categories from continuous variables” section above, the analysis was then performed 
in each individual subset, and p-values were produced for each variable. Output was 
discussed with Professor Peter Holmans.
5.3 Results
As stated above, the final sample comprised 835 individuals, of which 436 
originated from the bipolar disorder family sample and 399 from the schizophrenia 
sample. The table below gives some general phenotype information on the sample:
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Variable Large Harmonised Dataset
Schizophrenia
Sub-sample
Bipolar Disorder 
Sub-sample
Duration of illness (years)
Mean (sd)
18.34(11.949) 17.2(11.384) 19.37(12.362)
Age of onset (years)
Mean (sd)
25.18(9.474) 23.90 (8.078) 26.37 (10.467)
LE Psychosis
%
81.0 96.9 64.0
LE (Hypo)Manic Episode
(BADDS>39) %
55.9 25.5 83.0
LE Depressive Episode
(BADDS>39) %
71.1 50.9 89.2
LE Manic Symptoms
(BADDS>19) %
62.0 33.8 86.0
LE Depressive Symptoms
(BADDS>19) % 81.0 66.6 93.9
Table 5-2: General information on the large harmonised dataset and the two sub-samples from 
which it was created.
The newly developed Extended Rating Scales, designed to be used on sets of 
data comprising features of both psychotic and affective illness, formed an important 
part of this work; the medians and ranges for each scale are presented in the table 
below. Number of individuals included in the analysis are also included to provide 
information on the number of cases for which it was possible to make a positive rating 
(as opposed to a missing data value) thereby giving an indication of scale-utility.
Extended Rating Scale Range of scale
Large
harmonised
dataset
Schizophrenia
sub-sample
Bipolar 
disorder sub­
sample
ERS1: Predominance Mania - N, 
median (range)
0-100 N=669 38 (100)
N=254 
0(100)
N=412 
50 (100)
ERS2: Relationship between 
psychosis and mood disturbance - N, 
median (range)
-20-120 N=725 55 (140)
N=371 
85 (140)
N=357
10(139)
ERS3: Fluctuations in mood - N, 
median (range)
0-100 N=576 0(100)
N=324
0(99)
N=250 
0 (100)
ERS4: Instability o f  clinical state - 
N, median (range)
0-100 N=616 20 (100)
N=285 
20 (100)
N=319 
20 (98)
ERS5: Periodicity o f  acute phases 
o f  illness - N, median (range)
0-100 N=696 90 (97)
N=318 
90 (97)
N=377 
90 (96)
ERS6: Predominance mixed 
episodes - N, median (range)
0-100 N=718 0(100)
N=350 
0(100)
N=367
0(100)
ERS7: Most dysphoric manic 
episode - N, median (range)
1-100 N=398 30 (100)
N=92 
40 (100)
N=306 
30 (100)
ERS8: Prototypical SZP vs 
prototypical affective disorder - N, 
median (range)
1-100 N=778 27 (100)
N-367 
70 (100)
N=410
7(94)
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Extended Rating Scale Range of scale
Large
harmonised
dataset
Schizophrenia
sub-sample
Bipolar 
disorder sub­
sample
ERS9: Predominance negative 
defect state - N, median (range)
1-100 N=7550(100)
N=348
10(100)
N=406
0(70)
ERS10: Catatonic symptoms 
- N, median (range)
0-4 N=7790(4)
N=366
0(4)
N=412
0(3)
ERS11: Disorganised 
behaviour - N , median (range) 0-2
N=647
1(2)
N=347
2(2)
N=297
0(2)
Table 5-3: Table showing N, median and range for each extended rating scale in the large 
harmonised datasets
The tables below summarise the results from the primary analyses. All variables 
in which significant familiality was found in the large harmonised dataset are
presented, along with results for analyses performed in the sub-samples. Results are
presented in the following 4 tables:
1. Variables showing significant familiality in the large harmonised dataset 
(LHD) and both sub-samples.
2. Variables showing significant familiality in the LHD and the 
schizophrenia sub-sample only.
3. Variables showing significant familiality in the LHD and the bipolar
disorder sub-sample only.
4. Variables showing significant familiality in the LHD only.
Variable Large Harmonised Dataset N=835
Schizophrenia Sub­
sample N=399
Bipolar Disorder Sub­
sample N=436
N* ICC p-val** N* ICC p-val** N* ICC p-val**
Length of 
Longest ADM
622
(355) 0.287 .000575
320
(178) 0.295 .014185
302
(157) 0.252 0.018417
Age at first 
admission
660
(349) 0.257 0.000592
345
(188) 0.289 0.004483
315
(161) 0.227 0.043807
Age at first 
impairment
752
(362) 0.223 0.00108
362
(193) 0.249 0.007335
390
(169) 0.200 0.049972
Course of 
Disorder
803
(371) 0.163 0.003936
377
(197) 0.233 0.046044
426
(174) 0.176 0.022756
ERS8 774(362) 0.127 0.028229
366
(192) 0.201 0.027985
408
(170) 0.158 0.023367
Table 5-4: Variables which showed significant familiality in the large harmonised dataset (LHD) 
and both the schizophrenia and the bipolar disorder sub-samples.
N*= Number of individuals (number of families). NA = Variable not analysed due to lack of 
variability within the sample or floor/ceiling effects. ** 1-tailed.
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Variable Large Harmonised Dataset N=835
Schizophrenia Sub­
sample N=399
Bipolar Disorder Sub­
sample N=436
N* ICC p-val** N* ICC p-val** N* ICC p-val**
LE Cannabis 
Abuse
632
(328) 0.689 0.000692
328
(186) 0.777 0.0000561 NA NA NA
Aggressive
Behaviour
655
(326) 0.273 0.000754
324
(177) 0.332 0.003238
331
(145) 0.144 0.175538
GAS Psychosis 598(329) 0.258 0.000967
370
(195) 0.264 0.004366
228
(134) 0.297 0.057433
BADDSI 586(324) 0.224 0.004835
362
(192) 0.285 0.003978
224
(132) 0.181 0.190856
ERS2 (extended 
BADDSI)
720
(352) 0.171 0.008974
369
(193) 0.265 0.004919
351
(159) 0.119 0.174016
Age at first 
contact
698
(353) 0.154 0.010922
357
(190) 0.241 0.008363
341
(163) 0.160 0.072433
AOO Psychosis 476(289) 0.221 0.014121
303
(180) 0.334 0.00341
168
(110) 0.039 0.821332
Chronic Defect 
State (0/1)
757
(367) 0.351 .040519
348
(194) 0.363 .039412 NA NA NA
Other Substance 
abuse
572
(315) 0.587 0.015648
283
(172) 0.537 0.046044
289
(143) 0.66 0.219751
Deterioration 
since onset
715
(362) .251 0.046044
362
(196) 0.391 0.032309
353
(166) 0.069 0.711282
Table 5-4: Variables which showed significant familiality in the large harmonised dataset (LHD) 
and the schizophrenia sub-sample only. N*= Number of individuals (number of families).
NA = Variable not analysed due to lack of variability within the sample or floor/ceiling effects. ** 1-
tailed.
Variable Large Harmonised Dataset N=835
Schizophrenia Sub-sample 
N=399
Bipolar Disorder Sub­
sample N=436
N* ICC p-val** N* ICC p-val** N* ICC p-val**
GASM 466(270) 0.257 0.001819
109
(81) 0.079 0.756684
357
(171) 0.201 0.034881
Psychomotor
retardation
720
(355) 0.268 0.003573
345
(188) 0.089 0.559253
375
(167) 0.367 0.002146
GASWE 811(370) 0.156 0.004466
385
(197) 0.164 0.059474
426
(173) 0.167 0.02302
Diminished
Libido
723
(356) 0.309 0.005054
346
(189) 0.095 0.621332
377
(167) 0.43 0.002343
Age at first 
mania
295
(190) 0.355 0.010842
66
(52) 0.361 0.303444
229
(138) 0.341 0.023206
Negative FTD 705(348) 0.355 0.014177
321
(180) 0.268 0.093096
385
(168) 0.601 0.021758
Marital Status 710(351) 0.273 0.020486
344
(188) 0.222 0.210498
366
(163) 0.336 0.038157
Anhedonia 717(356) 0.190 0.048
348
(189) 0.008 0.950
369
(167) 0.367 0.009
ERS10 749(364) 0.229 0.016
356
(192) 0.112 0.380
393
(141) 0.366 0.010
ERS11 625(330) 0.358 0.024
339
(189) 0.093 0.650
286
(141) 0.716 0.002
ERS7 398(231) 0.216 0.030712
92
(71) 0.139 0.65634
306
(160) 0.253 0.024203
BADDSP 729(355) 0.147 0.032996
363
(193) 0.089 0.425527
352
(160) 0.223 0.024527
Excessive Self 
Reproach
720
(356) 0.187 0.033034
348
(189) 0.013 0.91647
372
(167) 0.337 0.007146
138
Variable Large Harmonised Dataset N=835
Schizophrenia Sub-sample 
N=399
Bipolar Disorder Sub­
sample N=436
N* ICC p-val** N* ICC p-val** N* ICC p-val**
Delsoflnfl/Perse
cutionOl
677
(345) 0.223 0.039066 NA NA NA
339
(159) 0.316 0.018407
Table 5-5: Variables which showed significant familiality in the large harmonised dataset (LHD) 
and the bipolar disorder sub-sample only. N*= Number of individuals (number of families).
NA = Variable not analysed due to lack of variability within the sample or floor/ceiling effects. ** 1-
tailed.
Variable Large Harmonised Dataset N=835
Schizophrenia Sub-sample 
N=399
Bipolar Disorder Sub­
sample N=436
N* ICC p-val** N* ICC p-val** N* ICC p-val**
OP49 Positive 
FTD
681
(345) 0.448 0.012617
301
(177) 0.328 0.097254
382
(168) 0.659 0.075094
No Admissions 806(367) 0.171 0.014692
381
(194) 0.164 0.053156
425
(173) 0.123 0.148169
Age at first 
depression
296
(200) 0.313 0.027217
108
(84) 0.369 0.183258
118
(116) 0.317 0.065752
ERS9 Chronic 
Defect state
751
(364) 0.184 0.034616
347
(194) 0.185 0.058797
404
(170) 0.172 0.422987
Table 5-6: Variables which showed significant familiality in the large harmonised dataset (LHD) 
only. N*= Number of individuals (number of families). NA = Variable not analysed due to lack of 
variability within the sample or floor/ceiling effects. ** 1-tailed.
5.4 Discussion
5.4.1 Summary o f  Results
Performing systematic clinical ratings in both a sample comprising families 
enriched for schizophrenia and a sample comprising families enriched for bipolar 
disorder, enabled these two samples to be combined to form a single, well- 
characterised, large harmonised dataset, representing a spectrum of psychotic- 
affective illness. Exploratory analysis, using a mixed-effects regression model in 
which sample-of-origin and gender were included as covariates, identified significant 
intra-familial correlations for 31 variables. Subsequent analyses performed separately 
in the schizophrenia and bipolar disorder sub-samples revealed that 4 of these 
variables were also significant in both the schizophrenia and bipolar disorder sub­
samples (see table 5-4); 9 were also significant in the schizophrenia sub-sample, but 
not in the bipolar disorder sub-sample; see table 5-5); and 14 were also significant in
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the bipolar disorder sub-sample (but not in the schizophrenia sub-sample; see table 5- 
6).
Discussion o f methods used in analysis
Mixed-effects ordinal regression analyses were performed on the data, using 
the Fortran program MIXOR (Hedeker and Gibbons 1996a). For each variable, an 
intra-class correlation coefficient was generated, representing the proportion of the 
variance accounted for by family membership. One of the main advantages of this 
method was that it allowed for variation in family size. In the final dataset, the 
number of individuals per family ranged from one to seven (with a mean family size 
of 2.23). Other methods considered used paired-data and assumed that all pairs were 
independent; because a single family would frequently have contributed multiple pairs 
to the dataset, this assumption would have been violated. Using a single pair from 
each family would have addressed this issue, but would also have lead to a dramatic 
loss of data.
A second and extremely important advantage of using MIXOR was that it 
allowed for the inclusion of covariates within the model, and thus controlled for any 
familiality which may be caused by these variables. Sex-differences in clinical 
variables have previously been demonstrated in both studies of schizophrenia (Tang et 
al. 2007) and bipolar disorder (Benedetti et al. 2007), therefore gender was included 
as a covariate.
A second covariate included in the model was sample-of-origin. This referred 
to whether an individual was originally recruited to the study in the sample enriched 
for bipolar disorder, or in the sample enriched for schizophrenia. As stated 
previously, although there are many overlapping clinical features which occur in both 
disorders, there are also certain features of illness that are more characteristic of one
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or the other. For example, by definition, manic symptoms such as elation and 
irritability will occur more frequently in families enriched for bipolar disorder. If 
“irritable mood” is analysed in the large harmonised dataset, without controlling for 
sample-of-origin, an intra-class correlation coefficient of 0.372 is produced (p<0.001). 
However, if sample-of-origin is included as a covariate within the model, the intra­
class correlation is dramatically reduced to 0.057 (p>0.05), suggesting that the strong 
correlation produced in the first analysis was largely due to differences between the 
samples. The aim of this research was to identify variables that showed familiality 
over and above that caused by inter-sample differences; controlling for sample-of- 
origin made this possible.
Because none of the data passed tests for normality (despite attempts made to 
transform the data), MIXREG -  the Fortran program designed for use in continuous 
data, which assumes that data are normally distributed (Hedeker and Gibbons 1996a) 
-  could not be used. It was therefore necessary to convert continuous variables into 
ordinal categories before they could be analysed in MIXOR. It is inevitable that 
whenever continuous data are converted into fewer, more general categories, some 
fine-detail of the data will be lost. As described in the methods section, a 
considerable amount of care was taken when converting the continuous data into 
ordinal categories; for example, high numbers of categories were created to keep loss- 
of-information to a minimum. Even so, it is important to consider this when 
interpreting results as it is possible that significant correlations may be seen as a 
spurious result of the way the categories were created. In the current research, 
reassurance that this was not the case and that the results reflected a genuine 
relationship in the data, was provided via two means. Firstly sensitivity testing, in
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which significant correlations were re-tested using a different arrangement of 
categories (see methods) -  all variables tested remained significant.
Secondly, variables in which significant results were produced using the 
mixed-effects ordinal regression analysis were also analysed using Spearman’s Rho 
correlations, as performed in SPSS (Statistical Package for the Social Sciences, 
Version 12.0.2, 2004). To overcome the issue of non-independent pairs, a randomly- 
selected single pair was used from each family (see methods). Spearman’s Rho 
analyses were performed on the variables which were found to be significant when 
analysed using the mixed-effects regression method, firstly in the LHD, and 
subsequently in the individual schizophrenia and bipolar disorder sub-samples. 
Because sample-of-origin was not controlled for using this method, care must be 
taken in interpreting results for variables analysed in the large harmonised dataset. 
Results for the sub-samples are more directly comparable to those generated using the 
mixed effects regression analysis. A significant result produced using these methods 
on the raw continuous data supports the suggestion that there is a genuine familial 
effect in the sample. A non-significant result produced using these methods suggests 
that the significant result reported in the primary analysis may be due to an artefact 
produced by the reduction of continuous data into ordinal categories. For each 
variable discussed below, the Spearman’s-rho correlations are presented alongside the 
results found in the primary analyses.
As stated in the methods section, due to time constraints only variables that 
were significant in the large harmonised dataset were followed up in the individual 
subsamples. This meant that there was a risk of missing significant correlations in 
either the schizophrenia or the bipolar disorder sub-set of cases. This is discussed 
further in chapter 6.
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Discussion o f  Results
The aim of this research was to identify clinical variables more likely to be 
under genetic influence, which therefore may be useful in the advancement of 
molecular genetic studies. However, members of the same family are more likely to 
share environmental risk factors which studies have consistently shown to be 
important in the pathogenesis of both schizophrenia (for example, reveiwed in Tsuang 
et al. 2001) and bipolar disorder (for example, reviewed in Leboyer and Henry 2005). 
It was not possible to investigate the relative contributions of genetic factors and 
environmental influences on the familiality of these variables; this could be 
investigated using twin or adoption studies. However, of the 157 variables included 
in the analyses, the 31 for which significant intra-familial correlations were produced 
are most likely to be genetically influenced, and therefore may be useful in future 
molecular genetic studies.
Due to the large number of variables for which significant intra-familial 
correlations were generated, I have chosen to focus in on those which are particularly 
relevant to the focus of this thesis. The variables that are discussed in more detail 
below are those for which significant results were found in the large harmonised 
dataset and in one or both sub-samples. A significant result produced in at least one 
of the sub-samples provides strong, contextual support for the robustness of the 
familial findings for that variable. Variables are discussed below in the following 
order:
1. Variables which are significant in the large harmonised dataset and in 
both the schizophrenia and the bipolar disorder sub-samples.
2. Discussion of variables which are significant in the large harmonised 
dataset (p<0.01) and in one of the sub-samples.
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3. Brief discussion of variables which are significant in the large
harmonised dataset (p>0.01) and in one of the sub-samples.
4. Brief discussion of variables which are significant in the large
harmonised dataset only.
5.4.2 A note about the risk o f false positives
As stated at a number of points throughout this thesis, my primary analysis 
was exploratory in nature. One hundred and fifty seven variables were tested, 
covering a broad range of clinical characteristics. Although thirty-one variables were 
found to be significantly correlated within families in the large harmonised dataset, 
the large number of tests performed introduces a high risk of false positives.
Although each significant result is discussed in detail below, it should be 
remembered that no significant result withstood corrections made for multiple-testing. 
It is entirely possible that the majority of significant results reported here are false- 
positives and this must be considered when reading the discussion of significant 
findings below.
Conversely it is entirely possible that the majority of significant results 
represent true findings. As is the nature of all exploratory analyses, the main of this 
research was to facilitate future hypothesis-driven studies which aim to replicate these 
findings. This is discussed further in this chapter and in chapter 6.
Variables significant in the large harmonised dataset and across both sub-samples
In relation to the aim of this work, i.e. to identify variables that show 
familiality across traditional diagnostic boundaries, the variables that show significant 
intra-familial correlations across the large harmonised dataset and both sub-samples 
are of particular interest. The fact that significant results were produced in both the
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schizophrenia and bipolar disorder sub-samples indicates that the variable could be 
measured commonly enough in both, and that enough variability had occurred within 
the data to produce such results. These overlapping clinical features are more likely 
to reflect overlapping genetic aetiologies that influence the functional psychoses 
across the Kraepelinian divide between schizophrenia and bipolar disorder.
Results from the Spearman’s Rho analyses are presented along with the results 
from the primary analyses (i.e. the mixed-effects regression analyses) for each 
variable. Results using this alternative method were consistent with those reported in 
the primary analyses for all four variables. This provides reassurance that there was a 
genuine familial effect in the data, and that the significant results produced were not 
merely caused by the conversion of the continuous measures into ordinal categories.
Results are discussed individually below.
Age at onset
Measure: Age at onset (years) was measured in four different ways: age at 
first symptom, age at first impairment, age at first contact with psychiatric-services 
and age at first admission to a psychiatric hospital.
Results: Significant intra-familial correlations were identified for ages at first 
impairment, first contact and first admission. Age at first admission and age at first 
impairment were significant in the large harmonised dataset (LHD) and both the 
schizophrenia and the bipolar disorder sub-samples; age at first contact was 
significant in the LHD and the schizophrenia sub-sample only. Results from the 
mixed-effects regression analyses (MERA) are presented in Tables 5-8 -  5-9 below, 
along with the results produced using the Spearman’s Rho analyses (SRA), performed 
on the sub-set of randomly selected, independent sibling-pairs.
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Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder Sub- 
Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.257 0.00059 0.289 0.0045 0.227 0.044
SRA (r, 
P)
0.350 0.000001 0.325 0.00032 0.364 0.00039
Table 5-7: Age at first admission - comparison of results from primary analyses with results from 
Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder Sub- 
Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.223 0.00108 0.249 0.007335 0.200 0.050
SRA (r, 
P)
0.342 0.000001 0.333 0.00014 0.333 0.00045
Table 5-8: Age at first impairment - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion;
The significant result for age at illness-onset found in the large harmonised 
dataset, as well as in the individual schizophrenia and bipolar disorder sub-samples, is 
consistent with previous studies which have shown age at onset to be familial in both 
schizophrenia (Burke et al. 1996; Kendler et al. 1987; Tsuang 1967) and bipolar 
disorder (Leboyer et al. 1998; O’Mahony et al. 2002). A significant intra-familial 
correlation was also reported in a sample of bipolar pedigrees described by Schulze et 
al (2006a), who used very similar methods to those described in this chapter, although 
their results for age at onset did not remain significant after corrections were made for 
multiple testing.
Further evidence implicating age at illness onset as a clinical marker of 
underlying genetic variability has been suggested by molecular genetic studies. For 
example, Lin et al (2005) performed linkage analysis on their sample of patients with 
bipolar disorder and included age at onset as a covariate. They identified two regions
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of interest: 21q22.13, which showed increased linkage in patients with early onset 
bipolar disorder (onset before 21 years); and 18pll.2, which showed increased 
linkage in patients with later onset bipolar disorder (onset after 21 years). In their 
genome-wide linkage study of age of onset in schizophrenia, Cardno et al (2001) 
found suggestive evidence for linkage at chromosome 17q, although none of the LOD 
(Logarithm of Odds) scores produced in their analyses reached genome-wide 
statistical significance.
Association studies have also addressed the possible role of genes in 
influencing age at onset. For example, Chao et al (2008) found the Val66Met variant 
of the BDNF gene to be associated with age at first psychiatric admission and age at 
first schizophrenic symptoms in a sample of African American patients diagnosed 
with schizophrenia; this was consistent with Numata et al (2006) who originally 
reported the association in a Japanese sample. However, negative results for this gene 
have also been published (Gourion et al. 2005; Naoe et al. 2007).
One limitation of this analysis is that age at onset is a censored variable, i.e. 
siblings within the sample are correlated in chronological age, and are therefore also 
likely to be similar in their ages at onset. LeBoyer et al (1998) encountered a similar 
problem in their study which aimed to investigate age at onset and gender 
resemblance in siblings with bipolar disorder. They tried to overcome it by 
performing their analysis in a sub-set of siblings over the age of 35. However, this 
resulted in a loss of data.
In their study into the familiality of various clinical variables in siblings with 
bipolar disorder which used similar methods to those described in this thesis, Schulze 
et al (2006) included age at interview as a covariate in the model. This was not done 
in the primary analysis described here as this information was not available for all
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individuals, therefore including it as a covariate would have lead to a reduction in the 
sample-size. However, because it is particularly relevant for age at onset, the analysis 
was performed again including age at interview as a covariate. A significant result 
was maintained (ICC=0.230, p=0.00164). As Schulze and colleagues (2006) point 
out, although this approach does not fully compensate for the censoring present within 
the data, it should eliminate large biases due to age.
Further work looking to investigate the familiality of age at onset should 
include systematic ascertainment and long-term follow up of unaffected siblings.
As shown in the tables above, the most significant results were produced for 
age at first admission. One possible reason for this is that, in general, the most 
detailed information available was for cases involving at least one hospital admission. 
It was also more likely that these cases contained multiple sources of data, i.e. 
casenotes and discharge letters as well as information collected at interview. Previous 
studies have shown case-notes to be the best individual source of such data 
(Brockington et al. 1992) and have stressed the importance of having multiple sources 
of data (Brockington and Meltzer 1982). Therefore, age at first admission is likely to 
be the most reliable measure. In contrast, age at first symptom relies largely on 
patient-recollection and is more likely to be subject to random variation and/or bias.
Alternatively, it may be because age at first admission is more likely to be 
influenced by environmental factors than age at first impairment. For example, 
because members of the same family are more likely to live in closer proximity to 
each other and are therefore more likely to be under the care of the same psychiatric 
services. The availability and quality of such services is likely to influence whether 
or not an individual is admitted to hospital (e.g. availability of home-treatment teams, 
number of beds on psychiatric wards, etc). Siblings are also more likely to have a
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similar level of support from individuals within their family, particularly from shared 
parents. The willingness and ability of a family-member to care for an individual 
when they become unwell is likely to influence their need for admission.
In summary, the significant intra-familial correlations produced in the mixed 
effects regression analysis of age at onset are consistent with numerous lines of 
research which suggest that variation in onset-age may be related to underlying 
aetiological variation. Age at onset may therefore be useful in identifying more 
biologically homogeneous subgroups of patients amongst those suffering from 
psychotic-affective illness.
Course of disorder
Measure: The Operational Criteria (OPCRIT) (McGuffin et al. 1991)
definition of course of disorder was used. As demonstrated in the table below, the 
scale comprised a 0-5 scale which aimed to measure the extent to which the illness 
was remitting vs. chronic and deteriorating in course.
Rating Criteria
1 Patient has only experienced a single episode of illness from which they have made a full recovery
2 Patient has experienced multiple episodes, with good recovery between episodes.
3 Patient has experienced multiple episodes with partial recovery between episodes
4 Patient has a continuous chronic illness
5 Patient has a continuous chronic illness with deterioration
Table 5-9: Summary of Operational Criteria for course of disorder.
Results: Results from the mixed-effects regression analyses (MERA) are
presented in Table 5-10 below, along with the results produced using the Spearman’s
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Rho analyses (SRA), performed on the sub-set of randomly selected, independent 
sibling-pairs.
Large Harmonised
Dataset
Schizophrenia Sub- 
Sample
Bipo]
Sul
ar Disorder 
3-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.163 0.0039 0.233 0.046 0.176 0.023
SRA (r, 
P)
0.665 0.0000005 0.325 0.000005 0.244 0.001
Table 5-10: Course of disorder - comparison of results from primary analyses with results from 
Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: Course of disorder was first shown to be significantly correlated 
within families with psychotic illness by Slater et al (1953). This finding has since 
been replicated in a number of studies involving samples of patients with 
schizophrenia and non-affective psychosis (Bleuler 1978; Burke et al. 1996; Kendler 
et al. 1997; Wickham et al. 2002). Fewer studies have investigated the familial 
aggregation of illness course in bipolar disorder. However, Duffy et al (2002) found a 
strong association between the quality of remission between parents with bipolar 
disorder and their affected children. Further, familiality of episode frequency has 
been reported in samples of patients with bipolar disorder (Fisfalen et al. 2005; 
O'Mahony et al. 2002).
In bipolar disorder, course of illness has also been significantly associated 
with other variables that show familiality such as mood-incongruent psychotic 
symptoms, age at onset and severity of disorder (for example, Strakowski et al. 2000). 
In schizophrenia, negative symptoms, associated with a more chronic illness course, 
have also been found to show familiality (Burke et al. 1996), as has the deficit 
syndrome of schizophrenia, which describes individuals with chronic negative 
symptoms which persist during periods of clinical stability (Ross et al, 2000).
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The evidence summarised above suggests that illness course may help identify 
individuals who are more genetically homogeneous.
Length of longest admission
Measure: The length of the patient’s longest admission was measured in
weeks.
Results: Results from the mixed-effects regression analyses (MERA) are
presented in Table 5-11 below, along with the results produced using the Spearman’s 
Rho analyses (SRA), performed on the sub-set of randomly selected, independent 
sibling-pairs.
Large Harmonised
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.287 0.000058 0.295 0.014 0.252 0.018
SRA (r,
P) _
0.323 0.0000025 0.281 0.002 0.325 0.001
Table 5-11: Longest admission - comparison of results from primary analyses with results from 
Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: As far as the author is aware, the length of a patient’s longest 
hospital admission has not been included in previous studies investigating the 
familiality of clinical variables within psychotic-affective illness. However, it follows 
that the number of weeks for which a patient requires hospitalisation is related to the 
course of the illness, discussed above, with a more chronic illness requiring more 
extensive periods of hospitalisation.
However, as with age at first hospital admission, duration of admission is also 
likely to be influenced by environmental factors more likely to be shared by members 
of the same family. Examples include availability of appropriate housing, ability of
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shared family-members to care for individuals when ill and the availability and 
quality of local services (see discussion above).
Extended Rating Scale 8: Prototypical schizophrenia vs. prototypical affective 
disorder
Measure: Extended Rating Scale 8 (ERS8) is a novel measure, the
development of which is discussed in chapter 2. ERS8 gives a lifetime measure of 
how prototypically “affective” or “schizophrenic” an individual’s illness is (see 
chapters 2 and 6).
Results: Results from the mixed-effects regression analyses (MERA) are
presented in Table 5-12 below, along with the results produced using the Spearman’s 
Rho analyses (SRA), performed on the sub-set of randomly selected, independent 
sibling-pairs.
Large Harmonised
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.127 0.028 0.201 0.028 0.158 0.023
SRA (r, 
P)
0.746 0.000001 0.272 0.001 0.155 0.031
Table 5-12: Extended Rating Scale 8 - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: This scale had no fixed anchor points and was far more
subjective than the other measures used in this research. Prototypical schizophrenia 
was defined in the rating guidelines as, “a chronic illness characterised by insidious 
onset, positive and negative symptoms and no evidence of affective disturbance,” 
whilst in contrast prototypical affective disorder was defined as, “episodic illness 
characterised by one or more manic or depressive episodes with good recovery in
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between multiple episodes and with no evidence of psychotic or near psychotic 
symptoms.” Raters were required to use these definitions along with their overall 
impression of the illness to place an individual at the most appropriate point on this 0- 
100 scale, based on all of the available information. Again, ERS8 is related to 
chronicity of illness, although less specifically as the numerous other factors 
associated with prototypical forms of illness are also considered.
It is of relevance that three of the four variables identified as showing 
significant intra-familial correlations in the LHD and across both sub-samples focus 
on an overlapping area of the phenotype. These are measures which delineate more 
typical schizophrenic illness from more typical affective disturbance and therefore 
relate directly to the foundation of Kraepelin’s dichotomy which differentiated 
dementia praecox - a chronic deteriorating illness; from manic-depressive insanity - 
an episodic, remitting illness with a good prognosis.
These results provide support for Kraepelin’s hypothesis that course of illness 
is an important aetiological factor. However, they do not support the hypothesis that 
the dichotomy is the best approach to the classification of the functional psychoses. 
The fact that these results show familiality over and above that resulting from the 
differences between the schizophrenia and bipolar disorder samples suggests that 
these variables are important both across traditional boundaries and within diagnostic 
categories, and may be used to differentiate groups of patients more likely to share a 
common genetic pathogenesis.
5.4.3 Discussion o f  variables which are significant in the large harmonised dataset
(p<0.01) and in one o f  the sub-samples.
When analysed using the mixed-effects regression analysis, the variables 
discussed below showed significant intra-familial correlation in the large harmonised
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dataset (LHD) and either the schizophrenia sub-sample or the bipolar disorder sub­
sample. There are several possible reasons as to why significant results were found in 
one sub-sample but not the other. It may be that genetic and/or environmental factors 
which influence the variable are more specific to one diagnostic group than the other. 
Alternatively it may be that, within one of the sub-samples, there is insufficient power 
to detect familiality, due to the sample size. Variability within the sub-samples is also 
an important issue. If a variable is present in the majority of cases, or in very few 
cases (i.e. floor/ceiling effects), there may not be enough variability to detect a 
familial effect. For example, the vast majority of patients with schizophrenia will 
have experienced psychotic symptoms at some point during their illness, therefore 
there is unlikely to be sufficient variability within the schizophrenia sub-sample to 
produce significant results.
As presented in table 5-5 in the results section, 9 variables were significant in 
the LHD and the schizophrenia sub-sample, of which 5 had a p<0.01; and 14 
variables were significant in the LHD and the bipolar-disorder sample, of which 4 had 
p<0.01 (table 5-6). The nine most significant variables, which are discussed in detail 
in this section are: Cannabis abuse/dependence; aggressive behaviour; level of
impairment (as measured using the Global Assessment Scale) during worst psychotic 
episode, worst manic episode and worst ever episode; psychomotor retardation; scores 
on the BADDS Incongruence dimension; scores on Extended Rating Scale 2, which 
measures the relationship between psychotic and affective symptoms; and diminished 
libido.
Cannabis abuse/dependence
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Measure: The item from the OPCRIT symptom checklist was used to record 
the lifetime-occurrence of cannabis use or abuse.
Results: Significant intra-familial correlations were found in the large
harmonised dataset (LHD) and in the schizophrenia sub-sample, using the mixed 
effects regression analyses. These results were supported by the Spearman’s-rho 
analyses performed on the smaller dataset in which each family was represented by a 
single pair of individuals. Mixed-effects regression analysis was not performed in the 
bipolar disorder sample because cannabis abuse/dependence was only reported in 12 
cases (less than 2%). Of the 157 variables considered overall in these analyses, 
results produced for cannabis abuse/dependence in the LHD and the schizophrenia 
sub-sample were the most strongly correlated and highly significant. Results are 
presented in the table below.
Large Harmonised
dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.689 0.0006 0.777 0.000056 NA NA
SRA (r, 
P)
0.510 0.000 0.610 0.000001 -0.047 0.326
Table 5-13: Cannabis abuse/dependence - comparison of results from primary analyses with 
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: The significant intra-familial correlation produced for cannabis 
abuse/dependence is consistent with previous studies which have shown that 
substance abuse in general, and cannabis abuse in particular, correlates within 
families (Mirin et al. 1991), suggesting a possible genetic effect. Interestingly, 
“substance misuse” was the most significant finding in a study by Schulze et al 
(2006a) which looked at the familiality of various phenotypic variables in a sample of 
families enriched for bipolar disorder, using methods very similar to those described
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in this chapter (ICC=0.304, p<0.001). This suggests that genetic effects may also 
influence substance abuse in bipolar disorder.
Although there is evidence to suggest that cannabis abuse is clustered within 
families, this does not necessarily indicate a common genetic cause. There are many 
environmental factors that have been shown to increase an individual’s susceptibility 
to drug-abuse and which are likely to be shared amongst family-members. These 
include increased environmental exposure to drugs, impaired parenting behaviour, 
negative life-events, disrupted family structure and social deprivation (Merikangas et 
al. 1998).
It is beyond the scope of this thesis to investigate the relative contributions of 
genetic factors and environmental influences on the strong intra-familial effect of 
cannabis abuse seen within the sample described in this chapter. However, genetic 
influences have been shown to play a role in the development of cannabis abuse, with 
heritability estimates ranging from 0.30 -  0.70 (Agrawal and Lynskey 2008). Kendler 
& Prescott (1998) looked at cannabis use, abuse and dependence in a sample of 
female monozygotic and dizygotic twin-pairs. They found evidence to suggest that 
heritability of cannabis use was moderate with genetic risk-factors accounting for less 
than half of the overall liability. In contrast when they studied cannabis heavy use 
(using cannabis more than 10 times in a month), and cannabis abuse (defined using 
DSMIV criteria), their results suggested that genetic factors were responsible for 60- 
80% of the variance in liability. This may be because cannabis use is more likely to 
be associated with the availability of the drug, whereas abuse is a behavioural trait 
more likely to be related to underlying biological factors.
This evidence suggests that, although common environmental risk-factors 
such as those described above, increase susceptibility to substance abuse within
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families, genetic factors also have a role to play. These genetic factors may be 
independent of risk factors for schizophrenia or bipolar disorder, i.e. they may modify 
the course of illness rather than influence the risk of the illness itself.
Studies have consistently shown that cannabis use in populations with 
psychotic disorders is higher than that in the general population (Regier et al. 1990). 
The main psychoactive compound within cannabis (delta-9-tetrahydrocannabinol) 
acts through the cannabinoid receptor CRN1 which is located on 6q 14-15 -  a region 
of replicated linkage for schizophrenia (Lewis et al. 2003). Although findings have 
been inconsistent, several studies have provided evidence suggesting association 
between variation at CRN1 and schizophrenia (Ujike et al. 2002).
Another gene that has been hypothesised to interact with cannabis abuse is 
catechol-o-methyl transferase (COMT) -  a gene involved in the degradation of 
dopamine in the brain which has previously been implicated in both schizophrenia 
and bipolar disorder (Li et al. 1996; Papolos et al. 1998). A common polymorphism 
in COMT results in a valine/methionine substitution which has been shown to 
associate with corresponding high-activity and low-activity enzyme variants 
(Lachman et al. 1996). Increased mesolimbic dopamine transmission has been 
implicated in the pathogenesis of psychotic symptoms -  because of this, Caspi et al 
(2005) hypothesised that the high-activity (158Val) allele would confer increased risk
of psychosis in individuals using cannabis. Their results supported this hypothesis,
• •  * 1with carriers of the COMT valine allele who first smoked cannabis before the age
of 18 being at the highest risk of developing psychotic symptoms and of going on to 
develop schizophreniform disorder. No such effect was found in individuals 
homozygous for the COMT methionine158 allele. However, results have been 
inconsistent and no such findings were reported in a larger sample of schizophrenic
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patients (Zammit et al. 2007), even when using the same cut-off period of cannabis- 
use prior to the age of 18.
Given this evidence and despite the somewhat inconsistent results, it is 
reasonable to suggest that groups of patients with psychotic illness and comorbid 
cannabis abuse may represent a more genetically homogeneous sub-sample of 
patients, and that the identification of such groups may facilitate future molecular 
genetic studies.
Aggressive Behaviour
Measure: Aggressive behaviour was measured using a 4-point scale as shown 
in table 5-14 below.
Rating Criteria
1
Behaviour which is perceived as threatening and is out of proportion to 
the circumstances. Includes verbal aggression. Rated with a low 
threshold.
2
Acts of physical aggression which do not meet the criteria for “3”. 
Includes damage to property and mild acts of unprovoked violence 
towards others.
3 Severe acts of aggression which result in physical injury to others, police involvement or in the individual being restrained.
4 Multiple act of severe aggression which meet the criteria for “3”.
Table 5-14: Summary of rating guidelines for novel measure of aggressive behaviour.
Results: Significant intra-familial correlations were found in the large
harmonised dataset and in the schizophrenia sub-sample, using the mixed effects 
regression analyses. These results were consistent with the Spearman’s Rho analyses 
performed on the smaller dataset in which each family was represented by a single 
pair of individuals. Results are presented in the table below.
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Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.273 0.00754 0.332 0.003238 0.144 0.175538
SRA (r, 
P)
0.319 0.000001 0.285 0.001 0.081 0.200
Table 5-15: aggressive behaviour - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: Aggressive behaviour is an important issue in psychiatry,
particularly as it is a major factor contributing to the stigma surrounding mental 
illness in general and schizophrenia in particular. As is the case with cannabis abuse, 
aggressive behaviour is associated with a number of environmental factors such as 
abuse in childhood (Sappington 2000). Another factor that has been consistently 
associated with aggressive behaviour is substance abuse (Grunebaum et al. 2006). To 
ensure that the significant result produced here for aggressive behaviour was not 
merely due to its association with substance abuse, the analysis was performed again 
in the large harmonised dataset, with the inclusion of substance-abuse (a binary 
variable denoting the presence or absence of alcohol and/or illicit drug 
abuse/dependence) as a covariate. A significant result was maintained (ICC= 0.269, 
p=0.0097), suggesting that the significant result produced for aggressive behaviour 
was not due to its association with substance abuse.
As far as the author is aware, aggressive behaviour has not previously been 
studied by researchers attempting to identify familial variables in samples of patients 
with affective or psychotic illness. However, twin and adoption studies support the 
hypothesis that antisocial behaviour such as aggression is influenced by both genetic 
and environmental factors (Gustavsson et al. 1996) and it is estimated that genetic 
factors account for 40-50% of variance in risk in the general population (Rhee and 
Waldman 2002).
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Molecular genetic studies have also investigated the possibility that aggressive 
behaviour may be genetically influenced. For example, recent studies suggest that 
genes involving the degradation of catecholamines, such as MAOA (Monoamine 
Oxidase A) (Fresan et al. 2007) and COMT (Catechol-O-Methyl Transferase, see 
Chapter 3) may be involved. Both genes have been implicated in both schizophrenia 
(Li et al. 1996) and bipolar disorder (Muller et al. 2007; Papolos et al. 1998) although 
findings have not been consistent (Norton et al. 2002).
It has been suggested that aggression is a heterogeneous construct, for 
example, Volavka et al (2008) list three subtypes of aggressive behaviour: 1. 
Aggression directly related to positive symptoms, e.g. persecutory delusions; 2. 
Impulsive aggression, which may be based on response inhibition; 3. Aggression 
stemming from co-morbidity with psychopathy. These subtypes are likely to be 
aetiologically different, therefore genetic studies may be facilitated by differentiating 
between them.
The significant results produced in the large harmonised dataset and the 
schizophrenia sub-sample are consistent with the hypothesis that aggressive behaviour 
is a clinical marker of underlying genetic heterogeneity. However, no such significant 
result was produced in the bipolar disorder sub-sample. This may be due to the fact 
that aggressive behaviour occurred less frequently in the bipolar disorder sub-sample 
(12% of the bipolar disorder sample had been physically aggressive at some point 
during their illness compared to 40% of the schizophrenia sample), therefore the 
negative result may be due to insufficient sample-size. Although aggression does 
occur in increased rates in bipolar disorder, particularly during manic and mixed 
states (Maj et al. 2003), this phenomenon has not been investigated in bipolar disorder
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to the extent that it has in schizophrenia. Further research is needed to investigate this 
further.
The significant result observed in the large harmonised dataset along with the 
research summarised above suggests that aggressive behaviour is influenced by 
genetic as well as environmental factors. This variable may therefore be useful when 
defining subgroups of patients who are more likely to share a common genetic 
pathogenesis. However, because aggression itself is a heterogeneous concept, this 
research may be further facilitated by refining the definition of aggressive behaviour 
into subtypes of aggression such as those described above.
Scores on the Global Assessment Scale
Measure: The Global Assessment Scale (GAS)(Endicott et al. 1976) is a 0- 
100 variable which can be used to measure an individual’s level of functioning during 
a specific period of time, thus giving an indication of illness severity (see Appendix 
B).
The GAS was used to measure impairment at five different points during the 
illness, where possible. These were: i) during the worst episode of psychosis (GAS- 
P); ii) during the worst manic episode (GAS-M); iii) during the worst episode of 
depression (GAS-D); iv) during the worst ever episode of illness (GAS-WE), and; v) 
during the week prior to their participation in the research (i.e. the week prior to 
interview; GAS-PW). Of these, significant results were found for GAS-P, GAS-WE 
and GAS-M. These results are discussed below.
Results: When data for GAS-P were analysed using the mixed-effects
regression method, significant intra-familial correlations were found in the large 
harmonised dataset (LHD) and the schizophrenia sub-sample; the result for the
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bipolar disorder sub-sample approached significance, as presented in table 5-16. 
When the data were analysed using Spearman’s Rho correlations, significant results
were produced for the large harmonised dataset and both sub-samples.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA
(ICC,p) 0.258 0.00097 0.264 0.0044 0.297 0.057
SRA (r, 
P)
0.270 0.000 0.279 0.00050 0.115 0.013
Table 5-16: GAS scores for worst ever psychotic episode - comparison of results from primary 
analyses with results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
When scores for GAS-WE were analysed using the mixed-effects regression 
method, a significant familial effect was identified in the LHD and in the bipolar 
disorder sub-sample; and results approached significance in the schizophrenia sub­
sample. When the smaller, paired dataset was analysed using Spearman analyses, 
significant correlations were found across all three samples. These results are 
summarised in Table 5-17.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.156 0.0045 0.164 0.059 0.167 0.023
SRA (r, 
P)
0.403 0.000 0.321 0.000046 0.231 0.002
Table 5-17: GAS scores for worst ever episode of illness - comparison of results from primary 
analyses with results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
When the primary analyses were performed on the GAS-M data, significant 
results were produced in the LHD and the bipolar-disorder sub-sample, and the results 
of the Spearman analyses were consistent with this. Results are presented in Table 5- 
18.
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Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.257 0.0018 0.079 0.76 0.201 0.035
SRA (r, 
P)
0.277 0.001 0.126 0.304 0.220 0.009
Table 5-18: GAS scores for worst ever manic episode - comparison of results from primary 
analyses with results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion; The fact that both GAS-P and GAS-WE are significant or 
approaching significance across all three samples when analysed using the mixed- 
effects regression analysis, and that they are significant across all three samples when 
analysed using Spearman’s-rho correlations suggests that variation in illness-severity 
may reflect variation in underlying genetic mechanisms which act across traditional 
diagnostic boundaries. The fact that GAS-M scores are not significantly correlated 
within families in the schizophrenia sub-sample may be because of the smaller 
sample-size (as mania occurred less frequently within the schizophrenia sample).
These results, which suggest that illness severity aggregates within families, 
are consistent with findings from previous studies which have shown the overall 
severity of illness to be familial. For example, Wickham et al (2002), found 
impairment in functioning to be highly familial in their sample of patients with 
schizophrenia. Familiality has also been demonstrated for variables which have been 
shown to be associated with illness-severity such as incongruent psychotic features 
(Goes et al. 2007) and course of illness (see above).
Molecular genetic studies have also sought to investigate further the 
possibility that severity of illness is genetically influenced. For example, Zandi et al 
(2008) found a significant association between scores on the GAS and variation
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within the gene PPARD (peroxisome proliferators activated receptor delta) located on 
chromosome 6p21, a region previously implicated in schizophrenia (Lewis et al. 
2003).
The significant intra-familial correlations found when analyses were 
performed on Global Assessment Scale scores during the worst psychotic episode, 
worst manic episode, and worst over-all episode, support the hypothesis that this 
clinical variable may be genetically influenced. These finding are consistent with 
previous studies, which provide further evidence to suggest that future molecular 
genetic studies may be facilitated by taking variation in impairment during specific 
periods of illness into account.
Bipolar Affective Disorder Dimension Scale, Incongruence Dimension (BADDS-I) 
and Extended Rating Scale 2 (ERS2).
Measure: The BADDS Incongruence dimension (BADDS-I) gives a measure 
of the relationship between psychotic and affective symptoms. The bottom of the 
scale (0) represents affective illness in which the psychotic symptoms which have 
occurred are entirely congruent with the mood state in which they were experienced. 
Scores then increase as the balance shifts from mood-congruent to mood-incongruent 
psychosis and then with the presence of first-rank symptoms. Scores at the top end of 
the scale increase with the greater predominance of psychotic symptoms, and the 
decreasing prominence of affective disturbance.
Extended Rating Scale 2 (ERS2) was created as an extension of the BADDS 
Incongruence dimension (see chapters 2 and 6). The BADDS-I can only be rated for 
individuals who have experienced psychosis, ERS2 was created to allow ratings to be 
made across the entire spectrum of illness, from mood-disorder without psychotic
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symptoms to schizophrenia with no symptoms of mood-disturbance. The results 
produced for each variable are presented in Table 5-19 and Table 5-20 below.
Results: Both variables were significantly correlated within families in both 
the large harmonised dataset (LHD) and the schizophrenia sub-sample when analysed 
using the mixed-effects regression method and when analysed using Spearman
correlations.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.224 0.0048 0.285 0.0040 0.181 0.19
SRA (r, 
P)
0.688 0.000 0.344 0.000028 0.203 0.078
Table 5-19: BADDS-Incongruence dimension - comparison of results from primary analyses with 
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.171 0.0090 0.265 0.0049 0.119 0.17
SRA (r, 
P)
0.724 0.000 0.333 0.000036 0.092 0.161
Table 5-20: Extended Rating Scale 2 - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: DSMIV (APA, 1994) defines mood-incongruent psychotic
symptoms as those with “content...inconsistent with depressive themes such as guilt, 
illness, personal inadequacy or catastrophe,” or, “inconsistent with manic themes such 
as inflated worth, power, knowledge, identity or special relationship to a deity or 
famous person.” Previous studies have found that incongruent psychotic symptoms 
are correlated within families with affective disorder. A recent study by Goes et al 
(2007) found that relatives of individuals with bipolar disorder who had experienced 
mood-incongruent psychosis were significantly more likely to have had mood-
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incongruent psychotic symptoms themselves. They went on to perform a genome- 
wide linkage scan incorporating incongruent psychosis as a covariate. This revealed 
evidence for linkage on chromosome 13q21-33, a region previously implicated in 
both schizophrenia and bipolar disorder, and 2pll-q l4 , previously implicated in 
schizophrenia.
Hamshere et al (in press) also found evidence that incongruent-psychotic 
features aggregate within families; when covariate linkage analysis was performed in 
a large sample of bipolar pedigrees, which included individuals from the sample 
described in this chapter, genome-wide suggestive linkage signals were found at 
chromosomes lq32.3, 7pl3 and 20ql3.31 -  none of which were identified when 
incongruent psychosis was not included as a covariate. This provides further 
evidence to suggest that the nature of the psychotic symptoms in affective disturbance 
may reflect underlying genetic heterogeneity.
However, not all findings have been consistent, for example O’Mahony et al 
(2002) found that the BADDS Incongruence dimension was associated with moderate 
intra-familial correlation in their sample of sibling-pairs with bipolar disorder but this 
was not significant after corrections were made for multiple testing.
Despite these positive findings, no significant familiality was demonstrated in 
the bipolar disorder sub-sample. This may be due to differences in the way 
incongruence was measured. The studies which have reported familiality for this 
variable (Goes et al. 2007; Hamshere et al, In Press) used a binary-variable, indicating 
the lifetime presence or absence of mood-incongruent psychosis; this is in contrast to 
the continuous measures described here.
The congruence of psychotic symptoms within schizophrenic illness has not 
been considered in previous research; this is probably because unless affective
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disturbance is prominent enough to warrant a diagnosis of schizoaffective disorder, it 
is usually discounted under the diagnostic hierarchy (see chapter 1). It is therefore 
particularly interesting that scores on the BADDS Incongruence dimension, and on 
ERS2, were significantly correlated within families in the schizophrenia sample. 
This, alongside previous research suggesting the relationship between psychotic and 
affective symptoms is important in affective disorder, suggests that the relationship 
between psychotic and affective disturbance is a potential indicator of underlying 
biological heterogeneity.
Slowed activity
Measure: The OPCRIT symptom checklist was used to define slowed
activity. To be scored positively on this measure an individual must have experienced 
a feeling of being slowed-up or unable to move. This is a symptom typically 
associated with depression.
Results: Using both methods of analysis, significant results were produced 
within the large harmonised dataset (LHD) and the bipolar disorder sub-sample, as 
presented in Table 5-21.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.268 0.0036 0.089 0.56 0.367 0.0021
SRA (r, 
P)
0.225 0.000001 0.042 0.251 0.305 0.000001
Table 5-21: slowed activity - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: Of all the binary variables analysed during this research, the most 
significant results were produced for slowed activity. This variable is related to 
psychomotor retardation and is a symptom associated with depression. Studies have
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shown that psychomotor retardation is a clinical feature that is more likely to occur in 
bipolar-depression, than unipolar-depression (Mitchell et al. 2008).
Pychomotor poverty is one of five independent symptom dimensions 
associated with schizophrenia (Liddle 1987), which includes poverty of speech, a 
reduction in spontaneous movement and restricted affect. Wickham et al (2001) 
found this psychomotor poverty dimension to be familial. Additionally, they found 
that psychomotor poverty was associated with a more chronic and deteriorating 
course of illness and single marital status, both of which were found to correlate 
within families in this research.
In their twin-study of older adults, Gatz et al (1992) found that, of the 20 
depressive symptoms they studied, genetic factors were most influential for symptoms 
of psychomotor retardation and somatic complaints. Further support for the 
biological significance of this symptom is its association with decreased presynaptic 
dopamine function in the left caudate of depressed patients (Martinot et al. 2001).
In summary, the significant intra-familial correlations produced using the 
methods described in this chapter, along with evidence from the previous research 
such as that summarised above, support the hypothesis that defining groups according 
to the presence or absence of psychomotor retardation may facilitate molecular 
genetic research.
Diminished Libido
Measure: Diminished libido was defined according to the OPCRIT symptom 
checklist (McGuffin et al. 1991) as “a definite and persistent reduction in sexual drive 
or interest as compared with before the onset of the disorder.”
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Results: Using both methods of analysis, significant results were produced 
within the large harmonised dataset (LHD) and the bipolar disorder sub-sample, as 
presented in Table 5-22.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.309 0.0051 0.095 0.62 0.430 0.0023
SRA (r, 
P)
0.182 0.002 0.065 0.240 0.255 0.002
Table 5-22: Diminished libido - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Discussion: As far as the author is aware, diminished libido has not been 
investigated within previous studies which have sought to identify clinical variables 
which aggregate within families. The significant result found within this sample 
suggests that this variable warrants further investigation in future studies.
Brief discussion of variables which are significant in the large harmonised 
dataset (p>0.01), and in one o f the sub-samples 
Age at first psychosis
Measure: The measure reported here was the age at which the individual first 
experienced psychotic symptoms. Significant results were also produced when 
measuring age at first impairment due to psychosis.
Results: Significant intra-familial correlations were demonstrated in the large 
harmonised dataset (LHD) and in the schizophrenia sub-sample using the mixed- 
effects regression analyses. When Spearman correlations were used, significant 
results were found across all three samples. These results are presented in the table 
below:
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Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.211 0.014 0.334 0.0034 0.039 0.82
SRA (r, 
P)
0.339 0.000 0.330 0.001 0.400 0.016
Table 5-23: Age at first psychosis - comparison of results from primary analyses with
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment; The fact that the results found in the bipolar disorder sub-sample 
using the two methods differed to such an extent suggests that the way in which the 
continuous data for this variable were converted to ordinal categories may have 
obscured a genuine familial effect in the families enriched for bipolar disorder. 
However, no significant intra-familial correlation was found when the continuous data 
were categorised differently during sensitivity analyses (see methods). An alternative 
explanation is that the smaller, paired dataset did not contain a representative sample 
of patients. The result may also be influenced by gender effects which were not 
controlled for when using this alternative method. However, when the mixed effects 
regression analysis was run without gender as a covariate, the result remained non­
significant (ICC=0.066; p=0.731). The points relating to age at onset in general, 
which are also relevant to this variable, are discussed in section 1 above.
Chronic defect state
Measure: This was rated using a binary measure, formed by dichotomising 
the results from Extended Rating Scale 9 (ERS9) into individuals who had 
experienced features characteristic of a chronic defect state, and those who did not.
Results: Using the mixed effects regression method, significant results were 
found in the large harmonised dataset (LHD) and in the schizophrenia sub-sample 
(analyses were not performed in the bipolar disorder sub-sample due to the small
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number of individuals who scored positively on this measure). However, when the 
smaller, paired datasets were analysed using Spearman’s Rho correlations, the 
significant results seen in the schizophrenia sub-sample were not maintained. This 
may be due to a decreased power to detect familial effects, caused by the smaller 
sample size. It may also be that gender effects which are not controlled for may be 
obscuring a significant effect within the data.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.351 0.041 0.363 0.039 NA NA
SRA (r, 
P)
0.335 0.000 0.031 0.370 -0.048 0.285
Table 5-24: Presence/absence of a chronic defect state - comparison of results from 
primary analyses with results from Spearman’s-rho analyses in a sub-sample of independent 
sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: Negative features have previously shown familiality using
alternative methods. This is discussed in chapter 6, along with Extended Rating Scale
9 (ERS9). The deficit syndrome of schizophrenia, which is characterised by chronic
negative features which persist for at least 12 month during periods of clinical
stability, has also been shown to correlate significantly within families (Ross et al,
2000).
Other substance abuse/dependence
Measure: “Other substance abuse” refers to any illicit substance other than 
cannabis, which is dealt with using a separate measure (as described above)
Results: Significant intra-familial correlations were found in the large
harmonised dataset (LHD) and in the schizophrenia sub-sample using the mixed- 
effects regression analyses on the full datasets and using the Spearman’s Rho analyses 
performed on the smaller, paired samples.
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Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.587 0.016 0.537 0.046 0.660 0.22
SRA (r, 
P)
0.321 0.000 0.411 0.0000054 0.051 0.300
Table 5-25: Other substance abuse - comparison of results from primary analyses with 
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: Substance abuse has been shown to be familial in previous
studies. This is discussed in section 2 under “cannabis abuse/dependence”.
Deterioration since onset
Measure: The OPCRIT definition of deterioration was used to measure
deterioration. An individual was scored positively on this item if they did not regain 
their premorbid social, occupational or emotional functioning after an acute phase of 
illness (McGuffin et al. 1991).
Results: Significant intra-familial correlations were found in the large
harmonised dataset (LHD) and in the schizophrenia sub-sample using the mixed- 
effects regression analyses. When using the Spearman’s Rho analyses, which were 
performed on the smaller, paired samples, significant results were found in the LHD 
only, although results approached significance in the schizophrenia sub-sample.
These results are presented in table 5-26.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.251 0.046 0.391 0.032 0.069 0.71
SRA (r, 
P)
0.529 0.000 0.136 0.063 0.087 0.19
Table 5-26: Deterioration since onset - comparison of results from primary analyses with 
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
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Comment: Although significant results were produced for this variable, the 
fact that this variable is only just significant suggests that when identifying more 
homogeneous subgroups of patients by illness course, the continuous measure (i.e. 
course of disorder, discussed above) is likely to be more useful than this binary 
measure.
Extended Rating Scale 10: Catatonic features
Measure: Extended Rating Scale 10 (ERS10) was one of the novel measures 
used within this thesis. Originally developed by Dr George Kirov, it comprised a 0-4 
scale in which a point was added for each feature of catatonia experienced, over the 
lifetime course of the illness. This scale is discussed in more detail in chapter 6.
Results: Using both methods to analyse the data, significant results were 
produced within the large harmonised dataset (LHD) and the bipolar disorder sub­
sample, as presented in Table 5-27.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.229 0.016 0.112 0.380 0.366 0.010
SRA (r, 
P)
0.331 0.0000010 0.056 0.216 0.223 0.00017
Table 5-27: Extended Rating Scale 10, catatonic symptoms - comparison of results from 
primary analyses with results from Spearman’s-rho analyses in a sub-sample of independent
sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: The strong correlation found within the bipolar disorder sub­
sample is particularly interesting, as the familiality of catatonic features has not 
previously been studied within samples of patients with affective illness. However, 
previous familiality studies of schizophrenia samples have reported catatonia to 
correlate significantly within families (Kendler et al. 1997; Tsuang 1967). Negative
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results have also been reported in schizophrenia family-samples for catatonic 
symptoms (Kyeong-Sook Choi et al, 2007). ERS10 is discussed in more detail in 
chapter 6.
Extended Rating Scale 11 - Disorganised behaviour
Measure: Like ERS10, Extended Rating Scale 11 (ERS11) was one of the
novel measures used within this thesis and was originally developed by Dr George 
Kirov. It comprised a 0-2 scale in which a point was added for each feature of 
disorganised behaviour experienced over the lifetime course of the illness. This scale 
is discussed in more detail in chapter 6.
Results: Using both methods to analyse the data, significant results were 
found within the large harmonised dataset (LHD) and the bipolar disorder sub-sample, 
as presented in Table 5-28.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.358 0.024 0.093 0.650 0.716 0.002
SRA (r, 
P)
0.171 0.000010 0.055 0.205 0.264 0.0000010
Table 5-28: Extended Rating Scale 11, disorganised behaviour - comparison of results 
from primary analyses with results from Spearman’s-rho analyses in a sub-sample of 
independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s-rho Analyses.
Comment: Previous studies have not focussed on disorganisation using this
measure. However, the disorganisation dimension derived from factor analyses
performed in samples of patients with schizophrenia, has been shown to aggregate
within families (e.g. Cardno et al, 1999), although negative findings have also been
reported (Choi et al, 2007). This is discussed further in chapter 6.
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Anhedonia
Measure: The OPCRIT symptom checklist definition was used to determine 
whether this symptom was present/absent. This defines anhedonia as, “the pervasive 
inability to enjoy any activity” (McGuffin et al. 1991).
Results: Using both methods to analyse the data, significant results were 
produced within the large harmonised dataset (LHD) and the bipolar disorder sub­
sample, as presented in Table 5-29.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r p ICC/r P
MERA 
(ICC, p) 0.190 0.048 0.008 0.950 0.367 0.009
SRA (r, 
P)
0.207 0.0000010 0.000 0.500 0.224 0.0000070
Table 5-29: Anhedonia - comparison of results from primary analyses with results from 
Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: There have been no previous reports of anhedonia correlating 
within families of patients with bipolar disorder. However, anhedonia has been 
shown to be significantly correlated within families in a sample of schizophrenia 
patients (Schurhoff et al. 2003a). In contrast to this finding, the intra-class correlation 
coefficient approached zero when the schizophrenia sub-sample was analysed using 
the mixed-effects regression method. It would be useful to include this symptom 
within future studies investigating the familiality of clinical variables in both samples 
of families enriched for schizophrenia and in family-samples enriched for bipolar 
disorder.
Negative formal thought disorder
Measure: The OPCRIT definition of negative formal thought disorder
(NFTD) was used which requires the presence of one of the following features for a
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positive rating to be made: paucity of thought, frequent thought blocking, poverty of 
speech, or poverty of content of speech.
Results: Using both methods to analyse the data, significant results were 
found within the large harmonised dataset (LHD) and the bipolar disorder sub-sample, 
as presented in Table 5-30.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.355 0.014 0.268 0.093 0.601 0.022
SRA (r, 
P)
0.333 0.000 0.161 0.051 0.315 0.00009
Table 5-30: Negative formal thought disorder - comparison of results from primary
analyses with results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: In the majority of previous studies, negative formal thought
disorder (NFTD) would not have been rated unless it occurred outside of the context 
of mood, due to assumptions made about its underlying causes. It is therefore 
particularly interesting that this variable has shown significant familiality in the 
bipolar disorder sub-sample, as well as showing a trend towards significance in the 
schizophrenia sample. A previous study investigating the familiality of clinical 
variables within a sample of schizophrenia patients found NFTD to be significantly 
correlated within families (Kendler et al. 1997), further supporting the hypothesis that 
this variable may be influenced by genetic factors, and may therefore be useful in 
defining more homogeneous subgroups of patients in future molecular genetic studies. 
However, negative findings have also been reported in the literature. For example 
Choi and colleagues (2007) investigated the familiality of a related variable (poverty 
of speech) and found it to be non-significant in their sample of schizophrenia 
pedigrees.
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Marital Status
Measure: Marital status was a binary measure in which a rating of “1”
indicated that the individual had never been married and had never lived as married at 
any point during their life.
Results: In the primary analyses, significant intra-familial correlations were 
found in the LHD and the bipolar disorder sub-sample. When Spearman’s-rho 
analyses were used, results for the LHD and bipolar disorder sub-sample were 
consistent with the mixed effects regression analyses, and a significant result was also 
found in the schizophrenia sub-sample, as shown in table 5-31.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.273 0.020 0.222 0.21 0.336 0.038
SRA (r, 
P)
0.325 0.000 0.180 0.026 0.351 0.00003
Table 5-31: Marital status - comparison of results from primary analyses with results 
from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: These results are consistent with a recent study by Potash et al 
(2007) in which marital status was found to be significantly correlated within their 
large family-based sample enriched for bipolar disorder.
Extended Rating Scale 7: Dysphoric mania
Measure: Extended Rating Scale 7 (ERS7) measures the extent to which the 
individual’s most dysphoric manic episode was dysphoric in nature. It comprises a 0- 
100 scale in which scores range from a purely elated manic state (0), through 
irritability; scores then increase with the number of depressive features experienced 
during the episode. ERS7 is discussed further in the general discussion (chapter 6).
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Results: Using both methods to analyse the data, significant results were 
found within the large harmonised dataset (LHD) and the bipolar disorder sub-sample,
as presented in Table 5-32.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.216 0.031 0.139 0.66 0.253 0.024
SRA (r, 
P)
0.272 0.002 -0.215 0.22 0.291 0.003
Table 5-32: Extended Rating Scale 7 , most dysphoric mania - comparison of results 
from primary analyses with results from Spearman’s-rho analyses in a sub-sample of 
independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment: The significant intra-familial correlations found when analysing
this novel measure within the LHD and the bipolar disorder sub-sample, suggest that
the extent to which an individuals “most dysphoric” manic episode is characterised by
irritable or depressive symptoms as opposed to pure elation, may be influenced by
genetic or environmental factors.
Delusions of influence/persecution
Measure: A binary measure was used in which an individual was rated as “1” 
if they had experienced delusions of influence and/or persecutory delusions.
Results: Results using both methods were significant in the LHD and the
bipolar disorder. The analysis was not run in the primary analysis on the
schizophrenia sample, due to lack of variability within the data.
Large Harmonised
dataset
Schizophrenia Sub- 
Sample
Bipo]
Sul
ar Disorder 
7-Sample
ICC/r p ICC/r P ICC/r p
MERA 
(ICC, p) 0 .2 3 3 0 .0 3 9 NA NA 0 .3 1 6 0 .0 1 8
SRA (r, p) 0.299 0.000 NA NA 0.176 0.034
Table 5-33: Delusions of influence/persecution - comparison of results from primary 
analyses with results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
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MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Comment; This measure has not previously been analysed in studies 
investigating the familiality of clinical variables. The significant result found in this 
research suggests that it may be worth including this measure in future studies, 
particularly as, when analysed individually, persecutory delusions and delusions of 
influence were not shown to be significantly correlated within families.
5.4.4 Variables significant in the large harmonised dataset only
The variables discussed briefly below were significant in the large harmonised 
dataset only when analysed using the mixed-effects regression analysis. Of these four 
variables, positive formal thought disorder has previously identified as a familial 
variable in a sample of patients with schizophrenia and a sample with non-affective 
psychosis (Kendler et al. 1997), although negative findings for formal thought 
disorder have also been published (e.g. DeLisi et al, 1987); Extended Rating Scale 9 
(ERS9) has not been studied previously, but is associated with the negative syndrome 
for which familiality has been previously identified (Burke et al. 1996; Peralta and 
Cuesta 2007a) although again, negative findings have also been published (e.g. Loftus 
et al, 1998); and age at first depression is related to age at onset which is discussed 
above.
Number of admissions has not been identified as a familial variable in the past, 
although it is related to the course and severity of illness which have been identified 
as familial within this sample and which are discussed above. However, the number 
of times an individual has been admitted into hospital over the course of their illness 
is likely to be associated with the duration of their illness, i.e. individuals who were 
recruited after or during their first episode of illness may go on to have numerous
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hospital admissions over time. Further, as discussed above for the variables “age at 
first admission” and “duration of admission”, the number of times an individual has 
been admitted to hospital is likely to be particularly susceptible to environmental 
factors which are more likely to be shared by individuals from the same family (e.g. 
social situation, availability of local services, etc. See above).
The tables below present the results from the mixed effects regression analysis 
for each of these variables, along with results from the Spearman’s Rho analysis. The 
latter provide further evidence that positive formal thought disorder and number of 
admissions may be useful in identifying more homogeneous groups of patients across 
diagnostic boundaries. However, the significant results produced in the sub-samples 
may be due to a non-representative selection of cases within this smaller sample, or
gender effects which have not been controlled for.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.448 0.013 0.328 0.097 0.659 0.075
SRA (r, 
P)
0.338 0.000 0.257 0.007 0.418 0.000001
Table 5-34: Positive formal thought disorder - comparison of results from primary 
analyses with results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA
(ICC,p) 0.171 0.015 0.164 0.053 0.123 0.15
SRA (r, 
P)
0.283 0.000 0.287 0.0003 0.255 0.001
Table 5-35: Number of admissions - comparison of results from primary analyses with 
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
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Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.313 0.027 0.369 0.18 0.317 0.066
SRA (r, 
P)
0.417 0.001 0.473 0.032 0.390 0.01
Table 5-36: Age at first depression - comparison of results from primary analyses with 
results from Spearman’s-rho analyses in a sub-sample of independent sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
Large Harmonised 
Dataset
Schizophrenia Sub- 
Sample
Bipolar Disorder 
Sub-Sample
ICC/r P ICC/r P ICC/r P
MERA 
(ICC, p) 0.184 0.035 0.185 0.059 0.172 0.42
SRA (r, 
P)
0.406 0.000 0.031 0.371 0.124 0.069
Table 5-37: Extended Rating Scale 9, chronic defect state - comparison of results from 
primary analyses with results from Spearman’s-rho analyses in a sub-sample of independent 
sibling pairs.
MERA - Mixed-Effects Regression Analyses (primary analyses); SRA -  Spearman’s Rho Analyses.
5.4.5 Strengths and Limitations o f  the study design
Strengths
1. The sample.
The primary analyses were undertaken on a large, well-characterised sample of 
patients, comprising families enriched for schizophrenia and families enriched for 
bipolar disorder. This meant that analyses could be performed across traditional 
diagnostic boundaries, to investigate the familiality of clinical variables in 
prototypical functional psychoses.
It was also possible to dichotomise the large harmonised dataset back into the two 
samples from which it was comprised: the schizophrenia family-sample and the
bipolar disorder family-sample. This meant that analyses could also be performed on
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these sub-samples individually. These results were more comparable to those 
produced in previous studies, which have predominantly focussed on samples 
enriched for a single diagnostic category (i.e. bipolar disorder or schizophrenia).
Power analysis can be used to investigate the probability of detecting a true 
effect within a sample of interest, in this case the large harmonised dataset (LHD). 
However, due to the structure of the sample (i.e. families of varying size) and method 
of analysis (logistic regression allowing for covariates), it was not possible to perform 
power analyses that directly reflected the study design, as this would require a 
simulation approach which would be computationally intensive.
One method that could be used to give a rough “ball park” estimate of power 
within the sample was the Pearson product-moment coefficient (r). To calculate 
power, a test-statistic of p<0.05 was used, and effect sizes were defined according to 
Cohen (1988), i.e. small effect size: r=0.10; medium effect size: r=0.30; large effect 
size: r=0.50.
Power tables were used to investigate the statistical power (Cohen 1988). 
These were first applied to the entire paired-dataset (N pairs = 668), which included 
non-independent pairs; and in the dataset comprising independent pairs (i.e. each 
family is represented by a single related pair; N pairs = 310). The true power using 
the Pearson product-moment coefficient should lie somewhere between results 
reported for these methods. Whilst not being directly comparable with the power of 
the logistic regression method used, none-the-less, this estimate will provide a general 
guide to the power of my analysis. The results for these sample-sizes are presented in 
the table below:
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Sample Number of pairs
Power to detect 
small effect 
r=0.10 (approx 
%)
Power to detect a 
medium effect 
r=0.30 (approx 
%)
Power to detect a 
large effect 
r=0.50 (approx 
%)
All pairs N = 668 55 99 99
Independent 
pairs only
oCOIIz 28 99 99
Table 5-38: Power to detect small, medium and large effect sizes in the dataset comprising all 
related-pairs and in the dataset comprising one pair from each family.
For the majority of variables, data were not available for all individuals 
leading to a reduction in sample size. For example, it was possible to rate Extended 
Rating Scale 8, which gives a measure of whether the illness is “prototypically” 
schizophrenia or affective in nature, in the majority of cases within the sample, 
therefore the number of pairs for this variable were approaching those reported above 
(N=660 when all pairs were included; N=277 in the sample of independent pairs. In 
contrast, Extended Rating Scale 7, which gives a measure of dysphoric mania, could 
not be rated in such a large proportion of the sample and the number of pairs included 
in the analyses were greatly reduced (N=294 in the full sample and N=95). Power to 
detect significant effects would be greatly reduced as demonstrated in table 5-39.
Sample Number of pairs
Power to detect 
small effect 
r=0.10 (approx 
%)
Power to detect a 
medium effect 
r=0.30 (approx 
%)
Power to detect a 
large effect 
r=0.50 (approx 
%)
All pairs N = 294 23 81 99
Independent 
pairs only N = 95 8 73 95
Table 5-39: Power to detect small, medium and large effect sizes in the dataset comprising all 
related-pairs and in the dataset comprising one pair from each family, when using the data for 
Extended Rating Scale 7.
The power for the other variables considered in these analyses would lie 
somewhere in between those reported for the variable which could be rated in the 
fewest cases (ERS7) and for those that could be rated in the highest proportion of 
cases (ERS8).
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In summary, these estimates provide a general indication that my analysis was 
well powered to detect effects of large or medium size (at p<0.05) but that power was 
likely to be modest or poor to detect small effect sizes, particularly for those variables 
where data was incomplete.
2. Statistical methods
The main advantages of using the Fortran program MIXOR (Hedeker and 
Gibbons 1996b) to perform mixed effects regression analyses were that: i) it allowed 
for variations in family-size and; ii) covariates could be included within the model 
and thus controlled for. By controlling for sample-of-origin effects it was possible to 
look for variables which showed significant intra-familial correlations above and 
beyond the familiality that would arise as a result of the natural differences between 
the schizophrenia and bipolar disorder sub-samples. Gender-effects could also be 
controlled for in this way.
3. A single rater was responsible for rating the entire sample of patients
After an extensive training period and participation in numerous reliability 
exercises, I was responsible for rating the entire sample of 835 patients, over a period 
of almost two years. This intensive procedure allowed me to become extremely 
familiar with the sample and eliminated the possibility of systematic errors which may 
be introduced by inter-rater differences. This issue is discussed further below.
4. Tools of measurement selected and developed
Both the established tools of measurement and the novel methods developed 
for use within this thesis demonstrated excellent reliability and utility. This is 
discussed further in chapters 2 and 6.
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5. Non-independent measures used to measure certain clinical features
Many of the measures used in which familiality was demonstrated were non- 
independent. This allowed major themes to be identified such as: ages at onset (as 
measures in overall illness, mania, depression and psychosis); illness course (e.g. 
related to course of disorder, ERS8, number and duration of admissions); and severity 
of illness (Global Assessment Scale measures for worst ever period of illness, worst 
manic episode, worst depressive episode and worst psychosis).
6. The schizophrenia and bipolar disorder family samples
The schizophrenia and bipolar samples, referred to as “sub-samples” within 
this thesis, as they are combined to form the large harmonised dataset, were originally 
collected as part of ongoing molecular genetic studies within the Department of 
Psychological Medicine in Cardiff University and the Department of Psychiatry in the 
University of Birmingham. Because the research teams have historically recognised 
the importance of phenotype definition, when these samples were originally recruited 
it was ensured that detailed information was collected on the clinical phenotype, from 
numerous sources of information. It was the quality and quantity of the data collected 
that made the research described in this thesis possible.
Limitations
1. Retrospective study design
As is true for all retrospective studies, the quality of the data used in this 
research was reliant on the quality and quantity of previously-collected data. To make 
positive ratings using the tools selected, detailed descriptions of the relevant items of 
psychopathology were essential. As stated above, in general each case was extremely
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well described, using numerous sources (e.g. interview vignettes, background 
information vignettes, case-notes, etc). However, there were items for which it was 
more difficult to make positive ratings, such as the novel measure Extended Rating 
Scale 3 which measured fluctuations in mood. To make a positive rating on this 
scale, the rater had to be convinced that at least two switches in mood had occurred 
during an acute phase of illness. It was often difficult to be sure whether fluctuations 
described were between mood states (e.g. mania to depression to mania), between 
affective disturbance and euthymia, or between different states within the same 
affective episode (e.g. irritability to elation within mania). In a prospective study, 
information required to make a specific rating could be collected specifically (i.e. 
questions could be asked directly relating to the rating criteria), thus facilitating the 
rating process.
However, although a prospective study would have allowed more project- 
specific data to be collected, it would have been an expensive and time-consuming 
procedure. Taking into account the size of the previously recruited samples, and 
given the amount of detail collected for each case, it would have been a considerable 
waste of resources to disregard these samples and to recruit further patients for this 
purpose. Given the time-scale of this thesis, it would also have resulted in the final 
dataset being substantially smaller in size. The study-design used allowed hypotheses 
to be generated, which can be tested prospectively (as discussed in chapter 6).
2. Multiple testing
Performing analyses on such a large number of variables within the sample 
(N=157) introduced multiple-testing issues that reduced power to detect significant
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effects. After corrections were made for multiple testing using the Bonferroni methd, 
no significant results were maintained.
Due to the large number of tests performed the risk of false positives is high. 
As stated previously, it is entirely possible that the majority of significant findings 
reported in this chapter are false positives. Future work is needed to replicate these 
findings.
However, this was very much an exploratory analysis, and the variables 
identified using these methods can be used to form hypotheses which can be tested in 
future studies. This is discussed further in chapter 6.
3. A single rater was responsible for rating the entire sample of patients
This methodological issue has also been discussed above, in relation to the 
advantages of using this method. However, there are also potential disadvantages 
which must be acknowledged. The fact that a single rater was involved in rating the 
entire sample over a considerable period of time, introduces the risk of rater-drift, in 
which an individual’s method of rating alters gradually over time. However, given 
the time-scale this was the only study-design feasible in creating such a large and 
richly described sample. The limitations of this method were recognised prior to the 
implementation of the methods, and were dealt with in the following ways. Firstly, 
before rating this sample, I underwent a rigorous training program, as described in 
chapter 2. This involved regular meetings with experienced members of the research 
team in both Cardiff University and the University of Birmingham, in which methods 
were discussed. I also participated in regular reliability exercises in which cases were 
rated by trained members of the research teams individually, and then discussed until 
a consensus rating was agreed upon for each measure.
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During the rating of cases comprising the large harmonised dataset, I carried 
out reliability analyses using the following methods: i) inter-rater reliability, in which 
my ratings were compared to the ratings of other members of the research team for 
each measure; ii) analyses in which cases rated in full by myself were then checked 
by Professor Nick Craddock, who highlighted any ratings with which he disagreed; 
iii) Rater-drift analyses, in which I re-rated cases which I had rated at an earlier stage 
of the research, and compared ratings made during the two different time-points. 
Excellent reliability was demonstrated using all methods, providing reassurance that 
my ratings were consistent both over-time and with ratings made by other members of 
the research team (see methods).
4. Possible bias caused by rating members of the same family together
Another possible risk was that rating members of the same family together 
would bias ratings made, i.e. characteristics that occurred between family-members 
would be considered more similar than those occurring between unrelated individuals. 
Because of this, where possible, family-groups were not rated consecutively, for 
example cases from the schizophrenia sub-sample and cases from the bipolar disorder 
sub-sample were rated alternately. The order in which the ratings were made was also 
influenced by the preparation of data for cases used in the Wellcome Trust Case 
Control Consortium (WTCCC 2007). Cases included in this study were prioritised. 
Because the WTCCC was an association study, only a single individual from each 
family was included, and their family-members were rated at a different and usually 
much later date. A list of individuals included in this study, which were also used 
within the WTCCC can be found in Appendix S.
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5. The sample is enriched for “prototypical” forms of the disorders
The samples used to create the large harmonised dataset (LHD) were collected 
on the basis of a proband with the “core diagnosis” (i.e. bipolar disorder or 
schizophrenia) and at least one sibling who met diagnostic criteria for a “broad 
diagnosis” (as described in Chapter 2). This meant that the combined sample was 
enriched for prototypical forms of the disorder, rather than for the more intermediate 
forms characterised by mixed features of both illnesses. It also meant that certain 
pairs were not included within the LHD -  for example there were no siblings within 
the sample who both had a diagnosis of DSMIV defined schizoaffective disorder.
The inclusion of families enriched for schizoaffective disorder would have 
resulted in a broader representation of the functional psychoses. This could be 
achieved by recruiting a sample of patients based on a proband with a diagnosis of 
schizoaffective disorder.
In addition to schizoaffective disorder, other diagnoses characterised by mood 
disturbance and/or psychotic features are not included within this sample, for example 
delusional disorder, brief psychotic disorder, dysthymic disorder, cyclothymic 
disorder, etc. Including these in future work would result in a sample more 
representative of a broad spectrum of functional psychoses.
The inclusion of families enriched for diagnoses such as schizoaffective 
disorder would facilitate phenotypic analyses across diagnostic boundaries. This was 
not possible during this research, which was focussed on samples previously 
collected, but would be an important consideration for future studies.
6. Lack of clinical training
As stated in Chapter 2, the fact that I had received no clinical training prior to 
the onset of my PhD made the training period I underwent prior to beginning my
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work on the schizophrenia and bipolar disorder datasets extremely important. A lack 
of clinical experience meant that my knowledge of the clinical features involved in 
these illnesses was limited to academic study of relevant articles and textbooks.
This is likely to have had some influence on the way in which I rated these 
cases. For example, when reviewing patient case-notes, a trained clinician would be 
more able to “read between the lines” and make judgements based on their own 
clinical experience. Raters with clinical training would also be more able to recognise 
the presence of symptoms based on descriptions of behaviour described in the case- 
notes; this would be a lot more difficult for an individual with no clinical training and 
in this way certain symptoms may have been missed.
However, despite these limitations, it could be argued that there are some 
potential advantages to a lack of clinical experience when undertaking methods 
described in this thesis. My training in the recognition of these symptoms was 
directly related to the rating guidelines used in my primary analyses. For example, 
the Operational Criteria (OPRCIT, McGuffin et al, 1991) was used to record the 
presence of specific symptoms and the glossary provides detailed definitions which 
must be fulfilled before a symptom can be deemed to be present. A rater with clinical 
training would be more likely to make a positive rating based on their prior 
understanding of what constitutes this particular clinical feature, rather than rating it 
positively only if it meets the specific criteria defined by the OPCRIT rating 
guidelines for this item of psychopathology. Rating according to the standard 
definition given by the rating guidelines is likely to increase reliability as it may 
reduce a degree of subjectivity introduced as a result of clinical experience. Such an 
effect has been observed during the research study (Professor Nick Craddock, 
personal communication).
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7. Non-systematic recruitment
Non-systematic recruitment may have resulted in ascertainment bias within 
the sample. Systematic ascertainment would have led to the samples being more 
representative.
8. No follow-up of participants
Participants were not followed up over time, therefore clinical information 
was only available up to the point they were recruited to the study. The majority of 
participants would be likely to experience more episodes of illness post-participation 
which would be likely to alter to some degree their ratings on various rating scales 
which cover the lifetime course of the illness.
9. Possibility of missing less severe episodes of illness
The clinical ratings which were made on the sample relied on detailed and 
accurate documentation of the individual’s illness. This information was obtained at 
interview (during which previous episodes of illness were asked about) and from 
psychiatric case-notes. General Practioner notes were also available for some, but not 
all cases. This meant that it was likely that some episodes of illness, particularly 
those that were insufficiently severe to require treatment, were not recorded and 
therefore not considered when clinical ratings were made.
5.4.6 General discussion o f  findings
The primary analyses performed on the large harmonised dataset identified 31 
variables that were significantly correlated within families. Due to the exploratory
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nature of this study, no individual result withstood corrections for multiple testing 
using the Bonferonni method. However, because many of the variables were non- 
independent, corrections made are likely to be over-conservative. Further, when 
testing 157 variables using a 5% significance level, 7.85 variables would be expected 
to show significant results by chance, assuming that these variables were independent. 
Although, as discussed above, not all the measures tested were independent in this 
research, the fact that 31 variables were identified suggests that many of these are 
likely to reflect a genuine effect within the sample, rather than chance-findings.
It is encouraging that many of the variables that were significantly aggregated 
within families in this sample are consistent with previous studies investigating 
familiality in clinical variables. As well as providing further evidence to support the 
hypothesis that there is a genuine familial effect, it also provides reassurance 
regarding the validity of the ratings made for this research. This is discussed further 
in chapter 6.
In the majority of cases, the Spearman’s-rho analyses performed on the paired- 
sample comprising a single pair from each family supported the results produced in 
the primary analyses. Where differences did occur, in the majority of cases the 
findings from the Spearman’s analyses were more significant than those found using 
the mixed effects regression analyses, and resulted in the variable reaching 
significance in the sub-sample in which no significant effect was found originally. 
This supports the hypothesis that the significant results reported in the primary 
analyses reflect a genuine familial effect within the data, and were not false-positives 
produced as a result of the way the continuous data were converted into ordinal 
categories.
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However, caution must be taken when interpreting the results from the 
Spearman’s analyses. Unlike in the primary analyses, gender and sample-of-origin 
were not controlled for, which could account for the differences observed in the 
results. Further, Spearman’s-rho correlations are influenced by the way the siblings 
are ordered, i.e. sibling 1 vs. sibling 2. If the order of some of the siblings were 
switched, results may be different. It may also be the case that, despite selecting pairs 
at random to form the smaller dataset, it may be unrepresentative of the larger sample 
from which it was formed.
It is particularly interesting that three of the four variables that were significant 
in the large harmonised dataset and both sub-samples were related to course of illness 
which Kraepelin (1919) used to differentiate patients with dementia praecox from 
patients with manic-depressive insanity. These results support Kraepelin’s hypothesis 
that course of illness is an important aetiological factor in the functional psychoses. 
However, the fact that significant familiality was demonstrated in the schizophrenia 
and bipolar disorder samples individually, as well as in the LHD after controlling for 
sample-of-origin effects, suggests that course of illness may be useful in defining 
more homogeneous subgroups of patients both within and across the traditional 
diagnostic boundary enforced by the dichotomy.
It is also interesting to note that several variables for which significant 
familiality was found in the LHD and in the bipolar disorder sub-sample have 
previously been thought of as more typically associated with schizophrenic illness. 
These include catatonic symptoms (ERS10), disorganised behaviour (ERS11) and 
negative formal thought disorder. It may be that these measures are more generally 
related to severity of illness, which would be consistent with the findings for GAS-M 
(which measured impairment during the worst ever episode of mania). For example,
193
for the symptoms included in the rating criteria for ERS10 and ERS11 to be rated, 
they had to be distinguishable from features more typical of affective disturbance, in 
terms of their nature or severity.
Although it is likely that shared environmental effects are involved in the 
pathogenesis of many of the variables identified in this study, of the 157 variables 
tested the variables for which a familial effect was demonstrated in this sample are the 
most likely to be genetically influenced, and therefore are the most likely to be of use 
on future molecular genetic studies. Future research studies into psychotic-affective 
illness should be informed by phenotypic analyses such as these. It is important that 
information allowing these measures to be rated are collected in the large samples 
needed to elucidate the genetic mechanisms involved in the functional psychoses. 
This is discussed further in chapter 6.
5.5 Conclusion
In conclusion the successful implementation of the methods described within this 
chapter resulted in the identification of 31 clinical variables which showed familiality 
in a mixed sample comprising families enriched for schizophrenia and families 
enriched for bipolar disorder (although due to the number of variables tested the risk 
of false positives is high). These may be useful in future studies to help identify 
subgroups of patients more likely to share a common genetic pathogenesis. It is 
hoped that in the future, increased understanding of the biological mechanisms 
involved in these debilitating disorders will lead to more successful treatments which 
are more tailored to the underlying biology of the illness, ultimately leading to 
improved quality of life for patients and their families.
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6 General Discussion
The aim of this thesis was to develop a set of measures that could be used 
across traditional boundaries on patients with psychotic-affective illness; to assess the 
familiality of these variables in a large sample of patients representing a spectrum of 
the functional psychoses; to perform phenotype assessment in a sample of patients 
with Velo-Cardio-Facial Syndrome (VCFS); and to perform analyses in a sample 
enriched for schizoaffective disorder. The results of these analyses are summarised 
below.
6.1 Summary of results
6.1.1 Primary A nalysis
The primary analysis was carried out on a large harmonised dataset comprising 
families enriched for psychotic and affective illness. Each case was rated on a set of 
approximately 200 clinical variables, which covered a wide-spectrum of clinical 
characteristics. Mixed-effects regression analysis was performed on the final dataset, 
which consisted of 835 individuals from 373 families, to investigate which of the 
clinical variables measured were significantly correlated within families. Thirty-one 
such variables were identified; these are presented in table 6-1 below.
At a 5% significance level, approximately 8 variables would be expected to 
show significant intra-familial correlations by chance. The fact that 31 variables were 
identified is therefore particularly encouraging and suggests that a number of these 
significant results are likely to be indicators of a genuine effect, rather than false- 
positives. However, none of these individual significant results withstood corrections 
for multiple testing, which is unsurprising given the large number of variables that 
were tested (N=157).
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However, few variables tested were likely to be completely independent. For 
example, age at onset was measured in a number of different ways (e.g. age at first 
symptom, age at first admission, age at first psychosis, etc). Level of impairment was 
also measured in a number of different ways using the Global Assessment Scales 
(GAS, Endicott et al, 1976), for example during worst depression, worst psychosis, 
etc. Further, many of the rating scales overlap to a degree. For example, ratings 
made using the GAS, the Bipolar Affective Disorder Dimension Scales (BADDS, 
Craddock et al, 2004), and Extended Rating Scale 8 (prototypical schizophrenia vs. 
prototypical affective disorder) are all influenced by the overall severity of an 
individual’s illness.
Because not all variables tested were independent, the corrections made for 
multiple-testing are likely to be over-conservative. However, due to the large number
of tests performed there is still a high risk of false positives, as discussed previously.
Clinical variables which 
showed significant IFC in 
the LHD and both sub­
samples
Clinical variables which 
showed significant IFC 
in the LHD and the SZP 
sub-sample
Clinical variables which 
showed significant IFC 
in the LHD and the BPD 
sub-sample
Clinical variables which 
showed significant IFC in 
the LHD only
Length of longest 
admission**
Age at onset**
Course of disorder*
ERS8: prototypical 
affective disorder vs 
prototypical SZP
LE Cannabis abuse**
Aggressive behaviour**
Impairment during worst 
psychosis**
Dimensional measure of 
incongruence*
ERS2: Relationship 
between psychotic and 
affective symptoms*
Age at first psychotic 
symptoms
Presence/absence of 
chronic defect state
Other substance abuse
Deterioration since 
illness onset
Impairment during worst 
mania*
Psychomotor retardation*
Impairment during worst 
illness*
Diminished libido*
Age at first mania
Negative formal thought 
disorder
Marital status
ERS7: Most dysphoric 
manic episode
Excessive self-reproach
Delusions of influence 
and/or persecution
ERS10: Catatonica
ERS11: Disorganised 
behaviour 
Anhedonia
Positive formal thought 
disorder
Number of admissions
Age at first depression
ERS9: Extent to which 
illness is characterised by 
a chronic defect state
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Table 6-1: Summary of variables for which a significant intra-familial correlation was produced 
in the large harmonised dataset (LHD) using mixed effects regression analysis.
*p<0.01 in the LHD, **pp<0.001 in the LHD. ERS -  “Extended Rating Scale” ; LE -  “Lifetime Ever”. 
IFC -  intra-familial correlation
ii. Velo-Cardio-Facial Syndrome Sample
To investigate the phenotype in a sample of 21 patients with Velo-Cardio- 
Facial Syndrome (VCFS) and a major psychiatric disorder I rated each case on a 
subset of the ratings used in the primary analyses. I also diagnosed each patient using 
the Research Diagnostic Criteria (RDC) (Spitzer, Endicott & Robins, 1975). The 
sample was characterised by high rates of schizoaffective disorder; 47.6% of the 
sample met RDC criteria for this diagnosis. Of the remainder, 23.8% were diagnosed 
with schizophrenia and 28.6% with major depressive disorder.
Using the Bipolar Affective Disorder Dimension Scales (BADDS, see chapter 
2), it was possible to further examine the rates of affective and psychotic disturbance 
within the sample. Psychotic symptoms were present in 71% of the sample (N=15). 
Rates of affective disturbance were high, with 81% of the sample (N=17) having 
experienced at least one episode of mania, hypomania or major depression. When the 
criteria were relaxed to include sub-clinical episodes of affective-disturbance, this 
rose to 95% (N=20). The relationship between psychotic features and affective 
disturbance is summarised in the graph overleaf.
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Figure 6-1: Prevalence and relationship between affective disturbance and psychotic symptoms 
within a sample of VCFS patients with a m ajor psychiatric diagnosis.
Depression was found to be particularly prevalent in the sample, with 62% 
(N=13) having experienced at least one episode of major depression, rising to 67% 
(N=14) if minor episodes of depression were also included. These results suggest that 
VCFS may be associated with a phenotype characterised by high rates of psychosis 
and mood disturbance, most frequently characterised by depressive episodes.
Hi. Schizoaffective sub-sample
Clinical ratings were also undertaken on a subset of patients from the LHD in 
which a genome-wide linkage scan had previously been undertaken (Hamshere et al, 
2005). These comprised 35 sibling-pairs enriched for schizoaffective disorder, for 
which significant genome-wide linkage had been reported on lq42, and suggestive 
linkage on 22qll and 19p 13. Estimations of the maximum-likelihood identical-by- 
descent (IBD) allele-sharing probabilities were available for each sibling-pair in the 
sample at these three chromosomal locations. IBD-scores on chromosome lq42 were
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correlated with the squared-difference in the between-sibling scores for each clinical 
variable that was rated. Similar analyses were also performed using the IBD-scores at 
the regions in which suggestive linkage had been reported (i.e. 22ql 1 and 19pl3).
A significant negative correlation was produced for the difference in Global 
Assessment Scale (GAS) scores in depression (N = 20, rs = -0.737, p=0.00021). This 
suggests that individuals who are more similar in terms of the severity of their worst 
episode of depression, are also more genetically similar at lq42. Significant negative 
correlations were also observed between IBD score at lq42 and sibling-similarity for 
age at first impairment (N=22, rs=-0.322, p=0.044), and between allele-sharing at 
chromosome 22qll and sibling-similarity for worst level of functional impairment 
experienced over the entire duration of illness (as measured by the GAS; N=33, rs=- 
0.418, p=0.015).
These results suggest, when using genetic linkage signals as biological validators, 
taking into account the severity of depressive illness, age at onset and the severity of 
illness during the worst overall episode may be useful in defining more homogeneous 
subgroups of patients with schizoaffective illness.
The two smaller samples of patients described in chapters 3 and 4 are of 
interest because both have phenotypes which have some biological validation; the 
VCFS sample because each case was deleted at chromosome 22qll, and the 
schizoaffective disorder sample because significant genome-wide linkage had been 
demonstrated at chromosomes lq42, and suggestive evidence for linkage was 
reported at 19pl 3 and 22ql 1. Further definition of the phenotype in samples such as 
these is particularly important due to the fact that findings can be related to underlying 
biological mechanisms. The fact that significant negative correlations were produced
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for three clinical variables in the schizoaffective sample provides further evidence to 
support the hypothesis that using such clinical measures as an adjunct to diagnostic 
categories may be useful in molecular genetic research.
It is interesting that depression was picked out as an important factor in both 
the VCFS sample, which was characterised by high rates of depressive illness, and in 
the sample enriched for schizoaffective disorder (bipolar type), in which between- 
sibling similarity on GAS scores during their worst episode of depressive illness were 
significantly correlated with their similarity at a genetic level. This provides further 
evidence to suggest that depression may be useful in defining more genetically 
homogeneous subgroups of patients, as suggested in previous studies. For example, 
as described in chapter 1, Hamshere et al (2006) performed genome-wide linkage 
analysis on a sample of patients with schizophrenia, conditioning on the occurrence of 
depressive episodes and found genome-wide significant linkage at 4q28.3 and 
suggestive evidence at 20ql 1.21. These regions did not meet the criteria for genome- 
wide significant or suggestive linkage when depressive episodes were not included 
within the model as a covariate.
It is interesting that age at illness-onset and GAS scores for the worst ever 
episode of illness were shown both to significantly aggregate within families in the 
LHD and to be significantly correlated with genetic similarity in analyses performed 
in the sub-sample of cases enriched for schizoaffective disorder. This provides 
further evidence to suggest that these variables are influenced by genetic factors and 
that they therefore may be useful in future studies, for example in refining linkage 
analyses (as discussed later in this chapter).
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6.2 Discussion of novel rating scales
The Extended Rating Scales (ERS) were developed to be used across 
diagnostic categories on cases involving affective disturbance and/or psychotic 
symptoms. Having now applied these scales to the 835 cases comprising the large 
harmonised dataset, it is possible to draw conclusions about the utility of these novel 
rating scales. Each measure is discussed below in relation to the following points: its 
reliability, ease of use within the samples of interest and whether significant results 
were obtained using the mixed-effects regression analyses to assess intra-familial 
correlation.
Extended Rating Scale 1 -  Proportion of affective episodes manic in nature.
The aim of Extended Rating Scale 1 (ERS1) was to assess the proportion of 
episodes of affective-disturbance that were manic in nature. As shown in figure 6-2, 
this was calculated by dividing the total number of manic episodes, by the overall 
number of episodes of affective-disturbance.
Mixed episodes were treated differently according to whether they were 
predominantly manic in nature, e.g. dysphoric mania (in which case 0.75 was added 
to the total number of manic episodes and 0.25 to the total number of depressive 
episodes), predominantly depressive in nature (0.25 was added to the total number of 
manic episodes and 0.75 to the total number of depressive episodes), or comprised a 
roughly balanced mixture of depressive and manic symptoms (0.5 was added to each 
total).
The scale therefore gave a measure of the extent to which the affective 
element of the illness was characterised by high mood.
As discussed in the introduction, a limitation of this scale was that it relied on 
detailed and accurate documentation of illness-episodes. Although less severe
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episodes were less likely to be documented in the case-notes, the majority of 
participants were asked in detail about these at interview. Where it was felt that there 
was not sufficient information to make an accurate rating, a score of “999” 
(unknown/uncertain) was given and the case was excluded from the analysis.
S c o r e  o n  E R S 1  =
T o ta l n o . m a n ic  e p i s o d e s
T o ta l n o . e p i s o d e s  a f f e c tiv e  
d i s t u r b a n c e
50%  D e p r e s s io n  
5 0 %  M an ia
100%  D e p re s s io n O R  1 0 0 %  M ixed  Q% D e p r e s s io n
0%  M ania 1 00%  M an ia
Figure 6-2: Summary of rating guidelines for ERS1.
Reliability
Excellent inter-rater reliability was demonstrated for ERS1 (ICC=0.987).
Utility
The detailed information available for these cases, usually from multiple sources, 
made the calculation of the number and nature of affective-episodes relatively simple 
in the majority of cases. It was possible to rate 80.1% of cases overall on ERS1. 
When considering the two sub-samples individually, it was possible to rate ERS1 in 
63.7% of the schizophrenia cases and 95.2% of the bipolar disorder cases. This is 
demonstrated in the graph below.
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Figure 6-3: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS1, and those for which no rating could be made.
“Data missing” refers to cases which were assigned a rating of “-99” for this 
scale; this data would therefore not be considered in analysis. In the case of ERS1, 
this would either be because there was insufficient data to make a confident rating or 
because no affective episodes had occurred over the lifetime course of the illness. 
The fact that a large proportion of cases were rated in the schizophrenia sub-sample is 
an indication that high levels of affective disturbance were present in this sample. 
Results from the mixed-effects regression analysis
Although ERS 1 succeeded in terms of its ease of utility and reliability, results 
produced using the mixed-effects regression analysis did not demonstrate that this 
measure was significantly correlated within families, as demonstrated in the table
below.
LHD S Z P  S u b - S a m p le B PD  S u b - S a m p le
ICC p -v alu e ICC p -v a lu e ICC p -v alu e
ERS1 0 .0 8 5 0 .22 0 .2 4 5 0 .1 4 0 .061 0 .3 5
Table 6-2: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 2 -  Relationship between psychotic and affective 
symptoms
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The aim of Extended Rating Scale 2 (ERS2) was to provide a measure of the 
relative balance of mood and psychotic psychopathology over the lifetime course of 
illness. ERS2 is an extension of the BADDS Incongruence dimension (BADDSI). 
BADDSI can be used only on cases in which psychotic symptoms have occurred. 
ERS2 extends this scale to include cases in which no psychosis has occurred, and 
cases in which only near-psychotic symptoms are reported; ERS2 can therefore be 
used on all cases of psychotic and/or affective illness. The rating criteria are
summarised in the table below, and can be found in full in Appendix E.
Score Rating Criteria
-20 E p iso d e s  of clinically s ig n ifican t m o o d  d is tu rb a n c e . N o p sy c h o tic  o r  n e a r  p sy c h o ticf e a tu re s  o c c u r
-19 Illness is p red o m in an tly  a ffec tiv e  b u t in c lu d e s  n e a r  p sy c h o tic  f e a tu re s  - o c c a s io n a l a t low e n d  o f ra n g e , f re q u e n t a t  high e n d  of ra n g e
0 P sy ch o tic  sy m p to m s  o c c u r  only  du ring  a ffec tiv e  e p is o d e s  a n d  a re  en tire ly  m o o d -c o n g ru e n t
20 P sy ch o tic  sy m p to m s  o c c u r  only  du ring  affec tiv e  e p is o d e s .  T h e re  is a n  a p p ro x im a te  b a la n c e  b e tw e e n  c o n g ru e n t a n d  in c o n g ru e n t s y m p to m s
40 P sy ch o tic  sy m p to m s  o c c u r  only during  a ffec tiv e  e p is o d e s  a n d  a re  en tire ly  m o o d -in c o n g ru e n t
43/47 P sy ch o tic  sy m p to m s  o c c u r  only  d u ring  affec tiv e  e p is o d e s  a n d  inc lude o n e  o r m o refirst ran k  sy m p to m s
50 P sy ch o tic  sy m p to m s  a r e  p ro b ab ly  p r e s e n t  o u ts id e  o f a n  e p is o d e  of m o o d -d is tu rb a n c e
60 P sy ch o tic  sy m p to m s  a r e  defin itely  p r e s e n t  in th e  a b s e n c e  of a n  affec tive  e p is o d e  ona t le a s t  o n e  o c c a s io n
80 P sy ch o tic  sy m p to m s  a r e  defin itely  p r e s e n t  in th e  a b s e n c e  of a n  affec tive  e p is o d e  onm a n y  o c c a s io n s
100 P sy ch o tic  sy m p to m s  d o m in a te  illn ess  a n d  o c c u r  ch ron ica lly  o u ts id e  of a ffec tiv e  e p is o d e s .  A ffective e p is o d e s  o c c u r  b u t a r e  n o t a  m a jo r  fe a tu re  of illness.
110 P sy ch o tic  sy m p to m s  d o m in a te  illness. A ffective sy m p to m s  o c c u r  w hich  d o  no t m e e t criteria  fo r an  e p is o d e  o f m o o d -d is tu rb a n c e .
120 Illness  is c h a ra c te r is e d  by p sy c h o tic  f e a tu re s  in th e  a b s e n c e  of a n y  d is tu rb a n c e  inm ood .
Table 6-3: Summary of rating criteria for ERS2.
Reliability
Excellent inter-rater reliability was demonstrated for ERS2 (ICC=0.979).
Utility
It was possible to rate 87.65% of the total sample, which when broken down 
into the sub-samples included 92.7% of the schizophrenia sub-sample and 82.6% of 
the bipolar disorder sub-sample, as demonstrated in the graph below.
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Figure 6-4: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS2, and those for which no rating could be made.
In ERS2, “data missing” refers to cases in which it was not possible to make a 
confident rating, due to the descriptions within the data, e.g. it was not clear whether 
psychosis had definitely occurred. In contrast, when BADDSI is used to make 
ratings, “data missing” refers to cases in which it was not possible to make a confident 
rating due to the data but also cases in which no psychotic symptoms had occurred at 
all. For this reason, it was possible to rate a far greater number of cases using ERS2, 
as demonstrated in the graph below.
C o m p a r is o n  o f  % c a s e s  it w a s  p o s s ib le  to  r a te  
u s in g  BA D D SI a n d  E R S 2
■  Bipolar Disorder Cases
■  Schizophrenia Cases
Positive Rating Positive Rating
(BADDSI) % (E R S 2) %
Figure 6-5: Comparison of positive ratings made using BADDSI with positive ratings made 
using ERS2.
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Results from  the mixed-effects regression analysis
ERS2 was found to be significantly correlated within families in both the LHD 
and the schizophrenia sample (see table 6-4 below). This suggests that the scale may 
be useful in the identification of subgroups of patients who are likely to be more 
genetically homogeneous. However, although ERS2 was shown to be significantly 
familial despite the greater numbers which could be included in the analyses, results 
produced for the BADDSI dimensions are actually more highly correlated and more 
significant in the LHD and the SZP sub-sample (see Table 6-4 below), which suggests 
that extending the BADDSI scale to include cases in which no clear psychotic 
symptoms occur may not be beneficial.
LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS2 0.171 0.0080 0.265 0.0049 0.119 0.17
BADDSI 0.224 0.0048 0.285 0.0040 0.181 0.19
Table 6-4: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples for ERS2 and BADDSI.
Extended Rating Scale 3: Fluctuations in mood
The aim of Extended Rating Scale 3 (ERS3) was to measure the maximum 
rapidity of mood fluctuations during an acute phase of illness. The guidelines used 
when rating a case on ERS3 are summarised below:
Score Rating Criteria
100 Fluctuations in mood occur over 1 day
90 Fluctuations in mood occur over 4 days
80 Fluctuations in mood occur over 1 week
70 Fluctuations in mood occur over 10 days
60 Fluctuations in mood occur over 2 weeks
50 Fluctuations in mood occur over 4 weeks
40 Fluctuations in mood occur over 8 weeks
30 Fluctuations in mood occur over 12 weeks
20 Fluctuations in mood occur over 26 weeks
10 Fluctuations in mood occur over 52 weeks
0 No fluctuations in mood occur
Table 6-5: Summary of rating criteria for ERS3.
206
Reliability
Excellent inter-rater reliability for ERS3 was demonstrated (ICC=0.99). 
However, it must be noted that in the cases used to measure reliability, only three 
individuals were rated as being greater than 0 - the remainder being scored as 
“unknown/uncertain” or “0” which indicates that no fluctuations had occurred.
Utility
It was possible to rate 69.5% of cases on this rating scale in the LHD, which when 
broken down into the sub-samples, included 81.2% of the schizophrenia cases and 
57.8% of the bipolar disorder cases. This is demonstrated in the graph below.
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o n
7 0
C i(\DU ■
50 -
■  Bipolar Disorder Cases
■  Schizophrenia Cases
4U -
o n30 - 
7 0
1 0
n
Data Missing Positive Rating
Figure 6-6: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS2, and those for which no rating could be made.
As mentioned above, a score of “0” is a positive rating, indicating that 
although episodes of mood disturbance have occurred, there have been no fluctuations 
in affect. Although a relatively large number of cases could be rated using this scale, 
a large proportion of these were rated “0” (64% of the LHD, 79.9% of the SZP sub­
sample and 47.9% of the BPD sub-sample). Fluctuating mood could only be 
measured in 9.3% of the schizophrenia cases and 9.9% of the bipolar disorder cases.
In general, the clinical information available for each case was extremely 
detailed. However, the rating guidelines state that enough information must be 
present to allow the rater to conclude both that these fluctuations involved definite
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swings from high/mixed mood to depression or vice versa, and to make a judgement 
of the time-scale over which these fluctuations occurred. Because of the specific 
nature of these requirements, it was often not possible to make a confident rating. 
Results o f the mixed-effects regression analysis
Due to the lack of variability within the sample, it is unsurprising that the 
mixed-effects regression analysis did not produce significant results (see Table 6-6 
below). However, this does not necessarily mean that ERS3 should be dismissed 
altogether and it may be useful to implement this scale on a sample of patients in 
which more detailed and specific information was collected regarding fluctuations in 
mood, e.g. by asking questions at interview, and ascertaining more specific 
information from case-notes regarding the exact nature of the affective episodes and 
the time-scales over which any fluctuations occurred.
LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS3 0.256 0.29 0.054 0.99 0.274 0.27
Table 6-6: Mixed-effects regression results produced for the large harmonised dataset (LHD),
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 4: Instability of clinical state.
The aim of Extended Rating Scale 4 (ERS4) was to give an indication of the 
maximum instability in clinical state during the most variable month of illness. 
Unlike ERS3, ERS4 allowed ratings to be made on instability even when the exact 
nature of the clinical state was unknown. For example, broad statements such as 
“rapid fluctuations in mood” which appeared frequently in hospital case-notes could 
be rated using anchor points on ERS4, whereas a score of “uncertain” would be made 
on ERS3 because: i. It would not be possible to be sure that the fluctuations involved 
switches in polarity or more subtle variations in clinical state and; ii. It would not be
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possible from this information to be certain of the time period in which variation 
occurred. The rating guidelines are summarised below; details of anchor points can 
be found in Appendix E.
Score Rating Criteria(refers to most variable month of illness)
100 Clinical state varies significantly during a period of 10mins
80 Clinical state varies significantly during a period of 1day
60 Clinical state varies significantly during a period of 1week
40 Clinical state varies significantly during a period of 2weeks
20 Clinical state varies significantly during a period of 4weeks
0 No variability in clinical state
Table 6-7: Summary of rating criteria for ERS4.
Reliability
Excellent inter-rater reliability was demonstrated for ERS4 (ICC=0.997)
Utility
Rating clinical variability using this measure was possible in 73.9% of cases in 
total -  71.9% of the schizophrenia cases and 75.5% of the bipolar disorder cases, as 
demonstrated in figure 6-7 below.
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Figure 6-7: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS4, and those for which no rating could be made.
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Further, only 18.3% of the schizophrenia cases and 19% of the bipolar 
disorder cases were given a rating of “0” indicating that no variation in clinical state 
had occurred over a period of 4 weeks or less. It was therefore possible to make 
measurements of clinical variability in 55.1% of cases (compared to 9.6% when using 
ERS3).
Results o f the mixed-effects regression analysis
Although ERS 4 succeeded in terms of its ease of utility and reliability, results 
produced using the mixed-effects regression analysis, which showed almost zero 
correlation, did not demonstrate that this measure was significantly correlated within 
families, as demonstrated in the table below.
LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS4 0.00 0.99 0.001 0.99 0.001 1.0
Table 6-8: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 5: Periodicity of acute phases of illness
The aim of Extended Rating Scale 5 (ERS5) was to measure the tendency to 
recurrence of acute phases of illness over the lifetime course of illness. The rating 
guidelines are summarised below, and can be seen in full in Appendix E.
Score Rating Criteria
100 5 acute phases of illness in 1 year
90 2 acute phases of illness in 1 year
70 2 acute phases of illness in 2 years
50 2 acute phases of illness in 5 years
30 2 acute phases of illness in 8 years
20 2 acute phases of illness in 10 years
10 2 acute phases of illness in 50 years
1 < 2 acute phases of illness in 50 years
0 Only 1 acute phase of illness
Table 6-9 Summary of rating criteria for ERS5.
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Reliability
Excellent inter-rater reliability was demonstrated for ERS5 (ICC=0.941). 
Utility
ERS5 was easy to use within the sample and could be rated in 83.3% of cases 
(79.7% of the schizophrenia sample and 86.9% of the bipolar disorder sample), as 
demonstrated in figure 6-8 below.
E x ten d ed  R ating S ca le  5
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Figure 6-8: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS5, and those for which no rating could be made.
Results o f the mixed-effects regression analysis
Although the implementation of ERS5 on the current sample was successful, 
no significant intra-familial correlation was produced, as demonstrated in Table 6-10 
below.
LHD S Z P  S u b - S a m p le B PD  S u b - S a m p le
ICC p-value ICC p-value ICC p-value
ERS5 0.046 0.443 0.075 0.499 0.031 0.681
Table 6-10: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 6: Proportion o f affective ep isodes o f  m ixed polarity.
The aim of Extended Rating Scale 6 (ERS6) was to assess the proportion of 
episodes of affective-disturbance that were mixed in nature, i.e. symptoms indicative
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of both mania and depression were present simultaneously. As shown in the diagram 
below, ratings on this scale were calculated by dividing the total number of manic 
episodes, by the overall number of episodes of affective-disturbance.
S co re  on  ERS6
Total no. mixed episodes
Total no. episodes affective 
disturbance
50% mixed
0% mixed 50% manic/depressive 100% mixed
100% manic/depressive 0% manic/depressive
Figure 6-9: Summary of rating guidelines for ERS6.
Reliability
Excellent inter-rater reliability was demonstrated for ERS6 (ICC=0.999). 
However, as for ERS3, it must be noted here that of the 20 cases considered in the 
reliability analysis, only two had been scored above “0” for this measure.
Utility
Generally ERS6 was easy to use within the sample, and it was possible to 
make positive ratings on 86.3% of cases (87.7% of the schizophrenia sub-sample and 
84.9% of the bipolar disorder sub-sample), as demonstrated in figure 6-10 below. The 
main reason that cases could not be rated was that there was not quite enough 
evidence to state whether the criteria for a mixed-episode had been reached. For 
example, a mention of “mixed episode” in the case-notes was not considered 
sufficient evidence that an episode of mixed mood had definitely occurred, according 
to DSMIV criteria.
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E x tended  R ating S c a le  6
■  Bipolar Disorder Cases
■  Schizophrenia Cases
Data Missing Positive Rating
Figure 6-10: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS6, and those for which no rating could be made.
Results o f the mixed-effects regression analysis
Although ERS 6 succeeded in terms of its ease of utility and reliability, results 
produced using the mixed-effects regression analysis did not demonstrate that this 
measure was significantly correlated within families, as demonstrated in the table 
below.
LHD S Z P  S u b -S a m p le B P D  S u b - S a m p le
ICC p-value ICC p-value ICC p-value
ERS6 0.309 0.075 0.256 0.60 0.318 0.086
Table 6-11: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 7: Most dysphoric manic episode
Extended Rating Scale 7 (ERS7) was developed to measure the extent to 
which a manic episode is dysphoric in nature. ERS7 was used to rate the “most 
dysphoric’' manic episode, i.e. the episode that was characterised by the highest 
number of dysphoric symptoms or, in the absence of these, the highest proportion of 
irritable mood. Rating guidelines are summarised in Table 6-12 below.
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Score Rating Criteria
100 Mania with 6 depressive items according to DSM IV
90 Mania with 5 depressive items according to DSM IV
80 Mania with 4 depressive items according to DSM IV
70 Mania with 3 depressive items according to DSM IV
60 Mania with 2 depressive items according to DSM IV
50 Mania with 1 depressive items according to DSM IV
40 Mania characterised by irritable mood and no elated mood
30 Mania with predominantly irritable mood and some elatedmood
20 Mania with a rough balance of irritable and elated mood
10 Mania with predominantly elated mood and some irritablemood
0 Mania with elevated mood and no irritability or dysphoricfeatures
Table 6-12: Summary of rating criteria for ERS7.
Reliability
Excellent inter-rater reliability was demonstrated for ERS7 (ICC=0.872).
Utility
ERS7 could only be measured in individuals who had experienced a manic or 
hypomanic episode, therefore a large proportion of individuals, particularly in the 
schizophrenia sample could not be rated. However, in cases in which mania had 
occurred, this scale could be applied easily to the data. In total, a positive rating could 
be made for 47.2% of the cases in the total sample (23.3% of the schizophrenia cases 
and 71.1% of the bipolar disorder cases), as demonstrated in figure 6-11 below.
E xtended  R ating S c a le  7
■  Bipolar Disorder C ases
■  Schizophrenia C ases
Data Missing Positive Rating
Figure 6-11: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS7, and those for which no rating could be made.
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Results from the mixed-effects regression analysis
As presented in Table 6-13 below, significant results were produced in the 
large harmonised dataset and in the bipolar disorder sample, suggesting that scores on
this measure aggregate within families.
LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS7 0.216 0.031 0.139 0.66 0.253 0.024
Table 6-13: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 8: Extent to which illness is characteristic of prototypical 
affective disorder vs. prototypical schizophrenia
Extended Rating Scale 8 (ERS8) was developed to allow raters to subjectively 
score each case on a scale of 0-100, from “prototypical affective disorder” to 
“prototypical schizophrenia”. Unlike for the other Extended Rating Scales, there are 
no anchor points or specific rating guidelines for ERS8, apart from the general guide 
demonstrated in figure 6-12 below. The rater must therefore make a judgement after 
considering all of the available information, and score each case according to their 
overall impression of the nature of the illness.
0
B a la n ce  of 
p ro to ty p ic a l 
s c h iz o p h re n ic  a n d  
a ffec tiv e  f e a tu re s 1 0 0
P ro to typ ica l 
affective d is o rd e r
5 0 P ro to ty p ica l
s c h iz o p h re n ia
Figure 6-12: Summary of rating guidelines for ERS8.
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Reliability
Despite the lack of stringent rating criteria, excellent inter-rater reliability was 
demonstrated for ERS8 (ICC=0.853).
Utility
The detailed information available for cases within the sample meant that 
ERS8 could be easily-utilised within the sample. Of all the Extended Rating Scales, 
ERS8 could be rated in the greatest proportion of cases. The lack of specific rating 
criteria meant that the rater did not have to rely on the presence of a detailed 
description of a specific item of psychopathology, which may or may not be present 
within the notes, but instead could use the data that was available to give an overall 
impression of the clinical picture for each individual. Positive ratings could be made 
in 93.4% of cases (92% of the schizophrenia cases and 94.7% of the bipolar disorder 
cases).
E x te n d e d  R ating  S c a le  8
■  Bipolar Disorder Cases 
u  Schizophrenia Cases
Positi\e RatingData Missing
Figure 6-13: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS8, and those for which no rating could be made.
Results from the mixed-effects regression analysis
ERS8 was the only Extended Rating Scale which was significantly correlated 
in the large harmonised dataset and both sub-samples. Results are demonstrated in 
Table 6-14 below.
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LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS8 0.127 0.028 0.201 0.028 0.158 0.023
Table 6-14: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 9: Predominance of chronic defect state
Extended Rating Scale 9 (ERS9) was developed to measure the proportion of 
the illness characterised by a chronic defect state -  which included negative 
symptoms (e.g. restricted affect, apathy, poor motivation and asociality) which 
appeared to be irreversible and were a longstanding feature of the overall clinical 
picture. Rating guidelines are summarised in the diagram below and can be found in 
full in Appendix E.
0
B a lan ce  o f  re v e rs ib le  
a c u te  sy m p to m s  an d  
n e g a tiv e  s y m p to m s
1 0 0
Illness c h a ra c te r ise d  
by ac u te  rev e rsib le  
sy m p to m s
5 0 Illn ess  c h a ra c te r is e d  
by c h ro n ic  d e fe c t 
s ta te
Figure 6-14: Summary of rating guidelines for ERS9.
Reliability
Excellent inter-rater reliability was demonstrated for ERS9 (ICC=0.806).
Utility
ERS9 was utilised with ease within the sample. A high proportion of the cases 
could be rated positively, as demonstrated in figure 6-15 below (90.5% of the sample 
overall; 87.2% of the schizophrenia sub-sample and 93.8% of the bipolar disorder 
sample). However, in the bipolar disorder sub-sample, a high proportion of these
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(84.2%) were scored “0” -  indicating that the illness was characterised entirely by 
reversible, acute symptoms.
E x te n d ed  R ating  S c a le  9
100 
90 
80 
70 
60 
50 
40 
30 H 
20 
10 
0 !-------------------------1
I Bipolar Disorder Cases 
l Schizophrenia Cases
Data Missing Positive Rating
Figure 6-15: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS9, and those for which no rating could be made.
Results from the mixed-effects regression analysis
As presented in Table 6-15, ERS9 was significantly correlated within families 
in the large harmonised dataset, and results approached significance in the 
schizophrenia sub-sample. It is unsurprising that no significant result was produced 
in the bipolar disorder sub-sample, due to a lack of variability within the data.
LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS9 0.184 0.035 0.185 0.059 0.172 0.42
Table 6-15: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scale 10: Measure of catatonic symptoms
Extended Rating Scale 10 (ERS 10) was originally developed by Dr George 
Kirov. The aim of the scale was to give a measure of catatonic symptoms during the 
lifetime course of the illness. Catatonic symptoms are rated on a 0-4 scale, as 
demonstrated below.
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Symptom
Waxy flexibility
Stupor (clear description of catatonic stupor = 2 points)
One point is awarded for the 
presence of any of the following 
symptoms (unless otherwise 
stated) up to a maximum of 4 
points
Physiological pillow
Excessive purposeless over-activity
Mannerisms
Grimacing
Echolalia, echopraxia, automatic obedience
Negativism (clear description needed)
Figure 6-16: Summary of rating criteria for ERS10.
Reliability
Excellent inter-rater reliability was demonstrated for ERS 10 (ICC=0.955)
Utility
ERS 10 was easily utilised within the sample. Originally the scale excluded 
symptoms that were “explicable by affective change”. This is because symptoms 
such as “excessive purposeless over-activity” cannot easily be distinguished from 
“excessive-activity” -  a symptom of mania -  if there is a distinction to be made at all. 
The same is true of “stupor” and “psychomotor retardation” -  a symptom of 
depression. Because this thesis aimed to perform analyses without making 
assumptions about the underlying causes of illness -  descriptions of excessive 
purposeless over-activity or stupor within episodes of affective illness were not 
necessarily dismissed. However, to be included in the ERS 10-rating, symptoms 
would have to meet the symptom definitions specified within the scale (e.g. excessive 
activity within the context of mania would have to be considered “purposeless”, and 
the rater should be able to differentiate them, in terms of their nature and/or severity, 
from symptoms typically described within the context of mania or depression.
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Descriptions of the catatonic symptoms therefore had to be well-described for 
a confident rating to be made. Despite these rigorous criteria it was generally easy to 
apply this rating scale to the data and ratings could be made on 93.6% of the LHD 
(91.7% of the schizophrenia cases and 95.6% of the bipolar disorder cases). Catatonic 
symptoms were relatively rare within the sample, therefore the majority of cases were 
rated “0” (76.7% of the schizophrenia cases and 89.2% of the bipolar disorder cases). 
The low incidence of catatonic features within the sample increases the risk of false 
positives.
E x te n d e d  R ating  S c a le  10
- in n
Qfi
a n
7 0
AHDU - 
^ 0
■  Bipolar Disorder Cases 
a  Schizophrenia Cases
4 0
^O
OOc \J  
1 0  -
o -
Data Missing Positive Rating
Figure 6-17: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS10, and those for which no rating could be made.
Results from the mixed-effects regression analysis
Significant intra-familial correlations were produced in the large harmonised
dataset and in the bipolar disorder sample, as presented in the table below.
LHD SZP Sub-Sample BPD Sub-Sample
ICC p-value ICC p-value ICC p-value
ERS10 0.358 0.024 0.093 0.65 0.716 0.0019
Table 6-16: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
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Extended Rating Scale 11: Measure of disorganised behaviour
Extended Rating Scale 11 (ERS11) was developed by Dr George Kirov 
to measure disorganised behaviour over the lifetime course of the illness. The rating 
guidelines are summarised in Table 6-18 below.
Symptom
Patient talks him/herself 
Laughing for no reason 
Hoarding rubbish 
Odd, inappropriate behaviour 
Acts of senseless violence 
Extremely poor personal hygiene
Figure 6-18: Summary of rating criteria for ERS11.
Reliability
Good reliability was demonstrated for Extended Rating Scale 11 (ICC=0.786)
Utility
As is the case for ERS10, the original rating guidelines for ERS11 stipulate 
that symptoms are only counted towards the rating if they are not explicable by 
affective state. Again, because this research aimed to perform analyses without 
making assumptions about the underlying causes, symptoms experienced within the 
context of an affective episode were not necessarily dismissed. However, several 
symptoms, such as “odd, inappropriate behaviour” and “laughing for no reason” are 
frequently observed in episodes of mania. Again, symptoms were not counted 
towards the rating unless they were extreme, beyond the typical manic presentation. 
However, it was occasionally difficult to make a confident judgement about the exact 
nature of these symptoms from the descriptions within the cases whether this was the 
case, which resulted in a rating of “unknown/uncertain”. Despite this, positive ratings
One point is awarded for the 
presence of any of the 
following symptoms up to a 
maximum of 2 points
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could be made in 77.9% of the LHD (87% of the schizophrenia cases and 68.7% of 
the bipolar cases), as demonstrated in figure 6-19 below.
E x te n d e d  R ating  S c a le  11
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Data Missing Positive Rating
■  Bipolar Disorder Cases
■  Schizophrenia Cases
Figure 6-19: Demonstration of proportion of cases for which it was possible to make a positive 
rating on ERS11, and those for which no rating could be made.
Results from the mixed-effects regression analysis
Significant results were produced for ERS11 in both the LHD and in the 
bipolar disorder sub-sample, as demonstrated in table 6-17 below.
LHD S Z P  S u b - S a m p le B P D  S u b - S a m p le
ICC p-value ICC p-value ICC p-value
ERS11 0.229 0.016 0.112 0.38 0.366 0.0098
Table 6-17: Mixed-effects regression results produced for the large harmonised dataset (LHD), 
and the schizophrenia (SZP) and bipolar disorder (BPD) sub-samples.
Extended Rating Scales -  Overall Conclusions
In general the extended rating scales showed ease of utility and excellent 
reliability, and can therefore be considered a success in terms of their use within this 
sample. It is particularly encouraging that, when analysed using the mixed-effects 
regression method to assess familiality, six out of the eleven scales developed 
produced significant results.
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It is of note that significant intra-familial correlations were not produced for 
either ERS3 or ERS4, both of which assessed variability within acute phases of 
illness. This suggests that such variability is either random in nature and not 
influenced by genetic or shared familial environmental factors, or that it is influenced 
by non-familial environmental risk factors.
That ERS8 was significant across all three samples is of particular interest as 
the clinical variability measured by ERS8 relates directly to Kraepelin’s dichotomy. 
The fact that significant results were demonstrated provides some support for the idea 
behind the dichotomy, suggesting that the extent to which illness is prototypically 
schizophrenic or affective in nature aggregates within families, and therefore may be 
influenced by genes.
In terms of utility, the main limitation of using the scales within this sample 
was that the cases had already been collected so it was not possible to ask specific 
questions relating to the scales, or to include extra details relevant to the rating criteria 
in the case-note vignettes. For this reason, it would be useful to continue to use all of 
these measures in future studies. This is discussed further in the “Future Work” 
section below.
6.3 Comparison of results of primary analyses with results from previous 
studies
As stated previously, the results reported in chapter 5 could be compared with 
previous findings by dividing the large, harmonised dataset into the individual bipolar 
disorder and schizophrenia family samples and performing the analysis separately on 
each. In the primary analysis only variables that were significantly familial in the 
large harmonised dataset were followed up in the sub-samples. As discussed
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previously, this meant that there was a risk of missing significant correlations that 
were only significant in one dataset.
To enable comparisons to be made between my work and previous findings, I 
undertook analysis on both the schizophrenia and bipolar disorder sub-samples for 
variables which had previously been found to be familial.
As discussed in detail in the previous chapter, several of the significant 
findings from the primary analysis were consistent with results from previous studies; 
these are summarised in the table below. It is of note that, with the exception of 
marital status, each of these variables has been reported to be significantly familial in 
more than one previous study. This, along with the fact that my results also replicate 
these findings, makes these variables the most promising candidates of those tested 
here for future phenotype refinement.
Variable studied  in 
the  literature
Previously 
reported  to  
be familial 
in:
M easure u sed  in 
th e  cu rren t 
re sea rch
Large
H arm onised
d a ta se t
SZP s u b ­
sam ple
BPD s u b ­
sam ple
ICC
P-
valu
e
ICC
P-
valu
e
ICC
P-
valu
e
Age at o n s e t1-2,3,4,5 SZP and BP Age a t first adm ission .287 .001 .295 .014 .252 .018
Psychotic symptoms BP BADDS P sy ch o sis .147 .033 .087 .426 .223 .025
Marital S ta tu s 3 BP Binary m easu re  Yes/No .273 .020 .222 .210 .336 .038
Lifetime course of 
illness 14-15-19-20 SZP and BP
C ourse of D isorder .163 .004 .233 .046 .176 .023
Extended Rating 
S cale  8 .127 .028 .201 .028 .158 .023
Negative symptom 
dimension ,16 SZP
Negative 
sym ptom s Y/N .351 .041 .363 .039 NA NA
Table 6-18: Summary of variables found to be familial in previous studies which were replicated 
in the primary analysis
LHD -  “large harmonised dataset”; SZP -  “schizophrenia”; BPD -  “bipolar disorder”; PFTD -  
“positive formal thought disorder”; NFTD -  “negative formal thought disorder”. +, familiality reported 
within previous samples; familiality not reported within previous samples. NA -  Analysis was not run 
because there was not enough variability within the sub-sample.
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References: 1. Leboyer et a l (1998); 2. O ’Mahoney et al (2002); 3. Schulze et al (2006); 4. Burke et al 
(1996); 5. Tsuang et a l (1967); 7. Jones &  Craddock (1987); 14. Kendler et a l (1997); 15. Blueler 
(1978); 16. Peralta &  Cuesta (2007); 19. Ross et a l (2000); 20. D uffy et al (2002).
Contrary to expectations, certain variables previously reported as showing 
familiality in schizophrenia family-samples, were found to be significantly correlated 
within families in the bipolar disorder sub-sample but not the schizophrenia sub­
sample. Similarly, variables previously reported as showing familiality within bipolar 
disorder family samples, were found to be significantly correlated within the 
schizophrenia families but not the bipolar disorder families. These results are
presented in the table below.
Variable studied in the 
literature
Previously 
repo rted  to  
be familial 
in:
M easure u sed  in the  
cu rren t re sea rch
Large
H arm onised
d a ta se t
SZP s u b ­
sam ple
BPD su b ­
sam ple
ICC P-value ICC
P-
value ICC
P-
value
S ubstance A buse 3 BP
C annab is a b u se .639 .001 .332 .003 NA NA
O ther s u b s ta n c e  a b u se .587 .016 .537 .046 .660 .220
LE mood-incongruent 
psychotic symptoms 3,6
BP BADDS Incongruence .224 .005 .285 .004 .181 .191
Anhedonia 11 SZP OPCRIT2: A nhedonia .190 .048 .008 .950 .367 .009
Negative formal thought 
disorder 14
SZP OPCRIT50: NFTD .355 .014 .268 .093 .601 .022
Catatonic symptoms 14,5 SZP Extended Rating S cale 10 .358 .024 .093 .650 .716 .002
Disorganisation 
dimension 4/l7'18 SZP
Extended Rating S cale 
11 .229 .016 .112 .380 .366 .010
Table 6-19: Summary of variables found to be familial in previous studies which were partially 
consistent with previous findings
LHD -  “large harmonised dataset”; SZP -  “schizophrenia”; BPD -  “bipolar disorder”; PFTD -  
“positive formal thought disorder”; NFTD -  “negative formal thought disorder”. +, familiality reported 
within previous samples; familiality not reported within previous samples. NA -  Analysis was not run 
because there was not enough variability within the sub-sample.
References: 3. Schulze et a l (2006); 5. Tsuang et a l (1967); 6. Goes et a l (2007); 11. Schurhoff et al 
(2003); 14. Kendler et al (1997); 17. Loftus et al (1998); 18. Cardno et al (1999).
As shown above, three variables found to be significantly familial but not in the 
sub-sample for which previous familiality had been reported, were “Negative Formal 
Thought Disorder”, “Catatonic Symptoms” (as measured using ERS10), and 
“Disorganisation” (as measured using ERS11). All three had been previously 
reported as being significantly familial within samples of patients with schizophrenia
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(although negative findings have also been reported for all three; Choi et al, 2007); in 
the current analysis, all three were found to show significant intra-familial 
correlations in the LHD and the bipolar disorder sub-sample but not in the 
schizophrenia sub-sample. One possible explanation for these apparently discrepant 
results is sample-variability. For example, studies which have reported significant 
familiality for these variables in schizophrenia samples may have been characterised 
by higher levels of affective disturbance than other studies, and would therefore be 
more comparable to the large harmonised dataset described here.
What is particularly interesting about these variables is that, in the past, rating 
guidelines for all three dictated extreme caution when rating these items within the 
context of affective disturbance. It is therefore unlikely that they would have been 
considered in previous studies involving samples of patients with mood-disorders. 
The fact that significant results were produced within such a sample provides support 
for the hypothesis that measuring items independently of the context in which they 
were experienced, and therefore without making assumptions about their underlying 
causes, may enhance research.
Another item which falls under this heading is “substance abuse”. Previous 
studies have reported this to show familiality within samples of patients with bipolar 
disorder. In the current study, substance abuse, as measured using the OPCRIT items 
“cannabis abuse” and “other substance abuse” (the latter referring to the abuse of any 
illicit substance other than cannabis), was found to show a strong intra-familial 
correlation within the schizophrenia sub-sample, along with the LHD, but not in the 
bipolar disorder sub-sample.
Results for incongruent psychotic symptoms were also inconsistent with the 
majority of previous studies, which have shown this variable to be correlated within
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families enriched for bipolar disorder (e.g. Hamshere et al, in press). Using a binary 
variable indicating whether incongruent psychotic symptoms were present/absent over 
the lifetime course of the illness did not yield significant results in any of the samples. 
However, when a dimensional measure of incongruence was used (using the BADDS 
Incongruence dimension), significant results were produced in the LHD and the 
schizophrenia sample but not in the bipolar disorder sample.
The final item which falls under this heading is “anhedonia”. A previous study 
demonstrated familiality of anhedonia in a family-based schizophrenia sample 
(Schurhoff, Szoke, Bellivier, et al, 2003). Schulze et al (2006) included loss of 
interest in their analysis and did not find this variable to be significantly correlated 
within their sample of families with bipolar disorder. When anhedonia was included 
in the mixed-effects regression analysis, significant intra-familial correlations were 
found in the LHD and the bipolar disorder sample, but not in the schizophrenia 
sample.
As stated above, one explanation for these findings is that (with the exception 
of anhedonia) these variables have not previously been tested in the sub-samples in 
which significant familiality was demonstrated here (e.g. negative formal thought 
disorder has not previously been investigated in family samples of patients with 
bipolar disorder.
However, due to the substantial number of tests performed in this work, the 
high risk of Type I errors must be acknowledged. It is likely that some, if not all, 
these discrepant results represent false positives rather than true findings. However, it 
would be interesting to follow up these variables in further samples.
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Variable stud ied  in the  
literature
P reviously  
rep o rted  to  
be familial 
in:
M easure u sed  in the  
cu rren t re sea rch
Large
H arm onised
d a ta se t
SZP s u b ­
sam ple
BPD s u b ­
sam ple
ICC P-value ICC
P-
value ICC
P-
value
Manic sym ptom s 2 B P
Binary Variable Y/N .187 .061 .256 .097 .136 .212
BADDS Mania .025 .724 .115 .224 .034 .298
Rapid Cycling 8 B P P resen t/A bsen t .252 .310 .275 .271 .397 .137
Rapid switches in mood 8 B P
P resen t/A bsen t .257 .293 NA NA .275 .274
E xtended Rating S cale  3 .256 .290 .054 .990 .274 .270
Puerperal Psychosis 7 B P P resen t/A bsen t .272 .293 .587 .714 .262 .287
Alcohol abuse  8,9 B P P resen t/A bsen t .176 .163 .185 .238 .162 .454
2 10Episode frequency ’ B P E xtended Rating S cale  5 .046 .443 .075 .499 .031 .681
Suicidal Ideation 3 B P P resen t/A bsen t .100 .274 .053 .721 .054 .658
Suicide A ttem pt3 B P P resen t/A bsen t .149 .115 .129 .273 .257 .070
Auditory Hallucinations 12 S Z P P resen t/A bsen t .063 .516 NA NA .131 .325
Hallucinations 13 S Z P Presen t/A bsen t .075 .403 NA NA .137 .243
Delusions 14 S Z P Presen t/A bsen t .161 .093 .084 .671 .189 .095
Positive formal thought 
disorder 14 S Z P OPCRIT49: PFTD .448 .013 .328 .097 .659 .075
Table: Summary of variables found to be familial in previous studies which were not supported 
by results from the primary analysis
LHD -  “large harmonised dataset” ; SZP -  “schizophrenia”; BPD -  “bipolar disorder”; PFTD -  
“positive formal thought disorder”; NFTD -  “negative formal thought disorder”. +, familiality reported 
within previous samples; familiality not reported within previous samples. NA -  Analysis was not run 
because there was not enough variability within the sub-sample.
References: 2. O ’Mahoney et a l (2002); 3. Schulze et a l (2006); 7. Jones &  Craddock (2001); 8. 
Saunders et a l (2008); 9. Potash et a l (2000); 10. Fisfalen et a l (2005); 12. Choi et a l (2007); 13. 
DeLisi et a l (1987); 14. Kendler et a l (1997).
The variables listed in the table above were found to show significant familiality 
within previous schizophrenia or bipolar disorder family samples, but not within the 
sub-samples used in the current study. Possible reasons for these discrepant findings 
include sample differences and differences in the ways in which items of 
psychopathology were measured. The fact that no significant results were found for 
these variables in the current work may also be due to a lack of power within the 
samples.
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6.4 Methodological Strengths and Limitations
The strengths and limitations of the methods utilised within this thesis have 
been discussed in detail in previous chapters, and the main points are summarised 
below:
Strengths
• Analyses were undertaken in a large dataset - in the primary analyses, 
combining the schizophrenia and bipolar disorder family samples resulted in a 
total sample of 835 cases from 373 families.
• A spectrum of psychotic and affective illness was represented, allowing 
analyses to be performed across traditional diagnostic boundaries.
• A new set of measures were developed specifically for use within this sample.
• After extensive training and participation in numerous reliability exercises, a 
single rater (myself) was responsible for rating the entire sample. This 
allowed me to become familiar with the sample and eliminated the risk of any 
variability caused by inter-rater differences.
• The mixed-effects regression method implemented in the primary analyses 
allowed for the inclusion of covariates which controlled for any familiality 
caused by these.
Limitations
• Data had been collected prior to the commencement of this PhD. This meant 
that the information collected for each case was not done so with this specific 
set of measures in mind. A prospective study design would have ensured 
adequate information was collected for this specific set of measures, 
facilitating the rating process.
• Participants were not followed up over time.
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• The ratings made relied on detailed and accurate documentation of the 
participant’s previous episodes of illness, therefore there was a risk of missing 
less severe episodes of particular that did not require the participant to seek 
treatment.
• Because the cases were collected on the basis of a proband with a diagnosis of 
bipolar disorder or schizophrenia, the sample was enriched for prototypical 
forms of the disorders. The inclusion of families enriched for schizoaffective 
disorder would have introduced more of a spectrum of illness, in which the 
intermediate phenotypes were better represented.
• In the primary analyses, continuous variables had to be converted to ordinal 
categories to allow the data to be analysed using the mixed-effects regression 
method. Reassuringly, significant results were supported by sensitivity 
analysis (see chapter 5) and the Spearman’s Rho analyses, which were used on 
the raw continuous variables.
• A single rater was responsible for rating the entire sample, introducing the risk 
of rater-drift. Reassurance that this had not occurred was provided by results 
produced in the reliability analysis, reported in Chapter 5.
• Investigating the familiality of such a large number of variables (N=157) 
introduced multiple-testing problems that reduced power to detect significant 
effects. It is therefore likely that some (or even a majority) of the variables 
for which significant results were found in this study are false positives. 
However, this was very much an exploratory analysis, and the variables 
identified using these methods can be used to form hypotheses which can be 
tested in future studies.
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6.5 Future Work
The main aim of this research was to perform analysis in a sample enriched for 
a spectrum of affective and psychotic disorders in order to identify clinical variables 
which aggregate within families. Although, due to the exploratory nature of this 
analysis, no significant results withstood corrections for multiple testing, it is the 
thirty-one variables identified that are most likely to be of use in refining the 
phenotype, the best candidates for future work being those that were consistent with 
previous findings (i.e. age at onset, psychotic symptoms, marital status, negative 
symptoms and lifetime course of illness). It is therefore important to ensure that 
information on these variables is collected where possible in future studies which aim 
to investigate the genotype or phenotype of the functional psychoses.
Ideally, a prospective study could be undertaken, involving the recruitment of 
a similar family-based sample representing a spectrum of diagnoses. This would have 
several major advantages; as well as allowing researchers to investigate whether these 
results generalise to other samples, the study could be designed specifically to focus 
in on these variables, allowing more detailed and specific information to be collected 
which would facilitate the rating process. Focussing in on a smaller number of 
variables (i.e. those for which significant results were produced in this thesis, and 
particularly those which were consistent with previously published work) would also 
reduce the impact of corrections made for multiple testing. However, to conduct such 
a study would be extremely expensive. A more cost-effective means of investigating 
whether or not these results generalise to other samples would be to collaborate with 
other research teams who have already recruited such samples.
As discussed in the previous chapter, although the results of the mixed-effects 
regression analyses suggest that those variables for which a significant familial affect
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was shown may be influenced by genes, it could be argued that this familiality may be 
due to shared environmental factors. Twin and adoption studies could be used to 
investigate the genetic and environmental influences on the clinical variables 
identified in this thesis (reviewed in Gottesman, 1991). Adoption studies compare 
adoptees with their biological parents under the hypothesis that similarities observed 
are more likely to be due to genetic rather than environmental effects. Under the 
equal environments assumption, twin studies aim to investigate the role of genetic 
influences by comparing concordance rates between monozygotic and dizygotic twin- 
pairs. Comparisons between affected and unaffected monozygotic twins may be used 
to study the role of environmental factors.
Again, although ideally carrying out a prospective study, as described above, 
would mean that specific information regarding the variables-of-interest could be 
collected, facilitating the rating process, in reality the more cost-effective approach of 
collaborating with other research teams who have been involved in recruiting samples 
is a more feasible way of conducting such future studies.
Clearly the ultimate test of whether the variables identified in the analyses 
described in Chapter 5 would be to utilise them within molecular genetic analyses. 
The recent technological advances in molecular genetic research, along with 
substantial reductions in the cost of implementing these methods (McCarthy, 
Abecasis & Cardon, 2008) make this a viable and cost-effective option. Further, 
because the family-samples described within this thesis were originally collected as 
part of ongoing molecular genetic studies in the Department of Psychological 
Medicine, Cardiff University, genetic data are available for these cases and can be 
used in future studies to investigate the genetic basis of the variables which showed 
familiality.
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One method by which clinical measures can be used to refine genetic analyses 
is by including them as covariates within linkage studies (Rice, Rochberg, Neuman, et 
al, 1999). Taking account of such variables within analyses may facilitate the 
identification of chromosomal regions which may be involved in influencing 
susceptibility to, or modifying the course of illness. For example, Hamshere et al (in 
press) performed multipoint model-free affected relative pair covariate linkage 
analysis on a sample of patients with bipolar disorder, in which the presence or 
absence of mood-incongruent psychotic features was included in the model as a 
covariate. This method involved the modelling of allele-sharing probabilities using 
logistic regression analysis, which allowed for the inclusion of covariates. They 
identified three regions showing suggestive linkage (lq32.3, 7pl3 and 20ql3.31), 
none of which were identified within the sample when univariate analyses were 
performed, in which bipolar disorder was considered a homogeneous entity.
Association analyses may be used to examine specific genetic variation that 
contributes to these clinical measures. For example, functional psychoses cases 
which include a specific clinical feature which has been shown to aggregate within 
families, such as incongruent psychotic symptoms, could be compared to unaffected 
controls, or to affected controls who have not experienced this particular clinical 
symptom in an attempt to identify genetic variation contributing to susceptibility to, 
or modifying the course of illness. For continuous variables, cases could be defined 
by their genotype (e.g. 00, 01, 11) and one-way analysis-of-variance (ANOVA) 
analysis could be performed to compare the means of the groups.
The variables identified in this thesis can therefore be used to form hypotheses 
which can be tested in future studies, using methodologies such as those discussed 
above.
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The methods described in this thesis focus on specific clinical variables that 
can be obtained from interview, case-notes etc and which are looked at individually. 
Rather than focus on these individual items, an alternative approach is to consider 
factor analysis, a method which has been applied to psychiatric measures since the 
1960s (Jablensky, 2006), and examines whether correlations occur between specific 
items. In this way, factors can be extracted from the correlation matrix in the form of 
dimensions, which account for the relationship amongst the variables of interest and 
explain a proportion of their variance. Methods aim to maximise the similarity 
between items loading on one factor, whilst simultaneously maximising the difference 
between factors (Farmer, McGuffin & Williams, 2002).
A number of studies have performed factor analysis within samples of patients 
with schizophrenia (reviewed in Jablensky, 2006). For example, a three-factor 
structure was proposed by Liddle (1987), who performed factor analysis on items 
from the Scales for the Assessment of Positive Symptoms (SAPS) (Andreasen, 
1984b) and Scales for the Assessment of Negative Symptoms (SANS) (Andreasen, 
1984a). In this model, negative symptoms load on a single factor, “psychomotor 
poverty”, whilst positive symptoms load on two separate factors, “reality distortion” 
(delusions and hallucinations), and “disorganisation” (disorganised speech, thought 
disorder).
Cardno et al (1996) performed factor analysis on a sample of schizophrenia 
patients, using items from the Operational Criteria symptom checklist (OPCRJT) 
(McGuffin, AE & Harvey, 1991). Their initial analyses produced a three-factor 
structure featuring positive, negative and disorganised dimensions. However, when 
they applied the scree test to the data -  which involves plotting the eigenvalues in 
descending order of magnitude against their factor numbers and determining where
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they level off (D'agostina & Russell, 2005) -  five factors were suggested, with the 
positive factor separating into three-factors characterised by paranoid symptoms, first 
rank delusions and first rank hallucinations.
A recent study by McGrath et al (2004) also identified five factors in their 
large sample of schizophrenia patients, which were associated with risk of psychoses 
and affective disorders in relatives: positive symptoms, negative symptoms, 
disorganisation, affective disturbance and early onset/development. Cuesta & Peralta 
(2001) suggested that a hierarchical 10-dimensional model was most appropriate on 
both statistical and clinical grounds.
Studies have also been performed to investigate whether dimensions identified 
via factor analysis aggregate within families. For example, Burke et al (1996) found 
the negative dimension, disorganisation dimension and reality distortion dimension to 
be significantly correlated within sibling-pairs in their sample of schizophrenia 
patients.
Performing factor analysis within the large harmonised dataset described in 
this thesis could be used to both reduce the number of variables and to detect the 
structure of relationships between them. Analyses could subsequently be performed 
to assess the familiality of these factors.
6.6 Final Conclusions
The research described in this thesis was undertaken under the hypothesis that 
looking beyond diagnostic categories to perform familiality analysis on a set of 
clinical measures that vary both within and across diagnostic categories, may facilitate 
the identification of sub-groups of patients who are more likely to be genetically
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homogeneous. The identification of such samples is likely to increase power in future 
molecular genetic studies.
Previous research has demonstrated the advantages of looking beyond 
diagnostic categories, and the hierarchy rooted in diagnostic tradition, to consider 
variables which cluster within families or which have some biological validation, e.g. 
22qll deletion in VCFS and genome-wide significant linkage at lq42 in SABP (see 
chapter 4).
The research described in this thesis aimed to explore the familial correlation 
of clinical measures within a large harmonised clinical dataset comprising samples of 
(a) families enriched for bipolar disorder, and (b) families enriched for schizophrenia. 
Cases were rated on a set of variables which included a new set of clinical ratings. 
These were designed specifically to be used within this sample and covered eleven 
clinical characteristics that varied across samples, that were not picked up on 
adequately by established measures, and which appeared to be potentially important 
in distinguishing between cases.
Analyses were performed across traditional diagnostic boundaries, and thirty- 
one clinical measures were found to be significantly correlated within families, after 
controlling for sample-of-origin and gender. However, due to the exploratory nature 
of this thesis the risk of false positives is high and this must be acknowledged when 
considering these findings.
Variables which correlate within families may be influenced by genetic factors 
and may therefore be used to identify subgroups of patients more likely to share 
common underlying genetic susceptibilities.
In an analysis of a subset of cases from the large harmonised dataset, which 
comprised sibling-pairs that were enriched for schizoaffective disorder, it was found
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that genetic similarity at chromosome lq42 was significantly associated with 
phenotypic similarity during the most severe depressive episode, as measured by the 
Global Assessment Scale (GAS) which measures functional impairment; and with age 
at onset. Genetic similarity at chromosome 22qll was significantly associated with 
phenotypic similarity during the most severe period of illness, again measured using 
the GAS.
I also undertook clinical ratings on a sample of previously-collected patients 
with Velo-Cardio-Facial Syndrome (VCFS) and found high-rates of both mood- 
disturbance and psychosis.
The findings reported in this thesis support the hypothesis that clinical ratings 
can be a useful adjunct to categorical diagnoses, and can be used to identify specific 
phenotypes which may be worth considering in future genetic studies. It is hoped that 
this will facilitate the identification of genes involved in the functional psychoses, 
leading to increased understanding of the aetiological processes underlying such 
disorders. This should allow researchers to develop new, more specific treatments 
which target the underlying biological mechanisms involved in these debilitating 
illnesses, leading to improved quality of life for patients and their families.
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Appendices
Appendix A
List of variables rated in the large harmonised dataset
DSMIV diagnosis 
ICD10 diagnosis 
RDC diagnosis 
BADDS Mania 
BADDS Depression 
BADDS Psychosis 
BADDS Incongruence
GAS -  impairment during worst ever depression
GAS -  impairment during worst ever mania
GAS -  impairment during worst ever psychosis
GAS -  impairment during worst ever episode of illness
Occurrence of section 2 symptoms over the lifetime course of illness
Mood congruence of psychotic symptoms over the lifetime course of illness
Occurrence of near-section 2 symptoms over the lifetime course of illness
Predominant manic affect
Occurrence of dysphoric mania over the lifetime course of illness
Number of manic episodes
Number of depressive episodes
Number of non-affective episodes
Number of post-natal episodes
Duration of longest episode of mania
Duration of longest episode of depression
Duration of longest episode of non-affective psychosis
Duration of longest post-natal episode
Age at first symptom
Age at first impairment
Age at first contact
Age at first admission
Age at first mania
Age at first depression
Age at first psychosis
Age at first post natal episode
Number of admissions
Length of longest admission
Proportion of time admitted
Proportion of time well since onset
First episode of illness post-natal (yes/no/unknown)
Occurrence of a post-natal episode over the lifetime course of illness 
Occurrence of rapid cycling over the lifetime course of illness 
Suicidal ideation
Occurrence of switches in mood over the lifetime course of illness.
Medication response
Psychiatric sequelae after each full-term delivery 
Extended Rating Scale 1: Predominance mania
Extended Rating Scale 2: Relationship between psychotic and affective symptoms
Extended Rating Scale 3: Fluctuations in mood
Extended Rating Scale 4: Instability of clinical state
Extended Rating Scale 5: Periodicity of acute phases of illness
Extended Rating Scale 6: Predominance of mixed affective state
Extended Rating Scale 7: Most dysphoric mania
Extended Rating Scale 8: Extent to which illness reflects prototypical affective 
disorder vs. prototypical schizophrenia
Extended Rating Scale 9: Predominance chronic defect state 
Extended Rating Scale 10: Catatonic symptoms 
Extended Rating Scale 11: Disorganised behaviour
The following items of psychopathology were recorded using the OPCRIT symptom
checklist:
1) Dysphoria
2) Anhedonia
3) Diurnal mood variation
4) Suicidal ideation
5) Excessive self reproach
6) Poor concentration
7) Slowed activity
8) Loss of energy/tiredness
9) Poor appetite
10) Weight loss
11) Increased appetite
12) Weight gain
13) Initial insomnia
14) Middle insomnia
15) Early morning waking
16) Excessive sleep
17) Diminished libido
18) Agitated activity
19) Elevated mood
20) Irritable mood
21) Thoughts racing
22) Pressured speech
23) Distractibility
24) Excessive activity
25) Increased self-esteem
26) Reckless activity
27) Reduced need for sleep
28) Increased sociability
29) Third person auditory hallucinations
30) Running commentary voices
31) Abusive/accusatory/persecutory voices
32) Other non-affective auditory hallucinations
33) Non-affective visual hallucinations
34) Non-affective hallucinations in any other modality
35) Thought echo
36) Thought insertion
37) Thought broadcast
38) Thought withdrawal
39) Delusions of passivity
40) Delusions of influence
41) Primary delusional perception
42) Persecutory delusions
43) Bizarre delusions
44) Other primary delusions
45) Bizarre behaviour
46) Catatonia
47) Speech difficult to understand
48) Incoherent
49) Positive formal thought disorder
50) Negative formal thought disorder
51) Restricted affect
52) Blunted affect
53) Inappropriate affect
54) Perplexity
55) Aggressive behaviour
56) Grandiose delusions
57) Delusions of guilt
58) Nihilistic delusions
59) Mood congruent third person auditory hallucinations
60) Mood congruent second person auditory hallucinations
61) Mood congruent visual hallucinations
62) Mood congruent hallucinations in any other modality
63) Other secondary delusions
Increase sexual activity (novel rating)
Aggressive behaviour (novel rating)
Details and history recorded using the OPCRIT checklist:
o Source of rating
o Time frame
o Sex
o Age of onset
o Mode of onset
o Single
o Unemployed at onset
o Duration of illness in weeks
o Poor work adjustment
o Poor pre-morbid social adjustment
o Premorbid personality disorder
o Alcohol/drug abuse within one year of onset
o Family history of schizophrenia
o Family history of other psychiatric disorder
o Coarse brain disease prior to onset
o Definite psychosocial stressor prior to onset
o Lifetime diagnosis of alcohol/cannabis/other substance abuse/dependence
o Information not credible
o Lack of insight
o Rapport difficult
o Impairment/incapacity during disorder
o Deterioration from premorbid level of functioning
o Psychotic symptoms respond to neuroleptics
o Course of disorder
Appendix B
The Global Assessment Scale (GAS)
(Endicott et al, 1976)
100-91  No symptoms, superior functioning in a wide range of activities, life’s
problems never seem to get out of hand, is sought out by others because of 
his warmth and integrity.
90 -  81 Transient symptoms may occur, but good functioning in all areas, interested
and involved in a wide range of activities, socially effective, generally satisfied 
with life, “everyday” worries that only occasionally get out of hand.
8 0 - 7 1  Minimal symptoms may be present but no more that slight impairment in
functioning, varying degrees of “everyday” worries and problems that 
sometimes get out of hand.
70 -  61 Some mild symptoms (e.g. depressive mood and mild insomnia) OR some
difficulty in several areas of functioning, but generally functioning pretty well, 
has some meaningful interpersonal relationships and most untrained people 
would not consider him “sick”.
60 -  51 Moderate symptoms OR generally functioning with some difficulty (e.g. few
friends and flat affect, depressed mood and pathological self-doubt; euphoric 
mood and pressure of speech, moderately severe antisocial behaviour).
50 -  41 Any serious symptomatology or impairment in functioning that most clinicians
would think obviously requires treatment or attention (e.g. suicidal 
preoccupation or gesture, severe obsessional rituals, frequent anxiety 
attacks, serious antisocial behaviour, compulsive drinking).
40 -  31 Major impairment in several areas, such as work, family relations, judgement,
thinking or mood (e.g. depressed woman avoids friends, neglects family, 
unable to do housework), OR some impairment in reality testing or 
communication (e.g. speech is at times obscure, illogical or irrelevant), OR 
single serious suicide attempt.
30 -  21 Unable to function in almost all areas (e.g. stays in bed all day), OR
behaviour is considerably influenced by either delusions or hallucinations, OR 
serious impairment in communication (e.g. sometimes incoherent or 
unresponsive) or judgement (e.g. acts grossly inappropriately).
20 -  11 Needs some supervision to prevent hurting self or others, or to maintain
minimal personal hygiene (e.g. repeated suicide attempts, frequently violent, 
manic excitement, smears faeces), OR gross impairment in communication 
(e.g. largely incoherent or mute).
1 0 - 1  Needs constant supervision for several days to prevent hurting self or others,
or makes no attempt to maintain minimal personal hygiene.
Notes: Rate the subject’s lowest level of functioning in the last week by selecting the lowest range that describes 
his functioning on a hypothetical continuum of mental health illness. For example, a subject whose “behaviour is 
considerably influenced by delusions” (range 21-30) should be given a rating in that range even though he has 
“major impairment in several areas” (range 31-40). Use intermediary levels when appropriate (e.g. 35, 58, 63). 
Rate actual functioning independent of whether or not subject is receiving, and may be helped by, medication or 
some other form of treatment.
Appendix C
Modified OPCRIT Symptom Checklist
Item Definitions 
McGuffin et al (1991)
DEPRESSIVE SYMPTOMS
Should be rated as present if present for at least 2 weeks.
Items marked * are not in the original OPCRIT.
All items are rated 0 No
1 Yes
9 Unknown/Missing
1. Dysphoria
Persistently low or depressed mood, irritable and sad mood or pervasive loss of 
interest.
Note that this item includes irritability which does not occur in the context of a manic 
syndrome. Includes pervasive loss of interest as well as depressed mood.
2. Loss of pleasure
Pervasive inability to enjoy any activity. Include marked loss of interest or loss of 
libido.
3. Diurnal variation (mood worse mornings)
Dysphoria/low mood and/or associated depressive symptoms are at their worst soon 
after awakening with some improvement (even if only slight) as the day goes on.
4. Suicidal ideation
Preoccupation with thoughts of death (not necessarily own). Thinking of suicide, 
wishing to be dead, attempts to kill self.
Include moderate and severe tedium vitae here.
5. Excessive self reproach
Extreme feelings of guilt and unworthiness. May be of delusional intensity ('worse 
person in the whole world').
Primarily guilt, but also low self-esteem. Rated if out of proportion to the situation.
6. Poor concentration
Subjective complaint of being unable to think clearly, make decisions etc.
7. Slowed activity
Patient complains that he feels slowed up and unable to move. Others may report 
subjective feeling of retardation or retardation may be noted by examining clinician.
8. Loss of energy/tiredness
Subjective complaint of being excessively tired with no energy.
9. Poor appetite
Subjective complaint that patient has poor appetite. Not necessarily observed to be 
eating less.
10. Weight loss
Rate as present for a loss of at least 2 lbs a week over several weeks. Do not score 
those who have reduced weight as a result of dieting.
11. Increased appetite
Patient reports increased appetite and/or 'comfort eating'.
12. Weight gain
Rate as present for a gain of at least 2 lbs a week over several weeks.
13. Initial insomnia
Patient complains that unable to get off to sleep and lies awake for at least one hour.
Rate positively if the patient has considerably more difficulty than usual in getting off 
to sleep, even if they cannot specify the time during which they lie awake
14. Middle insomnia (broken sleep)
Most nights sleep disturbed; subject awakes in the middle of sleep and experiences 
difficulty in getting back to sleep.
NB IF YOU ONLY HAVE INFORMATION ON 'INSOMNIA', SCORE ITEM 13 AND 14.
15. Early morning waking
Patient complains that persistently wakes up at least one hour earlier than usual 
waking time.
Rated positively if the patient wakes considerably earlier than usual, even if they are 
unable to specify the time of waking.
16. Excessive sleep
Patient complains that sleeping too much.
17. Diminished libido
Definite and persistent reduction in sexual drive or interest as compared with before 
onset of disorder.
18. Agitated activity
Patient shows excessive repetitive activity, such as fidgety restlessness, wringing of 
hands, pacing up and down, all usually accompanied by expression of mental 
anguish.
MANIC SYMPTOMS
Should be rated a s  p resen t if p resen t for a t le as t 4 days.
Items m arked * a re  not in the  original OPCRIT.
All items a re  rated 0 No
1 Y es
9 Unknown/Missing
19. Elevated mood
Patient's predominant mood is one of elation. (Can be co-rated with irritable mood).
20. Irritable mood
Patient's mood is predominantly irritable. (Can be co-rated with elevated mood).
21. Thoughts racing
Patient experiences thoughts racing through his head or others observe flights of 
ideas and find difficulty in following what patient is saying or in interrupting because of 
the rapidity and quantity of speech.
22. Pressured speech
Patient much more talkative than usual or feels under pressure to continue talking. 
Include manic type of formal thought disorder with clang associations, punning and 
rhyming etc.
23. Distractibility
Patient experiences difficulties concentrating on what is going on around because 
attention is too easily drawn to irrelevant or extraneous factors.
24. Excessive activity
Patient is markedly over-active. This includes motor, social and sexual activity.
25. Increased self esteem
Patient believes that he is an exceptional person with special powers, plans, talents 
or abilities. Rate positively here if overvalued idea but if delusional in quality also 
score grandiose delusions.
26. Reckless activity
Patient is excessively involved in activities with high potential for painful 
consequences which is not recognised, e.g. excessive spending, sexual indiscretions, 
reckless driving, etc.
Include sexual recklessness leading to risk of pregnancy or venereal disease.
27. Reduced need for sleep
Patient sleeps less but there is no complaint of insomnia. Extra waking time is 
usually taken up with excessive activities.
28. Increased sociability
Rate as present for loss of social inhibitions resulting in behaviour which is 
inappropriate to the circumstances and out of character.
28a. Increased sexual activity (NOVEL MEASURE)
0 - Not known to be present despite adequate clinical information.
1 - Increased sexual interest and / or activity.
2 - Increased sexual behaviour that caused harm (including physical, 
psychological, social, legal) to self or others.
Ratings o f  ‘2 ’ should also be co-rated at item 26 ‘reckless activity ’.
PSYCHOTIC SYMPTOMS
Should be rated a s  p re se n t if p resen t for a t least a  significant portion of tim e in a  1 m onth period or less 
if successfully trea ted
Items m arked * a re  not in th e  original OPCRIT.
All items (except #) a re  rated  0 No
1 Y es
9 Unknown/M issing
29. Third person auditory hallucinations
Two or more voices discussing the patient in the third person. Score if either 'true' or 
'pseudo' hallucinations, i.e. differentiation of the source of the voices is unimportant.
Two or more voices talking about the patient in the third person. May be rated 
without an example if a clear description is given that these occur. Rate if the notes 
say “third person auditory hallucinations”.
30. Running commentary voices
Patient hears voice(s) describing his actions, sensations or emotions as they occur. 
Score whether these are possible 'pseudo' hallucinations or definite ('true') 
hallucinations.
Voice must be in the third person. May be rated without an example if a clear 
description is given that commentary occurs.
31. Abusive/accusatory/persecutory voices
Voices talking to the patient in an accusatory, abusive or persecutory manner.
Voices must be in the second person. If voices are congruent with mood state also 
rate item 60.
32. Other (non affective) auditory hallucinations
Any other kind of auditory hallucination. Includes pleasant or neutral voices and non 
verbal hallucinations.
Note that this includes non-verbal auditory hallucinations. If hallucinations occur in 
the context of a mood episode and it is unclear whether they are congruent or 
incongruent, rate as congruent and rate’9 ’ for the equivalent incongruent item.
33* Non-affective visual hallucinations
Visual hallucinations in which the content has no apparent relationship to elation or 
depression.
If hallucinations occur in the context of a mood episode and it is unclear whether they 
are congruent or incongruent, rate as congruent and rate’9 ’ for the equivalent 
incongruent item.
34. Non-affective hallucination in any other modality
Hallucinations in which the content has no apparent relationship to elation or 
depression.
Rated positively if a dear description is given, even without a specific time period. If 
hallucinations occur in the context of a mood episode and it is unclear whether they 
are congruent or incongruent, rate as congruent and rate’9 ’ for the equivalent 
incongruent item.
NB. WHEN SCORING DELUSIONS PLEASE SCORE EACH SEPARATE 
DELUSION UNDER ONE AND ONLY ONE CATEGORY DESCRIBING THE 
SPECIFIC TYPE OF THE DELUSION i.e. AS EITHER; PERSECUTORY, 
GRANDIOSE, INFLUENCE/REFERENCE, BIZARRE, PASSIVITY,
PRIMARY DEL PERCEPTION, OTHER PRIMARY DEL, THOUGHT 
WITHDRAWAL, THOUGHT BROADCAST, THOUGHT INSERTION, GUILT, 
POVERTY OR NIHILISTIC.
35. Thought echo
Score if patient experiences thoughts repeated or echoed in his or her head or by a 
voice outside the head.
As with the other thought interference items, this is rated conservatively. Repeated 
thoughts must not be under the patient’s control. Ruminative thoughts do not qualify. 
Note that this definition includes a voice repeating a person’s thoughts.
36. Thought insertion
Patient recognises that thoughts are being put into his head which are not his own 
and which have probably or definitely been inserted by some external agency.
Definition from SCAN. Example required for positive rating. In particular, ideas taken 
on by the patient from influential people in their lives are not rated positively.
37. Thought broadcast
Patient experiences thoughts diffusing out of his head so that they may be shared by 
others or even heard by others.
Definition from SCAN. Example required for a positive rating. A belief that other 
people know what the patient is thinking and an elaboration of this belief that they can 
therefore read his/her mind does not qualify. Note that this definition includes 
thoughts being heard by others (loud thoughts).
38. Thought withdrawal
Patient experiences thoughts ceasing in his head which may be interpreted as 
thoughts being removed (or 'stolen') by some external agency.
Definition from SCAN. Example required for a positive rating.
39. Delusions of passivity
Include all 'made' sensations, emotions or actions. Includes all experiences of 
influence where patient knows that his own feelings, impulses, volitional acts or 
somatic sensations are controlled or imposed by an external agency.
The definition from SCAN is used. An example is required before a positive rating 
can be given. In particular, other people or hallucinatory voices telling the patient to 
perform a certain act and the patient acting under this pressure to do so is not rated 
positively.
40. Delusions of influence
Events, objects or other people in patient's immediate surroundings have a special 
significance, often of a persecutory nature. Include ideas of reference from the TV or 
radio, or newspapers, where patient believes that these are providing instructions or 
prescribing certain behaviour.
Require a definite delusion to rate this item. Delusion must refer to something 
outside of the body. Include delusional jealousy, delusional lover, and delusion of 
being spied upon.
41. Primary delusional perception
The patient perceives something in the outside world which triggers a special, 
significant relatively non understandable belief of which he is certain and which is in 
some way loosely linked to the triggering perception.
42. Persecutory delusions
Includes all delusions with persecutory ideation.
43. Bizarre delusions
Strange, absurd or fantastic delusions whose content may have a mystical, magical 
or 'science fiction' quality.
A particularly troublesome item. To be rated here, the delusion must be totally 
implausible in D S M IV  terminology. The RDC definition adds that it must be patently 
absurd or fantastic. Most simple delusions of reference or persecution are not 
included. Great caution should be applied before rating delusions of a religious or 
supernatural nature or delusions which involve extra-sensory perception. Note that 
Capgras syndrome and other delusions of misidentification are rated here. If a 
delusion is bizarre, but can be rated elsewhere, rate it as bizarre (except for first rank 
symptoms).
44. Other primary delusions
Includes delusional mood and delusional ideas. Delusional mood is a strange mood 
in which the environment appears changed in a threatening way but the significance
of the change cannot be understood by the patient who is usually tense, anxious or 
bewildered. Can lead to a delusional belief. A delusional idea appears abruptly in 
the patient's mind fully developed and unheralded by any related thoughts.
Include other delusions not classified elsewhere which are not secondary to mood 
disturbance, alcohol, or any other phenomena, e.g., delusion of thoughts being read, 
dysmorphophobia, hypochondriacal delusions.
45. Bizarre behaviour #
Behaviour that is strange and incomprehensible to others. Includes behaviour which 
could be interpreted as response to auditory hallucinations or thought interference.
Rated as present with low threshold including, e.g., an entry in case-notes saying that 
the patient’s behaviour was strange or bizarre for no apparent reason or possibly as a 
consequence of psychotic symptoms. Behaviour must not be explicable by affective 
change.
46. Catatonia #
Patient exhibits persistent mannerisms, stereotypies, posturing, catalepsy, stupor, 
command automatism or excitement which is not explicable by affective change.
Include automatic obedience.
47. Speech difficult to understand #
Speech which makes communication difficult because of lack of logical or 
understandable organisation. Does not include dysarthria or speech impediment.
May be rated ‘1’ if, e.g., a case-note entry says the patient’s speech was difficult to 
understand because it was disorganised, without a specific example of the nature of 
the disorganisation.
48. Incoherent #
Normal grammatical sentence construction has broken down. Includes "word salad"
and should only be rated conservatively for extreme forms of formal thought disorder.
Note this is only rated in extreme cases in addition to items 47 & 49. Entry of 
‘incoherent’ in notes is not sufficient, normally rated at item 47 unless there is more 
specific information about the nature of the speech disturbance.
49. Positive formal thought disorder #
The patient has fluent speech but tends to communicate poorly due to neologisms, 
bizarre use of words, derailments, loosening of associations.
This definition is similar to item 47. This item may be rated as well as item 47 if, in 
addition to an observation or description of disorganised speech, an example is given 
which allows it to be defined as positive formal thought disorder in Andreasen’s 
terminology or a description of the nature of the disorganisation is given which 
similarly allows it to be classified as a form of positive formal thought disorder. Do not 
include circumstantiality or clanging. Care is required regarding the meaning of an 
entry of ‘thought disorder’ in case-notes, i.e., formal thought disorder must be 
differentiated from schizophrenic thought disorder (that is, thought 
insertion/broadcast/withdrawal/control).
50. Negative formal thought disorder #
Includes paucity of thought, frequent thought blocking, poverty of speech or poverty 
of content of speech.
Excludes occurrence during a depressive episode. Note that this definition includes 
frequent thought blocking. Poverty of content of speech should be rated under item
49.
51. Restricted affect #
Patient's emotional responses are restricted in range and at interview there is an 
impression of bland indifference or 'lack of contact'.
Exclude flat affect during a depressive episode, i.e., care is required regarding the 
meaning of an entry of ‘flattened affect’ in case-notes. Care is required when flat 
affect is in the context of Parkinsonian side-effects.
52. Blunted affect #
Where the patient's emotional responses are persistently flat and show a complete 
failure to 'resonate' to external change. (NB. Differences between restricted and 
blunted affect should be regarded as one of degree, with 'blunted' only being rated in 
extreme cases).
If this item is rated positively, then so must item 51. Exclude flat affect during a 
depressive episode, i.e., care is required regarding the meaning of an entry of 
‘flattened affect’ in case-notes. Care is required when flat affect is in the context of 
Parkinsonian side-effects.
53. Inappropriate affect #
Patient's emotional responses are inappropriate to the circumstance, e.g. laughter 
when discussing painful or sad occurrences, fatuous giggling without apparent 
reason.
This item includes fatuous giggling for no reason, as well as emotional responses 
inappropriate to the circumstances. Care is required if in the context of a manic 
episode.
54* Perplexity#
Severe or marked confusion, bewilderment, perplexity or puzzlement. Proband is 
unable to judge correctly events in their surroundings. The proband may no longer 
understand the connections in the events around them and everything appears 
peculiar. The patient may keep on speaking about things not relevant to the theme 
but this is due to a failure to comprehend their environment rather than an abundance 
of flight of ideas. Proband may express feeling of being in a dream like state, being 
on another planet, or being like a zombie. Does not result from a lack of interest in 
surroundings (c.f. negative symptoms and depression). Not merely speech that is 
difficult to understand due to severe flight of ideas or formal thought disorder. Not due 
a change in the quality of perception of external space (c.f. de-realisation). Not the 
situation in which an individual can not make sense of a delusional system. Do not 
rate if obviously due to the effects of drugs (illicit or prescribed) or alcohol intoxication. 
NOTE: Very difficult to distinguish from a number of other symptoms including flight of 
ideas, negative symptoms, depression, marked delusional system, de-personalisation 
and de-realisation. Rate making the best estimate of whether symptom present based 
on all the available evidence.
54a: Aggressive Behaviour (NOVEL MEASURE)
l=Behaviour which is perceived as threatening and is out of proportion to the 
circumstances. Includes verbal aggression. Rate with a low threshold.
2=Act of physical aggression which does not meet the criteria for 3. Includes 
damage to property or minor acts of unprovoked violence towards others. 
3=Severe acts of aggression which result in physical injury to others or police 
involvement or individual needs to be restrained.
4=Multiple acts of severe aggression which fulfil the criteria for 3.
PSYCHOTIC AFFECTIVE SYM PTOM S
Should be  rated a s  p re se n t if p re se n t for a t le as t a  significant portion of tim e in a  1 m onth period or less 
if successfully trea ted
Items m arked * a re  not in th e  original OPCRIT.
All item s a re  rated  0 No
1 Y es
9 Unknown/M issing
55. Grandiose delusions
Patient has grossly exaggerated sense of own importance, has exceptional abilities 
or believes that he is rich or famous, titled or related to Royalty. Also included are 
delusions of identification with God, angels, the Messiah etc. (See also ‘increased 
self-esteem’).
Score as present if present for at least 4 days.
56. Delusions of guilt
Firm belief held by subject that they have committed some sin, crime or have caused 
harm to others despite absence of any evidence to support this.
Score as present if present for at least 2 weeks.
57. Delusions of poverty
Firm belief held by subject that they have lost all or much of their money or property 
and have become impoverished despite absence of any evidence to support this. 
Score as present if present for at least 2 weeks.
58. Nihilistic delusions
Firmly held belief that some part of patient's body has disappeared or is rotting away 
or is affected by some devastating or malignant disorder despite a lack of any 
objective supporting evidence.
Score as present if present for at least 2 weeks. Include patient’s belief that he/she is 
dead.
59. * Mood congruent third person auditory hallucinations
Two or more voices discussing the patient in the third person or patient hears voice(s) 
describing his actions, sensations or emotions as they occur. The content of the 
hallucinations has a clear relationship to a depressed/manic mood. Score if either 
'true' or 'pseudo' hallucinations, i.e. differentiation of the source of the voices is 
unimportant.
May be rated without an example if a clear description is given that these occur. Rate 
if the notes say “third person auditory hallucinations”. If hallucinations occur in the 
context of a mood episode and it is unclear whether they are congruent or 
incongruent, rate as congruent and rate’9 ’ for the equivalent incongruent item.
60. * Mood congruent second person auditory hallucinations
Second person auditory hallucinations, where the content of the voices has a clear 
relationship to a depressed/manic mood.
Include here mood congruent non-verbal auditory hallucinations. If voices are 
abusive/accusatory/persecutory also rate item 31. If hallucinations occur in the 
context of a mood episode and it is unclear whether they are congruent or 
incongruent, rate as congruent and rate’9 ’ for the equivalent incongruent item.
61* Mood congruent visual hallucinations
Visual hallucinations in which the content has a clear relationship to a 
depressed/manic mood.
If hallucinations occur in the context of a mood episode and it is unclear whether they 
are congruent or incongruent, rate as congruent and rate’9 ’ for the equivalent 
incongruent item.
Mood congruent hallucinations in any other modality
Hallucinations in which the content has a clear relationship to a depressed/manic 
mood.
Rated positively if a clear description is given, even without a specific time period. If 
hallucinations occur in the context of a mood episode and it is unclear whether they 
are congruent or incongruent, rate as congruent and rate’9 ’ for the equivalent 
incongruent item.
Other secondary delusions
Delusions not rated elsewhere in which there is a clear relationship to a 
depressed/manic mood.
Appendix D
The Bipolar Affective Disorder Dimension Scale (BADDS)
Craddock et al (2004)
General information
The Bipolar Affective Disorder Dimension Scale (BADDS) has been developed in order to address 
some of the disadvantages of a purely categorical approach to diagnostic classification of Bipolar 
Spectrum Disorders.
BADDS is a dimensional rating scheme that retains and builds upon current categorical 
classifications. It is intended for use in clinical samples from populations over-represented by Bipolar 
Spectrum illness. It was not developed for use in general population samples.
BADDS has been under development since 1996 and has now been used by a variety of 
researchers within our group on more than 1100 cases. It has proved to be user friendly and has 
excellent reliability, even on sets of diagnostically challenging cases.
BADDS comprises 4 dimensions: M: Mania; D: Depression; P: Psychosis; I: Incongruence. 
Each dimension is rated using integer scores on a 0 -  100 scale. Ratings are made after review of all 
available clinical data on a subject (e.g. case records, semi-structured psychiatric interview and 
information from an informant) and can be performed as a simple addition to the conventional 
consensus lifetime psychiatric diagnostic procedures already in use by many research groups. Each 
rating reflects a mixture of severity and frequency of clinical features. Guidelines are provided that 
define anchor points in the rating scales and specify how ratings should be made.
BADDS: General rating guidelines
1) Do not rate a dimension if  there is insufficient information - just leave the dimension blank.
2) Use all available information to make the best judgement for each rating.
3) It is expected that when used for research BADDS will be used within the accepted framework of 
the lifetime best-estimate consensus diagnostic procedure.
4) All ratings should be made using integers in the range 0 - 100.
5) Ratings for M and D are a mixture o f severity and frequency. Generally the severity o f the most 
severe episode identifies a range in which the rating will be made and the frequency determines the 
score assigned within the range. In assigning a rating, start at the lowest score in the range and then add 
points according to any relevant psychopathology over and above that o f the most severe episode 
according to the following guidelines:
a) In general each additional episode o f that level o f  severity will add a score o f 2 in a 20 point 
range and 1 in a 10 point range.
b) Scores in the identified severity range can and should be modified according to severity and 
duration o f total episodes -  but with a substantial down-weighting for episodes o f lower 
severity.
c) For episodes that are one level of severity lower than the rating range, add 0.25 points for 
each episode o f lower severity for a score in a 10 point range and 0.5 points for each episode 
of lower severity for a score in a 20 point range.
d) For episodes that are more than one level o f severity lower than the rating range the total 
adjustment should not normally exceed 1 or 2 points.
6) For the P and I dimensions anchor points are given in these guidelines. Judgment is used to assign 
scores between anchor points.
7) Under very exceptional circumstances a score can be rated outside the severity range. However, this 
should always be agreed by at least two raters and the rating should lie in the interval 0 - 100. Such a 
rating should be indicated by an asterisk (*) following the rating for that dimension. An example o f the 
applicability o f this rule is the rating up o f an episode in which the balance o f evidence clearly suggests 
a severe illness that is not adequately supported by the documented evidence because o f  poor 
documentation. Another example would be the rating down of an episode if the balance of evidence 
strongly suggests that the formal evidence clearly over-represents the clinical significance o f the 
episode.
1) Mania dimension (M)
• The rating reflects severity and frequency.
•  Use ICD10 to define symptom and duration criteria for hypomanic and manic syndromes.
• Sub-hypomanic features in the ranges 1 -1 9  and 2 0 -3 9  should be rated using judgement 
according to the balance o f number and duration o f symptoms.
• No impairment criterion is used for hypomania.
• The impairment criteria for mania are one or more of:
Disrupts work or social life more or less completely
Markedly inappropriate overspending that is reckless within the context of
the subject’s financial position
Fights
Lost job
Police involvement 
Family split up
Received specific treatment (including dose increase o f mood stabilizer) for  
acute mania 
Psychotic features
• Incapacitating mania refers to a severe manic episode that includes the presence o f one or 
more o f the following features: incoherence, disorientation, loss o f contact with reality (which 
includes psychotic features), frenzied or bizarre psychomotor activity. NB: Being admitted on 
a Section is an example o f  incapacitating mania.
•  Mixed episodes are rated on the M dimension. If  all manic episodes are mixed, add “m” to the 
rating (eg. 65m).
Key points and ranges on the M  dimension
0 No manic features.
1 - 19 Mild sub-hypomanic features. Elation/irritability and less than 3
symptoms.
2 0 -3 9 Sub-hypomanic features. Elation/irritability and 3+ symptoms for at
least 1 day.
4 0 -5 9 Hypomanic features. At least one hypomanic episode.
6 0 -7 9 Manic features. At least one manic episode.
80 - 100 Severe manic features. At least one episode o f incapacitating mania.
NB: a) if* enter as .01, e.g., 65* = 65.01
b) if  m enter as .02, e.g., 65m = 65.02
c) i f  both * and m enter as .03, e.g., 65*m = 65.03)
2) Depression (D)
• Rating reflects severity and duration.
• Use ICD10 to define depressive syndromes. This includes 10 symptoms o f depression that 
count for the purposes o f diagnosis:
A Depressed mood
Loss o f interest/pleasure 
Loss o f energy
B Suicidal ideation
Pathological guilt 
Loss o f confidence/self esteem 
Loss o f concentration 
Slowed activity 
Change o f appetite or weight 
Change in sleep pattern
• Depression severity: Mild - 4+ symptoms (2+ from A); moderate - 6+ symptoms (2+ from A);
severe - 8+ symptoms (3 from A). Refer to ICD10 for full definition o f syndromes and
symptoms.
• Duration criterion for Major Depressive Episode is 2 + weeks. If  1- 2 weeks, classify as Minor 
Depression.
• Rate depression as severe if  (a) ICD10 criteria fulfilled, or (b) criteria for major depression 
are fulfilled and there has been a serious suicide attempt, ECT treatment or hospital 
admission for depression.
• Minor depression refers to at least 1 week o f low mood accompanied by 2 or more depression 
items or to brief episodes that would otherwise meet criteria for Major Depression.
• Incapacitating depression refers to severe major depression that includes presence o f one or 
more of the following features: stupor; mutism; loss o f contact with reality (including 
psychotic features). NB: Being admitted on a Section is an example o f incapacitating 
depression.
• If psychotic features are present, a depressive episode can be rated as incapacitating if  the 
minimum criteria for major depression are satisfied (ie. 4 items).
Key points and ranges on D dimension
0 No features of depression during lifetime.
1 -  19 Sub-Minor depression.
20-39 Minor depression.
40-49 Mild major depression.
50-59 Moderate major depression.
60-79 Severe depression.
80 - 100 Incapacitating depression
NB: if* enter as .01, e.g., 65* = 65.01
3) Psychotic features (P)
• Psychotic features refers to delusions, hallucinations, positive formal thought disorder, 
catatonia or grossly disorganized behaviour (but see exclusions below).
• Ratings on this dimension exclude stupor or excitement during an affective episode or positive 
formal thought disorder during mania.
• Lifetime occurrence o f psychotic features is rated.
• Near psychotic schizotypal features refers to the following DSMIV schizotypal items: ideas of
reference; odd beliefs or magical thinking that influences behaviour and is inconsistent with 
sub-cultural norms; unusual perceptual experiences including bodily illusions; odd thinking 
and speech; suspiciousness or paranoid ideation; behaviour or appearance that is odd 
eccentric or peculiar. Depersonalization and derealization are not classified as near psychotic 
features.
• The period o f illness considered refers to all affective and non-affective periods of 
psychopathology.
• Rating should take account o f both number and duration o f episodes with and without 
psychotic features. If in doubt, “rate up” the psychotic features. Examples:
o If there have been two 1 week long affective psychotic episodes and a 1 year non-
psychotic depressive episode, rate 60 (ie. approx. 2/3 o f illness episodes). 
o If there have been nine 1 month non-psychotic affective episodes, one 1 month 
psychotic affective episode and 4 years o f chronic hallucinations outside 
affective episodes, rate 80 (ie. approx. 80% of illness duration).
•  The Uncertain category (P = 1) is used for situations in which insufficient information is 
available to determine if  sign or symptom meets criteria for near psychotic feature.
Key points and ranges on P  dimension
Absent.
Uncertain.
Near psychotic features: occasional at low end o f range, frequent at 
High end o f range. Occurrence o f true psychotic symptoms should not 
be rated in this range.
Brief clear-cut psychotic symptom that are not a prominent 
feature o f illness.
10 -  Single.
20 -  Multiple.
Psychotic symptoms that are a prominent feature in one o f more 
episodes o f illness.
25 - present for 25% of illness.
50 - present for 50% of illness.
75 - present for 75% o f illness.
100 - prominent psychotic features present throughout illness.
NB: a) I f  there is only one manic episode which is psychotic, then P=100.
b) Experiences which are unusual but not definitely schizotypal or 
psychotic should be rated 7  ’ (uncertain) here. Such experiences should 
be rated as 7  ’ on the ‘near section 2 features ’ variable.
c) When calculating the % o f episodes that are psychotic, milder episodes 
o f illness may be weighted down compared with more severe episodes (use 
clinical judgement). In general use the rule o f counting a mild episode as 
equivalent to 1/4 o f a more severe episode. For example, i f  there have 
been 2 episodes ofpsychotic mania and 3 episodes o f mild depression 
which have not needed treatment this would be counted as equivalent to [2 
+ (3x0.25)] = 2.75 episodes o f mood disturbance and rated P as 73, i.e., 2 
/[  2 + (3x0.25)] = 73.
0
1
2 - 9
10-20
21  -  100
4) Mood incongruence (I)
• DSMIV definitions o f congruence and incongruence are used.
• Rate incongruence o f lifetime occurrence o f psychotic features.
• For convenience, the set o f psychotic symptoms recognized as having special weight in the 
diagnosis o f schizophrenia and schizoaffective disorder (thought echo, insertion, withdrawal 
or broadcasting; passivity experiences; hallucinatory voices giving running commentary, 
discussing subject in third person or originating in some part o f the body; bizarre delusions; 
catatonia) are denoted in the guidelines as the “S set” .
• If Psychosis Features dimension, P < 10, leave I blank.
Key points on I dimension
0 -40 Psychotic symptoms occur only during affective episodes and do not include any o f
the S set.
Rating 0 -  virtually completely mood congruent.
Rating 20 -  approximate balance between mood congruent and incongruent.
Rating 40- virtually completely mood incongruent 
43 Psychotic symptoms occur only during affective episodes and include one or more of
the S set which have not definitely been present for 2 weeks.
47 Psychotic symptoms occur only during affective episodes and include one or more of
the S set which have definitely been present for 2 weeks.
50 - 59 Psychotic symptoms probably present for at least 2 weeks either side o f an affective
episode.
Rating 50 -  on at least one occasion.
Ratings o f 51-59 used to reflect recurrence and/or certainty.
60 - 100 Psychotic symptoms definitely present for at least 2 weeks either side o f an affective
episode.
Rating 60 -  on at least one occasion.
Rating 80- on many occasions.
Rating 100 -  Psychotic symptoms predominate illness and occur chronically outside 
(or in absence of) affective episodes.
NB: a) a rating o f  100 does not necessarily imply schizophrenia.
b) when rating congruence rate psychotic symptoms occurring outside the affective states as 
incongruent.
c) i f  there is a delusional system — some can be congruent and others incongruent with the 
affective state. Rate as congruent i f  all the delusions are understandable in relation to the 
mood.
d) mixed episodes -  i f  it is not possible to determine a temporal relationship between the 
affective states and psychotic symptoms rate 20 (approx. balance between congruence and 
incongruence). I f  it is possible to determine a temporal relationship, rate congruence in 
relation to the affective states.
Appendix E
The Extended Rating Scales
•  Use all available information to make the best judgement for each rating.
•  Ratings should only be made for cases which involve affective and/or psychotic 
features
Extended Scale 1: Predominance of Mania in lifetime mood disturbances
Aim: To measure the relative amount o f  depressive and manic episodes experienced during 
lifetime.
0......................................... 50..................................... 100
100% Balanced 100%
Depression Mania/Depression Mania
Rating Guidelines
•  Rating is calculated as percentage o f  mood episodes which are manic in nature.
i.e;_______________ No. of episodes_mania_______________  xlOO
[No. of episodes depression] + [No. of episodes mania]
• Episodes o f  illness must meet criteria for major depression (at least mild), mania or 
hypomania, be clinically significant and cause impairment to be included in 
calculation
•  Use best estimate o f  the number o f  episodes
•  Mixed episodes should be rated on this dimension according to these rules:
1. Approximate balance between mania and depression 
Mania = 0.5 Depression = 0.5
2. Episode is predominantly manic 
Mania = 0.75 Depression = 0.25
3. Episode is predominantly depressive 
Mania = 0.25 Depression = 0.75 
If in doubt, use rating 1
If no episodes o f mood disturbance are described, leave blank (do not rate 0).
Extended Scale 2: Relationship between Mood and Psychotic Symptoms
Aim of scale: To measure the relative balance o f mood and psychotic psychopathology over the
lifetime experience o f illness. This is an extension o f the I dimension o f B ADDS.
-20 Episodes o f clinically significant mood disturbance. No psychotic features.
-19 Illness is predominantly affective and includes near psychotic features: occasional at
low end o f range, frequent at high end o f range. Occurrence o f true psychotic 
symptoms should not be rated here.
-1 Unsure/uncertain as to whether or not psychosis has occurred
0 Psychotic symptoms occur but only during affective episodes and do not include any
o f the S set. Virtually completely mood congruent.
20 Psychotic symptoms occur but only during affective episodes and do not include any
of the S set. Approximate balance between mood congruent and incongruent.
40 Psychotic symptoms occur but only during affective episodes and do not include any
of the S set. Virtually completely mood incongruent.
43 Psychotic symptoms occur but only during affective episodes and include one or
more o f the S set which have not definitely been present for 2 weeks.
47 Psychotic symptoms occur but only during affective episodes and include one or
more o f the S set which have definitely been present for 2 weeks.
50 Psychotic symptoms probably present in the absence o f an affective episode such that
at least 2 weeks o f normal mood occurs between the mood disturbance and the 
psychotic symptoms (Rating 50 -  on at least one occasion. Ratings o f 51-59 used to 
reflect recurrence and/or certainty).
60 Psychotic symptoms definitely present in the absence o f an affective episode such
that at least 2 weeks o f normal mood occurs between the mood disturbance and the 
psychotic symptoms - on at least one occasion.
80 Psychotic symptoms definitely present present in the absence o f an affective episode
such that at least 2 weeks o f normal mood occurs between the mood disturbance and 
the psychotic symptoms - on many occasions.
100 Psychotic symptoms predominate illness and occur chronically outside affective
episodes. Affective episodes occur but are not a major feature o f illness.
110 Illness is predominantly psychotic and includes some affective symptoms which do
not meet the criteria for an episode.
120 Psychotic features in the absence o f any clinically significant mood disturbance.
Rating guidelines
• DSMIV definitions o f  congruence and incongruence are used.
• Rate incongruence o f lifetime occurrence o f psychotic features.
• For convenience, the set o f psychotic symptoms recognized as having special weight in the 
diagnosis o f schizophrenia and schizoaffective disorder (thought echo, insertion, withdrawal 
or broadcasting; passivity experiences; hallucinatory voices giving running commentary, 
discussing subject in third person or originating in some part o f the body; bizarre delusions; 
catatonia) are denoted in the guidelines as the “S set”.
• Where no psychotic features are present, rate -  20.
• Where no mood features are present, rate + 120.
Extended Scale 3: Fluctuation of mood within acute phases of illness 
Anchor points
100 Fluctuations in mood occur over 1 day during at least one acute phase o f illness.
90 Fluctuations in mood occur over 4 days during at least one acute phase o f  illness.
80 Fluctuations in mood occur over 1 week during at least one acute phase o f  illness.
70 Fluctuations in mood occur over 10 days during at least one acute phase o f  illness.
60 Fluctuations in mood occur over 2 weeks during at least one acute phase o f illness.
50 Fluctuations in mood occur over 4 weeks during at least one acute phase o f illness.
40 Fluctuations in mood occur over 8 weeks during at least one acute phase o f  illness.
30 Fluctuations in mood occur over 12 weeks during at least one acute phase o f illness.
20 Fluctuations in mood occur over 26 weeks during at least one acute phase o f illness.
10 Fluctuations in mood occur over 52 weeks during at least one acute phase o f illness.
0 No fluctuations in mood occur.
Rating Guidelines
•  Aim o f scale is to give an indication o f  the maximum rapidity o f  mood fluctuation 
during an acute phase o f  illness.
•  “Acute phase o f  illness” is defined as a continuous interval o f  time during which the 
individual has impaired function, compared with the usual functioning. (Thus, if  an 
individual has 3 months o f  depression with a switch to 2 months o f mania and a 
return to normal functioning, this is an acute phase lasting 5 months. If an individual 
has a chronic impairment relating to illness, it is the change from this usual (but 
impaired) function that is used as a reference baseline for determining acute phases).
• “Fluctuation” is defined as at least 2 changes of mood pole (ie. Depression — 
mania -  depression or mania-depression-mania).
•  Ratings should be made using an integer on the 0 -  100 scale that best represents the 
maximum rapidity o f  fluctuation that has occurred during the lifetime experience of 
illness.
• If there is insufficient information to rate accurately, leave blank.
Extended Scale 4: Instability of clinical state within acute phases of illness
Anchor points
100 Clinical state varies significantly during a period o f  10 minutes during the most
variable one month o f  illness.
80 Clinical state varies significantly during a period o f  1 day during the most variable
one month o f  illness.
60 Clinical state varies significantly during a period o f 1 week during the most variable
one month o f  illness.
40 Clinical state varies significantly during a period o f  2 weeks during the most variable
one month o f  illness.
20 Clinical state varies significantly during a period o f  4 weeks during the most variable
one month o f  illness.
0 No variability in clinical state during the most variable one month o f  illness.
Rating Guidelines
• Aim o f scale is to give an indication o f  the maximum instability in clinical state ever 
experienced during a one month phase o f  illness.
•  “Clinical instability” refers to substantial changes in the psychopathological state and 
includes the domains o f  mood, perception, cognition and behaviour.
•  Changes o f  mood that can be rated include mood states that meet full criteria for an 
episode and also more subtle variation o f  mood states that do not meet full criteria.
•  Note that it is possible to have fluctuations in mood (scale 3) over a 12 week period 
with instability o f  clinical state occurring over a period o f  1 day.
•  Ratings should be made using an integer on the 0 — 100 scale that best represents the 
maximum level o f  instability that has occurred during a one month period in the 
individual’s lifetime experience o f  illness.
• Anchor points: Where “rapid mood changes” are mentioned or where mood is 
described as “labile” with no additional information, rate as 90*; where mood is 
described as “variable” with no additional information, rate as 80*. This estimate can 
also be used for similar descriptions (e.g. “fluctuating affective state”, “mood up and 
down”, etc).
•  If a switch in mood is described, rate 20 unless it is clear that the switch definitely 
occurred over period o f  less than 4 weeks.
•  If it is clear that some degree o f  fluctuation occurs but there is insufficient 
information to make a definite rating on the scale, rate 10.
•  If there is insufficient information to rate accurately, leave blank.
Extended Scale 5: Periodicity of acute phases of illness
Anchor points
100 5 acute phases o f  illness in one year.
90 2 acute phases o f  illness in one year.
70 2 acute phases o f  illness in 2 years
50 2 acute phases o f  illness in 5 years
30 2 acute phases o f  illness in 8 years
20 2 acute phases o f  illness in 10 years
10 2 acute phases o f  illness in 20 years
1 2 acute phases o f  illness in 50 years
0 Only one acute phase o f  illness.
Rating guidelines
• Aim o f scale is to measure the tendency to recurrence o f acute phases o f  illness 
during the lifetime course.
• “Acute phase o f  illness” is defined as a continuous interval o f  time during which the 
individual has impaired function, compared with the usual functioning. (Thus, if  an 
individual has 3 months o f  depression with a switch to 2 months o f  mania and a 
return to normal functioning, this is an acute phase lasting 5 months. If an individual 
has a chronic impairment relating to illness, it is the change from this usual (but 
impaired) function that is used as a reference baseline for determining acute phases).
• A period o f  at least 2 months o f  usual functioning is required between adjacent acute 
phases o f  illness (which gives an upper limit o f  5 such phases within one year).
• Ratings should be made based on knowledge o f  the lifetime course o f illness 
experienced by the subject. Rate the maximum periodicity during the lifetime. Thus, if  
there were 2 acute phases o f illness in the first 10 years since onset and then 2 acute 
phases in one year, rate 90.
•  A single chronic phase lasting 20 years with no superposed acute phases should be 
rated as 0.
Extended Scale 6: Predominance of mixed episodes in episodes of mood disturbance
0............................................... 50............................................ 100
0% episodes o f  100% episodes o f
mood disturbance are mood disturbance are
mixed mixed
Rating Guidelines
•  Aim o f scale is to measure the relative amount o f  mood episodes that involve a mixed 
affective state.
• “Mixed episode” refers to an episode o f  mood disturbance in which both depressive 
and manic syndromes occur simultaneously. However, to recognize the difficulty o f  
obtaining adequate retrospective information about the depressive aspects o f  mixed 
states, one less symptom is required for determining the presence o f  depression (ie. 
Depressed mood + 3 symptoms).
•  Rating is calculated as proportion o f  affective episodes which are mixed in nature, 
i.e.
_______________________ No. of mixed episodes________________________ xlOO
[No. of mixed episodes]+[No. of episodes depression]+[No. of episodes mania]
•  Episodes o f  illness must be clinically significant and cause impairment to be included 
in calculation
• If no episodes o f  affective illness are described, leave blank (do not rate 0).
Extended Scale 7: Most dysphoric manic episode experienced 
Anchor points
100 Mania with
90 Mania with
80 Mania with
70 Mania with
60 Mania with
50 Mania with
40 Mania with
features.
30 Mania with predominantly irritable and some elated mood but no other
depressive features.
20 Mania with rough balance o f  elevated and irritable mood but no other
depressive features.
10 Mania with predominantly elevated mood and some evidence o f  irritability
but no other depressive features.
0 Mania with elevated mood and no irritability or dysphoric features.
Rating Guidelines
• Mania refers to manic episode as defined by DSMIV criteria.
•  Rate the manic episode in which the greatest number o f  depressive features occur.
•  Depressive items refers to those used in the diagnosis o f  a major depressive episode 
according to DSMIV (i.e. depressed mood, anhedonia, disturbance in appetite and/or 
weight loss or gain, psychomotor agitation or retardation, fatigue/loss o f energy, 
excessive se lf reproach, reduced concentration and suicidal ideation).
•  If an episode is described as being “mixed” with no additional information, rate as 
65*.
6 depressive items according to DSMIV.
5 depressive items according to DSMIV.
4 depressive items according to DSMIV.
3 depressive items according to DSMIV.
2 depressive items according to DSMIV.
one depressive item according to DSMIV.
irritable mood and no evidence o f  elated but no other depressive
Extended Scale 8: Extent to which illness is “purely” psychotic or “purely” affective
0......................................... 50......................................100
Prototypical affective Prototypical
disorder schizophrenia
•  Judgement to be made based on whole clinical picture over entire duration o f illness.
• “prototypical affective disorder” refers to episodic illness characterised by one or 
more manic or depressive episodes with good recovery in between multiple episodes 
and with no evidence o f  psychotic or near psychotic symptoms.
•  prototypical schizophrenia refers to chronic illness characterised by insidious onset, 
positive and negative symptoms and no evidence o f affective disturbance.
Extended Scale 9 -  Relationship between Positive and Negative Symptoms
0................................................50............................................100
Illness characterised by Illness characterised
by reversible acute symptoms chronic defect-state
•  Judgement to be made based on whole clinical picture over entire duration o f illness.
•  Chronic defect state includes negative symptoms such as affective flattening or 
blunting, alogia, avolition/apathy, anhedonia/asociality and poor attention, which 
appear to be irreversible and are a longstanding characteristic o f  the clinical picture.
•  Reversible acute symptoms include positive symptoms such as hallucinations, 
delusions, bizarre behaviour, positive formal thought disorder and affective 
symptoms/episodes.
Extended Scale 10: Catatonic Symptoms
One point should be given for the presence o f any o f  the following symptoms, up to a 
maximum o f 4 points.
Symptoms explicable by affective change should not be counted
• Waxy flexibility
• Stupor (clear description of catatonic stupor deserves 2 points, give 1 point 
for a condition described as sub-stupor. Do not rate here slowing down which 
is common in depressive episodes)
• Physiological pillow
• Excessive purposeless overactivity (not in a manic context)
• Mannerisms
• Grimacing
• Echolalia, echopraxia, automatic obedience (need clear descriptions)
• Negativism (need clear descriptions)
Extended Scale 10L: Catatonic Symptoms -  Lifetime Ever
One point should be given for the p resence o f  any o f  the fo llow ing sym ptom s, up to  a 
m axim um  o f  4 points.
Includes sym ptom s which occur during affective ep iso d es
•  Waxy flexibility
•  Stupor (clear description of catatonic stupor deserves 2 points, give 1 point 
for a condition described as sub-stupor. Do not rate here slowing down which 
is common in depressive episodes)
•  Physiological pillow
•  Excessive purposeless overactivity (not in a manic context)
•  Mannerisms
•  Grimacing
•  Echolalia, echopraxia, automatic obedience (need clear descriptions)
•  Negativism (need clear descriptions)
Extended Scale 11: Disorganised Behaviour
One point should be given if any the following symptoms that are present over the 
course of the illness. If an item is present repeatedly during the illness or if several 
items are present, a score of 2 should be given.
Sym ptom s explicable by affective change should not be counted
•  Talking to themselves
•  Laughing for no reason
•  Hoarding rubbish
•  Odd, inappropriate behaviour (e.g. undressing or urinating in public)
•  Acts of senseless violence
•  Extremely poor personal hygiene
Extended Scale 11L: Disorganised Behaviour
One point should be given if any the following symptoms that are present over the 
course of the illness. If an item is present repeatedly during the illness or if several 
items are present, a score of 2 should be given.
Includes sym ptom s which occur during an affective ep isod e
•  Talking to themselves
•  Laughing for no reason
•  Hoarding rubbish
•  Odd, inappropriate behaviour (e.g. undressing or urinating in public)
•  Acts of senseless violence
•  Extremely poor personal hygiene
Appendix F
Sheet used to rate the Velo-Cardio-Facial Syndrome Cases
STUDY ID INITIALS DOB
RATER DATE AGE AT INT.
GENDER ETHNICITY
DSM-IV ICD-10 RDC CYCLOID
Family History: Affective Disorders   Other
DIMENSION SCORES: M
D
P
I
GAS SCORES: LIFETIME WORST (IN DEP EPISODE)
LIFETIME WORST (IN NON-PN DEP EPISODE) 
LIFETIME WORST (IN PN DEP EPISODE) 
LIFETIME WORST (IN MANIC EPISODE) 
LIFETIME WORST (IN NON-PN MANIC EPISODE) 
LIFETIME WORST (IN PN MANIC EPISODE) 
LIFETIME WORST (IN PSYCHOSIS) 
LIFETIME WORST (IN NON-PN PSYCHOSIS) 
LIFETIME WORST (IN PN PSYCHOSIS) 
LIFETIME WORST EVER 
PAST WEEK
SECTION 2 (LE)  MOOD CONGRUENCE (LE)  NEAR SECTION 2 (LE)
SECTION 2 (PN )  MOOD CONGRUENCE (P N )_______________________
SECTION 2 (NON-PN)  MOOD CONGRUENCE (NON-PN)_________________
PREDOMINANT MAN AFFECT (LE)  DYSPHORIC MAN (LE)
PRED MAN AFFECT (NON-PN MAN) _ _ _  DYSPHORIC MAN (NON-PN MAN)
PRED MAN AFFECT (PN M A N )  DYSPHORIC MAN (PN M A N )________________
NO. EPISODES: MANIA
PN MANIA 
NON-PN MAN
DEPRESSION
PN DEPRESSION 
NON-PN DEPRESSION
LONGEST DURATION: MANIA_________________________________ _ DEPRESSION
PN MANIA ____  PN DEP
NON-PN MAN ____  NON-PN DEP
AGE ONSET:
SYMPTOM IMPAIRMENT CONTACT ADMISSION
FIRST DEPRESSION
FIRST PN DEPRESSION 
FIRST NON-PN DEP
FIRST SYMPTOMS MANIA_____ D EP_____
FIRST IMPAIRMENT MANIA_____ DEP_____
FIRST PSYCHIATRIC CONTACT ____________
FIRST ADMISSION MANIA_____ DEP_____
MOST RECENT ADMISSION MANIA  DEP_____
FIRST SYMPTOMS PN_D E P _____  NON-PN DEP
FIRST IMPAIRMENT PN_D E P _____  NON-PN DEP
FIRST ADMISSION PN_D E P_____  NON-PN DEP
MOST RECENT ADMISSION PN DEP NON-PN DEP
NO. ADMISSIONS: _____
LONGEST ADMISSION _____
AGE OF FIRST PSYCHOSIS (HALLUCINATION OR DELUSION): 
FIRST EPISODE POSTPARTUM? Y / N / UK /N A
PUERPERAL EPISODE ____ MENSTRUAL   RAPID CYCLING
SUICIDAL IDEATION (LE)
SUICIDAL IDEATION (PN) 
SUICIDAL IDEATION (NON PN)
LITHIUM RESPONSE ____  ANTI-DEPRESSANT RESPONSE (inc ECT)
SWITCH OF POLARITY FOLLOWING ANTI-DEPRESSANTS
PSYCHIATRIC SEQUELAE ONSET (WKS AFTER 
DELIVERY)
FULL-TERM DELIVERY 
#1
FULL-TERM DELIVERY 
#2
FULL-TERM DELIVERY 
#3
FULL-TERM DELIVERY 
#4
FULL-TERM DELIVERY 
#5
FULL-TERM DELIVERY 
#6
Delivery # of Episode rated in OPCRIT ______
EXTENDED RATING SCALES: Scale 1
Scale 2 
Scale 3 
Scale 4 
Scale 5 
Scale 6 
Scale 7 
Scale 8
(predominance mania)
(affective vs. psychotic features) 
(fluctuations in mood) 
(instability)
(periodicity)
(predominance mixed) 
(dysphoric mania)
(affective disorder vs. SZP)
STUDY ID 
DOB
MOLECULAR PSYCHIATRY GROUP
SYMPTOM CHECKLIST (Modified OPCRIT version 6 -  01.12.05)
INITIALS _______
DATE
RATER
NB: For women who have had puerperal illness please rate the worst puerperal episode (WE -  PN) 
and indicate the polarity below -  complete all sections o f the form independent ofpolarity o f episode. 
I f  the worst puerperal episode is depression please rate the worst non-puerperal episode o f  
depression (WE-NON-PN, and complete all sections o f the form). I f  the worst puerperal episode is 
mania/mixed please rate the worst non-puerperal episode o f mania/mixed (WE-NON-PN, and 
complete all sections o f the form). I f  the worst puerperal episode is psychosis only please rate the 
worst non-puerperal episode o f psychosis only (but if  there is not a non-PN episode o f psychosis 
only, please rate the worst non-puerperal episode o f mania/mixed).
The columns marked WE and LE should be rated in the usual way.
Polarity of worst puerperal episode 
DEPRESSIVE SYMPTOMS
1
2
3
4
5
WE
Depression
Mania
Mixed
Not applicable. Rate all males 1 
Psychosis only
LE WE (PN) WE
PN)
1. Dysphoria □ □ □ □
2. Loss of pleasure □ □ □ □
3. Diurnal variation (mood worse mornings) □ □ □ □
4. Suicidal ideation □ □ □ □
5. Excessive self reproach □ □ □ □
6. Poor concentration □ □ □ □
7. Slowed activity □ □ □ □
8. Loss o f energy/tiredness □ □ □ □
9. Poor appetite □ □ □ □
10. Weight loss □ □ □ □
11. Increased appetite □ □ □ □
12. Weight gain □ □ □ □
13. Initial insomnia □ □ □ □
14. Middle insomnia (broken sleep) □ □ □ □
15. Early morning waking □ □ □ □
16. Excessive sleep □ □ □ □
17. Diminished libido □ □ □ □
18. Agitated activity □ □ □ □
MANIC SYMPTOMS WE LE W E (PN) WE
PN)
19. Elevated mood □ □ □ □
20. Irritable mood □ □ □ □
21. Thoughts racing □ □ □ □
22. Pressured speech □ □ □ □
23. Distractibility □ □ □ □
24. Excessive activity □ □ □ □
25. Increased self esteem □ □ □ □
26. Reckless activity □ □ □ □
27. Reduced need for sleep □ □ □ □
28. Increased sociability □ □ □ □
PSYCHOTIC SYMPTOMS 
PN)
LE WE (PN) WE (NON-
29. Third person auditory hallucinations □ □ □
30. Running commentary voices □ □ □
31. Abusive/accusatory/persecutory voices □ □ □
32. Other (non affective) auditory hallucinations □ □ □
33.* Non-affective visual hallucinations □ □ □
34. Non-affective hallucination in any other modality □ □ □
35. Thought echo □ □ □
36. Thought insertion □ □ □
37. Thought broadcast □ □ □
38. Thought withdrawal □ □ □
39. Delusions o f passivity □ □ □
40. Delusions o f influence □ □ □
41. Primary delusional perception □ □ □
42. Persecutory delusions □ □ □
43. Bizarre delusions □ □ □
44. Other primary delusions □ □ □
45. Bizarre behaviour □ □ □
46. Catatonia □ □ □
47. Speech difficult to understand □ □ □
48. Incoherent □ □ □
49. Positive formal thought disorder □ □ □
50. Negative formal thought disorder □ □ □
51. Restricted affect □ □ □
52. Blunted affect □ □ □
53. Inappropriate affect □ □ □
54.* Perplexity □ □ □
PSYCHOTIC AFFECTIVE SYMPTOMS 
PN)
WE LE WE (PN) WE (NON
55. Grandiose delusions □ □ □ □
56. Delusions o f guilt □ □ □ □
57. Delusions o f poverty □ □ □ □
58.
59.*
Nihilistic delusions
Mood congruent third person auditory
□ □ □ □
60.*
hallucinations
Mood congruent second person auditory
□ □ □ □
hallucinations □ □ □ □
61.*
62.*
Mood congruent visual hallucinations 
Mood congruent hallucinations in any
□ □ □ □
other modality □ □ □ □
63.* Other secondary delusions □ □ □ □
ADDITIONAL CRITERIA -  OPCRIT Version 4.0
Details and History
1 Source of rating ( 1_6)
2 Time frame (1-4)
3 Gender (0, l)
4 Age of onset
5 Mode of onset (1-5)
6 Marital status (0, 1)
7 Unemployed (0, 1)
8 Duration o f illness in weeks
9 Poor premorbid work adjustment (0 ,1)
10 Poor premorbid social adjustment (0 ,1)
11 Premorbid personality disorder (0 ,1)
12 Alcohol/drug abuse within 1 year o f onset (0, 1)
13 Family history o f schizophrenia (0 ,1)
14 Family history o f other psychiatric disorders (0, 1)
15 Coarse brain disease prior to onset (0, 1)
16 Definite psychosocial stressor prior to onset (0 ,1)
Substance Abuse or Dependence
78 Lifetime diagnosis o f alcohol abuse/dependence (0, 1)
79 Lifetime diagnosis of cannabis abuse/dependence (0 ,1)
80 Lifetime diagnosis o f other abuse/dependence (0 ,1 )
81 Alcohol abuse/dependence with psychopathology (0 ,1 )
82 Cannabis abuse/dependence with psychopathology (0 ,1)
83 Other abuse/dependence with psychopathology (0, 1)
General Appraisal
84 Information not credible (0 ,1 )
85 Lack of insight (0, 1)
86 Rapport difficult (0, 1)
87 Impairment/incapacity during disorder (0,1,2,3)
88 Deterioration from premorbid level o f function (0 ,1 )
89 Psychotic symptoms respond to neuroleptics (0 ,1)
90 Course of Disorder (0-5)
Appendix G
List of variables analysed in the sample enriched for 
schizoaffective disorder
• BADDS Mania
• BADDS Depression
• BADDS Psychosis
• BADDS Incongruence
• GAS Depression
• GAS Mania
• GAS Psychosis
• GAS Worst Ever
• GAS Past Week
• No. Manic Episodes
• No. Dep. Episodes
• AOO Impairment
• Age of first mania
• Age of first depression
• Age of first psychosis
• ERS1
• ERS2
• ERS4
• ERS5
• ERS7
• ERS8
• ERS9
•  Course of Disorder
Appendix H
Inter-rater reliability analyses performed on the SABP sample
Variable ICC p-value
BADDS Mania 0.797 p<0.001
BADDS Depression 0.687 0.001
BADDS Psychosis 0.989 p<0.001
BADDS Incongruence 0.914 p<0.001
GAS Depression 0.980 p<0.001
GAS Mania 0.991 0.005
GAS Psychosis 0.899 p<0.001
GAS Worst Ever 0.982 p<0.001
GAS Past Week 0.912 p<0.001
No. Manic Episodes 0.962 p<0.001
No. Dep. Episodes 0.988 p<0.001
AOO Impairment 0.997 p<0.001
Age of first mania 0.999 p<0.001
Age of first depression 0.991 p<0.001
Age of first psychosis 1.000 -
ERS1 0.768 p<0.001
ERS2 0.971 p<0.001
ERS4 0.739 0.011
ERS5 0.509 0.016
ERS7 0.857 p<0.001
ERS8 0.934 p<0.001
ERS9 1.000 -
Course of Disorder 0.845 p<0.001
Appendix I
Rating sheet used to record ratings made for cases in the large harmonised dataset
STUDY ID ____________ INITIALS__________  D O B _______________
RATER__________  D ATE_____________
AGE AT IN T ._________________  DATE AT IN T .__________
GENDER________  [ETHNICITY________ ]
[STUDY__________________] []= Fields not for consensus rating meetings
DSM-IV ICD-10 RDC
Main: Main: Main:
2. 2. 2.
3. 3. 3.
4. 4. 4.
5. 5. 5.
PN CYCLOID NON-PN CYCLOID
FH AFF FH OTHER FH PN
BADDS SCORES: M
D
P
I
GAS SCORES:
LIFETIME WORST (IN DEPRESSIVE EPISODE)
LIFETIME WORST (IN MANIC EPISODE)
LIFETIME WORST (IN PSYCHOTIC EPISODE)
LIFETIME WORST EVER 
PAST WEEK
SECTION 2 (LE)  MOOD CONGRUENCE (LE)____
NEAR SECTION 2 (LE)_____
PREDOMINANT MAN AFFECT (LE)  DYSPHORIC MAN (LE)
NO. EPISODES:
MANIA  DEP  NON-AFFECTIVE PSYCHOSIS_____
LONGEST DURATION (EPISODE):
MANIA DEP NON-AFFECTIVE PSYCHOSIS
AGE OF ONSET:
SYMPTOM IMPAIRMENT CONTACT ADMISSION
MANIA DEP PSYCHOSIS PN
SYMPTOM
IMPAIRMENT
TREATMENT
ADMISSION
MOST REC. 
ADMISSION
NO. ADMISSIONS_______________________________
LENGTH OF LONGEST ADMISSION__________________________________
PROPORTION OF TIME ADMITTED____________________________________ %
PROPORTION OF TIME WELL SINCE O N SET_________________ % (Objective)
FIRST EPISODE PAST-PARTUM? Y / N / UK PUERPERAL EPISODE____
RAPID CYCLING____(NB: Rate 9 if less than 7 years since onset and/or fewer than 3 episodes)
SUICIDAL IDEATION (LE)____
MOOD SWITCH (D TO M )_________  MOOD SWITCH (M TO D )__________
MAXIMUM NUMBER OF SWITCHES IN ONE EPISODE__________
LITHIUM RESPONSE ANTI-DEPRESSANT RESPONSE (inc ECT)____
SWITCH OF POLARITY FOLLOWING ANTI-DEPRESSANTS____
PSYCHIATRIC SEQUELAE ONSET (WKS AFTER 
DELIVERY)
FULL-TERM DELIVERY 
#1
FULL-TERM DELIVERY 
#2
FULL-TERM DELIVERY 
#3
FULL-TERM DELIVERY 
#4
FULL-TERM DELIVERY 
#5
FULL-TERM DELIVERY 
#6
POLARITY OF FIRST AFFECTIVE EPISODE
PSYCHOTIC SYMPTOMS PRESENT BEFORE ANY MOOD DISTURBANCE
EXTENDED RATING SCALES: Scale 1 
Scale 2 
Scale 3 
Scale 4 
Scale 5 
Scale 6 
Scale 7 
Scale 8 
Scale 9 
Scale 10 
Scale 10L 
Scale 11 
Scale 11L
(predominance mania)
(affective vs. psychotic features) 
(fluctuations in mood)
(instability)
(periodicity)
(predominance mixed)
(dysphoric mania)
(affective disorder vs. SZP)
(Chronic defect state)
(Catatonic Symptoms) (Max. =4) 
(Catatonic -  LE)
(Disorganised Behaviour) (Max.=2) 
(Disorganised Behaviour -  LE)
ID: Initials:
Modified OPCRIT:
Polarity of worst puerperal episode 1 Depression
2 Mania
3 Mixed
4 Not applicable. Rate all males here.
5 Psychosis only
DEPRESSIVE SYMPTOMS:
W orst
Episode
(W E)
LE -  In 
context o f 
Dep 
mood
L E -
Context
Independent
WE
PN
WE
NON-
PN
1. Dysphoria
2. Loss of pleasure
3. Diurnal variation
4. Suicidal ideation
5. Excessive self-reproach
6. Poor concentration
7. Slowed activity
8. Loss of energy/tiredness
9. Poor appetite
10. Weight loss
11. Increased appetite
12. Weight gain
13. Initial insomnia
14. Middle insomnia
15. Early morning waking
16. Excessive sleep
17. Diminished libido
18. Agitated activity
MANIC SYMPTOMS: W orstEpisode
(W E)
LE -  In 
context of 
M  mood
L E -
Context
Independent
WE
PN
WE
NON-
PN
19. Elevated mood
20. Irritable mood
21. Thoughts racing
22. Pressured speech
23. Distractibility
24. Excessive activity
25. Increased self-esteem
26. Reckless activity
27. Reduced need for sleep
28. Increased sociability
28a.* Increased sexual activity (0-2)
PSYCHOTIC SYMPTOMS: L E - I n
mood
episode
LE -  Not 
in mood 
episode
LE WE
PN
WE
NON-
PN
29. Third person AHs
30. Running commentary voices
31. Abusive/accusatory/persecutory voices
32. Other (non-affective) AHs
33.* Non-affective VHs
34. Non-affective hall in any other modality
35. Thought echo
36. Thought insertion
37. Thought broadcast
38. Thought withdrawal
39. Delusions o f passivity
40. Delusions o f influence
41. Primary delusional perception
42. Persecutory delusions
43. Bizarre delusions
44. Other primary delusions
45. Bizarre behaviour #
46. Catatonia #
47. Speech difficult to understand #
48. Incoherent #
49. Positive formal thought disorder #
50. Negative formal thought disorder #
51. Restricted affect #
52. Blunted affect #
53. Inappropriate affect #
54.* Perplexity #
54a.* Aggressive behaviour (0-4)
PSYCHOTIC AFFECTIVE 
SYMPTOMS:
W orst
Episode
(W E)
L E - I n  
context of 
M/D 
mood
L E -
Context
Independent
W E
PN
WE
NON-
PN
55. Grandiose delusions
56. Delusions o f guilt
57. Delusions o f poverty
58. Nihilistic delusions
59*. Mood congruent third person AHs N/A
59 a.* D congruent third person AHs N/A
59b. * M  congruent third person AHs N/A
60,* Mood congruent sec person AHs N/A
60a. * D congruent second person AHs N/A
60b. * M  congruent second person AHs N/A
61.* Mood congruent VHs N/A
61a* D congruent VHs N/A
61b. * M  congruent VHs N/A
62. Mood cong Hs in any other 
modality
N/A
62a. * D cong Hs in any other modality N/A
62b. * M cong Hs in any other modality N/A
63.* Other 2ndry dels (not necess. cong) N/A
63a* Other dels secondary to D N/A
63b* Other dels secondary to M ...
DETAILS & HISTORY: [ NB 9=Unsure, 8=Not Applicable except stated otherwisel
1. Source of rating [ 1 -61 1
2. Time frame [1-4] 2
3. Sex [0,1] 3
4. Age o f onset [Unknown =991 4
5. Mode of onset [1-5] rate to one decimal place if necessary 5
6. Single [0,1] 6
7. Unemployed at onset [0,11 7
8. Duration o f illness in weeks [blank if  unknown] 8
9. Poor work adjustment [0,1] 9
10. Poor pre-morbid social adjustment [0,11 10
11. Premorbid personality disorder [0,1 ] 11
12. Alcohol/ drug abuse within one year o f onset o f psychotic symptoms [0,11 12
13. Family history o f  schizophrenia [0,1] 13
14. Family history o f other psychiatric disorder [0,1] 14
15. Coarse brain disease prior to onset [0,1] 15
16. Definite psychosocial stressor prior to onset [0,1] 16
SUBSTANCE ABUSE OR DEPENDENCE:
78: Lifetime diagnosis o f alcohol abuse/dependence [0,11 78
79. Lifetime diagnosis o f cannabis abuse/dependence [0,1] 79
80. Lifetime diagnosis o f other abuse/dependence [0,1] 80
81. Alcohol abuse/dependence with psychopathology [0,11 81
82. Cannabis abuse with psychopathology [0,1] 82
83. Other abuse/dependence with psychopathology [0,1] 83
GENERAL APPRAISAL:
84. Information not credible [0,1] 84
85. Lack of insight [0,1] 85
86. Rapport difficult [0,1] 86
87. Impairment/incapacity during disorder [0-31 87
88. Deterioration from premorbid level o f functioning [0,1] 88
89. Psychotic symptoms respond to neuroleptics [0,1 ] 89
90. Course of disorder [1-51 rate to one decimal place if necessary 90
EXTRA ITEMS -  COURSE OF DISORDER AND MODE OF ONSET:
91.* Acute episode onset [0-4] 91
92.* Characteristic pattern to course o f illness 92
93.* Mode of onset -  first M [1-5] rate to one decimal place if necessary 93
94.* Mode of onset -  first D [1-51 rate to one decimal place if necessary 94
95.* Mode of onset -  first P [1-51 rate to one decimal place if necessary 95
96.* Mode o f onset -  typical M [1-5] rate to one decimal place if  necessary 96
97.* Mode of onset -  typical D [1-5] rate to one decimal place if  necessary 97
98.* Mode o f onset -  typical P [1-5] rate to one decimal place if  necessary 98
Appendix J
Rating guidelines used to rate items of psychopathology in the large 
harmonised dataset, the VCFS sample and the sample enriched for 
schizoaffective disorder
Section 2 Features (LE)
Mood Congruence (LE)
0 Not present
1 Present
9 Unsure/unknown
0 No Section 2 features
1 Virtually all content congruent with affective state
2 More congruent than not
3 Congruent and incongruent equally
4 More incongruent than congruent
5 Virtually all content incongruent
9 Unsure/unknown
Near Section 2 Features
Pred Manic Affect (LE)
Dysphoric Mania (LE)
L ifetim e ever presence o f  near psychotic features. R efers to  
sch izo typal features, e.g., second sight, feeling presences or 
som e sym ptom s th a t com e close to  being psychotic but do 
n o t m eet the threshold  for clin ical significance:
0 N o t present
1 P resent
2 N o t applicable (as psychotic features present)
9 U nknow n
(NB: A rating o f  7  ’ here can be used to highlight 
experiences which are unusual but not definitely schizotypal 
or psychotic - this may be due to lack o f  information. Such 
experiences should be rated as ‘uncertain (1)’ on the P 
dimension o f BADDS).
1 E lation
2 Irritab ility
8 N o t applicable
9 U nknow n
(NB: The default rating for this item should be ‘elation ’. 
Requires clear evidence o f irritability to rate ‘2 )
0 N o
1 Y es (NB: Rating o f 1 should be used for patients who
have experienced at least one episode o f  mania in 
which the predominant mood state was dysphoria - 
ie. an unpleasant state characterized by unease or 
mental discomfort (including low mood).
8 N o t applicable
9 U nsure
Number of episodes:
Mania 
Depression 
Other psychotic
NB: For the following items, please remember to enter 0 if 
there have been no such episodes. If you are unsure please 
enter 999.
Number of episodes of mania **
Number of episodes of depression **
Number of episodes of non-affective psychotic illness **
(** NB: a d d .1 fo r  +, e.g., 6+ =6.1)
Longest Duration: For the following items, please enter 999 if  you are unsure of
duration.
Mania Longest episode of mania or hypomania in weeks **
Depression Longest episode of depression in weeks **
Oth psychot Longest episode of non-affective psychosis in weeks **
(** NB: use first decimal place fo r days, e.g., 0.3 = 3 days; and use 
second decimal place for hours, e.g., 0.03 = 3  hours -  if  >9hours 
round up to one day)
NB: Where only an age ranze is known for illness onset put 
the lowest in the range as first symptom, and the highest in 
the range as first impairment.
NB: for the following items, please enter 999 if  you are 
unsure.
NB: use judgement when rating age at onset o f  
schizoaffective cases. We are trying to rate the age at onset 
o f  the illness that we are interested in. 
age (years) of first symptom of affective illness. NB:
a) do not rate anxiety symptoms, unless there is evidence 
o f  accompanying mood disturbance.
b) if  age at first symptom is unknown, but known to be 
younger than first impairment — then leave age at first 
symptom blank.
age (years) of first impairment due to affective illness.
NB: symptoms occurring within the context o f a mood 
episode that produce clinically significant impairment. First 
episode o f  hypomania should be included here. 
age (years) of first contact with psychiatric services for 
affective disturbance.
NB: contact must be with secondary specialist mental health 
services.
age (years) of first admission to psychiatric hospital (include 
admission to a day hospital or intensive home treatment)
Number of admissions Number of psychiatric admissions (incl. Day Hospital &
intensive home treatment)
NB: admissions are counted separately even if  only 1 day 
between them.
NB: remember to enter 0 if  there have been no admissions. 
Enter 999 if  you are unsure.
Length of longest admission Duration in weeks of longest in-patient admission.
Proportion of time Enter as percentage of duration of illness (i.e., from age
at first
admitted impairment to current age), (incl. Day Hospital &
intensive home treatment)
NB: remember to enter 0 i f  there have been no 
admissions. Enter 999 i f  you are unsure.
Approx. time well
Since onset (objective) Enter percentage.
Enter 999 i f  unsure.
Puerperal Episode 0 No occurrence despite having had at least one child
(include “blues” here)
Age at onset:
Symptom
Impairment
Contact
Admission
1 M ania w ith in  6 w eeks o f  delivery  (include mania 
which begins exactly 6 weeks after delivery).
Include hypomania here.
2 D epression, but no t m ania w ith in  6 w eeks o f  
delivery  (include depression which begins exactly 6 
weeks after delivery)
3 O nset o f  affective d isturbance during pregnancy 
(NB: onset o f an episode is taken from the first 
impairment)
4  P sychiatric d isorder w ith onset w ithin 6 w eeks o f  
delivery  (include clear psychiatric disturbance 
which does not meet fu ll criteria for an episode)
5 M ania w ith in  3 m onths o f  delivery
6 P sychotic illness soon afte r delivery
7 D epression  fo llow ing  ch ildbirth  (usually  w ith in  6 
m onths, bu t rate unspecified  PN D  here).
8 N ev er given birth . R ate all m ales here.
9 U nknow n/unclear
NB: The cut-off for classing an episode as post-natal is 6 
months after delivery.
NB: In the case o f  a woman who has an episode o f mania/ 
hypomania following delivery and then an episode o f  
depression — rate the manic/hypomanic episode as post-natal 
and the depression as non-postnatal even if  the depression is 
within 6 months o f delivery.
NB: The onset o f  a puerperal episode is taken as the time o f  
‘change ’ from the prior mental state, this can be the onset o f  
symptoms or the onset o f impairment.
NB: Mania that begins >3 months and up to 6 months after 
delivery should be rated here as ‘9 ’. Please make a note in 
the comments box.
Rapid Cycling 0 R ap id  cycling  is not presen t or suspected despite a
period o f observation o f illness that includes at least 
7 years from onset and at least 3 episodes o f mood 
disorder
1 O ccurrence during illness o f  4  or m ore episodes 
(m ania o r depression) in a  12 m onth period
2 R ap id  cycling predom inates course o f  illness and has 
been  p resen t for at least 5 years during the total 
course o f  the illness
9 Insufficien t info to  m ake a rating o f  0, 1 or 2. This
ra ting  is used i f  there has been no rapid  cycling but 
there has been less than  7 years from  the onset o f  
illness and/or few er than  3 episodes o f  m ood 
d isorder
NB: Rapid cycling can be rated as present if  mood episodes 
do not include mania.
Suicidal Ideation (LE) R ate m ost severe lifetim e-ever:
0 A bsent
1 T edium  vitae
2 Suicidal ideation
3 Suicide attem pt unlikely to  result in death
4  Suicide attem pt likely to  resu lt in death
5 M ultiple suicide attem pts likely to result in death
9 U nknow n
NB: Suicidal ideation/attempt does NOT have to be in
the context of depression to be rated here.
Mood switch: (euthymia then) depression to mania
0 - Not known to occur despite good clinical information.
1 - Has occurred on at least one occasion.
2 - Has occurred commonly (i.e., in at least 50% of episodes of 
illness).
9 - Unknown or insufficient clinical information to make 
decision.
NB: this item does not rate any switches or cycling after the 
initial switch in a phase o f  illness.
NB: do include switches seemingly due to medication.
NB: a switch is defined as two periods o f  abnormal mood (one 
fulfilling criteria fo r  (hypo)mania and one fulfilling criteria fo r  
major depression) with an intervening period  o f  no more than 
one month.
Mood switch: (euthymia then) mania to depression
0 - Not known to occur despite good clinical information.
1 - Has occurred on at least one occasion.
2 - Has occurred commonly (i.e., in at least 50% of episodes of 
illness).
9 - Unknown or insufficient clinical information to make 
decision.
NB: this item does not rate any switches or cycling after the 
initial switch in a phase o f  illness.
NB: do include switches seemingly due to medication.
NB: a switch is defined as two periods o f  abnormal m ood (one fulfilling criteria fo r
(hypo)mania and one fulfilling criteria fo r  major depression) with an
Lithium Response 0 No evidence of response
1 Subjective good response
2 Objective evidence for beneficial response, ie, 
clear reduction in number and/or severity of 
episodes following introduction of lithium 
prophylaxis. (Can only be rated if at least 3 
episodes of illness have occurred before lithium 
prophylaxis and lithium response has been 
observed for at least 3 years)
3 Objective evidence for excellent response to 
lithium prophylaxis, ie, frequency of episodes 
reduced to <10% of frequency after lithium 
prophylaxis and/or 2 or more episodes of illness 
occurring within weeks of cessation of lithium. 
(Can only be rated if at least 3 episodes of 
illness have occurred before lithium prophylaxis 
and lithium response has been observed for at 
least 5 years)
Anti-Depressant Response 
(incl. ECT)
Switch of Polarity
Following Anti- 
Depressants
8 Unsure of response
9 Never taken
NB: Rate ‘unsure o f  response ’fo r  patients who have
been on Lithium, but had it stopped after a brief period
due to side effects.
0 N o  evidence o f  response
1 Subjective good response
2 O bjective evidence for beneficial response, ie, clear 
reduction in num ber or severity  o f  sym ptom s, but not 
3.
3 O bjective evidence fo r excellen t response, ie, alw ays 
return  to  usual se lf  and  usual level o f  function 
fo llow ing  anti-depressant treatm ent.
8 U nsure o f  response
9 N ev er taken
NB: Rate patients who go high after anti-D treatment as ‘3 —
excellent response ’ and rate the next item.
0 None
1 Som e m anic features
2 H ypom anic Episode
3 M anic Episode
4 U nsure (desp ite tak ing  anti-depressants)
8 N o t applicable
NB: The switch must occur within 6 months o f commencing 
anti-D treatment.
Appendix K
Inter-rater reliability for the Mood Disorders Research Team
Results provided by Dr Lisa Jones
1. Operational Criteria Symptom Checklist (OPCRIT)
SUMMARY
BP Field Team
Variable
Numbers correspond to OPCRIT item 
number, see Appendix E
Mean Kappa (Range) 
[95% Cl]
0.84 (0.70-1.00)
1 Dysphoria [0.64-1.00]
WE
1 Dysphoria 0.94 (0.77-1.00)
LE [0.76-1.00]
2 Loss Pleas 0.92 (0.88-1.00)
WE [0.82-1.00]
2 Loss Pleas 0.98 (0.90-1.00)
LE [0.90-1.00]
3 DVM 0.97 (0.86-1.00)
WE [0.85-1.00]
3 DVM 0.91 (0.80-1.00)
LE [0.74-1.00]
4 Suicidal 1.00(1.00-1.00)
WE [1.00-1.00]
4 Suicidal 0.98 (0.90-1.00)
LE [0.90-1.00]
5 Self Reproach 0.92 (0.69-1.00)
WE [0.68-1.00]
5 Self Reproach 0.92 (0.69-1.00)
LE [0.68-1.00]
6 Poor Cone 0.88 (0.75-1.00)
WE [0.75-1.00]
6 Poor Cone 0.94 (0.74-1.00)
LE [0.73-1.00]
7 Slowed 0.91 (0.70-1.00)
WE [0.68-1.00]
7 Slowed 0.95 (0.80-1.00)
LE [0.79-1.00]
8 Loss Ener 1.00(1.00-1.00)
WE [1.00-1.00]
8 Loss Ener 0.97 (0.86-1.00)
LE [0.85-1.00]
9 Poor App 0.98 (0.91-1.00)
WE [0.91-1.00]
9 Poor App 0.90 (0.83-1.00)
LE [0.79-1.00] 1
10 Loss Weig 0.94 (0.74-1.00)
WE [0.73-1.001
10 Loss Weig 0.93 (0.79-1.00)
LE [0.77-1.001
11 Inc App 1.00(1.00-1.00)
WE [1.00-1.001
11 Inc App 0.93 (0.84-1.00)
LE [0.79-1.001
12 Inc Weig 1.00(1.00-1.00)
WE [1.00-1.001
12 Inc Weig 1.00(1.00-1.00)
LE [1.00-1.00]
13 Init Insom 0.93 (0.80-1.00)
WE [0.78-1.00]
13 Init Insom 0.86 (0.68-1.00)
LE [0.65-1.00]
14 Mid Ins 0.96 (0.85-1.00)
WE [0.84-1.00]
14 Mid Ins 0.85 (0.70-0.92)
LE [0.69-1.00]
15EMW 0.92 (0.89-0.93)
WE [0.89-0.94]
15EMW 0.90 (0.86-0.92)
LE [0.86-0.95]
16 XS Sleep 0.97 (0.89-1.00)
WE [0.89-1.00]
16 XS Sleep 0.87 (0.69-1.00)
LE [0.66-1.00]
17 Dec Libido 0.92 (0.87-1.00)
WE [0.83-1.00]
17 Dec Libido 0.90 (0.78-1.00)
LE [0.75-1.00]
18 Agitation 0.96 (0.91-1.00)
WE [0.88-1.00]
18 Agitation 0.93 (0.89-1.00)
LE [0.85-1.00]
19 Elevation 0.80 (0.56-1.00)
WE [0.50-1.00]
19 Elevation 0.86 (0.45-1.00)
LE [0.42-1.00]
20 Irritable 0.87 (0.69-1.00)
WE [0.66-1.00]
20 Irritable 0.97 (0.88-1.00)
LE [0.87-1.00]
21 FOI 0.93 (0.85-1.00)
WE [0.79-1.00]
21 FOI 0.94 (0.77-1.00)
LE [0.76-1.00]
22 POS 0.86 (0.45-1.00)
WE [0.42-1.00]
22 POS 1.00(1.00-1.00)
LE [1.00-1.00]
23 Distract 1.00(1.00-1.00)
WE [1.00-1.00]
23 Distract 1.00(1.00-1.00)
LE [1.00-1.00]
24 XS Activ 0.91 (0.64-1.00)
WE r0.62-1.00]
24 XS Activ 0.82 (0.64-1.00)
LE [ 0 .4 9 - 1 .0 0 ]
25 Inc SE 0 .8 7  ( 0 .4 9 - 1 .0 0 )
WE [ 0 .4 7 - 1 .0 0 ]
25 Inc SE 0 .8 4  ( 0 .4 9 - 1 .0 0 )
LE [ 0 .4 5 - 1 .0 0 ]
26 Reckless 0 .7 8  ( 0 .7 1 - 0 .8 2 )
WE [ 0 .7 0 - 0 .8 5 ]
26 Reckless 0 .8 1  ( 0 .7 3 - 0 .8 9 )
LE [ 0 .7 0 - 0 .9 1 ]
27 Red Sleep 0 .7 4  ( 0 .3 2 - 1 .0 0 )
WE [ 0 .2 2 - 1 .0 0 ]
27 Red Sleep 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
28 Inc Soc 0 .7 3  ( 0 .4 7 - 1 .0 0 )
WE [ 0 .3 9 - 1 .0 0 ]
28 Inc Soc 0 .6 4  ( 0 .3 5 - 1 .0 0 )
LE [ 0 .2 1 - 1 .0 0 ]
29 AH3 0 .8 2  ( 0 .4 7 - 1 .0 0 )
LE [ 0 .4 4 - 1 .0 0 ]
30 AH Commenting 1 .0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
31 AH Abusive 1 .0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
32 Other AH 0 .7 7  ( 0 .4 8 - 1 .0 0 )
LE [ 0 .4 2 - 1 .0 0 ]
33 VH 0 .5 9  ( 0 .0 8 - 1 .0 0 )
LE [ 0 .0 0 - 1 .0 0 ]
34 Other H 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
35 Th Echo 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
36 TH Insert 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
37 Th Broad 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
38 Th Withd 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
39 Del Passivity 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
40 Del Influence 0 .9 5  ( 0 .9 0 - 1 .0 0 )
LE [ 0 .8 6 - 1 .0 0 ]
41 Primary Del Perception 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
42 Pers Del 0 .8 2  ( 0 .6 8 - 1 .0 0 )
LE [ 0 .6 0 - 1 .0 0 ]
43 Biz Del 0 .9 8  ( 0 .9 0 - 1 .0 0 )
LE [ 0 .9 0 - 1 .0 0 ]
44 Oth Pri Dels 1 .0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
45 Biz Beh 1 .0 0 ( 1 . 0 0 - 1 . 0 0 )
LE r i .o o - i .o o ]
46 Catatonia 0 .9 1  ( 0 .6 4 - 1 .0 0 )
LE [ 0 .6 2 - 1 .0 0 ]
47 Speech Diff to Understand 0 .9 7  ( 0 .8 6 - 1 .0 0 )
LE [ 0 .8 5 - 1 .0 0 ]
48 Incoherent 1 . 0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
49 PFTD 1 .0 0 ( 1 . 0 0 - 1 . 0 0 )
LE [ 1 .0 0 - 1 .0 0 ]
50 NFTD 1.00(1.00-1.00)
LE [1.00-1.001
51 Restrict Affect 1.00(1.00-1.00)
LE [1.00-1.001
52 Blunted Aff 1.00(1.00-1.00)
LE [1.00-1.001
53 Inapp Aff 1.00(1.00-1.00)
LE [1.00-1.001
54 Perplexity 1.00(1.00-1.00)
LE [1.00-1.001
55 Grand Del 0.83 (0.62-1.00)
WE [0.57-1.001
55 Grand Del 0.87 (0.78-1.00)
LE [0.71-1.001
56 Del Guilt 0.80 (0.49-1.00)
WE [0.45-1.001
56 Del Guilt 0.91 (0.62-1.00)
LE [0.60-1.001
57 Del Pov 1.00(1.00-1.00)
WE [1.00-1.001
57 Del Pov 1.00(1.00-1.00)
LE [1.00-1.00]
58 Nihil Del 0.97 (0.86-1.00)
WE [0.85-1.00]
58 Nihil Del 0.97(0.86-1.00)
LE [0.85-1.00]
59 MC AH3 1.00(1.00-1.00)
WE [1.00-1.00]
59 MC AH3 0.61 (0.37-1.00)
LE [0.16-1.00]
60 MC AH2 0.88(0.72-1.00)
WE [0.64-1.00]
60 MC AH2 0.80 (0.61-1.00)
LE [0.52-1.00]
61 MC VH 0.86 (0.45-1.00
WE [0.42-1.00]
61 MC VH 0.86 (0.45-1.00)
LE [0.42-1.00]
62 MC Oth H 1.00(1.00-1.00)
WE [1.00-1.00]
62 MC Oth H 1.00(1.00-1.00)
LE [1.00-1.00]
63 Oth Sec D 0.87 (0.49-1.00)
WE [0.47-1.00]
63 Oth Sec D 0.91 (0.74-1.00)
LE [0.71-1.00]
Inter-Rater Reliability of Key Phenotypic Variables (20 cases v consensus)
SUMMARY
Variable
Mean Kappa (Range) [95% Cl]
Puerperal Episode 0.97 (0.90-1.00) [0.91-1.00]
Section 2 Symptoms 0.97 (0.86-1.00) [0.89-1.001
Suicidality 0.94 (0.81-1.00) [0.84-1.00]
ICD10 Diagnosis 0.94 (0.81-1.00) [0.82-1.001
Co-occurrence (aff & psych) -  Item 1 0.90 (0.85-0.92) [0.80-1.001
Menstrual 0.90 (0.82-0.93) [0.84-0.961
Co-occurrence (aff & psych) -  Item 3 0.88 (0.63-1.00) [0.35-1.001
Dysphoric Mania 0.87 (0.45-1.00) [0.58-1.001
RDC Diagnosis 0.86 (0.74-0.91) [0.77-0.951
Near Section 2 Symptoms 0.85 (0.75-0.90) [0.78-0.931
Predominant Mania 0.84 (0.74-1.00) [0.70-0.971
DSMIV Diagnosis 0.84 (0.66-1.00) TO.69-0.99]
Rapid Cycling 0.81 (0.71-1.00) [0.66-0.951
Switch of Polarity following Anti-Ds 0.78 (0.71-0.84) [0.62-0.951
Lithium Response 0.76 (0.65-0.87) [0.65-0.871
Anti-D Response 0.76 (0.57-0.94) [0.56-0.961
Congruence 0.76 (0.49-0.94) [0.52-1.001
Co-occurrence (aff & psych) -  Item 2 0.67 (0.33-0.88) [0.01-1.001
Mean ICC (Range) [95% CI1
Age of 1st Psychosis 1.00(1.00-1.00) [1.00-1.001
Age of 1st Symptom 0.99 (0.98-1.00) [0.98-1.001
BADS-D 0.99 (0.98-0.99) [0.98-0.991
Age of 1st Mania 0.98 (0.95-1.00) [0.96-1.001
No. Episodes of Mania 0.98 (0.93-0.99) [0.94-1.001
Length Longest Episode of Depression 0.98 (0.92-0.99) [0.94-1.001
Number of Admissions 0.97 (0.94-1.00) [0.90-1.001
Age of 1st Impairment 0.97 (0.92-0.99) [0.93-1.001
BADS - M 0.96 (0.91-0.99) [0.90-1.001
Length Longest Episode of Mania 0.96 (0.91-0.99) [0.92-1.001
Age of 1st Contact 0.96 (0.87-0.99) [0.90-1.001
GAS -  Worst Mania 0.94 (0.87-0.98) [0.89-0.991
Age of 1st Depression 0.93 (0.86-0.99) [0.85-1.001
Number of Episodes of Depression 0.93 (0.83-0.99) [0.85-1.001
Age of 1st Admission 0.93 (0.70-1.00) [0.77-1.001
GAS -  Worst Depression 0.92 (0.84-0.98) [0.84-1.001
BADS - P 0.91 (0.77-0.99) [0.80-1.001
BADS - 1 0.89 (0.78-0.99) [0.77-1.001
GAS -  Past Week 0.87 (0.57-0.98) [0.66-1.001
Appendix L
Summarised examples of cases that would score “0”, “1” and “2” on the 
modified OPCRIT item 84: Information not credible
OPCRIT 84: Scored 2
There is not enough detail to make many positive ratings. The participant also had problems 
with her memory. No case-note information was present despite admissions to psychiatric 
hospital having occurred.
Summarised information from the participant’s interview-vignette. 
Case-notes were not available.
Mrs B was a 62 year old lady with a long history of mental health problems. She was 
unclear about many of the details of her illness as she describes problems with her 
memory. Mrs B presented as a pleasant but anxious lady.
Her first admission to psychiatric hospital was in her early 20s. She doesn’t 
remember why but she describes feeling very scared at the time.
She describes having experienced a “nervous breakdown” after the birth of her 
daughter. Her husband, who was present during the interview, describes this as a very 
difficult time during which she took to her bed for several weeks. She was eventually 
admitted to hospital for a period of 2-3 months.
She believes she has experienced episodes of depression in the past, although it was 
not possible to elucidate any specific symptoms during the interview.
She does not believe she has ever had a manic episode.
She did not recall any psychotic symptoms, although her husband believes that she 
was deluded during her first admission to hospital.
It was not possible to obtain any further detail on specific episodes of illness so the 
interview prematurely.
OPCRIT 84: Scored 1
This was rated “1” because: there is no information available on the participant’s hospital 
admission in 1978; further clarification/description of some of the symptoms referred to would 
be needed in order to make positive ratings, e.g. “thoughts being distorted”; examples would 
be needed to rate the symptoms of thought interference mentioned.
Summarised information from case-notes available and interview- 
vignette
He was first seen in 1974 when he presented with symptoms of depression and was 
hearing voices telling him to do things. These voices had been present over the 
previous 10 years. He associated his unhappiness with the shape of his nose, saying 
that, “everyone takes the mickey out of it”. He also had middle insomnia.
His first admission was in 1978 -  no information is available for this admission.
In 1978 he believed he was grasped by evil forces and that he had demons in his head. 
He also felt that his mind was being controlled by evil forces. He was apprehensive 
and agitated.
1979 -  “Depression”
March 1993 -  Worst episode.
He said he felt “aggravation in the brain”. He complained of inefficient thinking 
which he put down to his “thoughts being distorted”. He had poor concentration, low 
mood and a loss of enjoyment. He made several suicide attempts. He had social 
withdrawal, self-depreciation and irritability. He gave descriptions of thought 
insertion, thought broadcast and had delusions that his thoughts were being read. He 
also had delusions of religion and felt that alien forces were penetrating his body.
Month prior to interview: Depressive symptoms reduced, moderately depressed with 
moderate loss of interests, moderate feelings of hopelessness and some irritability. He 
complained that, “the devil has got hold of my brain and is persecuting it”. He felt 
electric shocks in his feet and voices in his head. He feels like he deserves to be
punished.
OPCRIT 84: Scored 0
A detailed account of illness was present in the interview-vignette which was corroborated by 
the case-note information obtained.
NAME: L
SEX: Male
HOSPITAL NUMBER:
INTERVIEW DATE: 29.7.97
INFORMATION FROM CASENOTES
30.12.61-17.1.62
Admitted depressed, onset October, anergia, poor concentration, feelings of hopelessness, 
apathetic and retarded, diagnosed endogenous depression treated with IM tryptizol.
27.2.62
Seen on DV, hysterical fugue, left house earlier in the day and was later found under a hedge, 
says he woke up and it was night with no recollection of what had happened.
20.2.64
Admitted depressed, treated with ECT. He was dysphoric with DMV, EMW, loss of appetite 
and thoughts of committing suicide by driving into the sea.
5.12.66-24.1.67
Admitted depressed, took OD of barbiturates when on leave, treated with ECT.
23.2.68
“having a bad run of luck on the farm. I felt that I could have done better for him had I been a 
veterinary surgeon rather than a medical practitioner”.
30.68- 11.1.69 
admitted depressed
15.12.70-8.1.71 
Admitted depressed 
14.1.71-25.2.71 
Admitted depressed
6.12.74-9.1.75
Admitted depressed given ECT -  noted that pronounced seasonal pattern and unresponsive to 
tricyclics and MAOI’s.
19.1.76-27.2.76 
Admitted depressed.
Nov 1977
Seen Op with recurrence of depressive symptoms 
1978Started on prophylactic antidepressants in September to avoid winter relapse. 
26.4.79-23.11.79
Admitted depressed, suicidal -  left home with a rope to hang himself, DVM am, anergia, 
EMW, wt loss, treated with ECT.
2.4.80-25.4.80 
Admitted depressed.
4.4.81 -  12.4.81
Admitted following OD, diagnosis personality disorder.
17.7.81-25.7.81
Admitted following possible OD, no evidence of depressive symptoms while on the ward, 
diagnosis attention seeking behaviour.
5.6.90
OP, symptoms described “that sound very much like hypomania”, wakes early at 5 am, feels 
full of energy and enthusiasm, “when I’m up no one can stop me”, cheerful and enthusiastic, 
Description from wife — high, 110%, hyperactive, sleeping only four hours, often happens 
when recovering from a depressive episode, hard to keep up with him, finds this state much 
better than his depression.
Hypomania — but not sufficiently high to warrant treatment with major tranquillisers.
1.7.91
OP, Hypomanic but not sectionable, elated, only sleeping three hours, possibly overspending.
8.8.91
Diagnosis -  difficult personality on which is superimposed mood swings -  depression in 
winter months and hypomania in the summer. Heavy alcohol intake noted.
16.4.93
GP letter -  depression for many years, “ I have also seen him euphoric and indeed in a high 
phase a few years ago he bought an additional farm at an inflated expense which has caused 
him a considerable debt burden”
20.4.93-8.10.93
Admitted, diagnosis -  bipolar disorder -  depressed phase.
1.11.94
OP, verbally aggressive to his wife, working too many hours a day, wife feels he is manic 
again, talkative at interview, lots of expansive plans, talking about spending money he has 
got, has been swindled out of £100,000, he is definitely euphoric but there is not enough 
evidence to call him manic, prescribed melleril.
INTERVIEW VIGNETTE
INTRODUCTION
66 year old married farmer seen at home following contact made via GP. Information 
considered reliable.
MSE AT INTERVIEW
Well, euthymic, no evidence of abnormal beliefs or perceptions.
BACKGROUND
Left school at 11 and has worked on the family farm since then. Tendency to get down at 
times throughout his life. Good relationships with others. Drinks 30 - 40 units a week and 
smokes 20 a day, no drugs.
PSYCHIATRIC HISTORY 
Episodes of illness
Over the last 30 years had had at least one episode of severe depression each year (30-50) 
which have occurred in the months of November to January. Has been admitted on most of 
these occasions. On 5 - 10 occasions has had highs lasting for up to six weeks - thinks he has 
only ever had highs when on antidepressant medication.
Manic episode rated: 3 years ago
Description of manic episode
Duration of 3-4 weeks, elated mood, racing thoughts, overtalkativeness, overactivity - was 
working 22 hours a day, sharpened thinking, witty, exaggerated self esteem, over optimism, 
excessive spending, did not sleep for days on end, got into fights in bars - would over react if 
someone nudged him, was arrested, wife finds it impossible to live with him when he’s high. 
Seen by psychiatrist on DV who adjusted medication and started him on lithium “to get me 
back on an even keel”.
Depressive episode rated:. 10 years ago 
Description of depressive episode
Unremitting depressed mood, duration of 6 months, tearful much of the time, total anhedonia, 
loss of hope of the future - “no light in the tunnel at all”, DVM am, preoccupied with death, 
suicidal - severe suicide attempt admitted to hospital, loss of confidence, social withdrawal, 
loss of self esteem, dulled perceptions, poor concentration, inefficient thinking, loos of 
interests, subjective and objective retardation, loss of energy, overwhelmed by everyday 
tasks, loss of appt, increased sleep - didn’t want to get up but stayed in bed all day.
Section 2 symptoms
Nil
Appendix M
Inter-rater reliability. ER’s rating vs. consensus ratings made during reliability 
meetings
Variable
ICC /
Kappa
used
ICC p-value
BADDSM ICC 0.888 p<0.001
BADDSD ICC 0.979 p<0.001
BADDSP ICC 0.983 p<0.001
BADDSI ICC 0.994 p<0.001
GASD ICC 0.904 p<0.001
GASM ICC 0.967 p<0.001
GASP ICC 0.966 p<0.001
GASWE ICC 0.967 p<0.001
GASPW ICC 0.986 p<0.001
S2 Kappa 1.000 p<0.001
MC ICC 0.700 p<0.001
Pred M Effect Kappa 1.000 0.002
Dysphoric
Mania Kappa 1.000 0.003
NEpsM ICC 0.948 p<0.001
NEpsD ICC 0.955 p<0.001
N Eps NAP ICC 0.629 0.006
Longest M ICC 0.517 0.035
Longest D ICC 1.000 p<0.001
Longest P ICC na na
AOOS ICC 0.999 p<0.001
AOOI ICC 0.998 p<0.001
AOOC ICC 1.000 -
AOO A ICC 1.000 -
AOOM ICC 0.999 p<0.001
AOO D ICC 0.971 p<0.001
AOO P ICC 1.000 -
No adms ICC 0.997 p<0.001
Longest adm ICC 0.996 p<0.001
% adm ICC 0.999 p<0.001
% well ICC 0.960 p<0.001
Puerperal Ep ICC 1.000 -
Rapid Cycling ICC 1.000 -
Suicidal
ideation
ICC 0.990 p<0.001
ERS1 ICC 0.961 p<0.001
ERS2 ICC 0.993 p<0.001
ERS3 ICC 1.000 p<0.001
ERS4 ICC 0.843 p<0.001
ERS5 ICC 0.864 p<0.001
ERS6 ICC 1.000 -
ERS7 ICC 0.786 0.002
ERS8 ICC 0.846 p<0.001
ERS9 ICC 0.784 p<0.001
ERS10 ICC na na
ERS11 ICC 0.957 p<0.001
Mood Switch Kappa 1.000 p<0.001
OPCRIT 1 Kappa 1.000 p<0.001
OPCRIT 2 Kappa 0.841 p<0.001
OPCRIT 3 Kappa 1.000 p<0.001
OPCRIT 4 Kappa 1.000 p<0.001
OPCRIT 5 Kappa 0.903 p<0.001
OPCRIT 6 Kappa 1.000 p<0.001
OPCRIT 7 Kappa 1.000 p<0.001
OPCRIT 8 Kappa 0.915 p<0.001
OPCRIT 9 Kappa 1.000 p<0.001
OPCRIT 10 Kappa 1.000 p<0.001
OPCRIT 11 Kappa 1.000 p<0.001
OPCRIT 12 Kappa 1.000 p<0.001
OPCRIT 13 Kappa 1.000 p<0.001
OPCRIT 14 Kappa 1.000 p<0.001
OPCRIT 15 Kappa 1.000 p<0.001
OPCRIT 16 Kappa 1.000 p<0.001
OPCRIT 17 Kappa 1.000 p<0.001
OPCRIT 18 Kappa 1.000 p<0.001
OPCRIT 19 Kappa 1.000 p<0.001
OPCRIT 20 Kappa 1.000 p<0.001
OPCRIT 21 Kappa 1.000 p<0.001
OPCRIT 22 Kappa 1.000 p<0.001
OPCRIT 23 Kappa 1.000 p<0.001
OPCRIT 24 Kappa 1.000 p<0.001
OPCRIT 25 Kappa 1.000 p<0.001
OPCRIT 26 Kappa 1.000 p<0.001
OPCRIT 27 Kappa 1.000 p<0.001
OPCRIT 28 Kappa 0.791 p<0.001
OPCRIT 28a Kappa 1.000 p<0.001
OPCRIT 29 Kappa na na
OPCRIT 30 Kappa 1.000 p<0.001
OPCRIT 31 Kappa 0.880 p<0.001
OPCRIT 32 Kappa 1.000 p<0.001
OPCRIT 33 Kappa 1.000 p<0.001
OPCRIT 34 Kappa na na
OPCRIT 35 Kappa 1.000 p<0.001
OPCRIT 36 Kappa na na
OPCRIT 37 Kappa na na
OPCRIT 38 Kappa 1.000 p<0.001
OPCRIT 39 Kappa 0.455 0.021
OPCRIT 40 Kappa 1.000 p<0.001
OPCRIT 41 Kappa na na
OPCRIT 42 Kappa 0.750 0.002
OPCRIT 43 Kappa 1.000 p<0.001
OPCRIT 44 Kappa 1.000 p<0.001
OPCRIT 45 Kappa 1.000 p<0.001
OPCRIT 46 Kappa na na
OPCRIT 47 Kappa 1.000 p<0.001
OPCRIT 48 Kappa na na
OPCRIT 49 Kappa na na
OPCRIT 50 Kappa na na
OPCRIT 51 Kappa na na
OPCRIT 52 Kappa na na
OPCRIT 53 Kappa 0.692 0.001
OPCRIT 54 Kappa 1.000 p<0.001
OPCRIT 54a ICC 1.000 p<0.001
OPCRIT 55 Kappa 1.000 p<0.001
OPCRIT 56 Kappa 1.000 p<0.001
OPCRIT 57 Kappa na na
OPCRIT 58 Kappa na na
OPCRIT 59 Kappa 1.000 p<0.001
OPCRIT 60 Kappa 1.000 p<0.001
OPCRIT 61 Kappa 1.000 p<0.001
OPCRIT 62 Kappa 0.791 p<0.001
OPCRIT 63 Kappa 1.000 p<0.001
OPCRIT2 4 ICC 1.000 -
OPCRIT2 5 ICC 0.927 0.004
OPCRIT2 6 Kappa 1.000 p<0.001
OPCRIT2 7 Kappa 0.692 p<0.001
OPCRIT2 8 ICC 0.947 p<0.001
OPCRIT2 9 Kappa 0.649 0.004
OPCRIT2 10 Kappa na na
OPCRIT2 11 Kappa na na
OPCRIT2 16 Kappa 1.000 0.002
OPCRIT2 78 Kappa 1.000 p<0.001
OPCRIT2 79 Kappa na na
OPCRIT2 80 Kappa na na
OPCRIT2 81 Kappa 0.692 0.001
OPCRIT2 82 Kappa na na
OPCRIT2 83 Kappa na na
OPCRIT2 84 Kappa 1.000 p<0.001
OPCRIT2 85 Kappa 0.821 0.001
OPCRIT2 86 Kappa 1.000 p<0.001
OPCRIT2 87 Kappa 0.894 p<0.001
OPCRIT2 88 Kappa 1.000 p<0.001
OPCRIT2 89 Kappa 1.000 p<0.001
OPCRIT2 90 ICC 0.923 p<0.001
- 100% agreement, no p-value produced 
- na = no variability within sample
Appendix N
Inter-rater reliability. ER’s rating vs. consensus ratings made during reliability 
meetings (N=20)
Variable
IC C /
K appa
u se d
ICC p-value
OPCRIT 1 Kappa 1.00 P<0.001
OPCRIT 2 Kappa 0.911 P<0.001
OPCRIT 3 Kappa 1.00 c
c<oVQ.
BADDSM ICC 1.00 P<0.001 OPCRIT 4 Kappa 1.00 P<0.001BADDSD ICC 1.00 P<0.001 OPCRIT 5 ICC 1.00BADDSP ICC 1.00 - OPCRIT 6 Kappa 1.00 P<0.001BADDSI ICC 0.975 P<0.001 OPCRIT 7 Kappa 1.00 P<0.001GASD ICC 1.00 - OPCRIT 8 Kappa 1.00 P<0.001GASM ICC 1.00 - OPCRIT 9 Kappa 1.00 P<0.001GASP ICC 1.00 - OPCRIT 10 Kappa 1.00 P<0.001GASWE ICC 1.00 - OPCRIT 11 Kappa 1.00 P<0.001GASPW ICC 1.00 - OPCRIT 12 Kappa 1.00 P<0.001S2 Kappa 1.00 P<0.001 OPCRIT 13 Kappa 1.00 P<0.001MC Kappa 1.00 P<0.001 OPCRIT 14 Kappa 1.00 P<0.001Pred M Effect Kappa 1.00 P<0.001 OPCRIT 15 Kappa 1.00 P<0.001Dysphoric
Mania Kappa 1.00 P<0.001 OPCRIT 16 Kappa 1.00 P<0.001OPCRIT 17 Kappa 1.00 P<0.001N Eps M ICC 1.00 - -OPCRIT 18 Kappa 1.00 P<0.001N Eps D ICC 1.00 - OPCRIT 19 Kappa 1.00 P<0.001N Eps NAP ICC 1.00 - OPCRIT 20 Kappa 1.00 P<0.001
Longest M ICC 1.00 - OPCRIT 21 Kappa 1.00 P<0.001
Longest D ICC 1.00 - OPCRIT 22 Kappa 1.00 P<0.001
Longest P ICC 1.00 - OPCRIT 23 Kappa 1.00 P<0.001
AOO S ICC 1.00 - OPCRIT 24 Kappa 1.00 P<0.001
AOO 1 ICC 1.00 - OPCRIT 25 Kappa 1.00 P<0.001
AOO C ICC 1.00 - OPCRIT 26 Kappa 1.00 P<0.001
AOO A ICC 1.00 - OPCRIT 27 Kappa 1.00 P<0.001
AOO M ICC 1.00 - OPCRIT 28 Kappa 1.00 P<0.001
AOO D ICC 1.00 - OPCRIT 28a Kappa 1.00 P<0.001
AOO P ICC 1.00 - OPCRIT 29 Kappa 1.00 P<0.001
No adms ICC 1.00 - OPCRIT 30 Kappa 1.00 P<0.001
Longest adm ICC 1.00 - OPCRIT 31 Kappa 1.00 P<0.001
% adm ICC 1.00 - OPCRIT 32 Kappa 1.00 P<0.001
% well ICC 1.00 - OPCRIT 33 Kappa 1.00 P<0.001
Puerperal Ep ICC 1.00 - OPCRIT 34 Kappa 1.00 P<0.001
Rapid Cycling ICC 1.00 - OPCRIT 35 Kappa 1.00 P<0.001
Suicidal
ideation ICC 1.00 -
OPCRIT 36 Kappa n a n a
OPCRIT 37 Kappa 1.00 P<0.001
ERS1 ICC 1.00 - OPCRIT 38 Kappa 1.00 P<0.001
ERS2 ICC 1.00 - OPCRIT 39 Kappa 1.00 P<0.001
ERS3 ICC 0.990 P<0.001 OPCRIT 40 Kappa 1.00 P<0.001
ERS4 ICC 1.00 - OPCRIT 41 Kappa 1.00 P0.001
ERS5 ICC 1.00 - OPCRIT 42 Kappa 0.906 P<0.001
ERS6 ICC 1.00 - OPCRIT 43 Kappa 1.00 P<0.001
ERS7 ICC 1.00 - OPCRIT 44 Kappa 1.00 P<0.001
ERS8 ICC 0.989 P0.001 OPCRIT 45 Kappa 1.00 P<0.001
ERS9 ICC 1.00 - OPCRIT 46 Kappa 1.00 P<0.001
ERS10 Kappa 1.00 PC0.0011 OPCRIT 47 Kappa 1.00 P<0.001
ERS10L Kappa 1.00 P<0.001 OPCRIT 48 Kappa 1.00 P<0.001
ERS11 Kappa 1.00 P<0.001 OPCRIT 49 Kappa 1.00 P<0.001
ERS11L Kappa 1.00 P<0.001 OPCRIT 50 Kappa 0.902 P<0.001
Mood Switch Kappa 1.00 P<0.001
OPCRIT 51 Kappa 1.00 P<0.001
OPCRIT 52 Kappa na na
OPCRIT 53 Kappa 1.00 P<0.001
OPCRIT 54 Kappa 1.00 P<0.001
OPCRIT 54a Kappa 1.00 P<0.001
OPCRIT 55 Kappa 1.00 P<0.001
OPCRIT 56 Kappa 1.00 P0.001
OPCRIT 57 Kappa 1.00 P<0.001
OPCRIT 58 Kappa 1.00 P<0.001
OPCRIT 59 Kappa na na
OPCRIT 60 Kappa 1.00 P<0.001
OPCRIT 61 Kappa 1.00 P<0.001
OPCRIT 62 Kappa 1.00 P<0.001
OPCRIT 63 Kappa 1.00 P<0.001
OPCRIT2 1 Kappa 1.00 P<0.001
OPCRIT2 2 Kappa 1.00 P<0.001
OPCRIT2 3 Kappa 1.00 P<0.001
OPCRIT2 4 ICC 1.00 -
OPCRIT2 5 Kappa 1.00 P<0.001
OPCRIT2 6 Kappa 1.00 P<0.001
OPCRIT2 7 Kappa 1.00 P<0.001
OPCRIT2 8 ICC 1.00 -
OPCRIT2 9 Kappa 1.00 P<0.001
OPCRIT2 10 Kappa 1.00 P<0.001
OPCRIT2 11 Kappa 1.00 P<0.001
OPCRIT2 12 Kappa 1.00 P<0.001
OPCRIT2 13 Kappa 1.00 P<0.001
OPCRIT2 14 Kappa 1.00 P<0.001
OPCRIT2 15 Kappa 1.00 P<0.001
OPCRIT2 16 Kappa 1.00 P<0.001
OPCRIT2 78 Kappa 1.00 P<0.001
OPCRIT2 79 Kappa 1.00 P<0.001
OPCRIT2 80 Kappa 1.00 P<0.001
OPCRIT2 81 Kappa 1.00 P<0.001
OPCRIT2 82 Kappa 1.00 P<0.001
OPCRIT2 83 Kappa 1.00 P<0.001
OPCRIT2 84 Kappa 1.00 P<0.001
OPCRIT2 85 Kappa 1.00 P<0.001
OPCRIT2 86 Kappa 1.00 P<0.001
OPCRIT2 87 Kappa 1.00 P<0.001
OPCRIT2 88 Kappa 1.00 P<0.001
OPCRIT2 89 Kappa 1.00 P<0.001
OPCRIT2 90 ICC 0.975 P<0.001
= 100% agreement, no p-value produced 
“na” = insufficient variability for analyses to be performed correctly
Appendix O
Rater-drift reliability analyses performed on the same cases rated at different 
time-points (N=20)
Variable
ICC / 
Kappa 
used
ICC p-value
BADDSM ICC 0.983 P<0.001
BADDSD ICC 0.970 P<0.001
BADDSP ICC 0.974 P<0.001
BADDSI ICC 0.975 P<0.001
GASD ICC 0.921 P<0.001
GASM ICC 0.827 P<0.001
GASP ICC 0.870 P<0.001
GASWE ICC 0.903 P<0.001
GASPW ICC 0.912 P<0.001
S2 Kappa 1.00 P<0.001
MC Kappa 0.853 P<0.001
Pred M 
Effect Kappa 1.00
P<0.001
Dysphoric
Mania Kappa 1.00
P<0.001
N Eps M ICC 0.990 P<0.001
N Eps D ICC 0.904 P<0.001
N Eps NAP ICC 0.981 P<0.001
Longest M ICC 0.843 P<0.001
Longest D ICC 0.734 P<0.001
Longest P ICC 0.999 P<0.001
AOO S ICC 1.00 P<0.001
AOO 1 ICC 0.998 P<0.001
AOO C ICC 0.995 P<0.001
AOO A ICC 0.999 P<0.001
AOO M ICC 0.997 P<0.001
AOO D ICC 0.931 P<0.001
AOOP ICC 0.995 P<0.001
No adms ICC 0.992 P<0.001
Longest adm ICC 0.992 P<0.001
% adm ICC 0.827 P<0.001
% well ICC 0.995 P<0.001
Puerperal Ep ICC 1.00 P<0.001
Rapid
Cycling ICC 1.00
P<0.001
Suicidal
ideation ICC 0.838
P<0.001
ERS1 ICC 0.962 P<0.001
ERS2 ICC 0.978 P<0.001
ERS3 ICC na na
ERS4 ICC 1.00 P<0.001
ERS5 ICC 0.983 P<0.001
ERS6 ICC na Na
ERS7 ICC 0.787 P0.001
ERS8 ICC 0.981 P<0.001
ERS9 ICC 0.936 P<0.001
ERS10 Kappa 1.00 P<0.001
ERS10L Kappa 1.00 P<0.001
ERS11 Kappa 1.00 P<0.001
ERS11L Kappa 1.00 P<0.001
Mood Switch Kappa 0.821 0.001
OPCRIT 1 Kappa 0.821 0.001
OPCRIT 2 Kappa 0.866 P<0.001
OPCRIT 3 Kappa 1.00 P<0.001
OPCRIT 4 Kappa 1.00 P<0.001
OPCRIT 5 ICC 1.00 P<0.001
OPCRIT 6 Kappa 1.00 P<0.001
OPCRIT 7 Kappa 1.00 P<0.001
OPCRIT 8 Kappa 1.00 P<0.001
OPCRIT 9 Kappa 0.785 P<0.001
OPCRITJO Kappa na Na
OPCRIT 11 Kappa 1.00 P<0.001
OPCRIT 12 Kappa 1.00 P<0.001
OPCRIT 15 Kappa 0.779 P<0.001
OPCRIT 16 Kappa na na
OPCRIT 17 Kappa 1.00 P<0.001
OPCRIT 18 Kappa 1.00 P<0.001
OPCRIT 19 Kappa 0.767 0.001
OPCRIT 20 Kappa 1.00 P<0.001
OPCRIT 21 Kappa 1.00 P<0.001
OPCRIT 22 Kappa 1.00 P<0.001
OPCRIT 23 Kappa 1.00 P<0.001
OPCRIT 24 Kappa 0.976 P<0.001
OPCRIT 25 Kappa 0.767 P<0.001
OPCRIT 26 Kappa 0.823 P<0.001
OPCRIT 27 Kappa 1.00 P<0.001
OPCRIT 28 Kappa 1.00 P<0.001
OPCRIT 28a Kappa na Na
OPCRIT 29 Kappa 1.00 P<0.001
OPCRIT_30 Kappa 1.00 P<0.001
OPCRIT_31 Kappa na Na
OPCRIT 32 Kappa 0.807 P<0.001
OPCRIT 33 Kappa 1.00 P<0.001
OPCRIT 34 Kappa 1.00 P<0.001
OPCRIT_35 Kappa Na Na
OPCRIT_36 Kappa Na Na
OPCRIT_37 Kappa na Na
OPCRIT 38 Kappa 1.00 P<0.001
OPCRIT_39 Kappa na Na
OPCRIT 40 Kappa 1.00 P<0.001
OPCRIT 41 Kappa na Na
OPCRIT 42 Kappa 0.885 P<0.001
OPCRIT_43 Kappa Na Na
OPCRIT_44 Kappa Na Na
OPCRIT 45 Kappa 0.904 P<0.001
OPCRIT_46 Kappa Na Na
OPCRIT_47 Kappa Na Na
OPCRIT_48 Kappa Na Na
OPCRIT_49 Kappa Na Na
OPCRIT_50 Kappa Na Na
OPCRIT 51 Kappa 0.738 0.001
OPCRIT 52 Kappa na Na
OPCRIT 53 Kappa 0.700 0.005
OPCRIT 54 Kappa 1.00 P<0.001
OPCRIT 54a Kappa 1.00 -
OPCRIT 55 Kappa 1.00 P<0.001
OPCRIT 56 Kappa 1.00 P<0.001
OPCRIT 57 Kappa na Na
OPCRIT 58 Kappa na Na
OPCRIT_59 Kappa na Na
OPCRIT 60 Kappa 1.00 P<0.001
OPCRIT 61 Kappa na Na
OPCRIT 62 Kappa na Na
OPCRIT 63 Kappa 0.640 0.009
OPCRIT2 5 Kappa 1.00 -
OPCRIT2 6 Kappa 1.00 P<0.001
OPCRIT2 8 ICC 0.981 P<0.001
OPCRIT2 10 Kappa 0.821 0.001
OPCRIT2 11 Kappa na Na
OPCRIT2 12 Kappa 1.00 P<0.001
OPCRIT2 13 Kappa 1.00 P<0.001
OPCRIT2 14 Kappa 1.00 P<0.001
OPCRIT2 15 Kappa 1.00 P<0.001
OPCRIT2 16 Kappa 1.00 P<0.001
OPCRIT2 78 Kappa 1.00 P<0.001
OPCRIT2 79 Kappa 1.00 P<0.001
OPCRIT2 80 Kappa 1.00 P<0.001
OPCRIT2 81 Kappa 1.00 P<0.001
OPCRIT2 82 Kappa 1.00 P<0.001
OPCRIT2 83 Kappa 1.00 P<0.001
OPCRIT2 84 Kappa na Na
OPCRIT2 85 Kappa 1.00 P<0.001
OPCRIT2 86 Kappa 0.852 P<0.001
OPCRIT2 87 Kappa 1.00 P<0.001
OPCRIT2 88 Kappa 0.843 0.002
OPCRIT2 89 Kappa 1.00 0.008
OPCRIT2 90 ICC 0.914 P<0.001
= 100% agreement, no p-value produced 
“na” = insufficient variability for analyses to be performed correctly
7
7
7
7
15
15
15
15
16
16
16
16
16
16
16
17
17
17
17
28
28
28
37
37
50
50
50
50
50
51
51
52
52
52
52
53
53
53
55
55
57
57
57
57
59
59
62
65
65
65
68
68
68
69
Appendix P
MIXOR Input Data
1 1 0 0
2 1 1 0
3 1 0 0
4 1 1 -99
2 1 1 0
4 1 1 -99
5 1 1 0
8 1 1 -99
1 1 1 0
2 1 1 0
3 1 1 0
4 1 1 -99
6 1 0 -99
7 1 0 0
9 1 0 0
1 1 1 1
2 1 0 1
4 1 1 0
7 1 1 0
1 1 0 0
6 1 0 0
7 1 0 0
18 1 0 0
19 1 0 -99
1 1 0 -99
3 1 1 0
10 1 1 0
11 1 0 0
12 1 0 0
6 1 1 -99
8 1 0 0
1 1 1 0
3 1 0 -99
5 1 1 0
7 1 1 0
4 1 0 0
5 1 1 0
8 1 1 0
1 1 0 0
4 1 0 0
1 1 1 0
3 1 0 1
4 1 0 0
5 1 0 1
4 1 0 0
5 1 0 -99
3 1 0 -99
5 1 1 0
7 1 0 -99
8 1 0 0
1 1 0 -99
3 1 0 0
4 1 0 0
1 1 1 0
Notes
Data saved in .txt format
Column 1 -  Family ID 
Column 2 -  Individual ID 
Column 3 -  Sample-of-origin (covariate) 
Column 4 -  Gender (covariate) 
Column 5 -  Variable-of-interest (in this 
example, cannabis abuse) 
Column 6 - Intercept
Appendix Q
MIXOR Output
MIXOR Output; -  d :\rn a \jD a n .o u t
MIXOR - The p r o f r u  for eixed-effects ordinal refression analysis 
(version 2)
MIXOR analysis on the larfe h a r a m u s e d  dataset 
Variable of interest - Cannabis Abase /Dependence (fender
Response function: logistic
Randnn-effects distribution: nornal
Covariate (s) and random  effect (s) nean subtracted from thresholds 
**> positive coefficient =  positive association between refressor 
and ordinal outcome
Kumbers of observations
berel 1 observations = 632
Level 2 observations —  328
The uuaabex of level 1 observations per level 2 unit a z e :
3 2 5 4 3 1 4 1 3 3
2 2 2 3 2 2 2 2 1 2
3 2 2 1 3 1 1 1 1 6
2 1 2 2 3 3 4 1 1 2
1 1 1 3 1 1 2 2 3 3
2 1 1 2 2 1 1 1 1 1
2 2 2 2 1 1 2 2 2 2
1 1 2 2 1 2 2 3 1 1
1 1 3 3 1 2 2 1 1 2
2 1 1 2 1 1 1 2 3
2 2 1 2 1 2 1 2 2 1
2 2 1 1 1 2 1 1 2 2
2 2 3 2 1 2 2 2 2 3
2 3 1 2 2 2 2 3 2
1 1 3 5 1 3 1 2 2 2
2 2 2 2 4 2 1 2 2 2
1 2 1 1 2 1 3 2 1 5
2 1 1 2 3
2 4 1 2 2 1 1 2 1
2 2 3 3 3 2 2 5 1
4 2 6 1 2 1 2 4 2
2 2 3 1 1 1 1 1 1
2 1 1 2 1 2 2 2 1
1 2 2 3 2 3 2 2 1
2 2 2 2 2 1 2 2 2
1 2 1 2 2 2 2 1 1
2 1 2 1 1 2 1 2 2
1 2 2 2 2 2 2 2 2
1 2 1 2 2 3 2 4 2
1 2 1 2 2 2 2 2 2
2 2 2 2 4 2 2 2 2
2 1 2 3 5 1 1 1 2
2 3 2 2 2 2 2 2 2
3 1 2 3 2 2 2 2 2
4 2 2 2 1 2 2 2 2
Descriptive statistics for all variables
Variable
outcome
Intercep
sample
fender
M i n i m m
0.00000
1.00000
1.00000
0.00000
M arim w an
1.00000
1.00000
2.00000
1.00000
M e a n
0.13449
1.00000
1.48101
0.47310
Stand. D e v .
0.34145
0.00000
0.50004
0.49967
Categories of the response variable outc
1
MIXDR Output - d:\rrm\Ban.out - continued
C a t c f o z y
0 .00
1.00
F r e ^ o e n e y
547.00 
05.00
Pzoportion
0.86551
0.13449
S t u t i n f  valoes
w i n  -2.678
COTmziates 0.459 0.290
▼nz. t w n w  0.574
**> The nnabez of level 2 obsezvationz with non-vazyinf responses 
» 301 ( 91.77 percent )
* Final Results - Naniaoa Marginal Likelihood Estimates *
Total Iterations = 13
Quad Pts per Din = 10
Log Likelihood = -202.344
Deviance |-21ogL) = 404. 688
Ridge = 0.000
Variable Bstinate Stand. Brror Z
Intercep
saaglc
gender
Random effect ve 
Intercep
0.99150 
-2.93990 
-1.30624
0.77373
0.71160
0.46094
riance term (standard deviation) 
2.66676 0.65510
1.28147
-4.13136
-2.83388
4.07078 0.
note: (1) = 1-tailed p-value
(2) s 2-tailed p-value
Calculation o£ the intracluster correlation
residual variance = pi*pi / 3 (assumed) 
cluster variance = (2.667 *  2.667) = 7.112
intracluster correlation = 7.112 / ( 7.112 + (pi*pi/3)) = 0.684
p-value
20003 (2)
00004 (2)
00460 (2)
00002  ( 1 )
2
Appendix R
Summary of Categories for Continuous data
BADDS Depression and Mania GAS Scores (depression, mania,
0 0 psychosis, worst ever)
1-10 1 0-9 1
11-18 2 10-14 2
19 3 15-20 3
20-29 4 21-25 4
30-39 5 26-30 5
40 6 31-35 6
41-46 7 36-40 7
47-59 8 41-45 8
60 9 46-50 9
61-64
65-70
10
11
51-55 10
72-75 12 GAS Scores (past week)
76-79 13 0-25 1
80 14 26-30 2
81-87 15 31-40 3
88-100 16 41-50
51-55
5
6
BADDS Psychosis 56-60 7
0 0 61-69 8
2-9 1 70-79 9
10-20 2 80-84 10
21
22-29
3
4
85+ 11
30-39 5 Number of episodes
40-49 6 1 1
50-59 7 2 2
60-69 8 3 3
70-75 9 4 4
76-85 10 5 5
86-90 11 6 6
91-98 12 7 7
99-100 13 8
9
8
9
BADDS Incongruence 10 10
0-5 0 11-20 11
6-15 1 21-30 12
16-24
25-33
2
3
31 + 13
34-40 4 Episode length (weeks)
41-49 5 <1 1
50-59 6 1-2 2
60-65 7 3-4 3
66-70 8 5-8 4
71-79 9 9-12 5
80-89 10 13-16 6
90-97 11 17-26 7
98-100 12 27-39
40-51
52
53-70
71-99
100+
8
9
10 
11 
12 
13
Proportion of time well since onset
Ages of onset 0 0
<17 1 1-5 1
17-19 2 6-10 2
20-22 3 11-20 3
23-25 4 21-30 4
26-29 5 31-40 5
30-34 6 41-50 6
35-39 7 51-60 7
40-49 8 61-70 8
50+ 9 71-80 9
81-85 10
Number of admissions 86-89 11
0 0 90-95 12
1 1 96-99 13
2 2
3 3 Extended Rating Scale 1
4 4 0 0
5 5 1 1-10
6 6 2 11-15
7-10 7 3 16-25
11-20 8 4 26-39
21 + 9 5 40-47
6 48-52
Longest admission 7 53-60
<1 1 8 61-70
1-2 2 9 71-75
3-4 3 10 76-80
5-8 4 11 81-89
9-12 5 12 90-99
13-16 6 13 100
17-26 7
27-35 8 Extended Rating Scale 2
36-51 9 -20 0
52-103 10 -19- -10 1
104+ 11 -9- -2 2
0-5 3
Proportion of time admitted 6-15 4
0 0 16-24 5
1-5 1 25-33 6
6-10 2 34-40 7
11-20 3 41-49 8
21-30 4 50-59 9
31-40 5 60-65 10
41-50 6 66-70 11
51-60 7 71-79 12
61-70 8 80-89 13
71-80 9 90-99 14
81-85 10 100-109 15
86-100 11 110-120 16
Extended Rating Scale 3
0 0
1-35 1
36-45 2
46-59 3
60-75 4
76-90 5
91-100 6
Extended Rating Scale 8
Extended Rating Scale 4 0 0
0 0 1-5 1
1-10 1 6-10 2
11-20 2 11-15 3
30-40 3 16-25 4
41-60 4 26-35 5
61-70 5 36-44 6
71-79 6 45-55 7
80 7 56-65 8
81-89 8 66-70 9
90 9 71-75 10
91-95 10 76-80 11
96-100 11 81-85 12
86-90 13
Extended Rating Scale 5 91-95 14
0 0 96-99 15
1-10 1 100 16
11-20 2
21-30 3 Extended Rating Scale 9
31-40 4 0 0
41-50 5 1-5 1
51-60 6 6-10 2
61-70 7 11-19 3
71-80 8 20-24 4
81-89 9 25-30 5
90 10 31-40 6
91-100 11 41-55 7
56-60 8
Extended Rating Scale 6 61-80 9
0 0 81-100 10
1-10 1
11-20 2
21-29 3
30-40 4
41-60 5
61-100 6
Extended Rating Scale 7 
0 0
1-10 1
11-20 2
21-30 3
31-40 4
41-50 5
51-60 6
61-70 7
71-100 8
Appendix S List of cases used included in
the Wellcome Trust Case 
Control Consortium (WTCCC)
7-1 527-3
15-2 528-5
17-1 529-6
28-1 533-9
37-18 535-3
50-11 537-4
51-8 540-4
52-3 542-5
55-4 543-8
57-3 548-7
59-5 549-5
62-3 550-9
65-7 551-6
68-3 553-3
69-1 554-7
72-11 557-4
75-3 558-6
76-3 559-8
79-4 560-6
80-4 562-4
81-3 563-3
83-6 569-6
84-5 572-3
85-4 573-3
86-3 574-4
87-9 575-9
104-2 576-9
500-4 577-3
501-8 579-4
504-5 580-3
505-6 581-6
507-4 582-5
508-7 583-3
509-3 584-6
510-5 585-6
511-5 586-6
512-4 587-4
513-3 589-5
514-4 592-5
515-3 595-3
516-5 597-8
517-3 598-3
518-4 599-6
519-4 600-6
520-6 601-3
522-4 602-5
523-7 603-9
524-5 605-3
525-5 607-4
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Appendix T
Search terms included in literature search.
The Functional Psychoses: Major mood and psychotic disorders of adulthood 
Keywords:
i. Schizophrenia
ii. Bipolar D isorder
iii. Functional psychosis OR Functional p sychoses
iv. Affective p sy c h o ses  OR Affective Psychosis
“i. OR ii. OR iii. OR iv” AND
V. Review
vi. Illness cou rse
vii. Illness o n se t
viii. A ge a t o n se t
ix. Epidemiology
X. Aetiology
xi. Heritability
Classification and nosology of the functional psychoses: Kraepelin’s Dichotomy 
Keywords:
xii. Kraepelin
xiii. K raepelin’s  Dichotomy
xiv. “psychiatry OR “i. OR ii. OR iii. OR iv.”” AND “nosology OR classification”
XV. Schizophrenia AND Bipolar D isorder
xvi. Schizophrenia AND “Affective d istu rbance OR Mood OR m ania OR m anic sym ptom s OR 
dep ressio n  OR dep ressiv e  sym ptom s”
xvii. First rank sym ptom s
xviii. Bipolar D isorder AND “P sychosis OR psychotic sym ptom s OR hallucinations OR delusions 
OR first rank sym ptom  m s”
xix. Schizoaffective D isorder OR Schizoaffective P sy ch o ses
XX. Schizoaffective D isorder AND “v. OR vi. OR vii. OR viii. OR ix. OR x.”
xxi. D iagnostic hierarchy
xxii. xx. AND xiii.
xxiii. “Family study OR familiality OR ped ig rees OR heridity” AND “i. OR ii. OR iii. OR iv. OR 
xviii”
“i. OR ii. OR iii. OR iv OR xix” AND xxiv-xxvii
xxiv. M olecular genetics
XXV. Linkage analysis OR genetic  linkage
xxvi. Association analysis OR genetic  associa tion
xxvii. G ene OR G en es
xxviii. COMT OR C atechol-o-m ethyltransferase
xxix. DISC1 OR Disrupted in Schizophrenia 1
XXX. DYSBINDIN OR dystrobrevin-binding protein 1
xxxi. DAOA OR D-amino acid ox idase activator
xxxii. NRG1 OR Neuregulin 1
Refining the phenotype
“i. OR ii. OR iii. OR iv. OR xix” AND:
xxxiii. P henotype
xxxiv. Familiality OR Familial
XXXV. Family Study
XXXV i. Heredity
xxxvii. Clinical fea tu res OR Clinical m easu res  OR Sym ptom s OR D im ensions OR F actors
NB: W here relevant pap e rs  w ere identified, citation-searches w ere perform ed to identify related pap e rs  
of interest.
